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Abstract	
Daptomycin	 is	a	bactericidal	antibiotic	of	 last	 resort	 for	 serious	 infections	caused	by	methicillin-
resistant	Staphylococcus	aureus	(MRSA).	Although	resistance	is	rare,	treatment	failure	can	occur	in	
>20%	of	cases	and	so	there	is	a	pressing	need	to	identify	and	mitigate	factors	that	contribute	to	
poor	therapeutic	outcomes.	Work	described	 in	this	 thesis	 revealed	that	 loss	of	 the	Agr	quorum-
sensing	 system,	 which	 frequently	 occurs	 in	 clinical	 isolates,	 enhanced	 S.	 aureus	 survival	 during	
daptomycin	 treatment.	Wild-type	 S.	 aureus	 was	 killed	 rapidly	 by	 daptomycin	 but	 Agr-defective	
mutants	 survived	 antibiotic	 exposure	 by	 releasing	 membrane	 phospholipid,	 which	 bound	 and	
inactivated	 the	antibiotic.	Although	wild-type	bacteria	also	 released	phospholipid	 in	 response	 to	
daptomycin,	Agr-triggered	secretion	of	small	cytolytic	toxins,	known	as	phenol	soluble	modulins,	
prevented	antibiotic	inactivation.	Phospholipid	release	by	S.	aureus	occurred	via	an	active	process	
that	 appears	 to	 involve	 the	 VraUTRS	 regulon,	 and	 was	 inhibited	 by	 the	 β-lactam	 antibiotic	
oxacillin,	 which	 slowed	 inactivation	 of	 daptomycin	 and	 enhanced	 bacterial	 killing.	 Subsequent	
work	revealed	that	next-generation	lipid	biosynthesis	 inhibitors	completely	blocked	phospholipid	
release,	 whilst	 the	 presence	 of	 host-associated	 fatty	 acids	 enhanced	 the	 release	 of	 membrane	
phospholipids.	Future	work	will	determine	the	molecular	mechanism	by	which	S.	aureus	releases	
phospholipids,	and	exploit	this	information	to	develop	new	therapeutic	approaches	that	enhance	
daptomycin	treatment	efficacy.	
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1.1 S.	aureus:	pathogen	and	commensal	
1.1.1 Basic	characteristics	of	S.	aureus		
Sir	 Alexander	Ogston	 first	 discovered	 the	 bacterium	Staphylococcus	 aureus	 in	 the	 year	 1880	 by	
microscopic	examination	of	the	pus	from	an	abscess	that	formed	in	a	surgical	wound.	Because	this	
examination	 revealed	 grape-like	 clusters	 of	 coccus-shaped	 bacteria,	 Ogston	 referred	 to	 it	 as	
micrococci	staphylococci.	By	injecting	mice	and	guinea	pigs	with	pus	collected	from	abscesses,	he	
was	able	to	recreate	the	infection,	which	revealed	that	staphylococci	were	the	causative	agent	of	
the	abscess1,2.		
Although,	Ogston	discovered	staphylococci,	it	was	Anton	J	Rosenbach	in	1884	that	isolated	
and	 characterised	 a	 pure	 culture	 of	 the	 bacterium.	 It	 was	 discovered	 that,	 although	 S.	 aureus	
preferentially	 grows	 via	 aerobic	 respiration,	 it	 is	 also	 a	 facultative	 anaerobe	 that	 can	 grow	 in	
anaerobic	 or	 microaerobic	 conditions3.	 Given	 its	 production	 of	 the	 carotenoid	 pigment	
staphyloxanthin,	 which	 resulted	 in	 golden	 colonies,	 Rosenbach	 revised	 the	 name	 of	 the	
staphylococci	species	as	Staphylococcus	aureus1,2.		
Based	 on	 taxonomic	 classification	 by	 16s	 rRNA	 sequences,	 S.	 aureus	 belongs	 to	 the	
firmicutes	 phylum,	 and	 the	Micrococcaceae	 family	 that	 includes	 all	 Gram-positive	 cocci,	 and	 is	
placed	 within	 the	 genus	 Bacillus-Lactobacillus-Streptococcus	 cluster4	 To	 date,	 128	 species	 of	 S.	
aureus	have	been	 identified	and	 their	 genomes	 completely	 sequenced	 (NCBI	 genome	database,	
https://www.ncbi.nlm.nih.gov/genome).	
Kuroda	et	al.,	were	the	first	to	sequence	the	genome	of	S.	aureus	in	2001.	This	revealed	a	
single	circular	chromosome	of	2.8	Mb,	with	a	distinctively	low	GC	content	of	36%5,6.	There	are	10	
dominant	 lineages	 associated	with	 the	 colonisation	 and/or	 infection	of	 humans,	with	 additional	
lineages	linked	to	animal	infections7,8.	These	lineages	differ	in	the	presence	of	genes	that	encode	
regulators	 or	 virulence	 factors	 such	 as	 surface	proteins.	Approximately	 15-20%	of	 the	S.	 aureus	
genome	 consists	 of	 mobile	 genetic	 elements	 (MGEs),	 which	 are	 acquired	 by	 horizontal	 gene	
transfer9.	 MGEs	 are	 diverse	 and	 include	 pathogenicity	 islands,	 the	 staphylococcal	 cassette	
chromosome,	plasmids	and	transposons,	many	of	which	are	 important	contributors	of	antibiotic	
resistance	(e.g.	the	low-affinity	penicillin-binding	protein	PBP2a	encoded	by	the	mecA	gene),	host	
adaptation,	 virulence	 factors	 (e.g.	 superantigens,	 Panton-Valentine	 leukocidin,	 the	 toxic-shock	
syndrome	toxin	island,	exotoxin	and	enterotoxin	islands	A,	B	and	C	that	cause	food	poisoning),	or	
the	evolution	of	new	clones6,9.	
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Because	of	 the	 thick	 peptidoglycan	 cell	wall	 and	 single	membrane,	S.	 aureus	 retains	 the	
Gram	 stain	 and	 is	 identified	 as	 a	 Gram-positive	 bacterium.	 S.	 aureus	 is	 spherical	 in	 shape	 and	
produces	 both	 catalase	 and	 coagulase,	 which	 is	 useful	 as	 a	 rapid	 diagnostic	 test3.	 Further	
diagnostic	approaches	exploit	the	ability	of	S.	aureus	to	grow	at	high	salt	concentrations,	enabling	
discrimination	 from	 other	 members	 of	 the	Micrococcaceae	 family.	 Diagnostic	 samples	 can	 be	
grown	on	mannitol	 salt	 agar	 (MSA)	plates10,	which	 contain	a	high	 (7.5%)	 salt	 concentration	and	
phenol	 red,	which	 is	 a	 pH	 indicator.	 Among	 the	members	 of	 the	Micrococcaceae	 family	 only	S.	
aureus	can	tolerate	the	high	salt	content,	whilst	the	growth	of	most	of	the	other	bacterial	species	
is	inhibited.	In	addition,	S.	aureus	ferments	mannitol,	which	results	in	a	drop	in	pH,	changing	the	
colour	of	the	MSA	medium	from	red	to	yellow	via	the	phenol	red	indicator10.	
	
1.1.2 The	staphylococcal	cell	envelope	
S.	aureus	has	a	single	phospholipid	membrane	surrounded	by	a	cell	wall	composed	of	a	thick	layer	
of	 peptidoglycan,	 lipoteichoic	 acids	 and	 wall	 teichoic	 acids,	 which	 are	 anchored	 to	 the	
phospholipid	membrane	 by	 diacylglycerol11	 and	 covalently	 anchored	 to	 the	 peptidoglycan	 layer	
respectively12	 (Fig	1.1).	Lipid	 II	 is	a	polyisoprenoid,	which	 is	anchored	 in	the	bacterial	membrane	
and	 is	 central	 to	 the	 assembly	 of	 peptidoglycan	 subunits	 on	 the	 cytoplasmic	 side	 of	 the	
membrane.	 Lipid	 II-linked	peptidoglycan	 precursors	 assemble	 at	 the	 division	 septa	 and	 form	an	
important	target	of	vancomycin13,14.	The	outermost	surface	of	many	strains	of	S.	aureus	is	coated	
with	a	polysaccharide	capsule14,15.		
The	 peptidoglycan	 consists	 of	 glycan	 chains	 composed	 of	 alternating	 amino	 sugars	
including	N-acetylglucosamine	and	N-acetylmuramic	acid.	Additionally,	stem	pentapeptides	(L-Ala-
D-iso-Gln-L-Lys-D-Ala-D-Ala)	 are	 synthesized	 in	 a	 step-wise	 manner	 by	 cell	 wall	 precursors	
including	FemA,	FemB,	FemC	and	FemX14,16.	The	synthesized	pentapeptides	are	then	attached	to	
the	carboxyl	group	of	each	N-acetylmuramic	acid.	The	 interpeptide	bridges	on	the	pentapeptide	
are	composed	of	5	glycine	residues	and	connect	the	lysine	component	of	one	stem	peptide	to	the	
penultimate	D-alanine	of	adjacent	stem	peptide14,17.	The	high	degree	of	murein	cross-linking	in	the	
cell	wall	enables	S.	aureus	to	bear	external	stresses,	particularly	osmotic	stress14,15.	
S.	 aureus	 encodes	 4	 penicillin	 binding	 proteins	 (PBPs),	 of	 which	 PBP1,	 PBP2	 and	 PBP3	
belong	 to	 the	high	molecular	weight	 class	of	PBPs,	whereas	PBP4	belongs	 to	 the	 low-molecular	
weight	class	of	PBPs.	PBP1	has	a	transpeptidase	(TPase)	function	which	links	the	penultimate	D-Ala	
to	 a	 glycine	 acceptor	 in	 the	 nascent	 cell	 wall14,18.	 This	 mono-functional	 TPase	 is	 essential	 for	
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important	for	cell	division	and	survival.	PBP2	has	a	transglycosidase	(TGase)	function	which	 links	
N-acetylglucosamine	 to	N-acetylmuramic	acid,	as	well	as	a	 transpeptidase	 (TPase)	 function.	This	
bifunctional	PBP	is	also	essential	for	cell	wall	synthesis	and	bacterial	growth14,17,	PBP3	is	involved	
in	autolytic	activity19	and	PBP4	functions	as	a	TPase	and	carboxypeptidase	20,21–23.	Neither	PBP3,	
nor	PBP4	are	essential	for	bacterial	growth18,24,19,20.	
The	teichoic	acids	represent	50%	of	the	S.	aureus	cell	wall,	and	WTAs,	which	are	covalently	
linked	to	the	peptidoglycan	layer,	are	decorated	with	N-acetylglucosamine	residues	and	positively	
charged	 D-alanine25.	 By	 contrast,	 LTAs	 are	 glycerol	 phosphate	 polymers	 linked	 to	 a	 glycolipid	
terminus	in	the	cytoplasmic	phospholipid	membrane25.	Teichoic	acids	are	involved	in	cell	division	
and	function	as	a	barrier	to	host	antimicrobial	peptides	and	antibiotics.	For	example,	the	positively	
charged	D-alanine	 residues	 of	 teichoic	 acids	 repel	 positively	 charged	 antimicrobial	 peptides26,27.	
WTAs	extend	beyond	 the	peptidoglycan	 layer,	whereas	 fully	 extended	 LTAs	may	not	be	 able	 to	
pass	the	peptidoglycan	layer12.		
The	 S.	 aureus	 cell	 membrane	 is	 composed	 of	 three	 major	 phospholipids:	
phosphatidylglycerol	(PG),	cardiolipin	(CL)	and	lysyl-PG	(LPG).	Both	PG	and	CL	have	a	net	negative	
charge	and	make	up	72.1%	±8.0	and	12.4%	±	6.5	of	the	total	quantity	of	membrane	phospholipids	
respectively28.	 By	 contrast,	 LPG	has	 a	 net	 positive	 charge	 and	 comprises	 15.4	 ±	 3.9	 of	 the	 total	
membrane	phospholipid	content28.		
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Figure	1.1.	S.	aureus	cell	wall	and	cell	membrane		
The	cell	wall	includes	the	peptidoglycan	layer,	wall-teichoic	acid	(WTA)	and	lipoteichoic	acid	(LTA).	
Penicillin	 binding	 proteins	 (PBPs)	 are	 required	 to	 synthesize	 the	 peptidoglycan	 layer.	 The	 cell	
membrane	is	composed	of	phosphatidylglycerol	(PG),	cardiolipin	(CL)	and	lysyl	PG	(LPG).	
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1.1.3 Carriage		
S.	aureus	is	primarily	a	human	commensal	that	resides	on	the	squamous	epithelial	surface	of	the	
anterior	nares	of	the	nasal	cavity29–32.	However,	it	has	also	been	isolated	from	the	skin,	perineum,	
and	axillae,	as	well	as	mucosal	surfaces	such	as	the	pharynx	and	gastrointestinal	tract29–32.		
Healthy	individuals	generally	exhibit	one	of	three	types	of	S.	aureus	nasal	carriage	profiles:	
20	%	of	individuals	are	identified	as	persistent	nasal	carriers	where	S.	aureus	nasal	colonization	is	
present	 for	 >	 154	days;	 30%	of	 individuals	 are	 identified	 as	 intermittent	nasal	 carriers	where	S.	
aureus	 nasal	 colonization	 is	 present	 for	 approximately	 4-14	 days,	 and	 50%	 of	 individuals	 are	
identified	 as	 non-carriers	where	 S.	 aureus	nasal	 colonization	 is	 present	 for	 <	 4	 days.	 Persistent	
carriers	are	colonized	by	a	higher	load	of	S.	aureus,	which	often	results	in	a	higher	risk	of	acquiring	
infection	because	of	seeding	from	the	nasal	cavity29,31–36.			
Although	 colonization	 with	 S.	 aureus	 usually	 occurs	 early	 in	 life,	 the	 carriage	 rate	 is	
dynamic	until	adulthood.	For	example,	at	least	70%	of	newborns	are	colonized	with	S.	aureus,	of	
which	45%	are	persistent	carriers,	but	within	6	months	of	birth	this	rate	of	carriage	falls	to	<21%.	
Nevertheless,	the	rate	of	carriage	then	increases,	reaching	its	highest	point	(~24%)	in	 individuals	
between	 the	ages	of	9-19	years,	before	again	declining	during	adulthood29,31–35.	 The	 route	of	S.	
aureus	transmission	from	the	environment	to	the	anterior	nares	is	believed	to	occur	via	the	hand,	
which	 is	 the	main	 vector	 of	 transmission37.	 The	 source	 of	 S.	 aureus	 colonization	 in	 neonates	 is	
most	likely	due	to	transmission	from	the	mother29,31,34,37–39.	
The	 carriage	 state	 is	 dependent	on	multiple	host	 and	bacterial	 factors.	Host	 factors	 that	
have	 been	 shown	 to	 be	 associated	with	 higher	 carriage	 rate	 include	 ethnicity,	 age	 and	 specific	
patient	groups	such	as	those	with	diabetes	mellitus,	individuals	undergoing	haemodialysis	or	last	
stage	renal	dialysis,	those	infected	with	HIV	and	patients	with	S.	aureus	skin	infection.	
Bacterial	 factors	 that	 influence	 the	 rate	 of	 carriage	 include	 the	 cell	 surface	 associated	
bacterial	 ligands	 that	mediate	 attachment	 to	 receptors	 in	 the	 nasal	 niche29,31,40.	 Some	 of	 these	
ligands	 include	cell	wall	 teichoic	acid,	 lipoteichoic	acid	and	 fibronectin	binding	proteins	 that	are	
able	to	bind	to	the	glycoproteins	and	proteoglycans	found	on	host	epithelial	and	mucosal	surfaces	
29,31,33,34.	 In	 addition,	 clumping	 factor	 B	 enables	 bacterial	 adhesion	 to	 the	 squamous	 type	 of	
epithelial	cells	found	in	the	lining	of	the	respiratory	tract40,41.		
Although	carriage	is	asymptomatic,	persistent	carriers	are	more	likely	to	acquire	infections.	
For	 example,	 nasopharyngeal	 S.	 aureus	 colonization	 can	 lead	 to	 pneumococcal	 infections	 and	
bacteraemia29,31,33,35,42.	
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1.2 S.	aureus	infections	
While	S.	aureus	 is	primarily	a	commensal	organism	it	 is	also	a	very	versatile	pathogen3,43.	 	 It	can	
infect	a	 large	number	of	different	anatomical	 sites	and	cause	a	wide	range	of	different	 types	of	
infection,	 including	 skin	 and	 soft	 tissue	 infections	 (SSTIs),	 pneumonia,	 bacteremia,	 infective	
endocarditis	 (IE),	bone	and	joint	 infections	such	as	osteomyelitis	and	septic	arthritis,	and	central	
nervous	system	(CNS)	 infections	 including	meningitis	 (Fig	1.2)3,43,44,45.	These	 infections	can	range	
from	mild	and	superficial	to	invasive	and	life-threatening3,43,46,47.	
Skin	 is	 the	 first-line	 of	 defence	 against	 infection,	 providing	 a	 physical	 barrier	 to	 bacteria	
that	 prevents	 entry	 into	 deep	 tissues	 and	 dissemination	 to	 distal	 sites	 within	 the	 body44,46,48.	
However,	S.	aureus	 is	one	of	 the	 leading	causes	of	SSTIs,	which	 is	 the	most	 frequent	 form	of	S.	
aureus	 infection29,44,46,48.	 The	 clinical	 manifestations	 of	 SSTIs	 present	 in	 various	 forms,	 ranging	
from	 uncomplicated	 and	 superficial	 to	 complicated	 SSTIs	 that	 involve	 bacterial	 invasion	 of	 the	
deeper	 layers	of	 the	skin	and	underlying	soft	 tissues46.	Uncomplicated	SSTIs	are	cutaneous,	self-
limiting	and	can	be	resolved	effectively	by	the	primary	immune	defence	against	S.	aureus,	which	is	
the	 neutrophil	 (polymorphonuclear	 leukocyte)	 and	 without	 the	 need	 for	 antibiotic	
treatment44,46,48.	 These	 SSTIs	 are	 clinically	 presented	 as	 impetigo,	 which	 is	 more	 frequent	 in	
children,	furuncles	(boils)	and	folliculitis	(inflammation	of	the	skin	surrounding	the	hair	shaft).	The	
clinical	manifestation	of	 complicated	 SSTIs	 often	 includes	 large	 abscesses	 and/or	 cellulitis44,46,48.	
Abscesses	are	essentially	a	mixture	of	neutrophils,	host	cell	debris	and	bacteria	surrounded	by	a	
fibrin	 capsule.	 Beyond	 the	 skin,	 abscesses	 can	 form	 within	 deeper	 tissues	 including	 underlying	
muscle	and	from	there	spread	to,	and	infect,	distal	sites	in	the	body	including	internal	organs46.	
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Figure	1.2.	Human	S.	aureus	infections		
S.	 aureus	 is	 able	 to	 cause	 a	 range	 of	 different	 infections	 at	 various	 sites	 in	 the	 human	 body.	
(Adapted	from	Wertheim	H.	et.	al.,	2005)31.	 	
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Complicated	 SSTI	 (cSSTI)	 can	 develop	 into	 necrotizing	 fasciitis,	 which	 is	 rare	 but	 life-
threatening.	 It	most	often	occurs	 in	middle-aged	patients	with	comorbidities	 including	diabetes,	
hepatitis	C,	AIDS	or	 intravenous	drug	users44,46,48.	 In	addition,	S.	aureus	SSTIs	can	cause	systemic	
manifestations	such	as	toxic-shock	syndrome	(TSS)	which	is	mediated	by	the	S.	aureus	toxin	toxic-
shock	 syndrome	 toxin-1	 (TSST-1),	 and	 Staphylococcal	 scalded	 skin	 syndrome	 (SSSS),	 which	 is	
mediated	by	S.	aureus	exfoliative	toxin	and	typically	occurs	in	very	young	children44,46,48.	
Although	 the	 skin	 provides	 a	 barrier	 to	 infection,	 S.	 aureus	 can	 exploit	 wounds	 or	
indwelling	medical	devices	as	an	access	point	to	the	deeper	tissues.	S.	aureus	is	highly	effective	at	
colonising	 the	 inert	 surfaces	 of	 indwelling	 medical	 devices	 including	 prosthetic	 heart	 valves,	
prosthetic	joints	and	intravenous	catheters,	which	typically	leads	to	the	formation	of	biofilms	that	
protect	 the	pathogen	from	host	 immune	defences	and	antibiotics49,50.	These	devices,	along	with	
subcutaneous	 wounds,	 provide	 the	 bacteria	 a	 gateway	 to	 the	 bloodstream,	 which	 enables	
dissemination49,50.		
Once	in	the	bloodstream,	metastatic	spread	frequently	occurs,	enabling	S.	aureus	to	cause	
a	wide	range	of	different	secondary	infections	including	infective	endocarditis	(IE),	osteomyelitis,	
septic	arthritis,	abscesses	in	tissues	and	organs,	and	meningitis3,29,43,46,51.	Typically,	most	S.	aureus	
infections	 are	 of	 an	 acute	 type,	 with	 a	 rapid	 onset	 of	 disease.	 Most	 superficial	 infections	 are	
successfully	 treated	 using	 antibiotic	 therapy	 and	 typically	 resolve	 within	 7	 days	 of	 onset52.	
However,	S.	aureus	 invasive	infections	can	take	on	a	persistent	course,	particularly	in	the	case	of	
osteomyelitis	or	IE52.	
The	 S.	 aureus	 strains	 that	 colonise	 wounds	 and	 catheters	 are	 most	 often	 derived	 from	
colonization	 sites	 such	 as	 the	 anterior	 nares	 and	 hands42.	 For	 example,	 frequent	 carriers	 of	 S.	
aureus	are	more	vulnerable	than	non-carriers	to	acquiring	S.	aureus	bacteremia	(SAB)42.	However,	
infections	 can	 also	 arise	 from	 strains	 acquired	 from	 others,	 with	 transmission	 of	 S.	 aureus	 a	
particular	problem	in	healthcare	facilities,	where	in-patients	and	healthcare	workers	contribute	to	
the	dissemination	of	S.	aureus53.		
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1.2.1 S.	aureus	is	a	major	cause	of	bacteraemia		
One	 of	 the	 most	 serious	 types	 of	 staphylococcal	 infections	 is	 bacteraemia,	 with	 S.	 aureus	
responsible	for	20	to	50	cases/100,000	population	per	year,	with	mortality	rates	between	16%	and	
30%51,52,54,55.	 One	 of	 the	 reasons	 for	 the	 high	mortality	 rate	 is	 that	 S.	 aureus	 bacteremia	 (SAB)	
frequently	 results	 in	bacterial	 seeding	 into	host	 tissues,	 leading	 to	a	diverse	 range	of	 secondary	
infections	 such	 as	 infective	 endocarditis	 (associated	 with	 4.3%	 -	 39%	 cases	 of	 SAB),	 vertebral	
osteomyelitis	 (10%	of	cases),	 septic	arthritis	 (24%	of	cases),	 tissue	abscesses	 (18%	of	cases)	and	
meningitis	 (5%	 of	 cases)51,54,56.	 Of	 these	 complications,	 the	 highest	 mortality	 rate	 occurs	 in	
patients	with	infective	endocarditis	(25%	-	66%	of	cases)	followed	by	bone	and	soft	tissue	infection	
(9%	–	29%	of	cases)52,55,56.		
Bacteraemia	can	resolve	rapidly	upon	the	commencement	of	antibiotic	therapy	or	persist	
for	many	days.	Although,	 the	definition	of	persistent	bacteremia	varies,	 it	 is	 typically	defined	as	
the	 duration	 of	 bacteremia,	 which	 is	 greater	 than	 3	 or	 7	 days52.	 In	 addition	 to	 persistent	
bacteremia,	 there	 are	 other,	 longer	 lasting	 infections.	 For	 example,	 when	 an	 individual	 first	
develops	 osteomyelitis	 or	 a	 skin	 infection	 it	 is	 termed	 as	 acute	 infection.	 However,	 this	 can	
become	a	 persistent	 infection	 if	 it	 lasts	 for	more	 than	 7	 days,	 and	 chronic	 if	 it	 lasts	 for	 several	
weeks.	Recurrent	infections	are	defined	as	having	a	couple	or	more	episodes	of	severe	infections	
within	a	year.	
This	 phenomenon	 is	 important	 because	 the	 greater	 the	 duration	 of	 culture-positive	
bacteremia,	 the	 greater	 the	 incidence	 of	 disseminated	 infection	 and	 resulting	 mortality.	 For	
example,	SAB	lasting	greater	than	7	days	was	associated	with	infective	endocarditis	in	13%	–	27%	
patients,	whilst	a	duration	of	less	than	3	days	was	associated	with	an	incidence	of	just	1.4%	-	5.3%	
57,58.	In	addition,	SAB	of	greater	than	7	days	was	associated	with	bone	and	soft-tissue	infection	in	
14%	of	patients	with	bacteremia,	whilst	SAB	that	resolved	in	less	than	3	days	was	associated	with	
an	incidence	of	just	5%57–59.	These	findings	very	likely	explain	why	SAB	lasting	greater	than	7	days	
was	associated	with	mortality	in	the	range	of	45%	-	55%	whereas	resolving	infections	of	less	than	3	
days	was	associated	with	mortality	in	the	range	of	9.4%	-	31.4%52,56,60.		
Therefore,	 the	 timely	 administration	 of	 appropriate	 antibiotic	 therapy	 that	 sterilizes	 the	
bloodstream	 is	 essential	 in	 preventing	 or	 reducing	 the	 incidence	 of	 secondary	 infections	 and	
therefore	 mortality.	 This	 principle	 has	 been	 validated	 by	 several	 clinical	 studies,	 which	
demonstrate	 that	 the	 delay	 in	 the	 use	 of	 appropriate	 antibiotics	 by	 2	 days	 results	 in	 a	 >2-fold	
increase	in	mortality	in	patients	with	bacteraemia	caused	by	methicillin-resistant	S.	aureus	(MRSA)	
52,61,62,63.	
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1.3 Antibiotic	treatment		
The	antibiotic	therapeutic	management	of	S.	aureus	 infections	is	guided	by	the	type	of	S.	aureus	
infection	and	more	importantly	the	susceptibility	of	the	isolate	(Fig	1.3).	For	infections	caused	by	
methicillin-sensitive	S.	aureus	(MSSA)	isolates	the	empirical	antibiotic	treatment	is	typically	a	semi-
synthetic	penicillin	such	as	flucloxacillin	or	first-generation	cephalosporins	such	as	cefazidin64–69.	In	
case	of	an	allergy	to	penicillin	patients	with	an	MSSA	infection	are	often	treated	with	daptomycin	
64–69.	 The	 glycopeptide	 vancomycin	 is	 typically	 not	 used	 to	 treat	 infections	 caused	 by	 MSSA	
because	 it	 is	associated	with	worse	outcomes	than	β-lactam	antibiotics,	although	the	reason	for	
this	is	unknown64–69.	Patients	that	have	a	MRSA	infection	are	generally	treated	with	vancomycin	or	
daptomycin64–69.	However,	in	the	case	of	SAB	treatment	daptomycin	is	more	frequently	associated	
with	persistent	and	relapsing	S.	aureus	 infection	than	vancomycin64,70.	 In	addition,	depending	on	
the	 antibiotic	 susceptibility	 profile	 of	 the	 causative	 organism,	 antibiotics	 such	 as	 linezolid,	
teicoplanin,	 ceftaroline,	 tedizolid	 and	 trimethoprim-sulfomethoxazole	 (TMP-SXT)	have	also	been	
used	to	treat	SAB	caused	by	MRSA	strains64–69.		
For	SAB	caused	by	MSSA	or	MRSA,	treatment	is	given	intravenously	(IV)	to	provide	a	high	
dose	of	antibiotic	to	directly	sterilize	the	bloodstream.	By	contrast,	for	uncomplicated	SSTI	caused	
by	 MRSA	 strains	 the	 empirical	 antibiotic	 treatment	 includes	 oral	 antibiotics	 such	 as	 TMP-SXT,	
clindamycin,	 tetracycline	 (doxycycline-minocycline)	 or	 linezolid,	 which	 is	 given	 for	 5-10	 days.	
However,	for	hospitalized	patients	with	more	serious	infections	antibiotics	including	vancomycin,	
daptomycin	or	 linezolid	are	given	 intravenously	 for	14	days66	 to	prevent	bacterial	dissemination	
into	the	bloodstream.		
Because	 many	 S.	 aureus	 can	 develop	 a	 persistent	 or	 relapsing	 course56,57,	 treatment	 is	
often	 given	 for	 several	 days	 or	 even	 weeks,	 particularly	 when	 infection	 involves	 MRSA	 strains	
resistant	 to	 first-choice	drugs.	 This	 is	 particularly	 true	 for	patients	with	osteomyelitis	 caused	by	
MRSA,	which	 are	 typically	 treated	with	 vancomycin	 or	 daptomycin	 for	 a	minimum	 of	 8	weeks.	
Where	 infection	has	already	developed	a	chronic	course,	an	additional	1-3	months	of	treatment	
with	 oral	 antibiotics	 including	 rifampin-based	 combination	 therapy	 with	 linezolid,	 TMP-SMX,	
clindamycin	or	doxycycline-minocycline	is	recommended	to	fully	eradicate	infection66.		
IE	is	another	infection	that	requires	long-term	antibiotic	therapy,	which	typically	consists	of	
vancomycin	or	daptomycin	given	intravenously.	However,	the	addition	of	gentamicin	or	rifampin	
to	vancomycin	is	not	recommended	for	the	treatment	of	native	valve	IE,	but	is	recommended	for	
prosthetic	IE66.		
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Figure	1.3.	The	timeline	of	antibiotic	resistance	emergence	in	S.	aureus		
R=	resistance	(adapted	from	Ventola	C.L,	2015	71).			 	
1940	Penicillin-R	Staphylococcus	
1962	Methicillin-R	Staphylococcus	
1977	Gentamicin-R	Staphylococcus	
2001	Linezolid-R	Staphylococcus	
2002	Vancomycin-R	Staphylococcus	
2011	Ce9aroline-R	Staphylococcus	
Penicillin	1943	
Methicillin	1960	
Gentamicin	1967	
Vancomycin	1972	
Linezolid	2000	
Daptomycin	2003	
Ce9aroline	2010	
An/bio/c	Introduced	in	clinics	 An/bio/c	resistance	reported	
2006	Daptomycin-R	Staphylococcus	
2001	Vancomycin-Intermediate	
Staphylococcus	
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1.4 Antibiotic	resistance	
1.4.1 					β-lactam	antibiotics	
In	the	pre-antibiotic	era	S.	aureus	bacteremia	was	almost	inevitably	fatal72,73.		The	introduction	of	
Penicillin	 G	 in	 1940	marked	 the	 beginning	 of	 the	 antibiotic	 era	 and	 dramatically	 improved	 the	
prognosis	of	patients	with	bacterial	infections73.		
Penicillin	 G	 (benzyl	 penicillin)	 was	 the	 first	 mass-produced	 β-lactam	 antibiotic,	 which	 is	
synthesised	by	the	members	of	the	Penicillium	genus	of	fungi	(P.	rubens)74,75.	The	β-lactam	ring	of	
Penicillin	 G	 is	 structurally	 similar	 to	 the	 terminal	 D-alanyl-D-alanine	 (D-Ala	 D-Ala)	 amino	 acid	
residues	of	the	peptidoglycan	precursors	N-acetylglucosamine	and	N-acetylmuramic	chains.	These	
peptidoglycan	precursors	are	cross-linked	by	transpeptidases	known	as	penicillin-binding	proteins	
(PBPs)	 to	 create	 the	 bacterial	 cell	 wall.	 However,	 the	 similarity	 of	 β-lactam	 antibiotics	 to	
peptidoglycan	precursors	enables	the	drug	to	occupy	the	active	site	of	PBPs,	irreversibly	blocking	
the	cross-linking	of	the	peptidoglycan	chains	and	thereby	inhibiting	cell	wall	synthesis72,76,77.	
	Because	penicillin	drastically	improved	the	prognosis	of	patients	with	bacterial	infections	it	
was	justifiably	referred	to	as	a	miracle	drug.	However,	after	just	two	years	of	the	introduction	of	
Penicillin	G	 into	 hospitals,	 S.	 aureus	 strains	were	 isolated	which	 had	 acquired	 resistance	 to	 the	
antibiotic.	By	the	1960s,	80%	of	S.	aureus	strains	were	resistant	to	penicillin72,78–80.	Resistance	to	
penicillin	was	found	to	be	mediated	by	the	blaZ	gene,	present	on	plasmids	or	the	chromosome,	
which	encodes	an	enzyme	called	β-lactamase	 that	hydrolyses	 the	β-lactam	ring	of	penicillin	and	
inactivates	the	antibiotic72,76,80–82.	
To	overcome	β-lactamase	resistance,	a	semi-synthetic	β-lactam	antibiotic	called	methicillin	
was	developed	and	introduced	in	the	year	1959	(Fig	1.3).		Methicillin	is	a	derivative	of	Penicillin	G	
in	which	the	phenol	group	 is	substituted	with	two	methoxy	groups.	Thus,	methicillin	has	a	 large	
side	group	on	the	β-lactam	ring	of	penicillin,	which	resists	hydrolysis	by	the	β-lactamase	via	steric	
hindrance76.	 However,	 as	 for	 Penicillin,	 resistance	 to	 methicillin	 emerged	 soon	 after	 its	
introduction,	giving	rise	to	strains	known	as	Methicillin-Resistant	S.	aureus	(MRSA)	(Fig	1.3).	Since	
then,	MRSA	has	become	a	global	concern,	with	a	recent	report	estimating	that	53	million	people	
are	 colonized	 with	 MRSA	 worldwide,	 leading	 to	 80,000	 invasive	 MRSA	 infections	 in	 the	 USA	
alone72,83,84.		
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Although,	it	took	just	2	years	for	resistance	to	be	identified,	it	took	two	decades	to	identify	
the	 cause	 of	 methicillin	 resistance,	 which	 was	 not	 due	 to	 a	 β-lactamase80,85.	 Horizontal	 gene	
transfer	of	a	mobile	genetic	element	termed	Staphylococcal	Cassette	Chromosome	mec	(SCCmec),	
most	 likely	 from	 Staphylococcus	 sciuri	 or	 Staphylococcus	 fleuretti,	 to	 S.	 aureus	 conferred	
resistance	 towards	methicillin.	 The	 SCCmec	 element	 harbors	 the	mecA	 gene,	which	 encodes	 an	
alternative	 penicillin-binding	 protein	 known	 as	 2a	 (PBP2a)86.	 β-lactam	 antibiotics,	 including	
methicillin,	target	one	or	more	of	the	4	PBPs	produced	by	S.	aureus,	blocking	the	cross-linking	of	
the	peptidoglycan	chains	essential	for	cell	wall	synthesis.	However,	PBP2a	has	a	very	low	affinity	
for	 β-lactam	 antibiotics,	 enabling	 it	 to	 continue	 to	 function	 in	 the	 presence	 of	 the	
antibiotic72,76,80,87.	Whilst	 the	 emergence	 of	MRSA	was	 not	 recognized	 until	 the	 introduction	 of	
methicillin,	 recent	 work	 has	 shown	 that	MRSA	 strains	 were	 present	 long	 before	 this	 antibiotic	
existed.	This	suggests	that	the	emergence	of	MRSA	was	initially	selected	for	by	the	introduction	of	
penicillin,	with	methicillin	providing	a	subsequent	selection	pressure88.			
The	SCCmec	contains	cassette	chromosome	recombinase	(ccr)	genes	that	enable	horizontal	
transfer	 of	 the	 element,	 and	 contributed	 to	 the	 evolution	 of	 11	 different	 types	 of	 SCCmec	
elements.	The	presence	of	SCCmec	in	S.	aureus	isolates	is	routinely	detected	by	polymerase	chain	
reaction	(PCR)	in	clinical	diagnostic	laboratories,	and	several	studies	have	shown	that	elements	I-IV	
are	most	prevalent	in	human	infections72,81,89,90.		
SCCmec	elements	I-III	are	usually	carried	by	hospital-associated	MRSA	(HA-MRSA)	strains,	
which	 harbor	 different	 combinations	 of	mec	 gene	 and	 ccr	 gene	 complexes	 and	 carry	 multiple	
genes	 conferring	 antibiotic	 resistance72,81,89,90.	 HA-MRSA	 strains	 are	 frequently	 isolated	 from	
patients	 who	 have	 a	 weakened	 immune	 system	 or	 other	 health	 problems	 including	 HIV	 and	
diabetes	 mellitus91.	 By	 contrast,	 the	 smaller	 type	 IV	 element	 is	 present	 in	 highly	 virulent	
community-associated	MRSA	 (CA-MRSA)	strains	such	as	USA300,	which	 infect	otherwise	healthy	
individuals92.	 It	 is	 thought	 that	 the	 smaller	 type	 IV	 element	mitigates	 the	 fitness	 costs	 seen	 in	
MRSA	 with	 type	 I-III	 elements,	 and	 these	 highly	 successful	 CA-MRSA	 strains	 are	 increasingly	
common	in	US	hospitals,	blurring	the	lines	between	the	original	HA-	and	CA-MRSA	classifications92.	
The	PBP2a	encoded	by	SCCmec	element	in	MRSA	strains	confers	resistance	to	almost	all	β-lactam	
antibiotics,	including	the	carbapenems.	An	exception	to	this	is	the	fifth-generation	cephalosporin	
Ceftaroline,	although	resistance	to	this	has	been	reported	via	point	mutations	in	pbp	genes72,93–95.		
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In	addition	to	MRSA	strains	that	infect	humans,	MRSA	has	also	emerged	in	livestock	such	
as	 cattle	 and	 pigs,	 where	 β-lactam	 antibiotics	 are	 used	 in	 abundance.	 However,	 methicillin-
resistance	in	livestock-associated	MRSA	(LA-MRSA)	is	conferred	by	the	mecC	gene96.	
	
1.4.2 	Gentamicin	
In	addition	 to	 conferring	 resistance	 to	β-lactam	antibiotics,	 the	SCCmec	 element	 contains	genes	
that	confer	resistance	to	other	antibiotics	such	as	gentamicin	or	erythromycin97–100.	Gentamicin	is	
an	aminoglycoside	antibiotic,	which	was	introduced	into	clinical	use	in	196771.	It	binds	irreversibly	
to	the	bacterial	30S	ribosomal	subunit,	which	leads	to	inhibition	of	protein	synthesis,	essential	for	
the	 growth	 of	 the	 bacterium,	 and	 is	 rapidly	 bactericidal101,102.	 S.	 aureus	 acquired	 resistance	 to	
gentamicin	 either	 by	 producing	 aminoglycoside-modifying	 enzymes103	 or,	 because	 gentamicin	
requires	 an	 electrochemical	 gradient	 to	 enter	 the	 cell	membrane	 and	 reach	 its	 target	 site104,	S.	
aureus	acquires	 resistance	 by	 reducing	 the	membrane	potential	 and	 impairing	 gentamicin	 from	
entering	the	cell	membrane105.	
	
1.4.3 Vancomycin	
The	emergence	of	MRSA	strains	that	are	resistant	to	first-choice	β-lactam	antibiotics	necessitates	
the	use	of	the	glycopeptide	antibiotic	vancomycin,	which	inhibits	cell	wall	synthesis.	Vancomycin	
binds	to	the	terminus	of	the	D-Ala	D-Ala	moiety	of	peptidoglycan	precursors	N-acetylglucosamine	
and	N-acetylmuramic	acid,	which	prevents	cross-linking,	inhibiting	cell	wall	synthesis14,106.		
Inevitably,	 the	 increase	 in	the	use	of	vancomycin	 in	response	to	the	emergence	of	MRSA	
led	to	the	emergence	of	vancomycin-intermediate	S.	aureus	(VISA)	strains	in	1997	(Fig	1.3)107,108.	
VISA	 is	defined	as	a	strain	with	a	vancomycin	minimum	inhibitory	concentration	(MIC)	of	4-8	μg	
ml-1.	However,	VISA	is	typically	a	heterogeneous	phenotype,	with	some	bacteria	in	the	population	
maintaining	sensitivity	(MIC	of	<	2		μg	ml-1)14,109,110.	
Vancomycin	insensitivity	typically	emerges	during	vancomycin	treatment,	and	is	mediated	
by	an	increase	in	peptidoglycan	synthesis	and	thickening	of	the	cell	wall.	This	provides	excess	D-
Ala	 D-Ala	 moieties	 that	 sequester	 vancomycin	 and	 prevent	 it	 from	 impairing	 peptidoglycan	
synthesis.	In	addition,	the	increase	in	cell	wall	thickness	reduces	the	access	of	vancomycin	to	sites	
of	peptidoglycan	biosynthesis14,80.	
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The	VISA	phenotype	arises	via	the	sequential	acquisition	of	numerous	mutations	that	result	
in	a	gradual	increase	('creep’)	in	the	MIC14.	These	mutations	can	occur	in	several	different	genes,	
including	 those	 of	 the	 vancomycin-resistance	 associated	 (vra)	 operon,	 the	 products	 of	 which	
regulate	the	cell	wall	stress	stimulon	that	maintains	cell	wall	homeostasis111,112.	VISA	strains	often	
lack	a	 functional	Agr	quorum-sensing	system,	although	the	causes	and	consequences	of	 this	are	
unclear14,113–117.	
In	addition	to	the	emergence	of	VISA	isolates,	the	increase	in	the	use	of	vancomycin	led	to	
the	 selection	 of	 the	 first	 vancomyin-resistant	 S.	 aureus	 (VRSA)	 isolate	 in	 2002.	 Resistance	 was	
mediated	by	the	acquisition	of	the	vanA	operon,	via	horizontal	gene	transfer	from	a	vancomycin	
resistant	Enterococcus	faecalis	(VRE)	strain14,118.	The	vanA	operon	encodes	an	alternative	terminal	
peptide	 D-Ala	 D-lac,	 which	 is	 not	 recognized	 by	 vancomycin	 and	 enables	 the	 cross-linking	 of	
peptidoglycan	precursors	and	the	synthesis	of	the	cell	wall80,119.	The	presence	of	vanA	enables	S.	
aureus	 to	 grow	 in	 the	 presence	 of	 >	 16	 μg	ml-1	 vancomycin,	which	 is	well	 above	 the	 clinically-
achievable	dose118.	Despite	the	emergence	of	VRSA,	vancomycin	resistance	is	much	less	prevalent	
than	strains	with	the	VISA	phenotype14.	
	
1.4.4 Daptomycin	
Daptomycin	is	a	cyclic	lipopeptide	bactericidal	antibiotic	used	as	a	last	resort	in	the	treatment	of	
infections	 caused	 by	multi	 drug-resistant	MRSA	 and	 VISA	 strains28,120.	 It	 is	 the	 only	 lipopeptide	
antibiotic	used	clinically	and	was	approved	 for	 the	treatment	of	S.	aureus	bacteremia	and	right-
sided	 endocarditis	 by	 the	 US	 Food	 and	 Drug	 Administration	 in	 the	 year	 200628,120.	 The	 exact	
mechanism	of	the	bactericidal	action	of	daptomycin	towards	S.	aureus	is	unclear,	as	most	studies	
have	been	conducted	using	the	model	organism	Bacillus	subtilis,	which	is	relatively	closely	related	
to	S.	aureus	but	non-pathogenic.		However,	it	is	well-established	that	daptomycin	requires	calcium	
for	 activity	 and	 inserts	 into	 the	 cytoplasmic	membrane	 of	 Gram-positive	 cells,	 where	 it	 targets	
phosphatidylglycerol	and	forms	oligomeric	complexes	(Fig	1.4)121–123.	
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These	oligomeric	complexes	cause	membrane	disruption,	resulting	in	rapid	depolarization	
and	potassium	ion	efflux.	This	is	followed	by	arrest	of	the	synthesis	of	the	cell	wall,	protein,	DNA	
and	RNA,	 leading	 to	bacterial	 cell	 death	without	 lysis28,120,124,125,126,127.	 The	use	of	 daptomycin	 is	
becoming	 more	 common	 given	 the	 rise	 of	 infections	 caused	 by	 MRSA	 strains	 that	 are	 not	
responding	to	vancomycin,	which	is	the	first	line	therapy	of	MRSA	strains80,118,128,	and	the	end	of	
the	patent	period,	enabling	generic	versions	to	be	produced	at	greatly	lowered	cost.	For	example,	
use	of	daptomycin	in	the	UK	increased	by	72%	between	2012	and	2015129.		
Daptomycin	resistance	or	 'non-susceptibility'	has	been	 identified	sporadically	 in	S.	aureus	
and	typically	arises	during	treatment.	As	for	the	emergence	of	VISA,	acquisition	of	the	daptomycin	
non-susceptible	(DNS)	phenotype	arises	via	mutations	in	various	genes,	which	lead	to	a	small	but	
clinically	 significant	 increase	 in	MIC.	 The	 best	 characterized	 route	 to	 the	DNS	 phenotype	 is	 the	
acquisition	 of	 gain-of-function	mutations	 in	 the	multiple	 peptide	 resistance	 factor	 (mprF)	 gene,	
which	 encodes	 a	 phosphatidylglycerol	 lysyltransferase28,126,130–132.	 These	 mutations	 result	 in	
increased	 lysyl-phosphatidylglycerol	 content	 in	 the	 membrane.	 The	 mechanism	 by	 which	 this	
reduces	daptomycin	susceptibility	is	unclear	but	proposed	to	either	repel	the	antibiotic	or	stabilize	
the	membrane28,131–133.	An	additional	route	to	the	DNS	phenotype	is	via	mutations	that	result	 in	
increased	 expression	of	 the	dlt	 operon,	which	 results	 in	 the	 addition	of	D-alanine	 esters	 to	 the	
teichoic	 acids	 of	 the	 cell	 wall134.	 As	 for	 mprF	 mutations,	 it	 is	 not	 clear	 how	 this	 decreases	
susceptibility	 but	 it	 may	 involve	 repulsion	 of	 daptomycin	 by	 the	 positively-charged	 teichoic	
acids28,126,130–132.	 In	addition,	DNS	strains	exhibit	changes	 in	the	cytoplasmic	membrane,	cell	wall	
stress	stimulon	and	altered	membrane	potential,	all	of	which	have	been	hypothesized	to	reduce	
the	 ability	 of	 daptomycin	 to	 depolarize	 the	 membrane134,135.	 However,	 to	 date,	 no	 dedicated	
daptomycin	resistance	mechanism	has	been	identified	in	S.	aureus136.		
Although	the	DNS	phenotype	is	rare,	daptomycin	treatment	failure	occurs	in	up	to	30	%	of	
staphylococcal	 infections	 including	 cSSTI,	 right-sided	 infective	 endocarditis	 and	 osteomyelitis136.	
Since	 this	 is	 a	 drug	 of	 last	 resort	 for	 treating	 infections	 caused	 by	MRSA	 and	 VISA,	 treatment	
failure	results	in	a	poor	prognosis.		
1.4.5 New	anti-MRSA	Antibiotics	
Whilst	daptomycin	is	the	most	recently-licensed	new	class	of	antibiotic,	variants	of	several	existing	
classes	 have	 been	 developed	 to	 combat	 MRSA,	 including	 linezolid,	 tigecycline	 and	 ceftaroline.	
However,	as	for	every	other	antibiotic	used	to	date,	S.	aureus	has	acquired	resistance	these	drugs,	
albeit	sporadically14,137,138.					
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Figure	1.4.	Daptomycin	mode	of	action	
Calcium	 enables	 the	 negatively	 charged	 daptomycin	 to	 bind	 to	 the	 negatively	 charged	
phosphatidylglycerol	 and	 insert	 into	 the	 cell	 membrane	 of	 Gram-positive	 bacteria.	 Each	
daptomycin	 molecule	 binds	 to	 two	 calcium	 ions	 in	 successive	 steps	 during	 this	 binding	 and	
insertion	 process139.	 After	 insertion,	 the	 daptomycin-calcium	 complexes	 oligomerise	 in	 the	
membrane,	which	is	necessary	for	bactericidal	activity.	This	leads	to	changes	in	membrane	fluidity,	
formation	of	membrane	blebs	and	 is	 thought	to	 induce	the	formation	of	pores	consisting	of	6-8	
daptomycin	molecules,	 which	 in	 turn	 results	 in	 potassium	 ion	 efflux,	membrane	 depolarization	
and	bacterial	cell	death132.		
		 39	
1.5 S.	 aureus	 virulence	 factors	 and	 the	 accessory	 gene	 regulator	 (Agr)	 quorum-
sensing	system	
The	ability	of	S.	aureus	 to	both	colonize	and	establish	a	wide	range	of	 infections	makes	it	a	very	
versatile	pathogen3.	This	versatility	is	attributed	to	its	production	of	numerous	different	virulence	
factors,	 the	 expression	 of	 which	 are	 coordinated	 by	 a	 quorum-sensing	 system	 known	 as	 the	
Accessory	 gene	 regulator	 (Agr)140–142.	 It	 was	 first	 identified	 via	 a	 transposon	 screen,	 when	 a	
mutant	with	a	 transposon	 inserted	between	 the	purB	and	 ilv	 genes,	was	 found	 to	be	unable	 to	
produce	 toxins	 such	 as	 α-	 toxin	 (Hla),	 β-	 toxin	 (Hlb),	 γ-	 toxin	 (Hlg),	 toxic	 shock	 syndrome	 toxin	
(TSST-1),	 but	 had	 strong	 production	 of	 Staphylococcal	 protein	A	 (SpA)	when	 compared	 to	wild-
type	S.	aureus143.	
Soon	 after	 this,	 Peng	 et.	 al.	 (1988)	 characterised	 the	 Agr	 quorum-sensing	 system	 by	
identifying	 agrA,	which	 is	 the	 response	 regulator	 of	 the	 agr	 operon144.	 Thereafter,	 Janzon	 and	
Arvidson,	 (1990)	and	Novick	et	al.	 (1993)	 identified	genes	 that	are	 regulated	by	 the	agr	 operon	
including	 the	 hld	 gene	 which	 is	 embedded	 within	 the	 regulatory	 RNA	 component	 of	 the	 agr	
operon	 known	 as	 RNAIII	 and	 is	 the	 primary	 effector	 molecule	 of	 the	 Agr	 quorum-sensing	
system145,146.	Finally,	Ji	et.	al.,	(1995)	showed	that	the	agr	operon	is	activated	by,	and	regulates	the	
expression	of	virulence	factors,	high	cell-density,	which	led	to	an	increase	in	the	concentration	of	
the	Agr-regulated	auto-inducing	peptide	(AIP)	signaling	molecule,	 in	turn	demonstrating	that	Agr	
functions	as	a	quorum-sensing	system147.	
Together,	 the	 studies	 described	 above	 revealed	 that	 the	 Agr	 quorum-sensing	 system	 is	
encoded	by	the	agr	operon,	which	consists	of	two-divergent	promoters,	P2	and	P3	that	transcribe	
RNAII	 and	 RNAIII	 respectively	 (Fig	 1.5).	 RNAII	 encodes	 the	 quorum-sensing	 system	 and	 RNAIII	
comprises	 a	 regulatory	 RNA	 molecule,	 which	 is	 the	 primary	 effector	 of	 the	 system,	 and	 also	
encodes	 the	 δ-toxin	 (Hld)	 RNAIII142,148.	 The	 P2	 promoter	 drives	 the	 transcription	 of	 a	 4-gene	
operon	comprised	of	agrB,	agrD,	agrC	and	agrA	to	generate	the	RNAII	transcript,	which	encodes	
the	quorum-sensing	system142.		
The	P2	products	AgrD	and	AgrB	are	responsible	for	the	production	of	the	quorum-sensing	
signaling	 molecule,	 known	 as	 auto-inducing	 peptide	 (AIP).	 AgrD	 encodes	 a	 pro-peptide	 that	
contains	 a	 N-terminal	 amphipatic	 leader	 sequence	 that	 directs	 it	 to	 AgrB,	 which	 is	 a	
transmembrane	 bound	 endopeptidase	 protein	 (Fig	 1.5).	 The	 type	 I	 signal	 peptidase	 SpsB	 along	
with	 AgrB	 cleaves	 the	 N-terminal	 of	 the	 propeptide	 and	 the	 C-terminal	 of	 the	 propeptide	
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respectively.	AgrB	 then	processes	 the	peptide	by	generating	a	 thiolactone	 ring	and	secretes	 the	
matured	AIP	molecule	in	the	extracellular	milieu147,149–153	(Fig	1.5).	
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divergent promoters, P2 and P3; P2 comprises a 4-gene operon (agrBDCA) encoding the 
quorum-sensing circuit, which regulates expression of the regulatory RNA molecule 
(effector molecule) RNAIII from P3 [27] (Figure 1). 
 
Expression of RNAIII leads to the production of cytolytic toxins (e.g. α-haemolysin, δ-
haemolysin), leukocidins (e.g. Panton-Valentine leukocidin) and decreased surface protein 
(e.g. staphylococcal protein A and fibronectin-binding proteins A and B) expression. In 
addition, AgrA directly regulates expression of the Phenol soluble modulin class of 
cytolytic toxins, and >80 genes involved in metabolism [30–32].  
The transmembrane P2 product AgrB is required for processing of the propeptide 
AgrD to produce the quorum signal molecule, autoinducing peptide (AIP). The AIP 
molecule functions as a specific ligand for the corresponding sensor kinase AgrC. AgrC 
possesses an extracellular N-terminal domain and seven transmembrane domains. 
Binding of AIP induces a conformational change within the cytoplasmic helix that links the 
sensor and kinase domains of AgrC, enabling autophosphorylation. Together, AgrC and 
AgrA comprise a classical two component signal transduction system, where ligand bound 
AgrC phosphorylates and activates the DNA-binding response regulator AgrA [27]. 
Activated AgrA dimers bind to the agr intergenic region (agr-IR) between P2 and P3 and 
trigger expression from these promoters [27]. 
The agr operon is regulated by numerous other global regulators, which converge 
at the P2 and P3 promoters, enabling S. aureus to respond to specific extracellular 
	
	
	
Figure	1.5.	Accessory	gene	 regulatory	quorum	sensing	 system	 regulates	 toxin	production	 in	S.	
aureus		
The	Agr	 operon	 controls	 the	 cell	 density-dependent	 virulence	 factor	 expression	 in	 S.	 aureus.	 In	
brief,	the	P2	promoter	encodes	the	production	of	the	signaling	molecule	AIP.	As	the	cell	density	
increases,	the	signaling	peptide	activates	the	AgrC-AgrA	two	component	signaling	system,	where	
the	 ligand	 bound	 AgrC	 phosphorylates	 and	 activat s	 the	 DNA-binding	 response	 regulator	 AgrA.	
Activated	AgrA	dimers	bind	to	the	agr	 intergenic	region	(agr-IR)	and	triggers	expression	from	P2	
and	 P3	 promoters.	 	 Expression	 of	 RNAIII	 leads	 to	 the	 production	 of	 cytolytic	 toxins	 (e.g.	 α-
haemolysin,	δ-	haemolysin),	leukocidins	(e.g.	Panton-Valentine	leukocidin)	and	decreased	surface	
protein	 (e.g.	 staphylococcal	 protein	 A	 and	 fibronectin-binding	 proteins	 A	 and	 B)	 expression.	 In	
addition,	AgrA	directly	regulates	expression	of	the	Phenol	soluble	modulin	(PSM)	class	of	cytolytic	
toxins,	and	>80	genes	involved	in	metabolism.	
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AIP	is	a	7-9	amino	acid	cyclic	peptide	that	contains	a	central	5-amino	acid	thiolactone	ring	
formed	between	 the	 cysteine	 amino	acid	 and	 carboxyl	 group149.	 	 The	N-terminal	 tail	 of	 the	AIP	
molecule	 subsequently	binds	 to	and	activates	 the	histidine-kinase	of	 the	 transmembrane	bound	
AgrC142,148,149.	 AgrC	 possesses	 an	 extracellular	 N-terminal	 domain	 and	 seven	 transmembrane	
domains.	 Binding	 of	 AIP	 to	 the	 second-transmembrane	 loop	 induces	 a	 conformational	 change	
within	 the	 cytoplasmic	helix	 that	 links	 the	 sensor	 and	kinase	domains	of	AgrC.	 This	 enables	 the	
autophosphorylation	 of	 the	 histidine	 residue	 within	 the	 histidine-kinase	 domain	 of	 AgrC154,155.	
Subsequently,	 this	autophosphorylation	enables	 the	activation	and	dimerization	of	 the	 response	
regulator	 AgrA	 by	 the	 transfer	 of	 its	 phosphate	 group	 to	 the	 conserved	 aspartate	 amino	 acid	
residue	 on	 AgrA148,154–157.	 	 AgrA	 is	 a	 member	 of	 the	 LytTR	 family	 of	 DNA-binding	 transcription	
factors.	Upon	activation	by	AgrC,	AgrA	binds	to	the	agr-intergenic	region	(IR)	that	lies	between	the	
P2	and	P3	promoter	region	of	the	agr	operon	and	further	drives	the	transcription	of	both	P2	and	
P3,	thereby	completing	the	auto-activation	circuit148,158–162.	
During	early	exponential	phase,	when	the	cell	density	is	low,	a	basal	level	of	expression	of	
the	Agr	quorum-sensing	system	is	maintained	by	the	binding	of	SarA	to	the	agr-IR163,164.	However,	
during	late	exponential/early	stationary	phase,	when	the	cell	density	is	high,	the	production	of	AIP	
increases,	with	a	corresponding	increase	in	phosphorylated	AgrA	within	staphylococcal	cells.	The	
phosphorylated	 AgrA	 binds	 to	 the	 agr-IR,	 driving	 increased	 transcription	 of	 agr,	 leading	 to	 an	
exponential	 increase	 in	 Agr	 activity165.	 In	 addition	 to	 driving	 the	 quorum-sensing	 circuit,	 the	
binding	 of	 phosphorylated	 AgrA	 to	 the	 agr-IR	 drives	 transcription	 from	 the	 agr-P3	 promoter,	
which	 leads	 to	 the	 production	 of	 the	 regulatory	 RNA	 molecule	 RNAIII,	 which	 also	 encodes	 δ-
toxin142,146,162.	
The	 RNAIII	 transcript	 is	 514	 nucleotides	 in	 length	 and	 contains	 14	 hairpins,	 and	 3	 other	
domains	 that	 enable	 it	 to	 function	 as	 both	 a	 post-translational	 activator	 and	 repressor	 of	
numerous	genes142,166.	The	half-life	of	RNAIII	 is	approximately	45	minutes	and	within	that	time	it	
positively	or	negatively	regulates	the	expression	of	its	target	genes	by	either	masking	or	revealing	
their	ribosome-binding	sites	(RBS)	8	bases	upstream	of	the	start	codon	(AUG)	of	the	target	mRNAs,	
that	 are	 required	 to	 initiate	 translation146,166,167.	 For	 example,	 the	 production	 of	 α-haemolysin	
(Hla)	is	dependent	upon	the	binding	of	the	5’	region	of	RNAIII	to	the	hla	mRNA,	which	relieves	a	
hairpin	 structure	 that	 contains	 the	 hla	 RBS,	 enabling	 engagement	 with	 the	 ribosome146,166,167.	
RNAIII	can	also	regulate	expression	indirectly.	For	example,	the	repressor	of	toxins	(rot)	transcript,	
is	degraded	by	the	RNAIII	coordinated	activity	of	RNase	III,	preventing	translation166–171.	
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The	onset	of	RNAIII	expression	marks	a	major	switch	in	the	virulence	profile	of	S.	aureus,	
from	the	expression	of	cell	surface	proteins	that	are	essential	for	adhering	to	the	host	cells,	to	the	
production	 of	 cytolytic	 toxins	 that	 are	 required	 to	 release	 nutrients	 and	 destroy	 host	 immune	
cells.	 However,	 although	 RNAIII	 is	 the	 principal	 effector	molecule	 of	 the	 Agr	 system,	 AgrA	 also	
contributes	to	the	phenotype	of	the	cell	by	directly	triggering	the	expression	of	a	small	group	of	
cytolytic	 toxins	 known	 as	 the	 phenol	 soluble	 modulins	 (PSMs)	 by	 binding	 to	 their	 promoter	
regions.	 Phosphorylated	 AgrA	 also	 reduces	 the	 expression	 of	 numerous	 genes	 associated	 with	
carbohydrate	and	amino	acid	biosynthesis158.	
Further	complexity	in	the	Agr	system	arises	from	variation	in	the	hypervariable	region	that	
spans	agrBDC,	resulting	in	4	allelic	variants	across	S.	aureus	strains172,173	referred	to	as	agr-types	I-
IV.	 Each	 type	 produces	 a	 different	 AIP	 molecule	 (AIP1-4)172.	 Depending	 on	 the	 combination,	
mismatched	 AIP	 and	 AgrC	 types	 can	 result	 in	 inhibition	 of	 Agr	 activity	 or	 only	 weak	
activation167,172.	 This	 is	because	binding	of	 the	 cognate	AIP	 to	AgrC	 induces	a	 counter-clockwise	
twist	 in	 the	 helical	 linker	 region	 of	 the	 AgrC	 histidine-kinase	 domain,	 whereas	 binding	 of	 the	
heterologous	AIP	to	AgrC	induces	a	clockwise	twist	 in	the	AgrC	linker	region,	which	prevents	the	
auto-phosphorylation	of	AgrC	and	activation	of	the	agr-operon157.	This	heterologous	AIP-mediated	
inhibition	of	the	agr	operon	is	known	as	agr-interference167,172.	
The	 regulation	 of	 virulence	 factor	 expression	 via	 a	 quorum-sensing	 system	 enables	 S.	
aureus	to	produce	the	required	virulence	factors	at	the	optimal	point	in	infection,	and	across	the	
whole	population.	This	 is	 important	because	 the	production	of	virulence	 factors	 is	metabolically	
costly	and	may	be	counter-productive	if	toxins	or	proteases	are	produced	at	inappropriate	stages	
of	 infection	or	 in	a	heterogeneous	manner.	For	example,	during	 the	earliest	 stages	of	 infection,	
when	there	are	few	S.	aureus	cells,	and	Agr	activity	 is	 low,	surface	proteins	are	produced.	These	
enable	 bacterial	 adhesion	 to	 host	 surfaces	 or	 indwelling	 medical	 devices,	 and	 support	 biofilm	
formation.	 Some	 of	 these	 surface	 proteins,	 such	 as	 protein	 A,	 also	 enable	 evasion	 of	 the	 host	
immune	response174,49.	However,	once	colonization	 is	established,	the	staphylococcal	population	
starts	to	replicate,	leading	to	an	increase	in	cell	density	and	Agr	activity175.	This	results	in	the	loss	
of	 surface	 proteins	 and	 the	 expression	 of	 toxins	 and	 proteases	 that	 liberate	 nutrients	 from	 the	
host,	 enable	biofilm	dispersal,	 tissue	 spread	and	 the	production	of	 leukocidins	 that	 kill	 immune	
cells142,167,176,177,178,179.		
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Whilst	 quorum-sensing	 systems	 primarily	 reflect	 population	 density,	 Agr	 also	 enables	 S.	
aureus	to	detect	enclosure	within	the	phagosome	of	neutrophils	or	other	immune	cells	by	acting	
as	a	diffusion	sensing	system180,181.	Once	within	a	phagocytic	vacuole,	Agr	expression	is	activated	
by	 an	 increase	 in	 the	 intracellular	 levels	 of	 AIP182,183–187.	 Although	 the	 production	 of	 reactive	
oxygen	species	(ROS)	by	nicotinamide	adenine	dinucleotide	phosphate	(NADPH)	oxidase	interferes	
with	the	activity	of	Agr	in	neutrophils,	overall	there	is	a	net	increase	in	Agr	expression180,182,188,189.	
With	an	intact	and	active	Agr	quorum-sensing	system,	S.	aureus	is	able	to	produce	AgrA	regulated	
PSMs,	 Luk	 AB/GH	 and	 LukED	 toxins178,190–193.	 In	 addition,	 due	 to	 nutrient	 limitation	 within	 a	
phagosome	 the	 stringent	 response	 is	 trigerred,	which	 then	 leads	 to	 the	 expression	 of	 PSMs192.	
These	 toxins	 lyse	 the	 neutrophils,	 which	 then	 enables	 S.	 aureus	 to	 escape.	 However,	 the	
mechanism	by	which	these	toxins	lyse	the	neutrophils	from	inside	is	yet	unknown.	There	are	two	
proposed	 hypothesis,	 (i)	 bacteria	 lyse	 the	 phagosome	 and	 then	 lyse	 the	 cell193	 and	 (ii)	 the	
production	of	toxins	induces	programmed	cell	death	of	the	neutrophil194.		
The	 contribution	 of	 Agr	 quorum-sensing	 to	 pathogenesis	 and	 the	 establishment,	 and	
progression	 of	 various	S.	 aureus	 infections,	 including	 SSTIs,	 bacteremia,	 IE,	 osteomyelitis,	 septic	
arthritis,	 abscess	 formation	 and	 pneumonia	 has	 been	 demonstrated	 in	 several	 in	 vivo	 animal	
infection	models164,195–201	(as	will	be	described	in	section	1.7	and	table	1.1).	
1.5.1 Regulation	of	the	Agr	system	by	other	transcription	factors	
Whilst	Agr	enables	S.	aureus	 to	 regulate	virulence	 factor	production	 in	a	cell	density	dependent	
manner142,	the	system	is	fine-tuned	via	regulatory	control	by	several	two-component	systems	that	
detect	and	 respond	 to	diverse	environmental	 stimuli142,167,202–204.	 These	 regulators	 can	 influence	
Agr	 either	 by	 binding	 directly	 to	 the	 agr-IR	 or	 indirectly	 by	 modulating	 the	 activity	 of	 other	
regulators	do	bind	directly	to	the	agr-IR202–204.	To	date,	the	global	regulators	CodY,	SrrA,	SarX	and	
SarR	have	been	shown	to	bind	directly	to	the	agr-IR	and	repress	the	expression	of	the	agr	operon	
whereas,	 Rsp,	 SarA,	 MgrA	 and	 SarZ	 bind	 directly	 to	 the	 agr-IR	 and	 activate	 agr	 transcription.	
However,	 several	 of	 these	 regulators	 also	 modulate	 the	 staphylococcal	 phenotype	 by	 directly	
regulating	 other	 genes.	 For	 example,	 Rsp	 is	 a	 highly	 conserved	 AraC-family	 DNA	 binding	
transcription	factor.	It	is	involved	in	regulating	the	expression	of	the	agr	operon	by	directly	binding	
to	the	agr-IR	and	recent	studies	have	shown	that	 loss	of	Rsp	function	results	 in	the	reduction	of	
the	agr	expression205,206.	However,	Rsp	is	also	involved	in	inhibiting	the	attachment	and	formation	
of	biofilms	by	directly	 repressing	expression	of	 the	 fibronectin	binding-protein-A	gene	 (fnbA)207,	
highlighting	the	regulatory	complexity	found	in	S.	aureus.	
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Indirect	Agr	regulators	include	SigB,	PSM-mec,	SarT,	MsA,	MsR,	Rsr,	AcnA,	RpiRC	and	CshA,	
which	 repress	Agr	activity,	whilst	 SarU,	 SarV,	ArlR,	CcpA,	ClpXP	and	CvfA	 indirectly	enhance	agr	
transcription202–204.	 This	 complex,	multi-layered	 regulatory	 network	 enables	 S.	 aureus	 to	 detect	
myriad	environmental	cues	and	respond	accordingly	by	altering	virulence	factor	production.		
	
1.6 Cell-surface	associated	virulence	factors	
S.	 aureus	 expresses	 20	 different	 surface	 proteins,	 which	 are	 typically	 secreted	 by	 the	 Sec	
translocon	and	covalently	linked	to	the	peptidoglycan	cell	wall	by	the	sortase	enzyme	that	cleaves	
and	 anchors	 the	 proteins	 via	 the	 LPXTG	motif49,208–211	 (Fig	 1.6).	 Several	 belong	 to	 the	microbial	
surface	components	recognizing	adhesive	matrix	molecules	(MSCRAMM)	family	of	proteins212,213.	
However,	 although	 the	S.	 aureus	 cell-surface	MSCRAMM	proteins	 are	 tethered	 to	 the	 cell	wall,	
several	other	adhesins	are	decorated	on	and/or	secreted	from	the	cell	surface	and	are	termed	as	
secreted	 expanded	 repertoire	 adhesive	 molecules	 (SERAM).	 Examples	 from	 the	 SERAM	 family	
include	extracellular	fibrinogen	binding	(Efb),	extracellular	matrix	binding	(Emb)	and	extracellular	
adhesive	 protein	 (Eap)	 212,213.	 The	 primary	 function	 of	 these	 cell-surface	 proteins	 is	 to	 promote	
adhesion	to	host	proteins	and	tissues49,209,210	and	thereby	enable	S.	aureus	to	colonize	host	tissues	
or	abiotic	surfaces	such	as	the	nares,	skin,	prosthetic	joints,	IV	catheters	or	sutures.	Many	of	these	
surface	proteins	are	multi-functional,	binding	to	multiple	 ligands	and/or	contributing	to	 immune	
evasion	 (as	 described	 in	 section	 1.6.1)	 and/or	 biofilm	 formation,	 which	 is	 associated	 with	
persistent	 infections49.	 A	 good	 example	 of	 this	 are	 the	 fibronectin-binding	 proteins	 A	 and	 B	
(FnBPA/B),	which	mediate	adhesion	of	S.	aureus	to	fibronectin,	fibrinogen	and	elastin,	some	or	all	
of	 which	 are	 exposed	 in	 surgical	 wounds,	 coat	 implanted	 medical	 devices	 and	 line	 the	
endothelium214–218,219,220.	 The	 engagement	 of	 fibronectin	 on	 host	 cell	 surfaces	 by	 FnBPA	 and/or	
FnBPB	 results	 in	 the	 clustering	 of	 α5β1	 integrins,	 triggering	 a	 signaling	 cascade,	 actin	
rearrangement	 and	 uptake	 of	 the	 bacterium	 into	 a	 vacuole219,221.	 Once	 inside	 the	 host	 cell,	 S.	
aureus	 can	 persist,	 protected	 from	 antibiotics	 and	 immune	 surveillance222–228.	 	 Alternatively,	 S.	
aureus	releases	cytolytic	toxins	via	Agr	activation,	leading	to	apoptosis	and	death	of	the	host	cell,	
which	 may	 contribute	 to	 bacterial	 dissemination	 216,229,222,223,230.	 For	 staphylococci	 attached	 to	
abiotic	 surfaces,	 FnBPA	 and	 FnBPB	 can	 also	 promote	 biofilm	 formation	 by	 mediating	 cell-cell	
adhesion231,232,49.	
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Figure	1.6.	S.	aureus	cell	surface	proteins	and	their	host	target	binding	sites	
These	 cell	 surface	 proteins	 are	 involved	 in	 establishing	 infection	 by	 mediating	 adhesion,	
colonization	and/or	immune	evasion.	
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Biofilm	formation	in	S.	aureus	can	occur	via	surface	proteins	or	polysaccharides,	depending	
on	the	strains	 involved	and	the	environmental	conditions.	Usually,	MRSA	strains	depend	on	cell-
surface	 associated	 proteins	 including	 biofilm-associated	 protein	 (Bap),	 clumping	 factor	 B	 (ClfB),	
FnBPs,	S.	aureus	surface	protein	C	(SasC),	S.	aureus	surface	protein	G	(SasG)	and/or	SpA	to	form	
biofilms49.	The	SasG	cell-surface	protein	contains	specific	protein	domains	termed	as	G5-E	which	
have	conserved	protein	sequences	and	tertiary	structure,	which	form	functional	units49,233.	 	SasG	
dependent	biofilm	formation	occurs	when	the	G5-E	repeats	of	SasG	on	adjacent	cells	twist	around	
each	 other	 in	 a	 zinc	 dependent	 manner	 to	 promote	 cell-to-cell	 aggregation49.	 In	 addition,	 as	
mentioned	before,	FnBPs,	SpA	and	SasC	can	also	mediate	biofilm	formation	by	promoting	the	cell-
to-cell	accumulation	by	binding	to	other	ligands	on	adjacent	cells	or	by	homophilic	protein-protein	
interactions49,231,232,234,235.		
The	primary	attachment	of	S.	aureus	to	biomaterials	is	promoted	by	cell-surface	proteins,	
which	attach	to	surfaces	that	have	been	conditioned	with,	for	example	host	plasma	or	attach	to	
unconditioned	 surfaces	 by	 releasing	 autolysins	 and	 coating	 the	 surface	 with	 extracellular	
DNA49,236.	
Besides	cell-surface	protein	dependent	biofilm	formation,	the	carbohydrate	polysaccharide	
intercellular	adhesin	(PIA)	can	also	contribute	to	biofilm	formation237,238.	The	precise	involvement	
of	each	of	these	factors	in	biofilm	appears	to	be	environment	dependent,	since	media-containing	
glucose	promotes	proteinaceous	biofilms,	whilst	 salt	 stress	 leads	 to	biofilms	containing	PIA.	The	
polysaccharide	PIA	is	positively	charged,	which	then	enables	S.	aureus	to	adhere	to	inert	surfaces	
237,238,239.		
In	addition	 to	 infection,	 several	 surface	proteins	are	also	 required	 for	nasal	 colonization,	
including	 ClfB,	 SasG,	 iron-regulated	 surface	 determinant	 A	 (IsdA),	 serine-aspartate	 repeat-
containing	 protein	 E	 (SdrE),	 as	 well	 as	 wall-teichoic	 acid	 (WTA)240–243.	 IsdA	 not	 only	 adheres	 to	
epithelial	cells,	it	also	binds	to	haemoglobin,	extracts	and	transports	haem	across	the	cell	wall	and	
membrane	and	then	into	the	cytoplasm	where	haemoxygenases	releases	the	iron49,244,245.	
In	 addition	 to	 mediating	 bacterial	 adhesion,	 several	 surface	 proteins	 also	 contribute	 to	
immune	evasion.	For	example,	the	cell-surface	associated	protein	SdrE	is	an	isoform	of	the	bone-
sialoprotein-binding	protein	(Bbp).	Bbp	adheres	to	the	extracellular	matrix	by	binding	to	the	host	
fibrinogen	α-chain,	whereas	SdrE	binds	to	the	C4b	binding	protein	and	complement	Factor	H	and	
prevent	the	activation	of	the	complement	system246	by	promoting	the	degradation	of	C3b	of	the	
complement	 system49,247,248.	 During	 S.	 aureus	 infection	 fibrinogen	 is	 deposited	 at	 the	 site	 of	
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infection	to	immobilize	the	microbes.	The	cell-surface	associated	protein	ClfA	evades	this	immune	
response	 by	 binding	 to	 soluble	 fibrinogen,	which	 results	 in	 platelet	 aggregation	 or	 clumping	 of	
bacteria	in	plasma49,249–251.	ClfA	also	promotes	the	degradation	of	C3b	of	the	complement	system	
by	binding	to	complement	factor	I49,248,252.	Furthermore,	previous	studies	have	reported	that	ClfA	
contributes	to	endocarditis,	septic	death,	survival	in	the	blood	and	kidney	abscess	by	adhering	to	
thrombin,	disrupting	complement	activation	and	 thereby	 reducing	 the	opsonophagocytosis	of	S.	
aureus253,49,254.	 Therefore	 both	 ClfA	 and	 SdrE	 contribute	 to	 immune	 evasion	 by	 disrupting	
complement	activation.	
In	addition	 to	 the	multi-functional	nature	of	many	surface	proteins,	 there	 is	also	a	 lot	of	
functional	 redundancy	 with	 several	 different	 proteins	 binding	 to	 the	 same	 host	 proteins	 or	
contributing	 to	 the	same	function	 (Fig	1.6).	For	example,	both	FnBPs	and	ClfA/B	bind	 fibrinogen	
enabling	 the	 colonization	 of	 wounds	 and	 cardiac	 vegetations,	 leading	 to	 SSTIs	 and	 infective	
endocarditis	respectively216,229.	Fibrinogen	is	also	bound	by	the	secreted	adhesin	Eap,	which	also	
binds	 fibronectin,	 vitronectin,	 prothrombin	 and	 ICAM-1211.	 Eap	 also	 triggers	 TNFα	 release	 from	
immune	cells,	which,	 in	turn,	enhances	the	adhesion	of	S.	aureus	 to	endothelial	cells	via	the	cell	
surface	associate	protein	SpA255.	
By	 contrast	 to	 fibrinogen,	 S.	 aureus	 encodes	 a	 single	 cell-surface	 protein	 that	 binds	
collagen-rich	tissue,	known	as	the	collagen	adhesin	(Cna),	which	was	associated	with	virulence	in	a	
murine	 model	 of	 septic	 arthritis	 infection256–258.	 Cna	 also	 contributes	 to	 immune	 evasion	 by	
binding	to	the	collagenous	domain	of	 the	complement	protein	C1q,	which	prevents	the	classical	
pathway	of	complement	activation	by	interfering	with	the	interaction	of	C1q	with	C1r49,259.		
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1.6.1 Immune	evasins	
Despite	neutrophils	playing	a	key	role	in	protecting	humans	against	S.	aureus	infection,	S.	aureus	is	
still	able	to	cause	diseases	in	immune-competent	individuals260.	S.	aureus	is	able	to	achieve	this	by	
employing	a	huge	range	of	immune-evasive	strategies	that	include	disruption	of	the	complement	
system,	 prevention	 of	 phagocytosis	 and	 neutrophil	 killing.	 During	 invasion	 and	 replication	 of	 S.	
aureus	 in	 host	 tissues,	 the	 bacteria	 release	 products	 including	 lipoproteins,	 peptidoglycan	 and	
formyl-peptides	 that	 act	 to	 produce	 inflamatory	 signals	 (chemoattractants	 and	 cytokines)	 and	
recruit	 immune	cells186,260.	However,	S.	aureus	subverts	neutrophil	extravasation	and	chemotaxis	
by	 secreting	 staphylococcal	 superantigen-like	 proteins	 (SSL)	 which	 bind	 to	 various	 neutrophil	
receptors	and	disrupt	their	function260.	For	example,	SSL3	binds	to	TLR-2	and	blocks	immune	cell	
recognition	 of	 S.	 aureus	 lipoproteins261,262.	 In	 addition,	 formyl-peptide	 receptor-like	 1	 inhibitor	
(FLIPr)	 and	 formyl-peptide	 receptor-like	 1	 inhibitor-like	 (FLIPrL)	 bind	 and	 inhibit	 the	 neutrophil	
Formyl-Peptide	 Receptor-1	 (FPR1)	 and	 FPR2263.	 The	 chemotaxis	 inhibitory	 protein	 of	
staphylococcus	(CHIPS)	 inhibits	the	complemenent	receptor	C5aR	and	neutrophil	receptors	FPR1	
and	FPR2264.	In	addition,	the	secreted	staphopain	(ScpA)	molecule	blocks	the	neutrophil	receptor	
chemokine-receptor	C-X-C	chemokine	receptor	(CXCR2)265.	
Complement	 activation	 and	 phagocytosis	 is	 a	 central	 component	 of	 the	 innate	 host	
defence	 system.	 Complement	 is	 composed	 of	 >30	 proteins	 and	 is	 activated	 by	 three	 pathways	
including	classical,	lectin	and	alternative	pathway.	All	the	three	routes	converge	in	the	assembly	of	
the	 C3	 convertase	which	 cleaves	 C3	 into	 C3a	 and	C3b266.	 C3b	 covalently	 binds	 to	 the	S.	 aureus	
surface	and	C3a	is	released	as	a	chemoattractant	for	phagocytes.	This	deposition	of	complement	
components	 on	 the	 surface	 of	 S.	 aureus	 is	 known	 as	 opsonisation	 and	 is	 required	 to	 promote	
recognition,	 phagocytosis	 and	 subsequent	 killing	 by	 host	 phagocytes260,266.	 S.	 aureus	 is	 able	 to	
block	 this	 by	 secreting	 inhibitory	 factors	 that	 interfere	 with	 the	 opsonisation	 of	 bacteria.	 For	
example,	 SSL10	 sequesters	 immunoglobulins	 to	 block	 their	 ability	 to	 promote	 complement	
activation	 i.e.	 SSL10	blocks	 IgG1	 from	binding	 to	 Fcγ	 receptor	of	 professional	 phagocytes	which	
results	 in	 the	 inhibition	 of	 phagocytosis	 of	 IgG1-opsonised	 S.	 aureus	 by	 immune	 cells	 267,268.	
Meanwhile,	 the	 Staphylococcal	 binder	 of	 immunoglobulin	 (Sbi)	 blocks	 the	 complement	 classical	
pathway	 activation	 by	 interfereing	 with	 C1q	 binding	 to	 immunoglobulin	 and	 thus	 evading	
opsonophagocytosis269,270.	 Staphylococcal	 complement	 inhibitor	 (SCIN)	 blocks	 all	 three	
complement	 pathways	 by	 stabilizing	 C3	 convertase	 and	 thus	 preventing	 opsonisation271.	 Other	
molecules	also	contribute	to	immune	evasion.	For	example,	the	extracellular	complement-binding	
protein	(Ecb)	and	Efb	inhibit	C3	convertases,	whilst	aureolysin	(Aur)	cleaves	the	complement	
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factor	 C3,	 which	 compromises	 opsonisation	 because	 the	 cleavage	 product	 C3b’	 and	 C3a’	 are	
inactive	 and	 are	 degraded	 by	 host	 proteins272–274.	 S.	 aureus	 is	 also	 able	 to	 inactivate	 the	
complement	factor	C3b	and	IgG	molecules	that	are	bound	to	the	surface	of	opsonised	cells	that	
are	 coated	 with	 host	 plasminogen	 by	 secreting	 staphylokinase	 (SAK)	 which	 activates	 the	
plasminogen.	The	activated	plasmin	then	cleaves	the	surface	associated	C3b	and	IgG,	which	results	
in	reduced	phagocytosis	by	neutrophils275,276.	
In	addition	to	binding	to	the	von	Willebrand	factor,	the	cell-surface	associated	protein	SpA	
also	binds	to	the	conserved	Fc	region	of	the	human	immunoglobulin	(IgG).	This	binding	promotes	
immune	 evasion	 by	 not	 eliciting	 the	 adaptive	 immune	 response	 as	 the	 binding	 prevents	
opsonisation	 and	 phagocytosis	 of	 S.	 aureus	 277.	 Also,	 as	 mentioned	 previously	 cell-surface	
associated	proteins	 including	BbP	and	SdrE	evade	 the	 immune	 response	by	bind	 to	C4b	binding	
protein	and	Factor	H	and	prevent	the	activation	of	the	complement	system	246.		
Despite	 these	 myriad	 of	 immune	 evasion	 system,	 S.	 aureus	 is	 often	 phagocytosed	 by	
neutrophils,	 where	 it	 is	 killed	 and	 degraded	 by	 various	 toxic	 products	 including	 ROS	 such	 as	
hydrogen	 peroxide	 and	 superoxide,	 proteases	 and	 antimicrobial	 peptides186,260.	 However,	 S.	
aureus	 is	 able	 to	 resist	 neutrophil-killing	 by	 expressing	 several	 enzymes	 and	 inhibitors.	 For	
example,	 the	 S.	 aureus	 synthesised	 carotenoid	 pigment	 staphyloxanthin,	 along	 with	 catalase	
(KatG)	 and	 alkylhydroperoxide	 reductase	 (AhpC),	 provides	 resistance	 to	 ROS278,279.	 Similarly,	
superoxide	 dismutases	 (SodA	 and	 SodM)	 are	 antioxidants	 that	 protect	 against	 oxidative	 stress	
caused	 by	 superoxides280.	 S.	 aureus	 is	 also	 able	 to	 resist	 killing	 by	 antimicrobial	 peptides	 by	
secreting	 Aur	 which	 cleaves	 the	 peptides,	 and	 by	 modyfying	 phosphatidylglycerol	 in	 the	
membrane	 with	 lysine,	 or	 promoting	 the	 D-alanylation	 of	 teichoic	 acids,	 which	 neutralizes	 the	
negative	charge	of	the	cell	surface	that	attracts	cationic	antimicrobial	peptides26,260,281.	
Typically,	S.	aureus	invasion	of	host	tissues	triggers	the	infiltration	of	neutrophils	at	the	site	
of	 the	 lesion.	 This	 causes	 the	 neutrophils	 to	 release	 their	 DNA	 commonly	 known	 as	 NETs	
(neutrophil	 extracellular	 traps),	 which	 immobilize	 the	 pathogen	 for	 subsequent	 clearance	 by	
macrophage	phagocytosis	and	by	enhancing	the	bactericidal	activity	of	host	antimicrobial	peptides	
(which	are	a	part	of	the	NETs)260,282,283.	However,	S.	aureus	 is	able	to	evade	this	innate	immunity	
response	by	converting	NETs	to	deoxyadenosine,	which	triggers	the	caspase-3	mediated	death	of	
macrophages282,283.		
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One	of	the	most	 important	mechanisms	of	 immune	evasion	that	S.	aureus	deploys	 is	 the	
multifunctional	 surface	protein	known	as	SpA.	Because	SpA	binds	 to	 immunoglobulin	molecules	
including	 IgG,	 IgA,	 IgD,	 IgM	and	IgE	with	high	affinity	and	other	 ligands	 including	TNF	receptor	1	
(TNFR1)	 and	von	Willebrand	 factor	 (VWF),	 it	 is	 able	 to	display	a	number	of	 immunosuppressive	
traits260,284,285.	 In	 particular,	 SpA	 binds	 to	 the	 Fc	 fragment,	 which	 results	 in	 the	 bacteria	 being	
coated	with	 IgG	molecules	 that	 are	 bound	 in	 the	 incorrect	 orientation	 to	 be	 recognised	 by	 the	
neutrophil	Fc	receptor260,285,286.	This	interaction	between	SpA	and	IgG	also		prevents	the	activation	
of	the	complement	system	via	the	classical	pathway	which	leads	to	the	evasion	of	phagocytosis	by	
S.	aureus49,285.	 In	addition	 to	 innate	 immunity,	S.	aureus	 is	also	able	 to	manipulate	 the	adaptive	
immune	response,	since	SpA	is	a	B	cell	superantigen260,285,286,287.	
	
1.7 Secreted	virulence	factors		
In	 addition	 to	 expressing	numerous	 cell-surface	 associated	proteins,	S.	 aureus	 also	 produces	 an	
even	 greater	 number	 of	 different	 secreted	 virulence	 factors,	 including	 haemolysins,	 cytolysins,	
leukocidins,	 exfoliative	 toxins	 and	 superantigens,	 in	 addition	 to	 secreted	 lipases,	 proteases,	
nucleases	 and	 coagulase	 that	 lyse	 host	 cells,	 enable	 bacterial	 dissemination,	 degrade	 host	
macromolecules,	liberate	nutrients	and	dysregulate	the	immune	system		(Fig	1.7)287–289.		
As	 described	 in	 section	 1.5,	 the	 vast	 majority	 of	 these	 secreted	 virulence	 factors	 are	
regulated	 by	 RNAIII158.	 However,	 the	 precise	 array	 of	 toxins	 expressed	 and	 the	 quantities	
produced	 is	 typically	dependent	on	 the	 type	of	S.	aureus	 strain.	 For	example,	CA-MRSA	 isolates	
have	increased	expression	of	Agr	and	thus	elevated	levels	of	secreted	toxin	production	relative	to	
HA-MRSA	isolates	with	large	type	I-III	SCCmec	elements.	CA-MRSA	isolates	are	also	associated	with	
the	 expression	 of	 the	 Panton	 Valentine	 Leukocidin	 (PVL),	which	 is	 typically	 absent	 in	 HA-MRSA	
strains.	 These	 factors	 likely	 explain	 why	 CA-MRSA	 is	 associated	 with	 severe	 SSTIs	 in	 otherwise	
healthy	individuals290–295.	
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Figure	1.7.	S.	aureus	secreted	toxins	and	their	host	target	sites	
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1.7.1 α-haemolysin	
As	 described	 above	 for	 surface	 proteins,	 the	 secreted	 virulence	 factors	 of	 S.	 aureus	 are	 often	
multifunctional	or	exert	their	effects	on	multiple	targets.	This	is	exemplified	by	α-haemolysin	(Hla),	
which	 lyses	erythrocytes,	epithelial	 cells,	monocytes,	 lymphocytes,	macrophage	and	platelets296–
299.	The	diverse	target	range	of	Hla	explains	why	it	has	been	shown	to	contribute	to	virulence	in	
diverse	animal	 infection	models	of	SSTIs,	bacteremia,	pneumonia,	peritonitis	and	sepsis196,198,300–
305.	It	also	appears	likely	that	the	increased	expression	of	Hla	by	CA-MRSA	isolates	contributes	to	
the	increased	virulence	of	these	strains290–293.	
Hla	was	 identified	via	 the	 isolation	of	a	 transposon	mutant	 that	 lacked	the	ability	 to	 lyse	
red	blood	cells	when	grown	on	Colombia	blood	agar	containing	erythrocytes	from	rabbits306.	This	
toxin	 lyses	 rabbit	 erythrocytes	 at	 nM	 concentrations	 and	 human	 erythrocytes	 at	 μM	
concentrations	of	protein296,307,308.	Hla	exists	as	a	33	kDa	monomer,	until	it	binds	to	the	membrane	
of	 specific	 host	 cells,	 at	 which	 point	 it	 oligomerises	 and	 forms	 a	 14	 Å	 beta-barrel	 heptameric	
pore307,309.	 This	 pore	 disrupts	membrane	 organization,	 leading	 to	 potassium	 ion	 efflux,	 calcium	
influx,	membrane	depolarization,	and	cell	death310–313.	In	addition	to	the	host	cell	membrane,	Hla	
can	also	bind	to	ADAM10	receptors	 in	the	membranes	of	epithelial	cells.	ADAM10	is	responsible	
for	 maintaining	 cell-cell	 adhesion314.	 However,	 the	 binding	 of	 Hla	 to	 ADAM10,	 leads	 to	 the	
cleavage	of	E-cadherin,	resulting	in	degradation	of	the	adhesion	junctions	and	finally	detachment	
of	the	basal	membrane,	which	separates	the	epithelium	from	the	underlying	connective	tissues314.	
The	breakdown	 in	 tissue	structure	enables	bacterial	dissemination	 to	 the	underlying	 tissues	and	
causes	severe	damage	to	the	host.		
	
1.7.2 β-haemolysin		
The	 β-haemolysin	 (Hlb)	 toxin	 is	 a	 sphingomyelinase	 that	 degrades	 the	 sphingomyelin	 in	
erythrocytes	 at	 37°C	 which	 after	 incubation	 at	 4°C,	 causes	 complete	 haemolysis	 315.	While	 Hlb	
lyses	a	range	of	host	cells	by	its	sphingomyelinase	activity	(and	not	via	pore	formation),	the	exact	
mechanism	of	cytolysis	is	unclear.	The	degradation	of	the	sphingomyelin	is	presumed	to	enhance	
the	vulnerability	of	the	cell	membrane	to	other	cytolytic	toxins	or	cold	shock289,316–319.		
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The	Hlb	toxin	lyses	sheep	erythrocytes	and	human	monocytes.	However,	Hlb	appears	to	be	
more	 important	 for	 infections	 in	 animals	 since	 many	 human	 isolates,	 including	 the	 CA-MRSA	
USA300	lineage	have	a	prophage	(ΦSa3)	inserted	with	the	hlb	gene,	that	results	in	complete	loss	
of	 expression	of	 the	 toxin289,315,319–321,322–324.	However,	 exposure	 to	oxidative	or	 other	 genotoxic	
stresses	may	 trigger	 loss	of	 the	phage	ΦSa3	and	enable	S.	aureus	 to	produce	a	 functional	 toxin	
321,325,326.	Furthermore,	 there	 is	evidence	 from	an	 in	vivo	study	 that	 subpopulations	of	human	S.	
aureus	isolate	undergo	phage	excision,	which	restores	Hlb	production	327.		
	
1.7.3 Phenol	soluble	modulins	(PSMs)	and	δ-haemolysin	
S.	aureus	encodes	6	small	peptide	cytolysins	known	as	PSMs,	which	are	encoded	on	two	operons	
on	the	chromosome	of	S.	aureus	regulated	by	AgrA.	One	operon	encodes	PSMα1,	α2,	α3	and	α4,	
which	are	20-22	amino	acids	in	size	and	positively	charged.	The	second	operon	encodes	two	PSMβ	
toxins	 (β1	 and	 β2),	 which	 are	 44	 amino	 acids	 long	 and	 negatively	 charged.	 PSM-Mec,	 which	 is	
encoded	on	type	II,	III	or	VIII	SCCmec	elements,	is	most	similar	to	PSMα.	However,	although	PSM-
Mec	 is	 positively	 regulated	 by	 the	 Agr	 quorum-sensing	 system,	 the	 binding	 of	 the	 activated	
response	regulator	AgrA	to	the	promoter	sequence	upstream	of	 the	psm-mec	promoter	has	not	
been	directly	demonstrated328,158.	By	contrast	to	the	other	PSMs,	psm-mec	RNA	binds	specifically	
to	 and	 down-regulates	 the	 expression	 of	 agrA,	 and	 its	 absence	 in	 CA-MRSA	 isolates	 has	 been	
hypothesized	to	contribute	to	elevated	Agr	activity	and	associated	increase	in	production	of	PSMα	
toxins329.		
δ	–haemolysin,	encoded	within	the	RNAIII	transcript	is	structurally	similar	to	PSMα,	but	is	
the	only	one	of	these	toxins	to	be	regulated	by	the	P3	promoter	and	not	AgrA.	All	PSMs	and	δ	-
haemolysin	 have	 an	 α	 -helical	 structure,	 which	 enables	 the	 peptides	 to	 insert	 into	 the	 cell	
membranes	of	erythrocytes,	leukocytes	and	neutrophils,	leading	to	membrane	depolarization	and	
cell	death176,294,330.							
		 55	
As	 described	 above,	 the	 key	 host	 defence	 against	 S.	 aureus	 is	 the	 neutrophil,	 which	
phagocytosis	 S.	 aureus	 and	 exposes	 it	 to	 a	 cocktail	 of	 reactive	 oxygen	 species,	 antimicrobial	
peptides	 and	 enzymes.	 PSMs	 have	 a	 formylated	 methionine,	 which	 is	 detected	 by	 the	 formyl	
peptide	receptor	on	the	surface	of	neutrophils,	leading	to	an	inflammatory	response.	However,	as	
described	previously,	the	Agr	system	enables	S.	aureus	to	detect	enclosure	within	the	phagocytic	
vacuole.	 This	 triggers	 the	 expression	 of	 PSMs,	 which	 lyse	 the	 phagocytic	 vacuole	 and	 enable	
bacterial	 survival176,294.	 The	 production	 of	 PSMs	 contributes	 to	 the	 initiation	 and	progression	 of	
SSTIs	and	bacteremia	as	shown	in	animal	models	of	these	infections294.		
In	 addition	 to	 pathogenesis,	 the	 pronounced	 amphipathic	 nature	 of	 PSMs	 gives	 these	
peptides	a	characteristic	surfactant-like	property,	which	enables	the	toxins	to	structure	biofilms.	S.	
aureus	 biofilms	 are	 known	 to	 form	 channel-containing	 biofilm	 structures,	 which	 enables	 the	
delivery	of	nutrients	in	deeper	layers176,331.	 	Although,	the	Agr-regulated	production	of	PSMs	has	
been	implicated	to	regulate	this	characteristic	channel-containing	biofilm	structure,	the	underlying	
molecular	mechanisms	remain	to	be	investigated.	However,	recent	studies	indicate	that	all	PSMs	
that	are	expressed	by	S.	aureus	function	in	biofilm	structuring	including	attachment,	maturation,	
detachment	and	dispersal370,372.	PSMs	also	function	by	disrupting	the	interaction	of	biofilm	matrix	
molecules	including	PIA	with	the	bacterial	cell	surface	that	leads	to	the	detachment	of	cell	clusters	
from	 biofilms176,177.	 This	 dispersal	 of	 biofilms	 by	 PSMs	 appears	 to	 be	 a	 key	 mechanism	 of	 the	
systemic	dissemination	of	biofilm	infections176,332.	In	addition,	it	has	been	reported	that	PSMs	can	
form	 amyloid	 fibers	 under	 specific	 in	 vitro	 conditions	 that	 contribute	 to	 the	 formation	 of	
biofilms176,333,334.		
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1.7.4 γ-haemolysin	and	bi-component	leukocidins	
Human	 isolates	of	 S.	 aureus	 produce	5	different	 types	of	 bi-component	 leukocidins,	 including	2	
forms	of	γ-haemolysin	(HlgAB	and	HlgCB),	PVL,	LukED	and	LukAB/GH.	By	contrast,	animal	isolates	
produce	 a	 single	 bi-component	 leukocidin	 known	 as	 LukMF’178,190,335,336.	 Leukocidins	 function	 as	
receptor-mediated	 toxins	 that	 lyse	 several	 different	 types	 of	 leukocytes	 including	 monocytes,	
macrophages	and	neutrophils	by	forming	beta-barrel	pores	 in	the	cell	membrane190	 	 (Table	1.1).	
Each	leukocidin	is	composed	of	2	components:	the	class	F	component	and	the	class	S	component.	
HlgB,	LukF,	LukD,	LukF’	and	LukA/G	belong	to	the	F	component	class	and	HlgA,	HlgC,	LukS,	LukM,	
LukE,	 LukB/H	 belong	 to	 the	 S	 component	 family288.	 Both	 components	 are	 required	 to	 lyse	 the	
targets	 cells	 and	 function	most	 effectively	when	 the	 S-	 and	F-components	 combine	within	 their	
corresponding	 type	 of	 leukocidin337,338.	 In	 each	 case,	 the	 S-component	 binds	 to	 its	 specific	
receptor	on	the	target	cell	membrane	and	subsequently	the	F-component	associates	with	the	S-
component.	This	induces	oligomerization	of	receptor-toxin	complexes,	forming	octameric	c-barrel	
pores	in	the	cell	membrane339–341.		
Because	leukocidins	target	species-specific	host	cell	receptors,	the	contribution	of	each	of	
the	 leukocidins	 during	 S.	 aureus	 infection	 has	 been	 difficult	 to	 assess	 using	 animal	 models	 of	
infection.	 For	 example,	 the	 PVL	 and	 LukAB/GH	 toxins	 are	 capable	 of	 lysing	 human	 and	 rabbit	
target	cells	but	not	mice179,342.	Therefore,	 studies	 in	mice	do	not	 reflect	 the	 function	of	 the	PVL	
toxins	in	humans.	Furthermore,	because	the	production	of	leukocidins	is	very	much	dependent	on	
the	 host	 environment,	 the	 culture	 medium	 used	 in	 in	 vitro	 studies	 can	 dramatically	 affect	
experimental	outcomes178.	
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Table	1.1.	S.	aureus	bi-component	leukocidins	
Leukocidin	 Receptor(s)	
specificity	
Target	cells	that	
are	killed	
Host(s)	
specificity	
Diseases	
PVL	(LukFS)	 C5aR,	C5L2	 Neutrophils,	
monocytes,	
macrophages	and	
lymphocytes	
179,343,344	
Human	and	
rabbit179	
SSTIs,	osteomyelitis,	
necrotizing	
pneumonia	and	
bacteraemia345–350	
HlgAB	 Unknown	 Erythrocytes,	
leukocytes	and	
lymphocytes338		
General190	 Septic	arthritis,	
ocular	infections,	
acute	sepsis,	
endophthalmitis	and	
bacteraemia	
342,351,352	
HlgCB	 Unknown	 Leukocytes	and	
erythrocytes	338	
General	190	 Septic	arthritis,	
ocular	infections,	
acute	sepsis,	
endophthalmitis	and	
bacteraemia	
342,351,352	
LukAB/GH	 CD11b	 Neutrophils,	
monocytes,	
macrophages	and	
dendritic	cells	
342,353,354		
Human	and	
rabbit342,355		
SSTIs	and	renal	
abscesses342,353	
LukED	 CCR5,	CXCR1/2	 Neutrophils,	
monocytes,	
macrophages,	
dendritic	cells,	
Natural	Killer	cells,	
lymphocytes	and	T	
cells356,357	
General191,357		 Acute	sepsis,	renal	
abscesses	and	
bacteraemia191,357		
LukMF’	 CCR1	 Bovine	neutrophils	
and	macrophages	
345,358			
Bovine345		 Bovine	mastitis336		
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1.7.5 Superantigens,	enterotoxins	and	exfoliative	toxins		
Many	 staphylococcal	 infections	 are	 believed	 to	 be	 facilitated	 by	 a	 combination	 of	 different	
cytolytic	 toxins.	 However,	 S.	 aureus	 also	 produces	 several	 toxins	 that	 are	 associated	 with	 very	
specific	conditions.	A	clear	example	of	this	is	the	TSST-1	toxin.	Typically,	foreign	antigens	that	are	
processed	 and	 presented	within	major	 histocompatibility	 complex	 (MHC)	 class	 II	molecules	 are	
presented	 to	 T	 cells.	 Upon	 interaction	with	 the	 T	 cell	 receptor	 (TCR),	 the	 T-cells	 are	 activated,	
releasing	 cytokines	 and	 replicating178.	 However,	 superantigens	 such	 as	 TSST-1	 bind	 to	 the	 Vβ	
region	 of	 the	 TCR,	 resulting	 in	 non-specific	 activation	 of	 20-50%	 of	 the	 T-cells	 in	 the	 host.	 This	
massive	activation	of	host	T-cells	 leads	 to	 the	production	of	pathological	 concentrations	of	pro-
inflammatory	 cytokines,	 resulting	 in	 the	 life-threatening	 condition	 toxic	 shock	 syndrome359.		
Furthermore,	this	process	results	in	the	destruction	of	the	T-cells,	preventing	the	development	of	
immunity	 towards	S.	aureus	 infection360,361.	Remarkably,	 the	onset	of	 toxic	 shock	does	not	even	
require	 infection	 since	 bacteria	 that	 have	 colonized	 tampons	 can	 trigger	 the	 condition	 in	
menstruating	woman362.	
Another	 example	 is	 the	 enterotoxins,	 SeA-E,	 G-J	 and	 R-T,	 that	 are	 responsible	 for	 food	
poisoning	that	 results	 in	diarrhea	and	emesis288.	S.	aureus	 typically	encodes	5-6	enterotoxins	on	
mobile	genetic	elements	that	are	believed	to	function	similarly	to	superantigens363,364.		
Finally,	infections	including	bulbous	impetigo	and	SSSS	are	caused	by	exfoliative	toxins	ETA	
and	 ETB	 that	 exfoliate	 the	 skin	 either	 locally	 (impetigo)	 or	 systemically	 (SSSS)365.	 S.	 aureus	
exfoliative	toxins	are	serine	proteases	that	function	by	cleaving	the	protein	desmoglein-1,	which	is	
found	 throughout	 the	 layers	 of	 the	 skin	 and	 is	 required	 to	maintain	 the	 cell-to-cell	 adhesion	of	
keratinocytes	that	make	the	outermost	layer	of	the	skin366.	When	desmoglein-1	is	cleaved	by	the	
exfoliative	 toxins	 the	outer	 layers	of	 skin	come	away	 leading	 to	 the	 formation	of	blisters,	which	
burst	and	make	the	host	vulnerable	to	secondary	infections365.		
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1.8 Invasive	infections	are	associated	with	loss	of	Agr	function		
As	described	above,	Agr	is	required	for	the	production	of	numerous	toxins	and	agr-mutants	have	
been	shown	to	be	avirulent	 in	several	different	animal	 infection	models.	Paradoxically,	however,	
invasive	staphylococcal	 infections	are	frequently	caused	by	strains	with	decreased	or	absent	Agr	
activity.	Furthermore,	the	loss	of	Agr	activity	is	associated	with	antibiotic	treatment	failure367,	368.	
For	example,	a	significantly	higher	frequency	of	agr-defective	strains	(37%	-	94%)	were	observed	in	
persistent	 bacteremia	 cases	 than	 in	 resolving	 bacteremia	 cases	 (39%	 -	 75%)369,	370,371.	 	 Similarly,	
Butterfield	et	al.	(2011)	observed	a	higher	rate	(68%)	of	agr-defective	isolates	associated	with	>72	
h	 of	 in	 hospital	 length	 of	 stay	 compared	 to	 a	 lower	 rate	 (16%)	 of	 agr-dysfunctional	 isolates	
associated	 with	 <72	 h	 of	 in	 hospital	 length	 of	 stay	 due	 to	 invasive	 staphylococcal	 infection372.	
Similarly,	Moise	et	al.	(2009)	found	a	significantly	higher	frequency	of	mixed	and	non-haemolytic	
strains	 (76%)	compared	 to	a	 lower	 frequency	 (24%)	of	agr-dysfunctional	 strains	 in	patients	with	
persistent	 bacteremia367.	 In	 keeping	 with	 this,	 loss	 of	 Agr	 is	 also	 associated	 with	 mortality.	
Schweizer	 et	 al.	 (2010)	 found	 fatal	 bacteremia	 involved	agr-dysfunctional	 strains	 in	 18%	 cases,	
whilst	resolving	bacteremia	was	associated	with	12%368.	 	
Agr-dysfunction	can	occur	via	several	different	routes.	Total	 inactivation	of	Agr	 in	clinical	
isolates	most	often	occurs	via	the	acquisition	of	mutations	 in	the	agrA	or	agrC	genes,	disrupting	
the	auto-activation	circuit	and	also,	therefore,	expression	of	RNAIII373,374.	Agr	activity	can	also	be	
suppressed	 in	 MRSA	 strains	 with	 high	 mecA	 expression	 and	 VISA	 strains,	 most	 likely	 due	 to	
changes	 in	 the	 cell	wall	 that	 prevent	 engagement	 of	 AIP	with	 AgrC14,375–379	 .	 A	 recent	 study	 by	
Laabei	 et.	 al.,	 (2015)	 demonstrated	 the	 association	 between	 Agr-dysfunctional	 strains	 with	
invasive	 S.	 aureus	 infections	 including	 bacteraemia	 and	 pneumonia380.	 However,	 this	 study	 also	
showed	 that	 Agr-dysfunction	 is	 not	 always	 due	 to	 mutations	 within	 the	 Agr	 locus	 but	 other	
mutations	elsewhere	in	the	genome.	For	example,	mutations	caused	by	a	premature	stop	codon	in	
the	 transcriptional	 regulator	 gene	 repressor	 of	 surface	 proteins	 (rsp)207	 resulted	 in	 reduced	Agr	
activity	 and	 has	 been	 implicated	 in	 the	 progression	 of	 fatal	 bacteraemia205,381–384.	 Therefore,	 it	
appears	 that	 strains	 defective	 for	 toxin	 production	 are	 associated	 with	 the	 most	 serious	 and	
difficult	to	treat	infections380.	
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The	 association	 of	 persistent	 bacteremia	with	 loss	 of	 Agr	 function	 is	 paradoxical	 since	 it	
abrogates	 the	 production	 of	 numerous	 cytolytic	 toxins,	 including	 leukocidins,	 which	 can	 kill	
immune	 cells.	 Therefore,	 it	 would	 be	 expected	 that	 Agr	 activity	 promotes	 survival	 in	 the	
bloodstream,	 rather	 than	 the	 clinical	 evidence	 that	 suggests	 loss	 of	 Agr	 activity	 promotes	
survival193.	This	raises	an	important	question:	what	advantage	does	loss	of	Agr	function	confer	to	
S.	aureus	during	persistent	bacteremia?		
During	 bacteraemia	 S.	 aureus	 faces	 two	 serious	 threats:	 the	 immune	 system	 and	
antibiotics.	 Both	 the	 host	 immune	 system	 and	 antibiotic	 treatment	 are	 essential	 in	 clearing	
invasive	S.	aureus	infections.	Previous	work	in	our	laboratory	and	from	others	has	shown	that	agr-
defective	bacteria	are	indeed	more	susceptible	to	killing	by	neutrophils	 in	blood	than	those	with	
intact	 agr	 operons186,374,385,386.	 However,	 whilst	 immune	 cells	 from	 healthy	 individuals	 appear	
effective	 at	 clearing	 infections	 caused	 by	 agr-defective	 S.	 aureus	 strains186,374,385,	 persistent	
bacteremia	is	often	associated	with	patients	with	a	weakened	immune	system,	such	as	the	elderly,	
patients	 receiving	 cancer	 chemotherapy	 or	 those	 with	 renal	 failure43	 .	 This	 suggests	 that	 Agr-
dysfunction	may	 confer	 an	 advantage	 to	 S.	 aureus	 exposed	 to	 antibiotics,	 rather	 than	 immune	
cells.	However,	the	evidence	for	this	is	limited,	with	just	a	few	studies	suggesting	a	link	between	
Agr-dysfunction	 and	 antibiotic	 susceptibility387–389.	 For	 example,	 Sakoulas	 et.	 al.,	 (2002)	
demonstrated	that	agr	null	strains,	but	not	wild-type	bacteria,	which	were	grown	in	sub-inhibitory	
concentrations	 of	 vancomycin,	 showed	 a	 small	 decrease	 in	 vancomycin	 susceptibility388,	
suggesting	 that	 loss	of	Agr	 enables	 resistance	development.	 In	 another	 study,	 Paulander	et.	 al.,	
(2012)	 demonstrated	 that	 in	 the	 presence	 of	 sub-lethal	 concentrations	 of	 antibiotics	 including	
ciprofloxacin,	 mupirocin	 and	 rifampin,	 agr-defective	 isolates	 had	 a	 fitness	 advantage	 over	 agr-
functional	isolates389.		
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1.9 Hypothesis	
Since,	 the	 loss	of	Agr	does	not	enhance	S.	aureus	 survival	 in	 the	presence	of	 immune	cells,	 the	
hypothesis	of	this	project	is	that	Agr-dysfunction	promotes	the	survival	of	S.	aureus	exposed	to	
antibiotics.		
	
1.10 Aim	of	the	project	
The	 aim	 of	 this	 project	 was	 to	 determine	 whether	 inactivating	mutations	 within	 agr	 modulate	
antibiotic	susceptibility	and,	if	so,	the	mechanism	by	which	this	occured.	
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Chapter	2	
Materials	and	Methods	
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2.1 Bacterial	strains	and	growth	conditions	
Staphylococcus	 aureus	 strains	 used	 are	 listed	 in	 Table	 2.1	 and	 were	 routinely	 cultured,	 unless	
otherwise	 stated,	 in	 Tryptic	 Soy	Broth	 (TSB)	or	 on	Tryptic	 Soy	Agar	 (TSA).	Mueller-Hinton	Broth	
(MHB)	was	used	in	some	susceptibility	assays	and	Columbia	Blood	Agar	(CBA)	supplemented	with	
5%	 sheep’s	blood	were	used	 to	 semi-quantitatively	 assess	haemolysis.	 The	 composition	of	 each	
growth	medium	is	detailed	in	Table	2.2.	For	some	assays	TSB	was	supplemented	with	fatty	acids	
including	oleic	acid,	linoleic	acid,	palmitic	acid,	myristic	acid	or	lauric	acid	at	a	concentration	of	up	
to	100	µM	(all	obtained	from	Sigma-Aldrich).		
Most	of	the	work	in	this	thesis	employed	strains	USA300	and	SH1000.	SH1000	was	selected	
because	it	is	fully	sensitive	to	all	front-	and	second-line	antibiotics	used	to	treat	infections	caused	
by	 S.	 aureus	 and	 previous	 work	 has	 established	 it	 has	 a	 fully	 functioning	 Agr	 system390,391,392.	
USA300	 was	 selected	 because	 it	 is	 representative	 of	 strains	 responsible	 for	 the	 majority	 of	
community-associated	MRSA	infections	in	the	USA,	exhibits	strong	Agr	activity	and	is	resistant	to	
the	frontline	antibiotic	flucloxacillin322,393,394.	It	was,	therefore,	an	appropriate	model	organism	for	
studying	 staphylococcal	 susceptibility	 to	 second-line	 antibiotics	 such	 as	 vancomycin	 and	
daptomycin.	
Bacteria	were	inoculated	onto	TSA	plates,	which	were	incubated	statically	at	37°C	for	15-17	
hours	in	air	unless	otherwise	stated.	Single	colonies	were	then	picked	and	grown	in	3	ml	broth	in	
30	ml	universal	tubes	and	incubated	at	37°C,	with	shaking	at	180	rpm	to	facilitate	aeration,	for	15-
17	 hours	 to	 stationary	 phase.	 Where	 required,	 the	 growth	 medium	 was	 supplemented	 with	
kanamycin	(50	μg	ml-1),	chloramphenicol	(10	μg	ml-1)	or	erythromycin	(10	μg	ml-1).	Staphylococcal	
colony	forming	units	(CFU)	were	enumerated	by	serial	dilution	in	sterile	PBS	and	plating	of	aliquots	
onto	TSA.	In	some	assays	the	Agr	system	of	the	USA300	strain,	was	inhibited	by	supplementing	the	
medium	with	synthetic	AIP-3	(10	μM,	Peptide	Protein	Research	Ltd).	Bacterial	stocks	were	stored	
in	growth	medium	containing	20%	glycerol	and	kept	at	-	80°C.	
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Table	2.1.	Bacterial	strains	used	in	this	study	
Bacterial	strain	 Relevant	characteristics	 Source/	reference	
S.	aureus		
SH1000							 Functional	rsbU+	derivative	of	NCTC8325-4.	 395	
SH1001		 SH1000	Δagr	 395	
SH1000-	 SH1000	with	H174L	mutation	in	agrA,	inactivating	quorum-sensing	 396	
SH1000-	+	pCN34	empty	 SH1000-	containing	pCN34	as	a	plasmid	control	 160	
SH1000-	+	pCN34	agrA	WT	 SH1000-	containing	pCN34	+	agrA	wild-type	 160	
SH1000	Δpsmα		
SH1000	Δpsmβ	
SH1000	Δpsmα/Δpsmβ	
SH1000	with	the	psmα1-4	genes	deleted	 	
SH1000	with	the	psmβ1-2	genes	deleted	
SH1000	with	the	psmα1-4	and	psmβ1-2	genes	deleted	 	
397	
397	
397	
SH348	 SH1000		ftsK::Tn	defective	for	DNA	translocase	FtsK	 This	study	
SH420	 SH1000	pbp3::Tn	defective	for	penicillin-binding	protein	3	 This	study	
SH1313	 SH1000		ftsH::Tn	defective	for	the	putative	cell	division	protein	FtsH	 This	study	
SH1633	 SH1000		SAUSA300_0918::Tn	defective	for	a	diacylglycerol	
glucosyltransferase	
This	study	
USA300	LAC		 LAC	strain	of	the	USA300	CA-MRSA	lineage		 322	
USA300	LAC		ΔagrA	 USA300	LAC	with	the	agrA	gene	deleted	 385	
USA300	LAC		ΔagrC	 USA300	LAC	with	the	agrC	gene	deleted	 385	
USA300	LAC		ΔagrC	+	
pCN34	empty	
USA300	LAC	ΔagrC	containing	pCN34	as	a	plasmid	control	 385	
USA300	LAC		ΔagrC	+	
pCN34	agrC	WT	
USA300	LAC	ΔagrC	containing	pCN34	+	agrC	wild-type	 385	
USA300	LAC		ΔRNAIII	 USA300	LAC	with	the	hld	gene	deleted	 385	
USA300	Δpsmα		
USA300	Δpsmβ	
USA300	Δpsmα/Δpsmβ	
USA300	with	the	psmα1-4	genes	deleted		 	
USA300	with	the	psmβ1-2	genes	deleted	
USA300	with	the	psmα1-4	and	psmβ1-2	genes	deleted	 	
294	
								294	
								294	
USA300	ΔvraUTSR	 USA300	with	the	vra	operon	deleted	 111	
USA300	JE2	 USA300	strain	cured	of	plasmids	 398	
NE72	 JE2	SAUSA300_2504::Tn	defective	for	an	acyltransferase	 398	
NE100	 JE2	SAUSA300_1482::Tn	defective	for	a	FtsK/SpoIIIE	family	protein	 398	
NE256	 JE2	SAUSA300_0535::Tn	defective	for	a	putative	pyridoxal	phosphate-
dependent	acyltransferase	
398	
NE260	 JE2	fadD::Tn	defective	for	acyl-CoA	dehydrogenase	 398	
NE263	 JE2	fadX::Tn	defective	for	a	putative	acyl-CoA	transferase	 398	
NE267	 JE2	sgtA::Tn	defective	for	a	putative	transglycosylase	 398	
NE268	 JE2	cls::Tn	defective	for	cardiolipin	synthase	 398	
NE348	 JE2	ftsK::Tn	defective	for	DNA	translocase	FtsK	 398	
NE402	 JE2	lytN::Tn	defective	for	a	cell	wall	hydrolase	 398	
NE420	 JE2	pbp3::Tn	defective	for	penicillin-binding	protein	3	 398	
NE460	 JE2	Atl::Tn	defective	for	autolysin	 398	
NE500	 JE2	SAUSA300_0226::Tn	defective	for	a	3-hydroxyacyl-CoA	dehydrogenase	 398	
NE539	 JE2	fadE::Tn	defective	for	acyl-CoA	synthetase	 398	
NE540	 JE2	SAUSA300_2615::Tn	defective	for	an	acetyltransferase	 398	
NE596	 JE2	sgtB::Tn	defective	for	a	monofunctional	glycosyltransferase	 398	
NE641	 JE2	lytM::Tn	defective	for	a	peptidoglycan	hydrolase	 398	
NE678	 SAUSA300_0099::Tn	defective	for	1-phosphatidylinositol	phosphodiesterase	 398	
NE679	 JE2	pbp4::Tn	defective	for	penicillin-binding	protein	4	 398	
NE721	 JE2	SAUSA300_2100::Tn	defective	for	a	lytic	regulatory	protein	 398	
NE814	 JE2	SAUSA300_0394::Tn	defective	for	a	FAD/NAD(P)-binding	Rossmann	fold	
superfamily	protein	
398	
NE1022	 JE2	fmtA::Tn	defective	for	a	low-affinity	penicillin-binding	protein		 398	
NE1092	 JE2	fadA::Tn	defective	for	a	putative	acyl-CoA	acetyltransferase	 398	
NE1313	 JE2	ftsH::Tn	defective	for	the	putative	cell	division	protein	FtsH	 398	
NE1481	 JE2	SAUSA300_1687::Tn	defective	for	a	FtsK/SpoIIIE	family	protein	 398	
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NE1513	 JE2	SAUSA300_1297::Tn	defective	for	an	acylphosphatase	 398	
NE1633	 JE2	SAUSA300_0918::Tn	defective	for	a	diacylglycerol	glucosyltransferase	 398	
NE1868	 JE2	mecA::Tn	defective	for	penicillin-binding	protein	2'	 398	
NE554	 JE2	vraR::Tn	defective	for	DNA-binding	response	regulator	 398	
NE823	 JE2	vraS::Tn	defective	for	two-component	sensor	histidine	kinase	 398	
MRSA	1	 MRSA	bacteraemia	isolate	
	
Imperial	
NHS	trust	
MRSA	2	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	3	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	4	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	5	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	6	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	7	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	8	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	9	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	10	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	11	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	12	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	13	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	14	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	15	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	16	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	17	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	18	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	19	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
MRSA	20	 MRSA	bacteraemia	isolate	 Imperial	
NHS	trust	
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Table	2.2.	The	composition	of	growth	media	used	in	this	study	
Media	 Composition	 Condition	
Tryptic	Soy	Broth	(BD)	BactoTM	
Tryptone	 (pancreatic	 digest	 of	
casein)	 (17.0	 g),	 papaic	 digest	
of	 soybean	 (3.0	 g),	 dextrose	
(2.5	 g),	 NaCl	 (5.0	 g),	
dipotassium	phosphate	(2.5	g)	
S.	aureus	growth	media	
Tryptic	Soy	Agar	(BD)	DifcoTM	
Pancreatic	 digest	 of	 casein	
(15.0	 g),	 papaic	 digest	 of	
soybean	 (5.0	 g),	 NaCl	 (5.0	 g),	
agar	(15.0	g)	
S.	aureus	growth	media	
Mueller-Hinton	Broth	(MHB)	
Beef	 infusion	 solids	 (2.0	 g),	
starch	 (1.5	 g),	 casein	
hydrolysate	(17.5	g)	
For	S.	aureus	MIC	assays	
Columbia	 Agar	 (Fluka)	 +	
sheep’s	 blood	 (E&O	
Laboratories	Limited)	
Special	nutrient	substrate	(23.0	
g),	 starch	 (1.0	 g),	 NaCl	 (5.0	 g),	
agar	(15.0	g)	
S.	 aureus	 growth	 medium	 to	
differentiate	between	Agr+	and	
Agr-	 strains	 via	 haemolysis	 of	
the	blood	
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2.2 Bacterial	growth	assays	
Stationary-phase	bacteria	were	adjusted	to	a	concentration	of	~107	CFU	ml-1	in	fresh	TSB	to	a	final	
volume	of	200	µl	in	the	wells	of	clear,	flat-bottom	microtitre	plates	(Greiner	Bio-One).	Microtitre	
plates	were	then	incubated	in	a	Polarstar	Omega	multiwell	plate	reader	at	37oC	with	shaking	(500	
rpm)	with	OD600	readings	taken	automatically	every	30	min	for	up	to	17	h392,399.		
	
2.3 Haemolytic	activity	of	clinical	isolates	
To	 identify	 clinical	 isolates	 with	 reduced	 or	 absent	 Agr	 activity,	 a	 semi-quantitative	 blood	 agar	
plate	haemolysis	assay	was	used.	Isolates,	previously	identified	as	MRSA	by	the	Imperial	NHS	Trust	
diagnostic	laboratory,	were	inoculated	onto	CBA	and	incubated	for	24	h.	The	degree	of	haemolysis	
was	scored	from	0	to	3,	where	0	represented	no	detectable	haemolysis	and	3	was	equivalent	to,	
or	 greater	 than,	 haemolysis	 caused	 by	 USA300.	 USA300	 ΔagrA	 was	 used	 as	 a	 control	 for	 no	
haemolytic	activity.		
	
2.4 Culture	supernatant	haemolysis	assay	
Spent	culture	supernatants	(1	ml)	 from	stationary	phase	bacteria	were	subjected	to	serial	2-fold	
dilution	 in	 fresh	 TSB	 up	 to	 1/32	 of	 the	 undiluted	 supernatant.	 The	 undiluted	 and	 diluted	
supernatants	 (400	 μl)	 were	 then	 mixed	 with	 400	 μl	 of	 2%	 defibrinated	 sheep	 blood	 (E&O	
Laboratories	Limited)	in	PBS	(VWR).	Supernatant	and	blood	mixtures	were	incubated	statically	at	
37oC	for	1	h,	after	which	intact	blood	cells	were	removed	by	centrifugation	at	500	x	g	for	10	min.	
The	 degree	 of	 haemolysis	 (red	 blood	 cell	 lysis)	 was	 determined	 by	 measuring	 A450392.	 Blood	
incubated	 in	 fresh	 TSB	 served	 as	 a	 negative	 control,	 whilst	 TSB	 containing	 0.1%	 Triton	 X-100	
served	as	a	positive	control	and	was	considered	to	represent	100%	haemolysis.			
	
2.5 Surfactant	activity	assay	
The	surfactant	property	of	PSM	peptides	was	measured	using	a	previously	described	protocol397.	
PSM	peptide	 solutions	 (2	μl)	were	 spotted	 in	 the	 center	of	 a	 soft	 TSA	plate	and	 thereafter,	 the	
surfactant	activity	was	determined	by	measuring	the	diameter	of	the	resulting	transparent	halo.	
PBS	 served	as	a	negative	control,	whilst	0.1%	Triton	X-100	 served	as	a	positive	control	and	was	
considered	to	represent	100%	surfactant	activity.	
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2.6 Phage	transduction		
Transposon	 mutants	 were	 generated	 in	 SH1000	 by	 phage	 transduction400	 of	 DNA	 containing	
transposons	from	mutants	in	the	NARSA	library398,	using	bacteriophage	Φ11.	Donor	strains	(Table	
2.3)	were	grown	to	stationary-phase	with	erythromycin	(10	µg	ml-1)	to	maintain	the	erythromycin	
resistance	cassette	contained	within	the	transposon.	Thereafter,	the	donor	strains	were	grown	in	
CY	broth	(0.1%	casamino	acids,	0.1%	yeast	extract,	0.5%	glucose,	0.6%	NaCl)	to	an	OD600	of	1.	CaCl2	
and	MgCl2	were	added	to	a	concentration	of	1	mM	and	1	ml	aliquots	of	the	culture	were	mixed	
with	 100	µl	 phage	Φ11	 suspension	 and	 incubated	 at	 37oC	 for	 3	 h	with	 shaking	 (180	 rpm)	 until	
complete	 lysis	was	 observed	 by	 comparison	 to	 a	 blank	 (CY	 broth	with	 CaCl2	 and	MgCl2),	 and	 a	
culture	without	phage.		
Lysed	 bacterial	 debris	 was	 removed	 by	 centrifugation	 (17,000	 x	 g,	 3	 min)	 and	 filtration	
through	 a	 0.22	 µm	 syringe	 filter	 to	 enable	 recovery	 of	 phage	 containing	 DNA	 from	 donor	 cells	
(phage	lysate	A).	The	above	steps	were	repeated	but	instead	of	fresh	lysate,	phage	lysate	A	(100	
µl)	was	added	to	the	1	ml	aliquots	of	the	donor	cells.	Following	incubation	at	37oC	for	3	h	leading	
to	 complete	 lysis,	 the	 phage	 lysate	 was	 centrifuged	 and	 filtered	 as	 described	 above.	 This	 was	
termed	phage	lysate	B	and	stored	at	4oC	until	subsequent	use.	
Recipient	bacteria	(SH1000	wild-type)	were	grown	to	stationary	phase	in	TSB	containing	1	
mM	CaCl2	and	MgCl2,	and	1	ml	was	mixed	with	100	µl	of	 the	phage	 lysate	before	 incubation	at	
37oC	 for	 20	 min.	 Sodium	 citrate	 (2	 ml,	 1%)	 was	 then	 added	 and	 the	 bacteria	 recovered	
immediately	 by	 centrifugation	 (17,000	 x	 g,	 3	 min).	 Bacterial	 pellets	 were	 resuspended	 in	 TSB	
containing	0.5%	sodium	citrate	and	incubated	at	37oC	for	1	h	before	plating	onto	TSA	containing	
sodium	citrate	(0.5%)	and	erythromycin	(10	µg	ml-1).		The	plates	were	then	incubated	at	37oC	for	
48	 h	 to	 allow	 growth	 of	 transductants.	 Colonies	 were	 picked	 and	 passaged	 3	 times	 on	 to	 TSA	
containing	sodium	citrate	 (0.5%)	and	erythromycin	 (10	µg	ml-1)	 to	cure	the	phage.	The	resulting	
SH1000	transductants	were	then	subjected	to	colony	PCR	using	the	primers	detailed	in	Table	2.3	
to	ensure	the	insertion	of	the	transposon	at	the	desired	locus	as	described	below	in	section	2.7.	
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Table	2.3.	Oligonucleotide	primers	used	in	this	study	
Locus	 Gene	 Forward	primer	 Reverse	primer	
SAUSA300_1512	 pbp3	 CAACACAATCGGAAATGTTGG CCGATTTTCGATAACAGTTG 
SAUSA300_0918	 diacylglycerol	glucosyltransferase	 GTGCAAATGCACAAGTAG CAGTTATTGTGATACCACCAG 
SAUSA300_1169	 ftsK	 GTCGGAAAGAAACCAAG CTCTGCATCAAACACTC 
SAUSA300_0489	 ftsH	 CTGAGAAGTTGGAAAAAGGTG CACCGTTTTGCTTTTTAGC 
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2.7 Colony	polymerase	chain	reaction	(PCR)	
Colony	 PCR	 was	 performed	 to	 efficiently	 identify	 and	 confirm	 successful	 transduction	 by	 using	
oligonucleotide	primers	that	amplified	the	transposon-targeted	gene.	Primers	were	synthesized	by	
Sigma-Aldrich	and	are	detailed	in	Table	2.3.	PCR	was	carried	out	using	PhusionR	High-Fidelity	DNA	
polymerase	 (NEB)	 because	 of	 its	 high	 sensitivity	 and	 tolerance	 for	 the	 presence	 of	 inhibitors	
released	 from	 lysed	 bacteria.	 Potential	 transductants	 were	 picked,	 resuspended	 in	 10	 µl	 of	
Molecular	Biology	Grade	Nuclease-Free	water	and	2	µl	spotted	onto	TSA	containing	erythromycin	
as	 described	 above.	 The	 remaining	 8	µl	 was	microwaved	 on	 full	 power	 for	 3	min	 in	 an	 800	W	
microwave.	The	microwave-treated	cells	were	pelleted	(17,000	x	g,	3	min)	and	1	µl	or	5	µl	of	the	
supernatant	was	added	to	the	PCR	reaction	as	detailed	in	Table	2.4	to	provide	template	DNA.	PCR	
was	 carried	 out	 in	 0.2	ml	 thin-walled	 PCR	 tubes	 (Greiner)	 in	 a	 PTC-200	 Peltier	 Thermal	 Cycler.	
Controls	 without	 DNA	 were	 used	 to	 check	 for	 contamination	 of	 reagents.	 The	 thermocycling	
conditions	used	for	PCR	are	detailed	in	Table	2.5.	For	colony	PCR	the	initial	denaturation	step	at	
98oC	was	extended	to	10	min	instead	of	the	usual	30	sec	-	5	min,	which	is	typically	used	when	the	
template	 is	 purified	 DNA.	 Agarose	 gel	 electrophoresis	 was	 used	 to	 analyse	 the	 amplicons	 by	
reference	to	a	DNA	ladder	(NEB).	
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Table	2.4.	Composition	of	the	PCR	reaction	
Reaction	component	 Volume	for	25	µ l	reaction	 Final	concentration	
Deionised	water	 Up	to	25	µl	 	
5x	Phusion	HF	buffer	 5	µl	 1x	
10	mM	dNTPs	 0.5	µl	 200	µM	
Primers	 1.25	µl	 0.2	µM	
50	mM	magnesium	chloride	 0.75	µl	 1.5	mM	
Template	DNA	 1	µl	or	5	µl	 10-20	µg	µl-1	
Phusion	DNA	Polymerase	 0.25	µl	 0.02	U	µl-1	
	
	
Table	2.5.	Thermocycling	conditions	for	PCR	reactions	
Reaction	phase	 Temperature	 Duration	 Number	of	cycles	
Initial	denaturation	 98°C	 10	min	 1	
Denaturation	 98°C	 10	sec	 30	
Annealing	 54-62°C	 20	sec	 30	
Extension		 72°C	 15-30s	per	Kb	 30	
Final	extension	 72°C	 5	min	 1	
Hold	 4°C	 ∞	 1	
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2.8 Agarose	gel	electrophoresis	
Agarose	gels	were	made	by	dissolving	1%	w/v	Agarose	(VWR)	in	1x	Tris-Borate	EDTA	(TBE)	buffer	
(0.89	M	Tris-borate,	0.02	M	EDTA,	pH	8.0)	with	heating,	followed	by	the	addition	of	4	µl	of	SYBR	
Safe	 DNA	 Gel	 Stain	 (Invitrogen)	 per	 50	 ml	 gel.	 The	 gel	 was	 poured	 into	 the	 casting	 tray	 with	
appropriate	combs	and	allowed	to	set	for	30	min	at	room	temperature.	PCR	reactions	(10	µl)	were	
then	mixed	with	2	µl	6x	DNA	loading	dye	(NEB),	and	loaded	into	wells	alongside	a	1	Kb	DNA	ladder	
(NEB)	to	determine	product	size.	Gels	were	run	in	1x	TBE	buffer	for	approximately	45	min	at	90	V	
until	the	dye	front	had	migrated	to	the	front	of	the	gel.	DNA	was	visualized	and	the	gel	image	was	
captured	using	a	UV	transilluminator	(Alpha	Innotech).		
	
2.9 Determination	 of	 antibiotic	 minimum	 inhibitory	 and	 bactericidal	
concentrations	(MIC/MBC)	
The	 minimum	 inhibitory	 concentrations	 (MICs)	 of	 the	 antibiotics	 used	 in	 this	 study	 were	
determined	using	the	2-fold	serial	broth	microdilution	protocol	for	bacteria	that	grow	aerobically	
as	described	in	the	Clinical	and	Laboratory	Standards	Institute	document	M07-A8401,402.		
The	range	of	antibiotic	concentrations	used	was	0	–	32	μg	ml-1	dissolved	 in	either	TSB	or	
MHB.	For	daptomycin	only,	media	were	supplemented	with	CaCl2	(50	µg	ml-1/0.5	mM).	This	range	
of	antibiotic	concentrations	was	generated	in	sterile	96-well	plates	(NuncTM	flat-bottom,	Thermo	
ScientificTM)	 by	 2-fold	 serial	 dilutions	 of	 the	 media	 containing	 the	 highest	 concentration	 of	
antibiotics	and	resulted	in	a	final	volume	of	200	μl.	Stationary-phase	S.	aureus	was	added	to	the	
serial	dilutions	of	media	containing	antibiotics	at	a	concentration	of	5	×	105	CFU	ml-1.	After	static	
incubation	at	37°C	for	18	hours,	the	MIC	was	defined	as	the	lowest	concentration	for	which	there	
was	no	visible	bacterial	growth	(no	turbidity)401,402.	To	ensure	that	correct	aseptic	technique	had	
been	performed,	two	wells	were	filled	with	media	without	bacteria.	
The	MBC	 is	 defined	 as	 the	 lowest	 concentration	 of	 antibiotic	 required	 for	 a	 >1000-fold	
reduction	 in	 CFU	 counts	 compared	 to	 the	 inoculum403,404.	 To	 determine	 the	 MBC	 value	
staphylococcal	 CFU	 counts	 in	 the	 wells	 of	 plates	 used	 for	 MIC	 assays	 were	 enumerated	 and	
compared	to	the	inoculum.		
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2.10 Determination	of	antibiotic	bactericidal	activity		
This	 assay	 was	 performed	 to	 measure	 the	 rate	 at	 which	 staphylococcal	 strains	 were	 killed	 by	
various	antibiotics	including	daptomycin	(20	μg	ml-1)	with	CaCl2	(0.5	mM),	gentamicin	(10	μg	ml-1),	
vancomycin	(10	μg	ml-1)	or	cloxacillin	(1.25	μg	ml-1),	or	the	antimicrobial	peptides	nisin	(20	μg	ml-1)	
or	 melittin	 (50	 μg	 ml-1).	 These	 antibiotic	 concentrations	 represented	 at	 least	 5	 x	 MIC	 and	 a	
previous	 study	 by	 Johnson	 and	 Levin	 (2013)	 demonstrated	 that	 these	 were	 sufficient	 for	
bactericidal	 antibiotics	 to	 kill	 stationary-phase	 S.	 aureus405.	 Furthermore,	 all	 antibiotic	
concentrations	 used	 fall	 within	 previously	 described	 free	 serum	 concentrations	 determined	 in	
humans	or	animals	that	had	received	clinically-relevant	therapeutic	doses405–410.	All	antibiotics	and	
peptides	 used	 in	 these	 assays	 were	 purchased	 from	 Sigma-Aldrich,	 with	 the	 exception	 of	
daptomycin	(TOCRISTM).	
Staphylococcal	strains	were	grown	to	stationary-phase	in	3	ml	TSB	with	shaking	(180	rpm)	
at	 37°C	 in	 30	 ml	 universal	 tubes	 as	 described	 above.	 They	 were	 subsequently	 adjusted	 to	 a	
concentration	of,	 ~1	 x	108	bacteria	ml-1	 in	 fresh	TSB	before	each	antibiotic	was	added.	Cultures	
were	 then	 incubated	 at	 37°C	with	 shaking	 (180	 rpm)	 and	 bacterial	 viability	 determined	 by	 CFU	
counts	every	2	hours	until	8	h.	Some	experiments	involved	additional	measurements	at	16,	24	and	
48	 h.	 Stationary	 phase	 bacteria	 were	 used	 because	 this	 is	 when	 Agr	 is	 active	 in	 vitro.	 Most	
experiments	used	mono-cultures	of	wild-type	or	agr-mutant	strains,	but	some	utilised	mixtures	of	
wild-type	 and	 agr-mutant	 bacteria,	 with	 the	 inoculum	 maintained	 at	 a	 total	 of	 108	 CFU	 ml-1.	
Because	daptomycin	is	an	anionic	lipopeptide,	calcium	ions	affect	its	structure	and	are	believed	to	
enable	 it	 to	 overcome	 the	 charge-to-charge	 repulsion	 caused	 between	 daptomycin	 and	 the	
anionic	 phospholipid	 heads	 of	 the	 Gram-positive	membrane	 in	 S.	 aureus132.	 Therefore,	 for	 this	
antibiotic	only,	the	culture	medium	was	supplemented	with	CaCl2	(0.5	mM).		
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2.11 Murine	infection	model	
All	 experimentation	 involving	 animals	was	 conducted	 in	 accordance	with	 the	 Animals	[Scientific	
Procedures]	Act	1986	outlined	by	the	UK	Home	Office	regulations.	Procedures	were	carried	out	by	
Dr	 Thomas	 Clarke	 (Imperial	 College	 London).	Work	was	 approved	 by	 the	UK	Home	Office	 after	
ethical	approval	from	the	Imperial	College	Animal	Welfare	and	Ethical	Review	Body	(AWERB).		
Six-	to	eight-week-old	female	C57BL/6	mice	(Charles	River,	United	Kingdom)	were	infected	
via	 the	 intraperitoneal	 route	with	2.5	×	 107	CFU	USA300	 LAC	or	 a	 1:1	mixture	of	wild-type	and	
ΔagrA	 mutant	 USA300	 LAC	 (total	 of	 2.5	 ×	 107	 CFU).	 For	 the	 indicated	 experiment,	 wild-type	
bacteria	were	 resuspended	 in	 spent	culture	supernatant	 from	either	wild-type	or	ΔagrA	mutant	
bacteria	exposed	to	daptomycin.	Mice	were	then	treated	with	250	µl	PBS	containing	daptomycin	
(40	μg	ml-1)	and	calcium	(0.5	mM),	with	or	without	oxacillin	(0.5	μg	ml-1),	which	was	injected	into	
the	peritoneal	cavity	 (i.e.	 the	daptomycin	concentration	within	the	peritoneal	cavity	was	~20	μg	
ml-1	and,	where	used,	oxacillin	was	present	at	~0.25	μg	ml-1).	Control	groups	were	treated	with	PBS	
alone.	Experiments	were	continued	 for	8	h	before	animals	were	humanely	 sacrificed	by	cervical	
dislocation	and	death	confirmed	by	severing	the	femoral	artery.		
The	peritoneal	cavity	was	washed	with	PBS	to	liberate	bacteria	and	CFU	counts	determined	
on	blood	 agar	 plates.	Wild-type	 and	ΔagrA	mutant	 bacteria	were	differentiated	on	 the	basis	 of	
haemolytic	 activity.	 The	 size	 of	 the	 groups	 used	 was	 determined	 prior	 to	 undertaking	 the	
experiment	 using	 power	 analysis	 based	 on	 in	 vitro	 data411.	 Tubes	 containing	 the	 inocula	 and	
antibiotic	 solutions	 were	 blinded	 prior	 to	 commencing	 the	 experiment.	 Mice	 were	 randomly	
allocated	to	individual	study	group	cages	by	animal	husbandry	technicians	who	were	not	involved	
in	 the	 study.	 Each	 group	was	 randomly	 allocated	 to	 a	 treatment.	 In	 keeping	with	 Home	Office	
regulations,	any	animals	that	displayed	2	or	more	of	the	following	signs	were	humanely	killed	by	a	
Schedule	1	method	and	excluded	from	the	study:	reduced	movement,	hunched	posture,	shivering,	
dyspnoea,	cyanosis	or	circling.		
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2.12 Daptomycin	activity	determination	
A	well	of	10	mm	was	made	in	TSA	plates	containing	50	µg	ml-1	CaCl2,	followed	by	the	spreading	of		
stationary	phase	wild-type	USA300	LAC	(60	μl,	~106	CFU	ml-1	in	TSB)	across	the	surface.	Thereafter	
the	 bacterial	 inoculum	 was	 allowed	 to	 air	 dry	 and	 the	 wells	 were	 filled	 with	 the	 supernatant	
recovered	 from	 cultures,	 which	 had	 been	 processed	 by	 centrifugation	 (17,000	 x	 g)	 and	 filter	
sterilization	 (0.22	 μm	 polyethersulfone	 membrane	 syringe	 filter	 (EMD	 Millipore))	 to	 remove	
bacterial	cells.	Plates	were	 incubated	for	16	h	at	37°C	and	the	zone	of	growth	 inhibition	around	
the	 well	 measured	 at	 4	 perpendicular	 points.	 In	 some	 assays,	 fresh	 daptomycin	 was	 added	 to	
culture	supernatants,	incubated	statically	at	37oC	for	up	to	8	h,	and	then	added	to	wells	in	TSA	as	
described	 above.	As	well	 as	 spent	 culture	 supernatants,	 some	assays	 used	 fresh	 TSB	 containing	
phospholipids	and/or	PSM	peptides	in	addition	to	daptomycin	for	filling	the	wells.		
To	 accurately	 quantify	 daptomycin	 activity,	 a	 standard	 plot	 was	 generated	 for	 each	
experiment	 by	measuring	 the	 zone	 of	 growth	 inhibition	 around	wells	 that	were	 filled	with	 TSB	
supplemented	with	range	of	daptomycin	concentrations.	This	enabled	the	conversion	of	the	size	
of	 the	 zone	 of	 inhibition	 into	 percentage	 daptomycin	 activity.	 	 To	 maintain	 consistency	 all	
replicates	in	a	given	experiment	used	the	same	batch	of	agar	plates.	
	
2.13 Characterisation	of	the	extracellular	daptomycin	inactivator		
To	determine	whether	the	daptomycin	inactivator	in	the	culture	supernatant	was	an	enzyme	or	a	
phospholipid,	 spent	 culture	 supernatants	 were	 treated	 with	 heat	 (80oC,	 20	 min),	 Triton	 X-100	
(0.1%),	phospholipases	A,	B,	D	(5	U	ml-1),	trypsin	(10	μg	ml-1)	or	proteinase	K	(10	μg	ml-1)	for	16	h	
at	37oC	prior	 to	 the	addition	of	20	µg	ml-1	 fresh	daptomycin	 (all	 reagents	 sourced	 from	Sigma).	
After	 1	 h	 incubation	 at	 37oC,	 the	 treated	 supernatants	 containing	 fresh	 daptomycin	were	 then	
subjected	to	the	daptomycin	activity	assay	described	above.	
	
2.14 Spent	culture	supernatant	bactericidal	activity	assay	
In	 addition	 to	 the	 daptomycin	 activity	 determination	 assay	 described	 above	 (section	 2.12),	 this	
assay	was	used	 to	 confirm	 the	bactericidal	 activity	of	daptomycin	 in	 spent	 culture	 supernatants	
from	bacteria	 that	had	been	exposed	 to	 the	antibiotic.	Bacterial	 cells	 that	had	been	exposed	 to	
daptomycin	were	removed	from	spent	culture	supernatant	by	centrifugation	(17,000	×	g,	10	min)	
and	filtration	through	a	0.22	µm	filter.		
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Similarly	 to	 the	 MBC	 assay	 described	 above	 (section	 2.9),	 wild-type	 USA300	 was	 then	
added	to	the	filtered	supernatant	to	a	density	of	5	×	105	CFU	ml-1	and	incubated	statically	at	37°C	
in	air	for	18	h	in	the	wells	of	sterile	96-well	plates.	Bacterial	CFU	counts	were	then	determined	by	
serial	dilution	and	plating	onto	TSA,	which	was	incubated	for	15-17	h.	As	with	the	MBC	assay,	the	
culture	supernatant	was	deemed	to	have	bactericidal	activity	if	there	was	a	>1000-fold	reduction	
in	CFU	counts	from	the	inoculum.	
	
2.15 Supernatant	swapping	assay	
To	determine	whether	the	spent-culture	supernatant	from	the	agr	mutant	bacteria	protected	the	
wild-type	bacteria	from	daptomycin,	the	spent-culture	supernatant	from	either	wild-type	or	agr-	
mutant	bacteria	 (exposed	or	not	 to	daptomycin)	were	 swapped	and	used	 to	measure	S.	aureus	
survival	upon	exposure	to	a	 fresh	dose	of	daptomycin	(20	μg	ml-1)	with	CaCl2	 (0.5	mM).	For	this	
assay,	 bacteria	 grown	 in	 TSB	 (3	 ml)	 were	 pelleted	 by	 centrifugation	 (17,000	 x	 g,	 5	 min),	 the	
supernatant	removed	and	filtered	as	described	above,	and	the	bacteria	resuspended	in	an	equal	
volume	of	filter-sterilised	spent	culture	supernatant	from	a	different	strain	before	immediate	use	
in	 assays.	 Daptomycin	 was	 added	 to	 the	 desired	 concentration	 and	 survival	 measured	 via	 CFU	
counts.		
	
2.16 Membrane	lipid	detection	
S.	aureus	membrane	 lipids	were	detected	and	quantified	using	FM-4-64	 (Life	Technologies)412,	a	
lipophilic	 dye	 that	 binds	 to	 membrane	 phospholipids	 with	 high	 specificity,	 resulting	 in	 the	
generation	of	a	fluorescent	signal.	
To	measure	whether	S.	aureus	released	phospholipids,	bacterial	culture	supernatants	(200	
μl)	were	recovered	by	centrifugation	(17,000	x	g,	5	min)	and	then	mixed	with	FM-4-64	to	a	final	
concentration	 of	 5	 µg	 ml-1	 in	 the	 wells	 of	 clear	 flat-bottom	 microtitre	 plates	 with	 black	 walls	
appropriate	 for	 fluorescence	 readings	 (Greiner	 Bio-One).	 Fluorescence	 was	 measured	 using	 a	
Tecan	microplate	 reader,	with	excitation	at	565	nm	and	emission	at	660	nm	to	generate	values	
expressed	 as	 relative	 fluorescence	 units	 (RFU).	 Samples	 were	 measured	 in	 triplicate	 for	 each	
biological	 repeat	 and	 TSB	mixed	with	 the	 FM-4-64	 dye	was	 used	 as	 a	 blank.	 	 The	 fluorescence	
readings	 were	 analyzed	 by	 subtracting	 the	 values	 from	 the	 blank	 readings	 and	 plotted	 against	
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time.	For	some	experiments,	standard	plots	of	purified	phospholipids	were	used	to	determine	the	
concentration	of	phospholipid	in	culture	supernatants.			
2.17 Lipid	extraction	and	thin-layer	chromatography	
Phospholipids	 were	 extracted	 from	 spent	 culture	 supernatants	 using	 a	 method	 based	 on	 that	
described	by	Bligh	and	Dyer413.	Acetic	acid	and	organic	solvents	such	as	chloroform	and	methanol	
were	used	at	99.8%	purity	and	purchased	from	VWR,	whilst	ammonium	hydroxide	was	purchased	
from	Sigma-Aldrich.	
Filter-sterilised	 culture	 supernatants	 or	 TSB	 containing	 various	 purified	 lipid	 standards	
and/or	daptomycin	were	extracted	with	1	sample	volume	of	chloroform:methanol	(2:1,	v/v).	The	
samples	 were	 mixed	 by	 vortexing	 and	 then	 centrifuged	 (17,000	 x	 g,	 10	 min)	 to	 separate	 the	
aqueous	and	organic	phases.	The	aqueous	phase	was	removed	and	the	organic	phase	evaporated	
at	ambient	temperature	and	pressure	 in	a	 fume	hood.	Dried	samples	were	then	resuspended	 in	
100	µl	of	chloroform:methanol	(2:1,	v/v).		
Samples	 were	 then	 separated	 by	 one-dimensional	 TLC	 as	 described	 previously414.	 Equal	
volumes	of	lipid	extracts	were	spotted	onto	silica	60	F254	HPTLC	plates	(Merck)	and	migrated	for	
25	min	with	chloroform:methanol:ammonium	hydroxide	(30%)	(65:30:4,	by	volume)414	.	TLC	plates	
were	 allowed	 to	 dry	 by	 evaporation	 before	 lipids	 were	 detected	 using	 iodine	 vapour	 (Sigma-
Aldrich).	 Purified	 lipid	 standards	 included	 phosphatidylglycerol,	 cardiolipin,	 lysyl-
phosphatidylglycerol,	phosphatidic	acid	and	phosphatidylethanolamine.		
All	 standards	 were	 purchased	 from	 Sigma-Aldrich,	 with	 the	 exception	 of	 lysyl-
phosphatidylglycerol	 (Avanti	 Polar	 Lipids).	 To	 enable	 accurate	 identification	 of	 phospholipids	 in	
spent	 culture	 supernatants,	 the	 purified	 lipid	 standards	 were	 added	 to	 TSB	 at	 100	 µM	 and	
daptomycin	 (20	 µg	 ml-1)	 added	 before	 the	 mixtures	 were	 subjected	 to	 the	 same	 extraction	
procedure	used	for	culture	supernatants.		
The	 identity	 and	 relative	 proportions	 of	 lipids	 were	 determined	 as	 described	 previously	
28,415.	Lipids	were	extracted	from	spent	culture	supernatant	into	chloroform:methanol	(2:1	v/v)	as	
described	above.	Samples	were	then	subjected	to	2D	TLC	using	silica	60	F254	HPTLC	plates,	firstly	
with	 chloroform:methanol:ammonium	 hydroxide	 (30%)	 (65:30:4,	 by	 volume)	 and	 then	 with	
chloroform:acetic	acid:methanol:water	 (170:25:25:4,	by	volume).	Plates	were	 then	air	dried	and	
lipids	visualised	with	iodine	vapour	as	described	above.		
The	identity	of	each	spot	was	determined	by	reference	to	the	migration	pattern	of	purified	
phospholipid	standards	as	described	previously415,416.	Each	spot	was	then	scraped	from	the	plate	
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using	a	sterile	scalpel	and	the	quantity	of	phospholipid	in	the	sample	determined	by	digestion	with	
0.3	ml	 70%	 perchloric	 acid	 (Sigma-Aldrich)	 at	 150oC	 (using	 a	 heat	 block)	 for	 3	 h.	 The	 digested	
phospholipid	was	 then	 incubated	with	a	detection	 reagent	 (10%	ascorbic	acid,	2.5%	ammonium	
molybdate,	5%	of	70%	perchloric	acid	used	at	a	1:1:8	ratio	by	volume,	all	chemicals	from	Sigma)	at	
37oC	for	2	h.	The	product	was	then	quantified	by	measurement	of	absorbance	at	750	nm	using	a	
microplate	 reader	 (iMARKTM	 BIO-RAD)	 and	 reference	 to	 standards	 of	 known	 phospholipid	
concentrations415,416.	 	The	concentration	of	each	 lipid	was	derived	 from	quantification	of	 lipid	 in	
culture	supernatant	from	USA300	WT	or	ΔagrA	mutant	bacteria	using	FM-4-64	and	reference	to	a	
standard	plot	generated	using	purified	phosphatidylglcyerol.	
	
2.18 Daptomycin	pull-down	assay		
To	measure	the	binding	of	released	phospholipids	to	daptomycin,	a	pull-down	assay	was	designed.		
Daptomycin	was	labelled	with	biotin	using	the	EZ-linkTM	NHS-Desthiobiotin	compound	(Pierce)	as	
described	 in	 the	 manufacturer’s	 instructions.	 Desthiobiotin	 (100	 µl,	 10	 mM)	 was	 mixed	 with	
daptomycin	 (100	µl,	 6	 mM)	 in	 PBS	 (1	 ml)	 before	 incubation	 at	 room	 temperature	 with	 gentle	
rocking	 for	1	h.	The	 reaction	mixture	was	 then	dialysed	against	H2O	at	4oC	 to	 remove	unbound	
desthiobiotin	using	a	Float-A-Lyser	G2	device	(Spectrum	Labs)	with	a	molecular	weight	cut-off	of	
0.1	kDa.	This	approach	was	chosen	because	the	EZ-link	enables	simple	and	efficient	labelling	of	the	
single	 free	 amine	 (R-NH2)	 group	 of	 daptomycin	 and	 the	 EZ-link	 spacer	 provides	 the	 spacer	 arm	
length	that	 reduces	any	steric	hindrance	caused	by	 the	 label417	 (Fig	2.1).	Liquid	chromatography	
mass	spectroscopy	(LC-MS)	was	used	to	confirm	that	daptomycin	had	been	successfully	 labelled.	
This	analysis	was	done	using	an	Agilent	1290	Infinity	LC	in	tandem	with	an	ABSCIEX	2000	QTrap	MS	
equipped	with	an	electrospray	ionization	(ESI)	interface	by	Dr.	Lisa	Haigh	from	the	Department	of	
Chemistry,	 Imperial	 College	 London.	 Then,	 to	 ensure	 that	 the	 biotin	 label	 did	 not	 significantly	
reduce	antibiotic	function,	an	MIC	assay	was	undertaken	using	unlabelled	antibiotic	as	a	control.		
Because	desthiobiotin	has	a	high	affinity	for	streptavidin,	beads	coated	in	this	protein	were	
used	to	pull	down	the	biotin-labelled	daptomycin	and	any	associated	phospholipids.	Furthermore,	
because	desthiobiotin	binds	streptavidin	with	lower	affinity	than	biotin	(Kd	of	10-11	M	vs.	Kd	of	10-16	
M),	the	 labelled	daptomycin	and	associated	phospholipids	could	be	eluted	from	the	beads	using	
an	elution	buffer	that	contained	biotin417.		
For	 the	pull-down	assay,	spent	culture	supernatant	 (1	ml)	was	 incubated	with	20	µg	ml-1	
desthiobiotin-labelled	daptomycin	 for	1	h	at	37oC	with	end-over-end	mixing	at	10	 rpm.	 In	 some	
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assays	PSMα1	(10	µM)	was	included.	Streptavidin-agarose	beads	(200	µl)	were	washed	with	PBS	
and	added	to	the	supernatant	containing	labelled	daptomycin	and	incubation	was	continued	for	1	
h	at	37oC.	Beads	were	then	allowed	to	settle	for	10	min	before	centrifugation	at	500	x	g	for	10	min	
to	 pellet	 any	 beads	 that	 remained	 in	 suspension.	 The	 supernatant	 was	 then	 removed	 and	 the	
pelleted	beads	washed	with	TSB.	An	additional	round	of	centrifugation	and	a	TSB	wash	was	done	
before	 the	 beads	 were	 resuspended	 in	 elution	 buffer	 (100	 µl,	 4	 mM	 biotin)	 (Sigma-Aldrich)	
followed	by	incubation	at	80oC	for	20	min	to	ensure	denaturation	of	the	streptavidin.	TSB	(100	µl)	
was	then	added	to	the	bead/elution	buffer	suspension,	mixed	by	pipetting	and	beads	removed	by	
centrifugation	 as	 described	 above.	 The	 supernatant	 (200	 µl)	 was	 recovered	 and	 lipid	 content	
measured	using	FM-4-64	dye	as	described	above.	
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Figure	2.1.	The	steps	required	to	biotinylate	daptomycin	
(a),	The	desthiobiotin	molecule	binds	to	the	free	amine	group	in	daptomycin	in	an	alkaline	buffer	
to	form	covalent	amide	bonds.	The	NHS	leaving	group	can	be	removed	by	salting	or	as	in	this	case	
by	passing	the	mixture	through	a	<0.1	KDa	membrane	filter.	(b),The	streptavidin	protein	can	bind	
up	 to	 4	 desthiobiotin	 molecules,	 which	 are	 conjugated	 to	 daptomycin	 to	 form	 an	 avidin-
desthiobiotin	complex.	(c),	Structure	of	biotin.	Because	biotin	binds	to	avidin	with	higher	affinity	
compared	to	desthiobiotin,	it	was	used	to	elute	the	desthiobiotin	molecule.	
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2.19 Biochemical	characterisation	of	phospholipid	release	
To	determine	whether	daptomycin	induced	phospholipid	release	and	S.	aureus	survival	occurred	
via	an	active	process,	critical	physiological	processes	of	the	bacteria	were	inhibited.	To	do	this,	a	
panel	 of	 specific	 inhibitors	 was	 used,	 including	 the	 respiratory	 inhibitors	 2-n-Heptyl-4-
hydroxyquinoline	N-oxide	(HQNO,	10	µg	ml-1)	and	sodium	azide	(0.05%),	and	the	protein	synthesis	
inhibitors	tetracycline	(10	µg	ml-1)	and	chloramphenicol	(20	µg	ml-1).	These	inhibitors	were	added	
to	assays	 individually,	along	with	daptomycin	(20	μg	ml-1)	and	CaCl2	(0.5	mM).	Assays	measuring	
phospholipid	release	were	then	performed	as	described	above.	An	additional	assay	was	done	at	
4oC	as	a	general	inhibitor	of	metabolic	function.	In	addition	to	inhibitors	of	respiration	or	protein	
synthesis,	some	assays	employed	the	β-lactam	antibiotic	oxacillin	(0.25	µg	ml-1)	as	an	inhibitor	of	
PBP1-4	function413,24,418.	Other	assays	employed	the	antibiotic	platensimycin	(7.5	µg	ml-1)	to	block	
fatty	acid	synthesis,	and	thus	also	block	phospholipid	production419,420.	
	
2.20 Measurement	of	cell-associated	daptomycin	
To	 measure	 the	 relative	 quantity	 of	 daptomycin	 bound	 to	 the	 bacterial	 cells,	 daptomycin	 was	
labelled	with	the	fluorophore	BoDipy	FL	SE	(D2184,	Life	Technologies).	Daptomycin	(50	µl,	50	mg	
ml-1)	was	mixed	with	BoDipy	FL	SE	(100	µl,	10	mg	ml-1)	and	the	reaction	volume	made	to	1	ml	with	
sodium	 bicarbonate	 buffer	 (0.2	M	 pH	 8.5)	 before	 incubation	 at	 37oC	 for	 1	 h.	 	 The	 succinimidyl	
esters	of	the	BoDipy	fluorophore	enabled	labelling	via	the	amine	(R-NH2)	group	of	daptomycin421.		
Unbound	BoDipy	was	 removed	by	dialysis	as	described	above	 for	desthiobiotin	 labelling.	
Also	as	above,	the	antibiotic	activity	of	the	BoDipy-labelled	daptomycin	was	confirmed	using	a	MIC	
assay,	and	LC-MS	analysis	of	BoDipy-labelled	daptomycin	was	employed	to	confirm	labelling	of	the	
antibiotic.		
Bacterial	cells	were	incubated	in	TSB	containing	the	labelled	antibiotic	and	CaCl2	(0.5	mM)	
for	 0-8	 h	 at	 37oC	with	 shaking	 (section	 2.10),	 before	 rounds	of	washing	 in	 TSB.	 BoDipy-labelled	
daptomycin	bound	to	bacterial	cells	(200	µl)	was	detected	and	quantified	with	a	Tecan	microplate	
reader	 using	 excitation	 at	 502	 nm	 and	 emission	 at	 510	 nm.	 Data	 were	 expressed	 as	 relative	
fluorescence	units.	
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2.21 Daptomycin	resistance	emergence	assay	
Bacterial	strains	were	inoculated	into	TSB	containing	daptomycin	(20	μg	ml-1)	and	CaCl2	(0.5	mM)	
and	 survival	 over	8	h	measured	as	described	 in	 section	2.10	 for	 the	determination	of	 antibiotic	
bactericidal	activity.	After	8	h	bacteria	were	pelleted	by	centrifugation	(17,000	x	g,	5	min),	washed	
twice	in	TSB	and	resuspended	in	3	ml	fresh	TSB,	before	incubation	at	37oC	with	shaking	(180	rpm)	
for	 16	 h	 to	 stationary	 phase.	 The	 activity	 of	 daptomycin	 in	 the	 culture	 supernatant	 was	
determined	by	 the	 zone	of	 inhibition	assay	as	described	 in	 section	2.12.	 The	 re-grown	bacterial	
populations	 were	 then	 inoculated	 once	 again	 into	 TSB	 containing	 daptomycin	 (20	 μg	ml-1)	 and	
CaCl2	 (0.5	 mM)	 and	 survival	 over	 8	 h	 measured.	 In	 total,	 3	 rounds	 of	 daptomycin	 challenge	
followed	 by	 re-growth	 in	 antibiotic-free	medium	were	 done.	 After	 each	 round,	 the	 daptomycin	
MIC	 of	 the	 surviving	 bacterial	 population	 was	 determined	 as	 described	 in	 section	 2.9.	
Measurements	of	bacterial	survival	and	daptomycin	activity	were	also	made	for	all	three	rounds	of	
daptomycin	exposure.	
	
2.22 Synthetic	peptides	
Synthetic	peptides	were	generated	by	Peptide	Protein	Research	 Ltd,	UK	according	 to	previously	
described	 sequences,	 with	 formylated	 methione	 (fM)	 at	 the	 N-termini294:	 	 PSMα1	
fMGIIAGIIKVIKSLIEQFTGK;	PSMα2	fMGIIAGIIKFIKGLIEKFTGK;	PSMα3	fMEFVAKLFKFFKDLLGKFLGNN;	
PSMα4	 fMAIVGTIIKIIKAIIDIFAK;	 PSMβ1	 fMEGLFNAIKDTVTAAINNDGAKLGTSIVSIVENGVGLLGKLFGF;	
PSMβ2	 fMTGLAEAIANTVQAAQQHDSVKLGTSIVDIVANGVGLLGKLFGF.	 In	 addition,	 a	 peptide	
comprised	 of	 the	 reverse	 sequence	 of	 PSMα1	 (PSM-rev;	 KGTFQEILSKIVKIIGAIIGM)	 was	
synthesised.	Unless	otherwise	indicated,	peptides	were	used	in	assays	at	10	µM,	which	was	based	
on	 concentrations	 described	 for	 stationary	 phase	 cultures	 of	 USA300413.	 When	 used	 in	
combination,	 10	µM	of	 each	peptide	was	used.	As	described	 in	 the	manufacturer’s	 instructions	
and	due	to	their	amphipathic	nature,	the	PSM	peptides	were	dissolved	in	water	in	small	aliquots	
of	10	µl	and	stored	at	-20oC.	
	
2.23 Statistical	analyses	
Unless	 otherwise	 mentioned,	 data	 are	 represented	 as	 the	 arithmetic	 mean	 average	 from	 3	 or	
more	independent	experiments	and	error	bars	represent	the	standard	deviation	(SD)	of	the	mean.		
For	multiple	comparisons,	data	were	analysed	using	a	one-way	ANOVA	for	data	generated	from	a	
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single	time	point	or	a	two-way	ANOVA	for	data	collected	from	multiple	time	points.	Post-hoc	tests	
were	only	used	when	the	overall	ANOVA	P	value	was	<0.05.	Unless	stated	otherwise,	for	one-way	
ANOVA	the	Tukey	post-hoc	test	was	used	and	for	two-way	ANOVA	Dunnett’s	or	Sidak’s	multiple	
comparison	tests	were	used	as	appropriate.	For	single	comparisons	data	were	analysed	using	an	
unpaired,	two-tailed	Student’s	t-test.	Where	there	are	significant	differences	in	values,	these	are	
described	 in	 the	 legend	 and	 indicated	 on	 the	 figure	 (*).	 Non-significant	 differences	 are	 only	
highlighted	 for	 animal	 studies	 but	 were	 omitted	 from	 other	 figures	 for	 clarity.	 For	 each	
experiment,	n	refers	to	the	number	of	independent	biological	repeats,	followed	by	the	number	of	
technical	replicates	in	each	case.	CFU	counts	from	murine	experiments	are	presented	as	the	value	
obtained	from	each	animal.	These	data	were	compared	using	Mann-Whitney	or	two-way	ANOVA	
tests	as	indicated	in	figure	legends	and	median	values	were	used	for	comparisons.			
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Chapter	3		
Agr-defective	S.	aureus	survives	daptomycin	
challenge	
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3.1 Introduction	
S.	 aureus	 is	 responsible	 for	 many	 different	 types	 of	 infection,	 ranging	 from	 mild	 to	 lethal,	
superficial	to	invasive.	The	antibiotics	that	are	used	to	treat	S.	aureus	infections	are	guided	by	the	
susceptibility	 of	 the	 isolate.	 Accordingly,	 for	 the	 treatment	 of	 methicillin-sensitive	 S.	 aureus	
(MSSA)	 bacteremia	 the	 antibiotics	 that	 are	 currently	 available	 include	 penicillinase-resistant	
semisynthetic	 penicillins,	 such	 as	 flucloxacillin	 and	 first-generation	 cephalosporins,	 such	 as	
cefazolin62,64,65.	 Although	 flucloxacillin	 (the	 preferred	 therapeutic)	 demonstrates	 clinical	 success	
rates	of	>89%	for	the	treatment	of	MSSA	bacteremia,	it	cannot	be	used	to	treat	bacteremia	caused	
by	MRSA	since	these	bacteria	are	resistant64,422.	
For	patients	with	MRSA	bacteremia	or	infective	endocarditis,	the	treatment	of	choice	is	the	
glycopeptide	 vancomycin62.	 Treatment	 of	 MSSA	 bacteremia	 with	 vancomycin	 is,	 however,	
associated	with	poor	clinical	outcomes	including	a	higher	relapse	rate	(31.2%	cases	of	persistent	
MSSA	bacteremia)	compared	to	cefazolin	(5-13%	of	cases)	and	naficillin	(5.3%	of	cases)56,64	;	and	
increased	 rates	 of	 treatment	 failure	 and	 high	mortality;	 from	 a	 total	 of	 53%	MRSA	 bacteremia	
patients	that	experienced	treatment	failure	with	vancomycin,	21%	of	these	cases	were	associated	
with	mortality,	and	in	MSSA	bacteremia	76%	of	cases	were	associated	with	prolonged	duration	(>7	
days)	of	bacteremia423,424.	
When	 treatment	 with	 vancomycin	 fails,	 especially	 in	 patients	 with	 a	 high	 inoculum	
infection	 such	 as	 endocarditis,	 or	 the	 emergence	 of	 vancomycin-intermediate	 S.	 aureus,	
daptomycin	is	the	drug	of	last	resort52,387,423.	
Daptomycin	is	a	cyclic	lipopeptide	bactericidal	agent	that	was	approved	for	the	treatment	
of	S.	aureus	bacteremia	and	right-sided	endocarditis	by	the	US	Food	and	Drug	Administration	 in	
2006.	 Daptomycin’s	 mode	 of	 action	 is	 calcium-dependent	 and	 involves	 the	 insertion	 of	 the	
lipophilic	daptomycin	tail	into	the	cytoplasmic	membrane	of	Gram-positive	cells.	This	causes	rapid	
membrane	depolarization	and	potassium	 ion	efflux.	 This	 is	 followed	by	arrest	of	DNA,	RNA	and	
protein	synthesis	resulting	in	bacterial	cell	death28,120.	
Although	 daptomycin	 is	 highly	 bactericidal	 against	 both	 MRSA	 and	 MSSA	 in	 vitro,	
treatment	 failure	 occurs	 in	 up	 to	 30%	 cases.	 In	 rare	 instances,	 this	 is	 due	 to	 the	 emergence	 of	
isolates	with	 a	 ‘daptomycin	 non-susceptible’	 (DNS)	 phenotype,	 typically	 due	 to	 gain-of-function	
mutations	in	genes	involved	in	biosynthesis	of	phospholipids	or	cell	wall	components.		
Therefore,	whilst	 antibiotic	 resistance	 is	 a	major	 challenge	 in	 the	 treatment	of	S.	 aureus	
infections,	there	is	strong	evidence	that	additional	factors	result	in	treatment	failure	of	infections	
caused	by	apparently	drug-susceptible	bacteria.	
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Several	explanations	have	been	proposed	for	this	phenomenon,	including	the	formation	of	
biofilms,	persister	cells,	small	colony	variants	and	intracellular	residency	of	S.	aureus.		
An	additional	hypothesis	is	that	loss	of	function	of	the	Agr	quorum-sensing	system	confers	
a	selective	advantage	to	S.	aureus	exposed	to	antibiotics115,183,368,369,380,388,389,425.	Agr	regulates	the	
expression	of	many	virulence	factors142,146	and	consists	of	a	quorum-sensing	component	encoded	
by	a	4	gene	operon	(agrBDCA),	and	a	gene	encoding	a	regulatory	RNA	(RNAIII).	However,	invasive	
S.	aureus	infections	often	give	rise	to	Agr-defective	strains183,368,375,377,387,425.		
However,	 whilst	 Agr-dysfunctional	 strains	 are	 associated	 with	 persistent	 infections	 and	
antibiotic	 tolerance,	 there	 is	 a	 lack	 of	 direct	 evidence	 that	 Agr	 directly	 modulates	 drug-
susceptibility.	Furthermore,	the	underlying	mechanism	by	which	loss	of	Agr	function	promotes	the	
survival	of	bacteria	exposed	to	antibiotics	is	unexplored.	Therefore,	the	hypothesis	to	be	tested	in	
this	chapter	is	that	loss	of	Agr	function	in	S.	aureus	promotes	bacterial	survival	during	antibiotic	
exposure.		
	
3.2 Justification	of	strains	used	
To	test	the	hypothesis,	it	was	decided	to	focus	on	the	S.	aureus	USA300	LAC	strain,	because	(i)	it	is	
the	most	prevalent	strain	found	within	the	United	States	of	America322;	(ii)	it	is	a	CA-MRSA	strain,	
which	 is	 resistant	 to	 first-line	β-lactam	antibiotics	and	 is	associated	with	more	than	a	 third	of	S.	
aureus	bacteremia	cases	in	the	U.S.394;	(iii)	it	is	widely	used	in	the	laboratory	as	a	representative	of	
the	MRSA	strain	and	has	not	undergone	any	curing	of	phage393,394;	(iv)	it	is	well	characterised	with	
respect	to	Agr-function322.		
Due	to	the	phenotypic	and	genotypic	diversity	of	S.	aureus,	a	second	strain,	SH1000,	was	
used	because	(i)	 it	 is	a	MSSA	strain,	which	 is	sensitive	to	 first-line	β-lactam	antibiotics;	 (ii)	 it	 is	a	
well-characterised	rsbU+	(sigB)-repaired	derivative	of	the	S.	aureus	lineage	8325-4,	with	regulatory	
systems	intact390,391;	(iii)	Agr	function	has	been	well	characterized	in	this	strain392.	
To	determine	whether	Agr	directly	modulates	antibiotic	 tolerance,	a	panel	of	strains	and	
tools	were	assembled.	This	included	well-characterized	isogenic	agr	mutants	of	both	USA300	and	
SH1000	 strains	 (Table	 2.1).	 The	 mutations	 in	 the	 agr	 operon	 of	 USA300	 had	 been	 previously	
constructed	 via	 complete	 deletion	 of	agrA,	 agrC	or	 RNAIII.	 In	 addition,	 these	mutants	 had	 also	
been	 complemented	 with	 a	 copy	 of	 the	 relevant	 gene	 on	 a	 plasmid	 and	 characterized	
phenotypically400,407.	
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Since	 growth	 rate	 can	 affect	 antibiotic	 susceptibility,	 this	was	measured	 for	 each	 of	 the	
strains	 used	 in	 antibiotic	 susceptibility	 experiments.	 (Fig	 3.1)	 As	 has	 been	 observed	 previously	
there	were	 slight	differences	 in	growth	profile	between	 the	wild-type	and	agr	mutants	at	 some	
time	 points,	 indicating	 that	 Agr	 has	 a	 subtle	 impact	 on	 the	 growth	 of	 S.	 aureus392,399	 (Fig	 3.1).	
However,	 differences	 in	 growth	 were	 less	 apparent	 in	 stationary	 phase,	 which	 was	 used	 in	
subsequent	experiments	as	this	is	when	Agr	is	active	and	bacteria	are	most	drug-tolerant392,399.	
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Figure	3.1.	Growth	of	USA300	LAC-derived	and	SH1000-derived	S.	aureus	strains		
Growth	of	USA300	wild-type	(WT),	ΔagrA,	ΔagrC,	ΔagrC	transformed	with	pCN34	empty	or	pCN34	
agrC	WT,	or	ΔRNAIII	mutant	(a),	SH1000	wild-type,	SH1001	(Δagr)	and	SH1000-	(agrA-)	(b)	 in	TSB	
was	measured	by	 taking	OD600	 readings	 over	 time.	 In	 all	 cases,	 n=3	 in	 duplicate.	 Error	 bars	 are	
omitted	for	clarity	but	standard	deviations	were	within	10%	of	the	mean.		
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	Figure	3.1	Growth	of	USA300	LAC-derived	and	SH1000-derived	S.	aureus	strains.	Growth	of	USA300	
wild-type	(WT),	ΔagrA,	ΔagrC,	ΔagrC	transformed	with	pEmpty	or	pagrC,	or	ΔRNAIII	mutant	(a),	SH1000	
wild-type,	SH1001	(Δagr)	and	SH1000-	(agrA-)	(b)	in	TSB	was	measured	by	taking	OD600	readings	over	
Tme.	In	all	cases,	n=3	in	duplicate.	Error	bars	are	omiWed	for	clarity	but	standard	deviaTons	were	within	
10%	of	the	mean.		
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3.3 Agr-activity	modulates	susceptibility	to	daptomycin	but	not	other	antibiotics	
Two	 approaches	were	 used	 to	measure	 antibiotic	 susceptibility.	 Firstly,	 the	minimum	 inhibitory	
concentration	 (MIC)	 was	 determined	 for	 each	 antibiotic	 and	 each	 strain.	 Secondly,	 the	
susceptibility	of	each	strain	to	bactericidal	concentrations	of	each	antibiotic	was	measured.	
In	 each	 case,	 the	 MICs	 of	 vancomycin	 and	 gentamicin	 for	 wild-type,	 ΔagrA,	 and	 ΔagrC	
mutants	in	the	USA300	strain	or	wild-type,	Δagr	and	agrA-	mutants	in	the	SH1000	strain	were	the	
same	(Table	3.1).	However,	for	the	USA300	ΔRNAIII	mutant	the	MIC	was	half	that	of	the	wild-type	
for	 these	 antibiotics.	 Loss	 of	Agr	 function	 in	 SH1000	 strains	 did	 not	 affect	MIC	 values,	with	 the	
exception	 of	 cloxacillin,	with	 one	 of	 the	agr	mutants	 having	 half	 the	MIC	 of	 the	wild-type.	 For	
daptomycin,	all	strains	had	an	 identical	MIC	(1	µg	ml-1).	Cloxacillin	was	not	used	for	the	USA300	
strains	because	 it	 is	resistant	but	otherwise	all	of	the	MICs	were	below	breakpoint	and	thus	the	
strains	were	deemed	sensitive	to	the	antibiotic	used.	Because	daptomycin	activity	 is	affected	by	
ionic	strength,	MHB,	which	is	a	well-established	susceptibility-testing	medium	was	used.	The	MIC	
of	daptomycin	for	S.	aureus	 in	MHB	was	2-fold	lower	compared	to	TSB,	which	is	 in	keeping	with	
previous	 findings426.	 Taken	 together,	 these	 findings	 indicated	 that	 the	 lack	 of	 the	 Agr-quorum	
sensing	system	did	not	significantly	affect	antibiotic	susceptibility	of	S.	aureus	(Table	3.1).		
To	determine	the	antibiotic	killing	kinetics	of	USA300	and	SH1000	strains	and	their	isogenic	
agr	 mutants,	 bacteria	 were	 challenged	 with	 the	 same	 group	 of	 clinically	 relevant	 antibiotics,	
including	cloxacillin,	vancomycin,	gentamicin	and	daptomycin.	The	concentrations	used	for	all	the	
antibiotics	were	within	the	previously	described	free	serum	concentrations	from	studies	in	animals	
or	 humans	 and	 corresponded	 to	 at	 least	 5	 x	 MIC,	 which	 has	 been	 shown	 previously	 to	 be	
bactericidal	for	these	antibiotics405–410.		
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Table	3.1.	Antibiotic	minimal	inhibitory	concentrations	for	strains	used	in	this	study		
Data	show	the	MIC	(μg	ml-1)	for	cloxacillin,	vancomycin	and	gentamicin	in	TSB	(Tryptic	Soy	Broth),	
and	daptomycin	 in	TSB	and	Mueller-Hinton	broth	 (MHB).	Data	 represent	 the	median	value	of	3	
independent	experiments	done	in	duplicate.			
	
	
	
	 	
USA300	and	SH1000	–	derived	
Medium	–	TSB	
+	AnTbioTc		
(μg	ml-1)	
SH1000	 SH1001	(Δagr)	
SH1000-	
(agrA-)	
USA300
WT	
USA300
ΔagrA	
USA300		
ΔagrC	
USA300		
ΔRNAIII	
Cloxacillin	 0.25	 0.25	 0.125	 NA	 NA	 NA	 NA	
Vancomycin	 2	 2	 2	 2	 2	 2	 1	
Gentamicin	 2	 2	 2	 2	 2	 2	 1	
Daptomycin	 1	 1	 1	 1	 1	 1	 1	
Table	3.1.	AnGbioGcs	minimal	inhibitory	concentraGons	for	strains	used	in	this	study.	Data	show	the	
MIC	(μg	ml-1)	for	cloxacillin,	vancomycin	and	gentamycin	in	TSB	(TrypTc	Soy	Broth)	determined	by	broth	
microdiluTon	as	described	previously.	The	MIC	was	determined	a^er	24	h	 incubaTon.	Data	represent	
the	median	value	of	3	 independent	experiments	done	 in	duplicate.	 In	keeping	with	previous	ﬁndings,	
the	values	for	MIC	were	idenTcal.		
USA300	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔagrC	
ΔagrC	+		
pCN34	agrC	WT	 ΔRNAIII	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraGons	for	strains	used	in	this	
study.	Data	show	the	MIC	 (μg	ml-1)	 for	daptomycin	 in	TSB	 (TrypTc	Soy	Broth)	or	MHB	(Muller-Hinton	
Broth)	determined	by	broth	microdiluTon	as	described	previously.	All	media	were	supplemented	with	
CaCl2	to	50	μg	ml-1	and	MIC/MBC	determined	a^er	24	h	incubaTon.	Data	represent	the	median	value	of	
3	independent	experiments	done	in	duplicate.	In	keeping	with	previous	ﬁndings,	the	values	for	MIC		and	
MBC	were	idenTcal.		
SH1000	–	derived	
Medium	+	
	Dapt.	 WT	 SH1001	 SH1000
-	 SH1000
-	+	
pCN34	empty	
SH1000-	+	
pCN34	agrA	WT	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	
Dapt.	 thrC	 ebpS	 murA	
Membran
e	protein	 tcaA	
Universal	
stress	
protein	
hlgA	 htrA	 clpC	
MerR	family	
transcripTona
l	regulator	
MerR	family	
transcripTonal	
regulator	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	
Table:		
Table:		
Table:		
Table:		
USA300	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔagrC	
ΔagrC	+		
pCN34	agrC	WT	 ΔRNAIII	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraGons	for	strains	used	in	this	
study.	Data	show	the	MIC	 (μg	ml-1)	 for	daptomycin	 in	TSB	 (TrypTc	Soy	Broth)	or	MHB	(Muller-Hinton	
Broth)	determined	by	broth	microdiluTon	as	described	previously.	All	media	were	supplemented	with	
C Cl2	to	50	μg	ml-1	and	MIC/MBC	determined	a^er	24	h	incubaTon.	Data	 epresent	the	median	value	of	
3	in ependent	experiments	done	in	duplic te.	In	keeping	with	previous	ﬁndings,	the	values	for	MIC		and	
MBC	were	idenTcal.		
SH1000	–	derived	
Medium	+	
	Dapt.	 WT	 SH1001	 SH1000
-	 SH1000
-	+	
pCN34	empty	
SH1000-	+	
pCN34	agrA	WT	
TSB	 1	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	
Dapt.	 thrC	 ebpS	 murA	
Membran
e	protein	 tcaA	
Universal	
stress	
protein	
hlgA	 htrA	 clpC	
MerR	family	
transcripTona
l	regulator	
MerR	family	
transcripTonal	
regulator	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	
Table:		
Table:		
Table:		
Table:		
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For	cloxacillin,	vancomycin	and	gentamicin	there	were	no	differences	in	the	killing	kinetics	
of	wild-type	 and	agr	mutants,	 indicating	 that	 Agr	 status	 does	 not	 affect	 the	 susceptibility	 of	 S.	
aureus	 to	 bactericidal	 concentrations	 of	 these	 antibiotics	 (Fig	 3.2a-e).	 However,	 in	 the	 case	 of	
daptomycin,	 the	 Agr	 status	 of	 both	 USA300	 and	 SH1000	 had	 a	 large	 and	 significant	 effect	 on	
survival	(Fig	3.3a).	During	the	first	2	hours	of	exposure	of	USA300	strains	to	daptomycin,	a	rapid	
decrease	 in	 CFU	 was	 observed	 in	 both	 the	 wild-type	 and	 ΔagrA,	 ΔagrC	 and	 ΔRNAIII	 mutants.	
However,	by	4	h	the	ΔagrA	and	ΔagrC	mutants	(but	not	the	ΔRNAIII	mutant)	began	to	recover,	and	
the	CFU	count	increased	100-fold	between	4	h	and	8	h.	By	contrast,	viability	of	the	wild-type	and	
ΔRNAIII	 mutant	 continued	 to	 decrease	 up	 to	 8	 h.	 Thus,	 the	 loss	 of	 the	 quorum-sensing	
components	 of	 Agr	 (AgrA	 or	 AgrC),	 but	 not	 the	 regulatory	 RNAIII	 molecule,	 enabled	 S.	 aureus	
USA300	 to	 survive	 exposure	 to	 daptomycin	 (Fig	 3.3a).	 To	 confirm	 that	 inactivation	 of	 Agr	 was	
responsible	 for	 the	 survival	 of	 USA300	 ΔagrA	 and	 ΔagrC	 mutants,	 the	 ΔagrC	 mutant	
complemented	with	a	wild-type	copy	of	the	agrC	gene	and	exposed	to	daptomycin.	Restoration	of	
Agr	 activity	 in	 the	ΔagrC	mutant	 restored	 sensitivity	 to	daptomycin,	whereas	 the	ΔagrC	mutant	
transformed	with	plasmid	alone	was	not	susceptible	to	the	antibiotic	(Fig	3.3b).		
As	observed	 for	USA300,	daptomycin	 caused	a	 significant	decrease	 in	CFU	 counts	of	 the	
SH1000	wild-type	strain.	By	contrast,	whilst	CFU	counts	of	the	agrA	mutant	strain	declined	slightly	
over	the	first	4	hours,	they	subsequently	recovered.	Complementation	of	the	agrA	mutation	with	
a	wild-type	copy	of	the	gene	restored	sensitivity	to	daptomycin	confirming	the	contribution	of	the	
quorum-sensing	system	to	daptomycin	susceptibility	(Fig	3.3c).		
To	further	investigate	the	relationship	between	Agr	activity	and	daptomycin	susceptibility,	
USA300	wild-type	and	agr	mutants	were	exposed	to	daptomycin	for	48	h.	As	observed	previously,	
CFU	 counts	 of	 the	 ΔagrA	 and	 ΔagrC	 mutants	 dropped	 initially	 before	 rapidly	 recovering.	
Surprisingly,	although	CFU	counts	of	the	wild-type	fell	more	than	10,000-fold	over	8	h,	they	had	
fully	recovered	by	24	h	(Fig	3.3d).	Taken	together,	these	data	indicated	that	S.	aureus	could	adapt	
to	and	survive	exposure	to	a	high	dose	of	daptomycin,	but	that	adaptation	was	much	more	rapid	
in	mutants	lacking	an	intact	Agr	quorum-sensing	circuit.	
Before	 investigating	 these	 findings	 further,	 it	 was	 decided	 to	 explore	 whether	 Agr-
mediated	modulation	of	daptomycin	susceptibility	occurred	in	vivo	or	was	simply	restricted	to	the	
in	vitro	environment.	To	test	this,	a	murine	model	of	acute	 invasive	MRSA	infection	was	used	 in	
collaboration	with	Dr.	Thomas	Clarke	(CMBI,	Imperial	College	Londn)	who	undertook	all	aspects	of	
the	work	that	 involved	animal	procedures.	Mice	were	 inoculated	via	the	 intraperitoneal	route301	
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with	wild-type	USA300	S.	aureus	or	the	ΔagrA	mutant,	and	then	treated	with	daptomycin	or	PBS	
for	 8	 h.	 Subsequently,	 bacterial	 survival	 was	 measured	 by	 recovering	 and	 enumerating	 CFUs.	
Similar	 to	 that	 reported	 previously427,	 daptomycin	 treatment	 reduced	 the	 size	 of	 the	wild-type	
population	15-fold	after	8	h	treatment,	compared	with	mice	treated	with	PBS	alone	(Fig	3.3e).	By	
contrast,	 daptomycin	 treatment	 did	 not	 significantly	 decrease	 the	 size	 of	 the	 ΔagrA	 mutant	
population	 when	 compared	 with	 PBS	 treatment	 (Fig	 3.3e).	 Therefore,	 the	 loss	 of	 Agr	 quorum-
sensing	activity	conferred	a	selective	advantage	to	S.	aureus	during	daptomycin	exposure	in	vivo,	
resulting	in	treatment	failure.	
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Figure	3.2.	Agr	does	not	 influence	the	susceptibility	of	S.	aureus	 to	vancomycin,	gentamicin	or	
Cloxacillin		
S.	 aureus	 SH1000	 and	 associated	 agr	 mutants	 were	 exposed	 to	 cloxacillin	 (1.25	 µg	 ml-1)	 (a),	
vancomycin	 (10	µg	ml-1)	 (b)	or	gentamicin	 (10	µg	ml-1)	 (c)	 for	8	h	and	survival	measured	by	CFU	
counts.	The	survival	of	USA300	wild-type	and	associated	agr	mutants	in	the	presence	of	identical	
concentrations	of	vancomycin	(d)	or	gentamicin	(e)	was	determined	as	described	for	SH1000.	Data	
represent	 the	mean	 of	 3	 independent	 experiments	 done	 in	 duplicate.	 Error	 bars	 represent	 the	
standard	deviation	of	the	mean.	There	were	no	significant	differences	in	the	survival	of	wild-type	
strains	and	associated	agr	mutants	in	the	presence	of	any	of	the	antibiotics.		
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	Figure	3.2.	Agr	does	not	inﬂuence	the	suscepGbility	of	S.	aureus	to	vancomycin,	gentamicin	or	oxacillin.	
S.	aureus	SH1000	and associated	agrA	mutant	were	exposed	to	1.25	µg	ml-1	clox cillin	(a),	10	µg	ml-1	
vancomycin	(b)	or	10	µg	ml-1	gentamicin	(c)	for	8	h	and	survival	measured	by	CFU	counts.	The	survival	of	
USA300	wild-type	and	associated	agr	mutants	in	the	presence	of	10	µg	ml-1	vancomycin	(d)	or	10	µg	ml-1	
gentamicin	(e)	was	determined	as	described	for	SH1000.	Data	represent	the	mean	of	3	independent	
experiments	done	in	duplicate.	Error	bars	represent	the	standard	deviaTon	of	the	mean.	There	were	no	
signiﬁcant	diﬀerences	in	the	survival	of	wild-type	strains	and	associated	agr	mutants	in	the	presence	of	
any	of	the	anTbioTcs.	For	all	panels	error	bars	represent	the	standard	deviaTon	of	the	mean.	
	
SH1000			
USA300			
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Figure	3.3.	Agr-defective	S.	aureus	survives	daptomycin	exposure	both	in	vitro	and	in	vivo	
Survival	 of	 USA300	 WT	 or	 agr	 mutants	 (a).	 Survival	 of	 the	 ΔagrC	 mutant,	 ΔagrC	 mutant	
transformed	with	pCN34	empty	or	pCN34	containing	the	wild-type	agrC	gene	under	the	control	of	
the	agr	 P2	 promoter	 (b).	 	 Survival	 of	 the	 SH1000	WT,	agrA-	mutant,	agrA-	mutant	 transformed	
with	pCN34	empty	or	pCN34	containing	a	copy	of	the	wild-type	agrA	gene	under	the	control	of	the	
agr	P2	promoter	(c).	All	strains	were	exposed	to	20	µg	ml-1	daptomycin.	Data	represent	the	mean	
of	3	independent	experiments	done	in	duplicate	(n=3),	for	WT	vs	ΔagrA	or	ΔagrC	P	<	0.05,	and	for	
wild-type	 vs	 ΔagrC	 with	 empty	 plasmid	 P	 <	 0.001	 at	 indicated	 time	 points	 (*).	 There	 was	 no	
significant	 difference	 between	WT	 and	 ΔagrC	 pCN34	 agrC	WT.	 	 Survival	 of	 USA300	WT	 or	 agr	
mutants	over	48	h	(n=3	in	duplicate,	for	WT	vs	ΔagrA	or	ΔagrC	P	<	0.0001	at	indicated	time	points	
(*).	CFU	counts	of	USA300	WT	or	ΔagrA	mutant	after	8	h	in	the	peritoneal	cavity	of	mice,	treated	
with	20	µg	ml-1	daptomycin	 (+)	or	PBS	only	 (-)	 (*	P	<	0.05,	NS	P	>	0.05,	Each	circle	 represents	a	
single	 mouse.	 for	WT	 groups	 n=9,	 for	 ΔagrA	 groups	 n=10).	 Data	 in	 panels	 a,	 b,	 c	 and	 d	 were	
analysed	using	a	two-way	ANOVA	with	Dunnett’s	post-hoc	test.	Data	in	panel	e	was	analysed	by	
Mann-Whitney	test.	Where	shown,	error	bars	represent	the	standard	Deviation	of	the	mean.	
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Figure	3.3.	Agr-defecGve	S.	 ureus	s rvives	daptomycin	exposure	both	in	vitro	and	in	vivo.	a,	survival	of	USA300	wild-type	(WT)	
or	agr	mutants	b,	ΔagrC	mutant,	the	ΔagrC	mutant	transformed	with	pCL55	(pEmtpy)	or	the	ΔagrC	mutant	transformed	with	
pCL55	containing	a	copy	of	the	wild-type	agrC	gene	(pagrC)	under	the	control	of	the	agr	P2	promoter		c,	SH1000	WT	or	agr	
mutants	or	agrA-	mutant	transformed	with	pCN34	containing	a	copy	of	the	wild-type	agrA	gene	(pagrA)	under	the	control	of	the	
agr	P2	promoter,	during	exposure	to	20	µg	ml-1	daptomycin	was	measured	over	8	h	by	quanTﬁcaTon	of	CFU.	Data	represent	the	
mean	of	3	independent	experiments	done	in	duplicate	(n=3),	for	WT	vs	agrA	or	agrC	P	<	0.05	and	for	wild-type	vs	agrC	with	empty	
plasmid	P	<	0.001		at	indicated	Tme	points	(*).	There	was	no	signiﬁcant	diﬀerence	between	WT	and	ΔagrC	pagrC.		d,	survival	of	
USA300	WT	or	agr	mutants	over	48	h	in	the	presence	of	20	µg	ml-1	daptomycin	(n=3	in	duplicate,	for	WT	vs	agrA	or	agrC		P	<	
0.0001	at	indicated	Tme	points	(*).	e,	CFU	counts	of	USA300	WT	or	ΔagrA	mutant	a^er	8	h	in	the	peritoneal	cavity	of	mice,	treated	
with	20	µg	ml-1	daptomycin	(+)	or	PBS	only	(-)	(*	P	<	0.05,	NS	P	>	0.05,			each	circle	represents	a	single	mouse,	for	WT	groups	n=9,	
for	ΔagrA	groups	n=10).	Data	in	panels	a,	b,	c	and	d	were	analysed	using	a	two-way	ANOVA	with	DunneW’s	post-hoc	test.	Data	in	
panel	e		was	analysed	by	Mann-Whitney	test.	Where	shown,	error	bars	represent	the	Standard	DeviaTon	of	the	mean.	
	
		 95	
3.4 Clinical	 S.	 aureus	 isolates	 with	 dysfunctional	 Agr	 are	 less	 susceptible	 to	
daptomycin	than	isolates	with	a	functional	Agr	system	
To	further	explore	the	clinical	relvance	of	Agr-modulated	daptomycin	susceptibility,	a	collection	of	
20	 independent	 clinical	MRSA	 isolates	 from	bloodstream	 infections	was	 examined.	 Each	 isolate	
was	 plated	 onto	 Columbia	 Blood	 Agar	 and	 Agr	 activity	 inferred	 using	 a	 semi-quantitative	
haemolysis	 assay.	 Since	 haemolysis	 is	 a	 surrogate	 marker	 of	 Agr	 activity368,370.	 Isolates	 were	
defined	 simply	 as	Agr-functional	 (haemolytic)	 or	Agr-dysfunctional	 (non-haemolytic)	 (Fig	 3.4).	 In	
keeping	with	previous	 findings,	 7/20	 isolates	 (35%)	were	defined	 as	Agr-dysfunctional,	with	 the	
reminder	having	detectable	haemolytic	activity.	Strains	were	then	exposed	to	daptomycin	for	8	h	
and	survival	measured	by	quantification	of	CFU	counts.	The	median	survival	of	Agr-dysfunctional	
strains	was	greater	than	10%,	whereas	those	strains	classified	as	Agr-functional	had	survival	levels	
of	 less	 than	0.3%	 (Fig	3.4).	 Therefore,	 the	association	between	Agr	 activity	 and	 susceptibility	 to	
daptomycin	appears	to	be	conserved	in	clinical	isolates.		
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Figure	3.4.	Agr-defective	clinical	isolates	are	less	susceptible	to	daptomycin	than	Agr-functional	
S.	aureus		
S.	 aureus	 isolates	 (20)	 were	 obtained	 from	 the	 Imperial	 College	 NHS	 diagnostic	 laboratory.	
Because	 haemolysis	 is	 a	 useful	 surrogate	marker	 for	 Agr	 activity,	 strains	were	 assessed	 for	 Agr	
function	 by	 examination	 of	 haemolytic	 activity	 on	 blood	 agar	 plates	 as	 described	 previously10.	
Isolates	that	produced	clear	zones	of	haemolysis	(a)	(representative	image,	n=13)	were	considered	
to	have	 functional	Agr	 systems,	whilst	 those	defective	 for	haemolysis	 (b)	 (representative	 image,	
n=7)	were	considered	to	lack	a	functional	Agr	system10.	The	survival	of	each	isolate	after	exposure	
to	20	µg	ml-1	daptomycin	 for	8	h	was	 then	measured	using	duplicate	 cultures	 in	3	 independent	
assays.	 The	mean	 average	 survival	 for	 each	 isolate	 is	 plotted	 as	 a	 single	 point	 above	 (c).	 Lines	
represent	 the	 median	 value.	 Survival	 of	 the	 Agr-defective	 (non-haemolytic)	 isolates	 was	
significantly	greater	than	that	of	the	Agr-functional	(haemolytic)	strains	as	determined	by	a	Mann-
Whitney	test	(P		<	0.0001).		
	 	
H a
em
o l
y t
ic
N o
n -
h a
em
0 .0 1
0 .1
1
1 0
1 0 0
1 0 0 0
%
	su
rv
iv
al
	
HaemolyTc		
(Agr+)	
Non-haemolyTc		
(Agr-)	
a	 b	
c	
Figure	3.6	.	Agr-defecGve	clinical	isolates	are	less	suscepGble	to	daptomycin	than	Agr-funcGonal	S.	
aureus.	S.	aureus	isolates	(20)	were	obtained	from	the	Imperial	College	NHS	diagnosTc	laboratory.	
Because	haemolysis	is	a	valid	surrogate	marker	for	Agr	acTvity,	strains	were	assessed	for	Agr	funcTon	by	
examinaTon	of	haemolyTc	acTvity	on	blood	agar	plates	as	described	previously10.	Isolates	that	produced	
clear	zones	of	haemolysis	(a,	representaTve	image,	n=13)	wer 	considered	to	have	funcTonal	Agr	
systems,	whilst	those	defecTve	for	haemolysis	(b,	representaTve	image,	n=7)	were	considered	to	lack	a	
funcTonal	Agr	system10.	The	survival	of	each	isolate	a^er	exposure	to	20	µg	ml-1	daptomycin	for	8	h	was	
then	measured	using	duplicate	cultures	in	3	independe t	assays.	The	mean	av rage	survival	for	each	
isolate	is	ploWed	as	a	single	point	above	(c)	Lines	represent	the	median	value.	Survival	of	the	Agr-
defecTve	(non-haemolyTc)	isolates	was	signiﬁcantly	greater	than	that	of	the	Agr-funcTonal	(haemolyTc)	
strains	as	determined	by	a	Mann-Whitney	test	(P		<	0.0001).		
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3.5 Survival	of	agrA	mutants	exposed	to	daptomycin	is	not	due	to	the	emergence	
of	resistance	
Resistance	 to	 daptomycin	 can	 arise	 spontaneously	 and	 typically	 involves	 gain-of-function	
mutations	in	genes	related	to	phospholipid	or	cell	wall	biosynthesis428,28,131.	To	determine	whether	
the	 survival	 of	agr	mutants	 in	 daptomycin	was	 due	 to	 the	 emergence	 or	 presence	 of	 resistant	
mutants,	agrA	mutants	 in	 the	USA300	and	 SH1000	backgrounds	were	exposed	 to	20	μg	ml-1	 of	
daptomycin	for	8	h	as	for	the	killing	assays	described	above.	To	detect	resistant	mutants,	the	total	
bacterial	population	was	plated	onto	TSA	containing	daptomycin	at	4	μg	ml-1	or	20	μg	ml-1	at	the	
start	(0	h)	and	end	of	the	assay	(8	h).	A	very	small	fraction	of	bacteria	(0.001%)	were	able	to	grow	
at	4	μg	ml-1	of	daptomycin,	but	no	bacteria	were	able	to	grow	at	20	μg	ml-1	of	daptomycin.	The	
size	of	the	fraction	that	could	grow	at	4	μg	ml-1	did	not	change	significantly	after	8	h	exposure	to	
daptomycin	(Fig	3.5a	and	b).	 	This	ruled	out	resistance	as	an	explanation	for	bacterial	survival	 in	
broth	containing	20	μg	ml-1	of	daptomycin.	
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Figure	3.5.	Survival	of	agr	mutants	in	the	presence	of	daptomycin	is	not	due	to	the	emergence	of	
resistance	
USA300	 (a)	 and	 SH1000	 (b)	 wild-type	 and	 agr	 mutant	 strains	 were	 exposed	 to	 20	 μg	 ml-1	 of	
daptomycin	for	8	h.	CFU	were	quantified	on	TSA	only,	TSA	supplemented	with	daptomycin	at	4	μg	
ml-1	 or	 TSA	 supplemented	 with	 20	 μg	 ml-1	 at	 the	 start	 (0	 h)	 and	 end	 (8	 h)	 of	 the	 assay.	 No	
significant	differences	were	found	between	the	number	of	CFU	on	TSA	plates	supplemented	with	
4	 μg	ml-1	 daptomycin	 at	 the	 start	 and	 end	 of	 the	 assay	 by	 one-way	 ANOVA.	 No	 colonies	were	
observed	on	TSA	plates	supplemented	with	20	μg	ml-1	daptomycin	at	either	time	points	(detection	
limit	100	CFU).	Data	points	represent	the	mean	average	of	3	independent	cultures	and	error	bars	
represent	the	standard	deviation	of	the	mean.	
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Figure	3.4.	Survival	of	agr	mutants	in	the	presence	of	daptomycin	is	not	due	to	the	emergence	of	
resistance.	a,	The	USA300	ΔagrA	mutants	strain	and	b,	SH1001	(ΔagrA)	mutant	strain	were	exposed	to	20	
μg	ml-1	of	daptomycin	for	8	h.	CFU	were	quanTﬁed	on	TSA	only,	TSA	supplemented	with	daptomycin	at	4	
μg	ml-1	and	TSA	supplemented	with	20	μg	ml-1	at	the	start	(0	h)	and	end	(8	h)	of	the	assay.	No	signiﬁcant	
diﬀerences	were	found	between	the	number	of	CFU	on	TSA	supplemented	with	4	μg	ml-1	daptomycin	
plates	at	the	start	and	end	of	the	assay.	No	colonies	were	observed	on	TSA	supplemented	with	20	μg	ml-1	
daptomycin	plates	at	eith r	Tme	points	(below	the	detecTon	limit	of	100	CFU).	The	number	of	CFU	 n	TSA	
supplemented	with	4	μg	ml-1	daptomycin	plates	at	the	strat	and	end	of	the	assay	was	signiﬁcantly	lower	
than	the	number	of	CFU	on	TSA	only	plates	(p	<0.05)	(*).	Data	points	represent	the	mean	average	of	3	
i dependent	cultures	and	error	bars	r present	the	standard	deviaTon	of	the	mean	
b	a	
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3.6 Agr-defective	 mutants	 promote	 survival	 of	 wild-type	 S.	 aureus	 exposed	 to	
daptomycin		
	Since	staphylococcal	 infections	are	often	caused	by	mixed	populations	of	wild-type	bacteria	and	
agr	mutants368,369,380,425,	 it	was	 investigated	how	this	affected	daptomycin	 susceptibility.	Various	
ratios	of	USA300	wild-type	and	ΔagrA	mutant	S.	aureus	were	prepared	(WT	4:1,	2:1,	1:1,	1:2	and	
1:4	 ΔagrA)	 and	 then	 exposed	 to	 daptomycin.	 Haemolysis	 was	 used	 to	 distinguish	 the	 Agr-
functional	(haemolytic)	wild-type	strains	from	the	Agr-dysfunctional	(non-haemolytic)	agr	mutants	
in	the	mixed	populations	by	incubating	samples	on	2%	CBA	plates.	It	was	found	that	larger	ΔagrA	
mutant	sub-populations	resulted	in	greater	survival	of	both	the	Agr-defective	strain	and	the	wild-
type,	indicating	that	the	agr	mutant	protected	the	wild-type	from	daptomycin	(Fig	3.6a).		
A	 similar	assay	with	S.	aureus	 SH1000	wild-type	and	ΔagrA	mutant	at	a	 ratio	of	1:1	also	
found	greater	survival	of	the	wild-type,	relative	to	a	mono-culture	(Fig	3.6b),	confirming	that	agr-
mutants	protect	the	wild-type	from	daptomycin.		
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Figure	3.6.	Agr-defective	S.	aureus	 in	a	mixed	population	promote	daptomycin	 survival	of	 the	
whole	population	in	vitro		
Survival	of	mixed	populations	of	USA300	WT	and	ΔagrA	mutant	at	various	ratios	after	8	h	in	the	
presence	of	20	µg	ml-1	daptomycin	(n=3	in	duplicate)	(a).	Wild-type	SH1000	(WT)	or	SH1000-	(agrA)	
were	incubated	in	broth	containing	20	µg	ml-1	daptomycin	for	8	h	either	as	mono-cultures	(Mon)	
or	 mixed	 at	 a	 1:1	 ratio	 (Mix)	 and	 survival	 of	 both	 strains	 measured	 (b).	 Survival	 of	 wild-type	
SH1000	was	significantly	greater	in	mixed	culture	than	mono-culture	(P	<	0.05	by	Student’s	t-test).	
Data	 represent	 the	mean	of	3	 independent	experiments	done	 in	duplicate.	Error	bars	 represent	
the	standard	deviation	of	the	mean.		
	 	
CF
U
	m
l-1
	
108	
109	
107	
106	
105	
4:1	 2:1	 1:1	 1:2	 1:4	
RaTo	wild-type:agrA	
¨		wild-type	
¢		agrA	
USA300	
Fig	3.7.	Agr-defecGve	S.	aureus	in	a	mixed	populaGon	promote	daptomycin	survival	of	the	whole	
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a^er	8	h	in	the	presence	of	20	µg	ml-1	daptomycin	(n=3	in	duplicate).	The	data	was	analysed	using	a	two-
way	ANOVA	with	DunneW’s	post-hoc	test.		
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3.7 The	ΔagrA	mutant	protects	wild-type	USA300	from	daptomycin	in	vivo	
Since	 the	 ΔagrA	 mutant	 survived	 daptomycin	 in	 vivo	 and	 protected	 wild-type	 bacteria	 from	
daptomycin	in	vitro	it	was	decided	to	test	whether	the	ΔagrA	mutant	also	protected	the	wild-type	
in	vivo.	Mice	were	infected	via	the	intraperitoneal	route	with	a	1:1	mixture	of	wild-type	bacteria	
and	 ΔagrA	 mutant.	 As	 a	 control,	 mice	 were	 also	 infected	 with	 wild-type	 alone	 (as	 before,	 all	
animal	procedures	were	undertaken	by	Dr.	Thomas	Clarke,	CMBI,	Imperial	College	London).	Mice	
were	then	treated	with	daptomycin	for	4	or	8	h,	and	bacterial	survival	measured	by	recovery	and	
quantification	 of	 CFUs.	 As	 described	 previously	 (Fig	 3.3e),	 daptomycin	 significantly	 reduced	 the	
number	 of	 CFU	 in	 mice	 infected	 with	 wild-type	 bacteria	 alone	 (Fig	 3.7a,	 b).	 However,	 in	 mice	
infected	with	 a	mixture	of	wild-type	and	ΔagrA	mutant	bacteria,	 daptomycin	had	no	 significant	
effect	on	the	number	of	CFU	of	either	strain	after	4	or	8	h	treatment	(Fig	3.7a,	b).	
Therefore,	the	presence	of	the	ΔagrA	mutant	in	the	peritoneal	cavity	of	mice	appeared	to	
have	 protected	 wild-type	 bacteria	 from	 daptomycin,	 providing	 additional	 evidence	 that	 agr-
mutants	promote	daptomycin	treatment	failure.		
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Figure	3.7.	Agr-defective	S.	aureus	promotes	survival	of	WT	bacteria	exposed	to	daptomycin	in	
vivo	
CFU	counts	from	the	peritoneal	cavity	of	mice	infected	with	wild-type	S.	aureus	or	a	1:1	mixture	of	
wild-type	 and	 ΔagrA	 mutant	 bacteria	 after	 4	 h	 (a)	 or	 8	 h	 (b)	 of	 treatment	 with	 20	 µg	 ml-1	
daptomycin	(+,	n=10)	or	PBS	only	(-,	n=9)	(NS	P	>	0.05,	each	circle	represents	a	single	mouse).	Data	
were	analysed	by	a	Mann-Whitney	test.	Each	circle	represents	a	single	mouse.	
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Fig	3.9.	Agr-defecGve	S.	aureus	in	a	mixed	populaGon	promote	daptomycin	survival	of	the	whole	
p pulaGon	in	vivo.	a,	CFU	counts	from	the	peritoneal	cavity	of	mice	infected	with	wild-type	S.	aureus	or	
a	1:1	mixture	of	wild-type	and	ΔagrA	mutant	bacteria	a^er	4	h	and	b,	8	h	of	treatment	with	20	µg	ml-1	
daptomycin	(+,	n=10)	or	PBS	only	(-,	n=9)	(NS	P	>	0.05,	each	circle	represents	a	single	mouse).	Data	in	
panels	a	 	b	we e	analysed	 y	Mann-Whitney	test.	Where	shown,	error	bars	represent	the	Standard	
DeviaTon	of	the	mean.
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3.8 Daptomycin	activity	is	lost	during	incubation	with	the	ΔagrA	mutant	
Two	hypotheses	were	generated	to	explain	the	ability	of	agr-mutant	S.	aureus	to	survive	exposure	
to	 daptomycin:	 (i)	 S.	 aureus	 degraded	 or	 otherwise	 inactivated	 the	 antibiotic	 or	 (ii)	 S.	 aureus	
adapted	to	the	presence	of	the	antibiotic,	for	example	by	over-expressing	the	mprF	or	dlt	operon	
genes.			
To	 test	 the	 first	 hypothesis,	 the	 activity	 of	 daptomycin	 in	 the	 culture	 medium	 was	
measured	using	 two	assays:	 a	 zone	of	 inhibition	assay	and	a	bactericidal	 assay.	 For	 the	 zone	of	
inhibition	 assay,	 a	 standard	 plot	 of	 the	 size	 of	 the	 zones	 of	 inhibition	 caused	 by	 increasing	
concentrations	 of	 daptomycin	 (0,	 5,	 10	 and	 20	 μg	 ml-1)	 was	 generated.	 For	 this,	 various	
concentrations	 of	 daptomycin	 in	 TSB	were	 added	 to	 10	mm	wells	made	 in	 TSA	plates	 that	 had	
been	overlaid	with	USA300	wild-type,	and	incubated	for	16	h	at	37oC.	Thereafter,	the	size	of	each	
zone	 of	 inhibition	 was	 calculated	 from	 4	 perpendicular	 measurements	 (Fig	 3.8a	 and	 b).	 The	
standard	 plot	 enabled	 the	 size	 of	 the	 zone	 of	 inhibition	 to	 be	 converted	 to	 perecentage	
daptomycin	activity.	
For	the	daptomycin	bactericidal	assay,	wild-type	S.	aureus	(5	x	105	CFU	ml-1)	was	inoculated	
into	 TSB	 containing	 a	 range	 of	 daptomycin	 concentrations	 and	 incubated	 for	 16	 h	 at	 37°C.	
Subsequently,	the	change	in	CFU	counts	for	each	of	those	concentrations	was	determined	after	24	
h	 incubation	to	determine	the	minimum	bactericidal	concentration	 (the	 lowest	concentration	at	
which	all	bacteria	are	killed).	Concentrations	≥	1.25	μg	ml-1	killed	all	bacteria	in	the	inoculum	but	
lower	concentrations	were	sub-lethal.	In	keeping	with	previous	reports	429,430,431	this	indicated	that	
the	MIC	value	is	the	same	as	the	MBC	value	of	daptomycin	for	S.	aureus	(Table	3.1)		
Using	the	zone	of	inhibition	assay	it	was	found	that	over	8	h	of	incubation	with	wild-type	
USA300,	 daptomycin	 activity	 in	 the	 spent	 culture	 supernatant	 decreased	 slowly	 but	 steadily	 by	
50%.	However,	using	the	bactericidal	assay	it	was	found	that	this	level	of	daptomycin	activity	was	
still	sufficient	for	bacterial	killing	as	there	was	a	>1000-fold	decrease	in	the	CFU	counts	from	the	
starting	 bacterial	 inoculum	 (Fig.	 3.9a,	 b	 and	 c).	 By	 contrast,	 the	 activity	 of	 daptomycin	 in	 the	
culture	 supernatants	of	 the	ΔagrA	mutant	was	completely	 lost	by	4	h.	This	 indicated	 that	 there	
was	a	much	more	 rapid	 loss	of	daptomycin	activity	 in	 cultures	of	 the	ΔagrA	mutant.	 In	keeping	
with	this,	we	found	that	the	antibiotic	was	no	longer	bactericidal	(Fig.	3.9a,	b	and	c).		
Similar	findings	were	obtained	with	S.	aureus	SH1000,	where	the	Δagr	mutant	inactivated	
daptomycin	 within	 4	 h,	 whereas	 this	 did	 not	 occur	 until	 8	 h	 with	 the	 wild-type	 (3.10a).	 This	
confirmed	that	daptomycin	is	inactivated	by	both	wild-type	and	agrA	mutant	S.	aureus	but	the	loss	
of	Agr	function	makes	the	process	significantly	more	efficient.	
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To	ensure	that	daptomycin	was	not	degraded	in	TSB	alone	(the	medium	used	to	culture	the	
bacteria),	we	 incubated	 the	antibiotic	 in	 the	growth	medium	without	bacteria	 at	 37°C	 for	24	h.	
There	was	no	significant	loss	of	daptomycin	activity	during	this	period	(Fig	3.10b).		
Taken	together,	these	complementary	assays	demonstrated	that	the	agrA	mutant	rapidly	
inactivated	daptomycin,	which	presumably	explains	the	recovery	in	CFU	counts	of	this	strain	from	
4	h	after	daptomycin	exposure.	The	wild-type	was	also	able	to	partially	inactivate	daptomycin	but	
much	 less	 efficiently	 than	 the	 agrA	 mutant,	 which	 may	 explain	 why	 CFU	 counts	 were	 able	 to	
recover	after	24	h	exposure	to	the	antibiotic,	as	shown	in	Fig	3.3d.	
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Figure	3.8.	Daptomycin	activity	assays.	The	activity	of	daptomycin	in	spent	culture	supernatant	
was	assessed	using	a	daptomycin	zone	of	inhibition	assay		
A	 standard	 plot	 of	 the	 size	 of	 zones	 of	 inhibition	 generated	 by	 TSB	 containing	 various	
concentrations	of	daptomycin	(open	circle)	or	various	concentrations	of	daptomycin	and	0.25	µg	
ml-1	 oxacillin	 (filled	 circles)	 (a).	 The	 plot	 enabled	 zone	 size	 to	 be	 converted	 to	 percentage	
daptomycin	 activity,	 where	 20	 µg	ml-1	daptomycin	 was	 considered	 to	 be	 100%.	 Data	 show	 the	
mean	of	n=3	in	duplicate.	Error	bars	represent	the	standard	deviation	of	the	mean.	The	presence	
of	oxacillin	had	no	significant	effect	on	the	zone	size.	Representative	images	of	zones	of	inhibition	
caused	by	various	concentrations	of	daptomycin	from	3	independent	experiments	(b).	The	size	of	
each	zone	was	calculated	from	4	perpendicular	measurements	as	shown.	NB,	data	for	daptomycin	
combined	with	oxacillin	relates	to	work	done	in	chapter	5.	
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	Figure	3.10	Daptomycin	acGvity	assays.	The	acTvity	of	daptomycin	in	spent	culture	supernatant	was	
assessed	using	two	assays:	a	daptomycin	inhibitory	assay	(a,b)	and	a	daptomycin	bactericidal	assay	(c).	a,	
standard	plot	of	the	size	of	zones	of	inhibiTon	generated	by	TSB	containing	various	concentraTons	of	
daptomycin	(open	circle)	or		various	concentraTons	of	daptomycin	and	0.25	µg	ml-1	oxacillin	(ﬁlled	circles).	
The	plot	enabled	zone	size	to	be	converted	to	%	daptomycin	acTvity,	where	20	µg	ml-1	daptomycin	was	
considered	to	be	100	%.	Data	show	the	mean	of	n=3	in	duplicate.	Error	bars	represent	the	standard	
deviaTon	of	the	mean.	The	presence	of	oxacillin	had	no	signiﬁcant	eﬀect	on	the	zone	size.	b,	representaTve	
images	of	zones	of	inhibiTon	caused	by	various	concentraTons	of	daptomycin	from	3	independent	
experiments.	The	size	of	each	zone	was	calculated	from	4	perpendicular	measurements.	c,	daptomycin	
MBC	assay.	Wild-type	S.	aureus	(5	×	105	CFU	ml-1)	was	inoculated	into	TSB	containing	a	range	of	
daptomycin	concentraTons	and	the	change	in	CFU	counts	determined	a^er	24	h	incubaTon.	
ConcentraTons	≥	1.25	µg	ml-1	killed	the	inoculum	but	lower	concentraTons	were	sub-inhibitory.	Data	show	
the	mean	of	n=3	in	duplicate.	Error	bars	represent	the	standard	deviaTon	of	the	mean.	
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Figure	3.9.	Agr-defective	S.	aureus	inactivates	daptomycin	
Representative	 images	 (from	 at	 least	 3	 independent	 experiments)	 of	 zones	 of	 inhibition	 from	
culture	supernatants	from	the	USA300	wild-type	or	ΔagrA	mutant	incubated	with	daptomycin,	at	
various	time	points	(a).	Daptomycin	activity	in	culture	supernatants	(S/N)	from	wild-type	or	ΔagrA	
mutant	exposed	to	the	antibiotic	using	a	zone	of	inhibition	assay	(b),	or	bactericidal	assay	(c)	(n=3	
in	duplicate,	WT	vs	agrA	supernatant	P	<	0.0001	at	indicated	time	points	(*)	Data	in	panels	b	and	c	
were	 analysed	using	 a	 two-way	ANOVA	with	Dunnett’s	 post-hoc	 test.	Where	 shown,	 error	 bars	
represent	the	standard	deviation	of	the	mean.	
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Figure	3.12	Agr-defecGve	S.	aureus	survives	daptomycin	exposure	by	inacGvaGng	the	
anGbioGc.	a,	representaTve	images	(of	at	least	3	independent	experiments)	of	zones	of	
inhibiTon	from	culture	supernatants	from	the	USA300	wild-type	or	ΔagrA	mutant	incubated	with	
daptomycin,	at	various	Tme	points.b,c,	daptomycin	 cTvity	in	culture	supernatants	(S/N)	from	
wild-type	or	ΔagrA	mutant	exposed	to	the	anTbioTc	using	a	zone	of	inhibiTon	assay	(g),	or	
bactericidal	assay	(h)(n=3	in	duplicate,	WT	vs	agrA	supernatant	P	<	0.0001	at	indicated	Tme	
points	(*)	Data	in	panels	g	and	h	was	analysed	using	a	two-way	ANOVA	with	DunneW’s	post-hoc	
test.	Where	shown,	error	bars	represent	the	Standard	DeviaTon	of	the	mean.	
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Figure	3.10.	The	SH1000	agrA	mutant	inactivates	daptomycin	more	rapidly	than	the	wild-type	
Mono-cultures	of	SH1000	wild-type	or	SH1001	(Δagr)	were	exposed	to	20	µg	ml-1	daptomycin	over	
8	h	in	the	presence	of	0.5	mM	CaCl2	and	the	activity	of	the	antibiotic	at	various	time	points	was	
determined	using	a	zone	of	inhibition	assay	(a).	The	activity	of	daptomycin	was	lower	in	cultures	of	
the	agr	mutant	than	the	wild-type	at	2,	4	and	6	h	(for	wild-type	vs	agrA	P	<	0.01	at	the	indicated	
time	points	(*),	determined	by	two-way	ANOVA	with	Dunnett’s	post-hoc	test).	Daptomycin	activity	
in	 TSB	 without	 bacteria,	 incubated	 at	 37oC	 with	 shaking	 (b).	 There	 was	 no	 significant	 loss	 of	
daptomycin	activity	over	24	h	in	TSB	alone.	For	both	assays,	n=3	in	duplicate,	error	bars	represent	
the	standard	deviation	of	the	mean.		
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	Figure	3.13.	An	agr	mutant	inacGvates	daptomycin	more	rapidly	than	the	wild-type	in	the	SH1000	
background.	a,	mono-cultures	of	SH1000	wild-type	or	SH1001	(Δagr)	were	exposed	to	20	µg	ml-1	
daptomycin	over	8	h	in	the	presence	of	0.5	mM	CaCl2.	The	acTvity	of	the	anTbioTc	at	various	Tme	points	
was	determined	using	a	zone	of	inhibiTon	assay	as	described	in	the	Methods	secTon	and	in	Supplementary	
Figu 	4.	Data	represent	the	me ns	of	3	indep ndent	experiments	do e	in	duplic e.	Er or	bars	represent	
the	standard	deviaTon	of	the	mean.	The	acTvity	of	daptomycin	was	lower	in	cultures	of	the	agr	mutant	
than	the	wild-type	at	2,	4	and	6	h	(for	wild-type	vs	agrA	P	<	0.01	at	the	indicated	Tme	points	(*),	
determined	by	2-way	ANOVA	with	DunneW’s	post-hoc	test).	b,	daptomycin	acTvity	in	TSB	without	bacteria,	
incubated	at	37	oC	with	shaking	(n=3	in	duplicate,	error	bars	represent	the	standard	deviaTon	of	the	mean).	
There	was	no	signiﬁcant	loss	of	daptomycin	acTvity	over	24	h.	
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3.9 The	daptomycin	inactivator	is	present	in	the	culture	supernatant	of	the	ΔagrA	
mutant	exposed	to	daptomycin,	but	is	not	produced	constitutively	
To	 begin	 to	 characterize	 the	 daptomycin	 inactivation	 process,	 it	 was	 determined	 whether	 the	
inactivator	was	present	in	the	culture	supernatant	of	the	ΔagrA	mutant	or	was	cell-bound.	To	do	
this,	wild-type	USA300	was	recovered	by	centrifugation,	washed	in	PBS	and	resuspended	in	spent	
culture	supernatant	from	either	wild-type	bacteria	or	the	ΔagrA	mutant	that	had	been	exposed	to	
daptomycin.	 The	 resuspended	 wild-type	 bacteria	 were	 then	 exposed	 to	 a	 fresh	 dose	 of	
daptomycin	at	37oC	 for	8	h.	The	supernatant	 from	the	ΔagrA	mutant	 that	had	been	exposed	 to	
daptomycin	protected	 the	wild-type	 from	daptomycin	 challenge,	whereas	 the	 supernatant	 from	
the	wild-type	did	not	(Fig	3.11a).	This	indicated	that	the	inactivator	was	present	in	the	supernatant	
of	the	agrA	mutant.			
To	 investigate	 whether	 the	 culture	 supernatant	 from	 the	 ΔagrA	 mutant	 exposed	 to	
daptomycin	 protected	 wild-type	 bacteria	 from	 subsequent	 daptomycin	 challenge	 in	 vivo,	 mice	
were	 infected	with	wild-type	bacteria	that	were	resuspended	 in	culture	supernatants	 from	wild-
type	or	agrA	mutant	that	had	been	exposed	to	daptomycin.	Infected	mice	were	then	treated	with	
daptomycin	 for	 8	 h,	 before	 CFU	 from	 the	 peritoneal	 cavity	 were	 recovered	 and	 quantified.	
Similarly	 to	 the	 in	 vitro	 study,	 we	 found	 that	 the	 CFU	 recovered	 from	 the	mice	 that	 had	 been	
infected	with	the	wild-type	resuspended	in	the	culture	supernatant	from	the	ΔagrA	mutant	that	
had	 been	 exposed	 to	 daptomycin	 was	 significantly	 greater	 than	 the	 wild-type	 bacteria	
resuspended	 in	 the	 culture	 supernatant	 from	 the	wild-type	 bacteria	 that	 had	 been	 exposed	 to	
daptomycin	 (Fig	 3.11b).	 Thus,	 in	 keeping	 with	 the	 previous	 data	 (Fig	 3.7b),	 the	 USA300	 ΔagrA	
mutant	 protects	 wild-type	 bacteria	 during	 daptomycin	 challenge	 both	 in	 vitro	 and	 in	 vivo	 (Fig	
3.11a	and	b).		
Together,	 these	experiments	 indicated	 that	daptomycin	was	 inactivated	by	a	 secreted	or	
released	 factor.	 To	 investigate	 whether	 the	 ΔagrA	 mutant	 secreted	 the	 daptomycin-inactivator	
constitutively	or	 in	response	to	daptomycin,	culture	supernatants	from	ΔagrA	S.	aureus	exposed	
or	not	to	daptomycin	were	assessed	for	their	ability	to	inactivate	a	fresh	dose	of	daptomycin	(20	
μg	ml-1)	 (Fig	3.12a).	Culture	supernatant	 from	the	ΔagrA	mutant	exposed	to	daptomycin	 rapidly	
inactivated	 the	 fresh	 dose	 of	 daptomycin	 (Fig	 3.12b,	 c	 and	 d).	 By	 contrast,	 the	 spent	 culture	
supernatant	from	the	ΔagrA	mutant	that	had	not	been	exposed	to	daptomycin	did	not	inactivate	
the	 fresh	dose	of	daptomycin	 (Fig	3.12b,c	and	d).	Therefore,	 this	cell-free	system	demonstrated	
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that	the	daptomycin	inactivator	is	secreted	into	the	culture	supernatant	from	the	ΔagrA	mutant	in	
response	to	daptomycin	and	is	not	constitutively	produced	(Fig	3.12b,	c	and	d).			
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Figure	 3.11.	 Culture	 supernatant	 from	 the	 USA300	 ΔagrA	 mutant	 exposed	 to	 daptomycin	
protects	the	wild-type	from	a	subsequent	dose	of	the	antibiotic	in	vitro	and	in	vivo		
Wild-type	USA300	was	recovered	by	centrifugation,	washed	once	in	PBS	and	resuspended	in	spent	
culture	 supernatant	 from	either	wild-type	or	ΔagrA	mutant	S.	aureus	 that	had	been	exposed	 to	
daptomycin.	The	 resuspended	wild-type	bacteria	were	 then	challenged	 in	 vitro	 (a)	or	 in	 vivo	 (b)	
with	20	µg	ml-1	daptomycin	for	8	h.	For	a,	n=3	 in	duplicate,	*	P	<	0.01	compared	to	supernatant	
from	 the	 wild-type	 by	 Student’s	 t-test.	 Data	 show	 the	 mean	 of	 n=3	 in	 duplicate.	 Error	 bars	
represent	the	standard	deviation	of	the	mean.	For	b,	*	P	<	0.05	by	Mann-Whitney	test.	Each	circle	
represents	a	single	mouse	(for	each	group	n=8).	
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Figure	3.11	Culture	supernatant	from	the	USA300	ΔagrA	mutant	exposed	to	daptomycin	protects	the	
wild-type	from	the	anGbioGc	in	vitro	and	in	vivo.	Wild-type	USA300	was	recovered	by	centrifugaTon,	
washed	once	in	PBS	and	resuspended	in	spent	culture	supernatant	from	either	wild-type	or	agrA	
mutant	S.	aureus	that	had	been	exposed	to	daptomycin.	The	resuspended	wild-type	bacteria	were	then	
challenged	in	vitro	(a)	or	in	vivo	(b)	with	20	µg	ml-1	daptomycin	for	8	h.	For	a,	n=3	in	duplicat ,	*	P	<	0.01	
compared	to	supernatant	from	the	wild-type	by	student’s	t-test.	Data	show	the	mean	of	n=3	in	
duplicate.	Error	bars	represent	the	standard	deviaTon	of	the	mean.	For	b,	*	P	<	0.05	by	Mann-Whitney	
test.	Each	circle	represents	a	single	mouse	(for	each	group	n=8).	
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Figure	 3.12.	 The	 daptomycin	 inactivator	 is	 secreted	 in	 response	 to	 the	 antibiotic	 but	 not	
constitutively		
Schematic	outlining	the	experimental	protocol	to	study	the	daptomycin	inactivating	ability	of	the	
culture	 supernatant	 (a).	 To	 determine	whether	 the	 daptomycin	 inactivator	was	 secreted,	 spent	
culture	 supernatant	 from	 the	 ΔagrA	 mutant	 exposed,	 or	 not,	 to	 20	 µg	 ml-1	 daptomycin	 was	
assessed	 for	 its	 ability	 to	 inactivate	 a	 fresh	 dose	 of	 daptomycin	 at	 20	 µg	ml-1.	 The	 supernatant	
from	bacteria	that	had	been	exposed	to	daptomycin	rapidly	inactivated	the	fresh	dose	of	antibiotic	
(b,c).	By	contrast,	 supernatant	 from	the	ΔagrA	mutant	 that	had	not	previously	been	exposed	to	
daptomycin	 did	 not	 inactivate	 a	 fresh	 dose	 of	 antibiotic	 (n=3	 in	 duplicate,	 supernatant	 from	
bacteria	not	exposed	to	daptomycin	vs	supernatant	from	bacteria	exposed	to	daptomycin	P	<	0.01	
at	indicated	time	points	(*),	as	determined	by	two-way	ANOVA	with	Dunnett’s	post-hoc	test,	error	
bars	 represent	 the	 standard	 deviation	 of	 the	 mean).	 Therefore,	 the	 daptomycin	 inactivator	 is	
secreted	in	response	to	daptomycin	exposure.	To	confirm	that	daptomycin	was	fully	inactivated	by	
the	 spent	 culture	 supernatant	 from	 the	ΔagrA	mutant	exposed	 to	daptomycin,	 the	 supernatant	
incubated	with	 fresh	daptomycin	was	 then	 incubated	with	wild-type	S.	aureus.	 In	parallel,	wild-
type	S.	aureus	was	incubated	in	spent	culture	supernatant	from	the	ΔagrA	mutant	not	exposed	to	
daptomycin.	 	 There	was	no	 growth	defect	 in	 the	 supernatant	 from	 the	bacteria	 incubated	with	
daptomycin,	confirming	that	the	antibiotic	had	been	fully	inactivated	(d)	(n=3	in	duplicate).	For	c,	
and	d,	error	bars	represent	the	standard	deviation	of	the	mean.	
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3.10 Daptomycin	inactivation	does	not	enhance	the	emergence	of	resistance	
S.	aureus	can	become	insensitive	to	daptomycin	via	the	acquisition	of	gain-of-function	mutations	
in	 certain	 genes	 associated	 with	 the	 membrane	 and	 cell	 wall.	 Therefore,	 it	 was	 investigated	
whether	 the	ability	of	agr	mutant	S.	aureus	 to	 survive	daptomycin	exposure	 contributed	 to	 the	
emergence	 of	 insensitivity.	 To	 do	 this,	 a	 simple	 in	 vitro	 evolution	 experiment	was	 employed	 to	
select	 for	and	detect	 the	emergence	of	daptomycin	 insensitivity.	S.	aureus	USA300	wild-type	or	
ΔagrA	were	 inoculated	 into	 TSB	 containing	 daptomycin	 (20	 µg	 ml-1)	 and	 incubated	 for	 8	 h	 as	
described	for	killing	experiments	(Fig	3.3).	Bacteria	were	then	recovered	by	centrifugation,	washed	
with	 TSB	 and	 grown	 in	 TSB	 to	 stationary	 phase	before	 being	 re-exposed	 to	 daptomycin	 for	 8	 h	
(experiment	2).	This	procedure	was	 repeated	a	 third	 time	 (experiment	3).	 For	each	experiment,	
the	survival,	daptomycin	activity	and	MIC	at	8	h	were	determined	to	detect	whether	strains	had	
acquired	daptomycin	insensitivity.		
The	 MIC	 of	 both	 wild-type	 and	 ΔagrA	 was	 unchanged	 after	 a	 single	 exposure	 to	
daptomycin	(Fig	3.13a	and	b).	However,	in	keeping	with	a	previous	report432,	the	daptomycin	MIC	
of	both	strains	increased	after	a	second	exposure,	which	reduced	the	killing	rate	(Fig	3.13c	and	d)	
but	 did	 not	 affect	 daptomycin	 inactivation	 by	 the	 ΔagrA	 mutant	 (Fig	 3.13e	 and	 f).	 Despite	
increases	 in	 the	daptomycin	MIC,	 the	ΔagrA	mutant	 completely	 inactivated	daptomycin	 in	 all	 3	
experiments,	 whilst,	 the	 wild-type	 was	 consistently	 unable	 to	 inactivate	 daptomycin,	 despite	
surviving	the	second	and	third	exposure	to	daptomycin.		
Therefore,	 the	 release	 of	 the	 daptomycin-inactivating	 element	 does	 not	 provide	 an	
efficient	route	to	daptomycin	insensitivity.	Rather,	the	emergence	of	insensitivity	is	delayed	in	agr-
mutant	 S.	 aureus	 with	 efficient	 daptomycin	 inactivation.	 This	 suggests	 that	 daptomycin	
inactivation	 may	 enable	 S.	 aureus	 to	 survive	 short-term	 daptomycin	 exposure	 without	 the	
potential	 fitness	 costs	 associated	 with	 insensitivity	 conferred	 by	 genetic	 changes	 that	 result	 in	
changes	to	the	cell	wall	or	membrane.		
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Figure	 3.13.	 The	 recovery	 of	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin	 is	 not	 due	 to	 the	
emergence	of	resistance,	which	only	occurs	after	repeated	antibiotic	exposure		
S.	aureus	USA300	wild-type	or	ΔagrA	were	inoculated	into	TSB	containing	daptomycin	(20	µg	ml-1)	
and	 incubated	 for	 8	 h	 (experiment	 1).	 Bacteria	were	 then	 recovered	 by	 centrifugation,	washed	
with	 TSB	 and	 grown	 in	 TSB	 to	 stationary	 phase	before	 being	 re-exposed	 to	 daptomycin	 for	 8	 h	
(experiment	2).	This	procedure	was	 repeated	a	 third	 time	 (experiment	3).	 For	each	experiment,	
MIC	 (a,b),	 survival	 (c,d)	 and	daptomycin	 activity	 (e,f)	were	 determined.	 The	daptomycin	MIC	of	
both	strains	increased	after	the	second	exposure,	which	reduced	the	killing	rate	(c,d)	but	did	not	
affect	daptomycin	inactivation	by	the	agrA	mutant	(e,f,	(data	in	f,	are	all	0%)).	Data	in	c,d,e	and	f	
represent	the	mean	of	n=3	in	duplicate,	error	bars	represent	the	standard	deviation	of	the	mean.	
Data	in	a,b	represent	the	median	of	n=3	in	duplicate.	Data	in	panels	a,	b,	c	and	d	were	analysed	by	
two-way	 ANOVA	 with	 Dunnett’s	 post-hoc	 test,	 for	 data	 from	 experiment	 1	 vs	 data	 from	
experiments	2	or	3	P	<	0.01	at	the	indicated	time	points	(*).	In	panel	c,	for	the	final	time	point,	the	
data	from	experiment	3	but	not	2	are	significantly	different	from	experiment	1	as	determined	by	
two-way	ANOVA	with	Dunnett’s	 post-hoc	 test	P	 <	 0.05.	 For	 all	 panels,	 error	 bars	 represent	 the	
standard	deviation	of	the	mean.		
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3.11 Discussion	
Daptomycin	is	a	drug	of	last	resort	for	the	treatment	of	infections	caused	by	multi-drug	resistant	
Gram-positive	 organisms120,433.	 The	 emergence	 of	 daptomycin-resistant	 and	 daptomycin	 non-
susceptible	S.	aureus	isolates	is	rare	and	arises	due	to	spontaneous	mutations	(in	genes	including	
mprF	 and	 dlt)134.	 These	 spontaneously	 resistant	 strains	 exhibit	 changes	 in	 the	 cytoplasmic	
membrane,	cell	wall	stress	stimulon	and	in	membrane	potential,	all	of	which	are	hypothesized	to	
reduce	 the	 ability	 of	 daptomycin	 to	 depolarize	 the	 membrane134,135.	 However,	 although	
daptomycin-degrading	 enzymes	 have	 been	 identified	 in	 environmental	 isolates434,	 no	 dedicated	
daptomycin	resistance	mechanism	has	been	described	in	S.	aureus	or	any	other	pathogen.	Despite	
daptomycin	resistance	being	a	rare	event,	treatment	with	this	antibiotic	fails	to	cure	up	to	30%	of	
infections,	which,	given	the	last	resort	nature	of	daptomycin,	poses	a	very	serious	clinical	problem.		
Experiments	described	in	this	chapter	revealed	that	S.	aureus	strains	with	a	dysfunctional	
agr	 system	 can	 inactivate	 daptomycin,	 enabling	 bacterial	 survival	 and	 growth.	 Daptomycin	
exposure	 resulted	 in	an	 initial	period	of	killing	of	both	 laboratory	 (MSSA	and	MRSA)	and	clinical	
isolates	 followed	 by	 a	 period	 of	 bacterial	 recovery	 that	 coincided	 with	 the	 inactivation	 of	
daptomycin.	 This	 biphasic	 killing	 and	 subsequent	 recovery	 profile	 is	 similar	 to	 that	 observed	 in	
several	previously	 reported	daptomycin	killing	assays429–431.	However,	 the	phenomenon	was	not	
discussed	 and	 the	 contribution	 of	 Agr	 unappreciated.	 During	 extended	 incubation	 with	
daptomycin,	wild-type	strains	were	also	able	to	recover.	However,	this	occurred	at	a	much	slower	
rate,	 indicating	 that	 Agr	 activity	 reduces	 the	 efficiency	 of	 the	 daptomycin	 inactivation	 process,	
rather	than	blocking	it	entirely.	This	finding	may	also	explain	why	the	wild-type	and	agrA	mutant	
have	the	same	daptomycin	MIC	values,	since	these	are	measured	after	24	h	incubation.	
The	ability	of	Agr-defective	strains	to	rapidly	inactivate	daptomycin	is	due	to	the	presence	
of	an	 inactivator	secreted	or	released	 into	the	culture	supernatant	 in	response	to	the	antibiotic,	
indicating	 it	 is	 a	 specific	 response	 to	 daptomycin,	 rather	 than	 constitutively	 produced.	
Furthermore,	 the	 inactivator	 appears	 to	 be	 specific	 to	 daptomycin	 since	 Agr	 status	 did	 not	
influence	 the	 susceptibility	 of	 S.	 aureus	 to	 other	 antibiotics	 such	 as	 cloxacillin,	 vancomycin	 or	
gentamicin.	This	may	be	due	to	the	fact	that	daptomycin	is	a	lipopeptide	antibiotic	that	targets	the	
phospholipid	 membrane	 of	 the	 cell	 and	 therefore	 functions	 very	 differently	 to	 the	 other	
antibiotics	that	were	tested	100,106,120,435.	
The	 full	 clinical	 relevance	 of	 daptomycin	 inactivation	 by	 S.	 aureus	 is	 unclear.	 However,	
experiments	in	mice	indicate	that	it	can	contribute	to	treatment	failure.	In	addition,	because	this	is	
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more	of	an	immediate	and	transient	defence	tolerance	mechanism	employed	by	S.	aureus	against	
daptomycin,	it	will	not	be	identified	in	a	routine	diagnostic	lab	as	it	does	not	affect	the	MIC.		
There	 are	 very	 few	 studies	 examining	 the	 bacterial	 factors	 associated	 with	 daptomycin	
treatment	 failure.	 In	 particular,	 it	 has	 not	 yet	 been	 examined	 whether	 daptomycin	 treatment	
failure	is	associated	with	loss	of	Agr	function.	However,	our	work	and	that	of	many	other	groups	
has	shown	that	Agr-dysfunction	is	common	in	invasive	isolates	of	S.	aureus372,380,436.	Furthermore,	
it	is	important	to	note	that	daptomycin	is	used	to	treat	serious	MRSA	infections	and	many	MRSA	
isolates	in	the	UK	have	reduced	Agr	activity380,375,437,438	,	a	phenomenon	observed	in	our	panel	of	
20	clinical	isolates,	of	which	35%	lacked	detectable	haemolysis.	This	indicates	that	there	is	a	large	
fraction	of	 isolates	 that	are	capable	of	 inactivating	daptomycin.	 In	addition,	host	 factors	such	as	
serum	and	oxidants	can	reduce	Agr	activity439,	which	may	enable	wild-type	bacteria	to	efficiently	
inactivate	the	antibiotic	during	certain	types	of	invasive	infection.	
The	 emergence	 of	 daptomycin	 non-susceptible	 or	 resistant	 strains	 is	 rare	 but	 typically	
leads	 to	 treatment	 failure440,428,28,131.	 The	 data	 shown	 here	 do	 not	 indicate	 that	 daptomycin	
inactivation	by	ΔagrA	mutant	S.	aureus	provides	an	efficient	route	to	daptomycin	insensitivity	or	
resistance.	 In	 fact,	 it	 appears	more	 likely	 that	daptomycin	 inactivation	 reduces	 the	 selection	 for	
resistance	 to	emerge.	There	 is	 some	evidence	 that	daptomycin-insensitivity/resistance	confers	a	
fitness	 deficiency441,442.	 Therefore,	 daptomycin	 inactivation	 may	 provide	 short-term	 protection	
against	 daptomycin	 without	 the	 long-term	 costs	 of	 genetic	 changes	 that	 confer	 resistance	 via	
changes	to	the	cell	wall	or	membrane,	as	has	been	described	previously	for	phenotype-switching	
and	gentamicin	resistance443	.	
Taken	 together,	 the	 data	 presented	 in	 this	 chapter	 reveal	 that	 S.	 aureus	 can	 survive	
exposure	to	daptomycin	by	inactivating	the	antibiotic	via	a	process	that	is	inhibited	by	Agr	activity.	
However,	the	mechanism	by	which	daptomycin	is	inactivated,	the	role	of	Agr	and	the	relevance	of	
this	system	to	other	bacteria	is	unknown.	Addressing	these	gaps	in	our	knowledge	may	identify	an	
important	cause	of	daptomycin	treatment	failure	and	provide	targets	for	novel	therapeutics	that	
maintain	daptomycin	activity,	improving	therapeutic	efficacy.	
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Chapter	4		
Agr-defective	S.	aureus	inactivates	
daptomycin	by	releasing	phospholipids	
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4.1 Introduction	
The	data	presented	in	the	previous	chapter	demonstrated	that	loss	of	function	of	the	Agr	quorum-
sensing	 system	 enabled	 S.	 aureus	 to	 survive	 daptomycin	 challenge	 both	 in	 vitro	 and	 in	 vivo.	
Subsequent	work	revealed	that	the	ΔagrA	mutant	was	able	to	survive	daptomycin	by	secreting	or	
releasing	a	factor	that	inactivated	the	antibiotic.		
In	 general,	 antibiotic	 inactivation	 occurs	 via	 enzymes	 that	 employ	 one	 of	 two	modes	 of	
action:	 hydrolysis	 of	 the	 antibiotic	 or	 addition	 of	 a	 chemical	 group444–446.	 Antibiotics	 that	 are	
inactivated	 by	 hydrolysis	 include	 β-lactams447,	 the	 macrolide	 erythromycin,	 and	 epoxide	
antibiotics	 such	as	 fosfomycin.	Bacterial	enzymes	 such	as	amidases	and	esterases	 inactivate	 the	
antibiotic	 by	 targeting	 and	 hydrolyzing	 the	 chemical	 bonds	 or	 groups	 that	 are	 required	 for	
antibiotic	 activity.	 For	 example,	 β-lactamases	 belong	 to	 a	 group	 of	 amidases	 that	 cleave	 the	 β-
lactam	ring	of	penicillin	and	cephalosporin	antibiotics,	rendering	them	inactive444,448,449.	Similarly,	
macrolide	 esterases	 inactivate	 erythromycin	 by	 targeting	 the	 ester	 bond,	 which	 results	 in	 the	
opening	 of	 the	 macrolide	 ring444,450,	 whereas	 epoxidases	 inactivate	 the	 epoxide	 antibiotic	
fosfomycin	by	opening	the	reactive	fosfomycin	ring	via	hydrolysis451.	
In	 addition	 to	 antibiotic	 cleavage,	 some	 enzymes	 inactivate	 antibiotics	 by	 transfer	 of	 a	
chemical	 group	 onto	 the	 drug.	 Antibiotics	 that	 are	 inactivated	 by	 this	 mechanism	 include	 the	
aminoglycosides,	 chloramphenicol,	 macrolides,	 rifamycins	 and	 fosfomycin.	 The	 enzymes	
responsible	 are	 known	 as	 group	 transferases	 and	 inactivate	 antibiotics	 by	 covalent	 addition	 of	
chemical	moieties	 that	 cause	 structural	 changes	 that	prevent	 the	antibiotic	 from	binding	 to	 the	
target.	 There	 are	 6	 chemical	 strategies	 employed	 by	 group	 transferases	 which	 include:	 (i)	 O-
acylation	and	N-acylation	 (ii)	O-phosphorylation,	 (iii)	 thiol-transfer,	 (iv)	O-nucleotidylation,	 (v)	O-
ribosylation	 and	 (vi)	 O-glycosylation.	 Because	 the	 covalent	 modifications	 require	 co-substrates	
such	 as	 ATP,	 acetyl-CoaA,	 adenine	 dinucleotide	 (NAD+),	 UDP-glucose	 or	 glutathione,	 these	
enzymes	 are	 only	 active	 in	 the	 cytoplasm	 of	 the	 bacterial	 cell444–446,448,449.	 For	 example,	
aminoglycoside	 acetyltransferases	 inactivate	 aminoglycoside	 antibiotics	 via	 N-acetylation	 that	
disrupts	 the	hydroxyl	and	amine	groups	required	for	 the	 interaction	with	the	ribosome444,452.	By	
contrast,	 chloramphenicol	 acetyltransferases	 (CATs)	 are	 trimeric	 enzymes	 that	 employ	 the	 O-
acetylation	strategy	of	covalent	modification444,453.		
Daptomycin	is	comprised	of	13	amino	acids	cyclized	through	an	ester	linkage	between	the	
secondary	hydroxyl	 group	of	 the	 amino	acid	 threonine	 (Thr)	 and	 the	 carboxyl	 of	 the	C-terminal	
kynurenine	 (Kyn)	 amino	 acid	 residues.	 The	 N-terminus	 of	 the	 tryptophan	 (Trp)	 amino	 acid	 is	
attached	 to	 a	 C-10	 fatty	 acyl	 tail.	 The	 daptomycin	 ring	 structure	 and	 fatty	 acyl	 tail	 have	 been	
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demonstrated	 to	 be	 essential	 for	 antimicrobial	 activity	 (Fig	 4.1)434,454,455.	 A	 previous	 report	 by	
D’costa	 et	 al.	 in	 2012	 detailed	 how	 soil	 actinomycetes	 inactivate	 daptomycin	 using	 hydrolytic	
enzymatic	 mechanisms.	 These	 included	 ring	 hydrolysis	 of	 daptomycin	 and	 deacylation	 of	 the	
daptomycin	 fatty	 acyl	 tail434	 (Fig	 4.2).	 Ring-opening	 hydrolysis	 leads	 to	 the	 linearization	 of	 the	
cyclic	peptide	chain.	The	site	of	hydrolysis	and	inactivation	of	daptomycin	is	the	circularizing	ester	
linkage	formed	by	the	ester	bond	between	threonine	and	Kyn	amino	acid	residues,	which	means	
that	the	hydrolase	responsible	is	likely	a	serine	protease434.	By	contrast,	removal	of	the	fatty	acyl	
tail	 occurs	 via	 deacylation	 and	 occurs	 via	 cleavage	 of	 the	N-terminal	 Trp	 amino	 acid	 residue	 of	
hydrolyzed	daptomycin	via	a	protease434.		
In	 addition	 to	 the	 enzymes	 produced	 by	 soil	 bacteria,	 several	 commercially	 available	
proteases	 of	 mammalian	 origin	 including	 bovine-alpha	 chymotrypsin	 and	 Type	 I	 protease	
inactivate	 daptomycin	 by	 general	 hydrolytic	 cleavage434.	 Therefore,	 it	 appears	 that	 daptomycin	
can	be	inactivated	by	several	different	routes	including	proteases	with	broad	target	ranges.	
S.	 aureus	 produces	 several	 different	 proteases,	 including	 serine	 proteases,	 cysteine	
proteases	 and	 metalloproteases.	 These	 secreted	 proteins	 are	 known	 to	 function	 as	 virulence	
factors,	enabling	 the	acquisition	of	nutrients	 from	host	 tissues	and	degradation	of	antimicrobial	
peptides	 (AMPs)	 and	 antibodies456,456,457.	 Since	 some	 of	 these	 proteases	 are	 the	 same	 class	 as	
those	that	inactivate	daptomycin,	the	hypothesis	tested	in	this	chapter	is	that	the	ΔagrA	mutant	
produces	enzymes	that	degrade	and	inactivate	daptomycin.	
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Figure	4.1.	The	structure	of	daptomycin			
Daptomycin	 consists	 of	 13	 amino	acids.	 The	peptide	 core	 is	 composed	of	 amino	acids	 including	
Gly,	Orn,	Asp,	D-Ala,	Asp,	Gly,	D-Ser,	MeGlu	and	Kyn,	that	forms	an	ester	bond	with	Thr	and	builds	
up	the	10-member	macrolactone	ring	and	three	exocyclic	residues	including	Trp,	D-Asn	and	L-Asp.	
The	N-terminal	 Trp	 is	 attached	 to	 the	 fatty	 acyl	moiety,	which	 consists	 of	 10	 carbon	 atoms	 (n-
decanoyl).	In	addition,	daptomycin	is	a	member	of	the	acidic	lipopeptide	family	and	has	an	overall	
(-3)	charge.	The	bactericidal	activity	of	daptomycin	is	dependent	on	binding	to	calcium	because	it	
causes	a	 conformational	 change	 in	daptomycin	and	 forms	a	bridge	between	 the	cell	membrane	
and	daptomycin.	A	conserved	motif	 is	 responsible	 for	providing	calcium-binding	sites,	which	are	
shown	 in	red	and	 include	the	non-proteinogenic	amino	acids	 (amino	acids	 that	are	not	 found	 in	
the	genetic	code	of	any	organism)	are	shown	in	green.	The	numbers	indicate:	1,	Tryptophan	(Trp);	
2,	D-Asparagine	(D-Asn);	3,	L-Aspartic	acid	(L-Asp);	4,	Threonine	(Thr);	5,Glycine	(Gly);	6,	Ornithine	
(Orn);	7,	Aspartic	acid	(Asp);	8,	D-Alanine	(D-Ala);	9,	Asp;	10,	Gly;	11,	D-Serine	(D-Ser);	12,	(2S,3R)	
methylglutamate	(MeGlu),	and	13,	Kynurenine	(Kyn).	Biotin	and	BoDipy	molecules	can	be	attached	
to	 daptomycin	 via	 the	 free	 amine	 group,	 which	 is	 circled	 and	 highlighted	 in	 purple	 bold	 face	
(adapted	from	L	Robbel.	et.	al.,	2010)458.	
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Figure	4.2.	The	most	common	sites	of	cleavage	of	daptomycin	that	result	in	inactivation		
Ring	 hydrolysis	 between	 amino	 acids	 4-13	 and	 12	 and	 13	 (indicated	 by	 the	 blue	 spiral	 symbol)	
leads	 to	 linearization	 and	 hydrolysis	 between	 amino	 acids	 1-2	 and	 1-fatty	 acid	 tail	 leads	 to	
deacylation	of	the	lipid	tail	(adapted	from	D’Costa	et.	al.,	2012)434			
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4.2 Agr-deficient	S.	aureus	inactivates	daptomycin	by	releasing	phospholipids		
As	 a	 first	 step	 towards	 testing	whether	 S.	 aureus	 inactivated	 daptomycin	 via	 an	 enzyme,	 initial	
experiments	 sought	 to	 characterize	 the	 basic	 properties	 of	 the	 inactivator.	 Firstly,	 proteins	 in	
culture	supernatants	from	the	S.	aureus	USA300	ΔagrA	mutant	previously	exposed	to	daptomycin	
were	 degraded	 by	 treatment	 with	 proteinase	 K,	 a	 serine	 protease	 that	 exhibits	 a	 very	 broad	
cleavage	specificity459	or	 trypsin,	which	cleaves	peptide	chains	at	 the	carboxyl	side	of	 the	amino	
acids	lysine	or	arginine460.	Culture	supernatants	were	also	heat	treated	at	80	oC	for	20	minutes	to	
denature	 proteins	 by	 breaking	 hydrogen	 bonds	 and	 disrupting	 non-polar	 hydrophobic	 bonds461.	
However,	neither	the	proteases,	nor	heat	treatment	of	culture	supernatants	impeded	daptomycin	
inactivation	(Fig	4.3).	Whilst	not	conclusive,	these	data	strongly	indicated	that	the	S.	aureus	ΔagrA	
mutant	inactivated	daptomycin	via	an	enzyme-independent	process,	falsifying	the	hypothesis	(Fig	
4.3).		
To	determine	the	nature	of	the	daptomycin	inactivator	it	was	considered	how	daptomycin	
functions.	Daptomycin	targets	phosphatidylglycerol	 (PG),	the	most	abundant	phospholipid	found	
in	 the	 staphylococcal	 membrane,	 disrupting	 membrane	 organization	 and	 triggering	 membrane	
blebbing	without	lysis28,121,125,462,463.	Therefore,	it	was	hypothesised	that	membrane	phospholipids	
released	 into	 the	extracellular	 space	could	bind	and	 inactivate	daptomycin.	This	hypothesis	was	
supported	 by	 previous	 work	 showing	 that	 pulmonary	 surfactant,	 which	 contains	 phospholipids	
including	PG,	inactivates	daptomycin464,465.	To	test	this	hypothesis,	culture	supernatants	from	the	
S.	 aureus	 USA300	 ΔagrA	 mutant	 previously	 exposed	 to	 daptomycin	 were	 treated	 with	
phospholipases	 A1,	 A2	 and	 D	 or	 0.1%	 Triton	 X-100.	 Each	 phospholipase	 cleaves	 at	 a	 different	
position	on	the	phospholipid	molecule,	with	phospholipase	A1	cleaving	the	acyl	chain	attached	to	
position	 -1	of	 the	glycerol-3-phosphate	 substrate,	phospholipase	A2	cleaves	 the	 fatty	acid	 chain	
attached	to	position	-2	of	the	glycerol-3-phosphate	substrate	and	phospholipase	D	cleaves	at	the	
phosphate	 group	 to	 produce	 phosphatidic	 acid466.	 Triton	 X-100	 is	 a	 detergent	 that	 solubilizes	
phospholipids467.	 Each	 of	 the	 three	 phospholipases	 restored	 the	 activity	 of	 daptomycin	 as	 did	
Triton	 X-100	 (Fig.	 4.3),	 strongly	 indicating	 that	 the	 daptomycin	 inactivator	 found	 in	 the	 culture	
supernatants	of	the	ΔagrA	mutant	was	a	phospholipid.	
Since	 the	 daptomycin	 inactivator	 was	 only	 produced	 by	 the	 S.	 aureus	 ΔagrA	mutant	 in	
response	 to	 the	 antibiotic	 (Fig.	 3.12c),	 culture	 supernatants	 from	 bacteria	 exposed	 or	 not	 to	
daptomycin	were	examined	 for	 the	presence	of	 phospholipids.	 For	 this,	 a	 phospholipid-reactive	
dye	 (FM-4	 -64)468	 was	 used	 to	 detect	 and	 quantify	 phospholipids	 released	 in	 the	 culture	
supernatant	 during	 exposure	 of	 the	 S.	 aureus	 ΔagrA	 mutant	 to	 daptomycin	 (Fig	 4.4).	 In	 the	
		 122	
absence	of	daptomycin,	S.	aureus	 ΔagrA	 released	extremely	 low	 levels	of	phospholipid	 into	 the	
supernatant.	However,	bacteria	exposed	to	the	antibiotic	released	huge	quantities	of	phospholipid	
during	 the	 first	 4	 hours	 of	 exposure,	 after	 which	 the	 rate	 of	 phospholipid	 accumulation	 in	 the	
medium	decreased	significantly.	The	observed	kinetics	of	phospholipid	release	fits	with	the	data	in	
(Fig.	 3.9)	 showing	 that	 daptomycin	 is	 inactivated	 in	 the	 first	 4	 hr	 of	 incubation	 with	 S.	 aureus	
ΔagrA.	 Together,	 these	 data	 demonstrate	 that	 daptomycin	 triggers	 the	 release	 of	 a	 significant	
quantity	of	phospholipids	from	the	S.	aureus	ΔagrA	mutant,	and	that	the	released	phospholipids	
contribute	to	the	inactivation	of	daptomycin	(Fig	4.3	and	4.4).	
To	identify	the	phospholipids	present	in	the	culture	supernatant	from	the	S.	aureus	ΔagrA	
mutant	 that	 had	 been	 exposed	 to	 daptomycin,	 thin-layer	 chromatography	 (TLC)	 was	
employed132,416,131,415.	 Phospholipids	 were	 extracted	 using	 the	 chloroform:methanol	 Bligh-Dyer	
method.	Thereafter,	a	silica-based	TLC	plate	was	spotted	with	the	extracted	lipid	sample	and	run	
in	 chloroform:methanol:30%ammonium	 hydroxide	 (65:30:4	 v/v/v)	 solvent	 to	 separate	 lipids,	
which	 were	 then	 detected	 by	 iodine	 staining.	 The	 identity	 of	 each	 spot	 was	 determined	 by	
reference	 to	 the	 migration	 pattern	 of	 phospholipid	 standards	 purified	 from	 TSB	 containing	
daptomycin	as	described	for	experimental	samples.	These	phospholipid	standards	were	chosen	on	
the	basis	 that	 they	have	previously	been	 reported	 to	occur	 in	 the	staphylococcal	membrane,	or	
that	act	as	precursors	to	those	lipids	that	are	found	in	the	membrane	28,469.	
	 TLC	 analyses	 revealed	 that	 the	 culture	 supernatant	 contained	 PG,	 lysyl-
phosphatidylglycerol	 (LPG)	 and	 cardiolipin	 (CL)	 (Fig	 4.5).	 To	 quantify	 each	 of	 the	 identified	
phospholipids	2D-TLC	was	undertaken	and	 lipids	revealed	by	 iodine	staining.	Thereafter,	each	of	
the	lipid	spots	that	had	been	identified	as	PG,	LPG	and	CL	were	scraped	off	the	plate	and	subjected	
to	 a	 colorimetric	phosphate	quantification	assay.	 This	 revealed	 that	PG	was	 the	most	 abundant	
phospholipid	species	(>70%	of	total	phospholipid),	together	with	smaller	quantities	of	CL	and	LPG	
in	the	culture	supernatant	of	the	ΔagrA	mutant	exposed	to	daptomycin	(Table	4.1	and	Fig	4.5).	
Taken	 together,	 these	 findings	 confirmed	 that	 the	 ΔagrA	 mutant	 released	 membrane	
phospholipids	in	the	culture	supernatant	upon	exposure	to	daptomycin,	and	that	these	lipids	were	
likely	to	be	responsible	for	inactivating	the	antibiotic.	
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Figure	4.3.	Phospholipases	inhibit	the	inactivation	of	daptomycin	
	Daptomycin	 activity	 in	 TSB	 only	 (TSB)	 or	 culture	 supernatant	 from	 USA300	 ΔagrA	 exposed	 to	
daptomycin	and	subsequently	treated	with	heat	(80oC,	20	min),	proteinase	K	(prot.	K,	10	μg	ml-1),	
trypsin	(10	μg	ml-1),	phospholipases	(PLP)	A1,	A2	or	D	(each	at	5	U	ml-1),	or	0.1%	Triton	X-100	(TX-
100)	 (n=4,	 in	 duplicate,	 for	 untreated	 samples	 vs	 phospholipase	 or	 TX-100-treated	 samples	P	 <	
0.0001	 (*).	 Data	were	 analysed	 using	 a	 one-way	 ANOVA	with	 Tukey’s	 post-hoc	 test.	 Error	 bars	
represent	the	standard	deviation	of	the	mean.			
	
	
Figure	4.4.	Agr-defective	S.	aureus	releases	membrane	phospholipids			
Lipid	 release	 from	 USA300	 ΔagrA	 mutant	 exposed,	 or	 not,	 to	 20	 µg	 ml-1	 daptomycin	 (n=3	 in	
duplicate,	for	daptomycin	treated	vs	untreated	P	<	0.0001	at	indicated	time	points	(*).	Data	were	
analysed	using	a	two-way	ANOVA	with	Dunnett’s	post-hoc	test.	Error	bars	represent	the	standard	
deviation	of	the	mean.			
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Figure	4.2	.	Phospholipases	inhibit	the	inacLvaLon	of	daptomycin.	daptomycin	acKvity	in	TSB	only	(TSB)	or	
culture	supernatant	from	USA300	ΔagrA	exposed	to	daptomycin	and	subsequently	treated	with	heat	(80	
oC,	20	min),	proteinase	K	(prot.	K,	10	μg	ml-1),	trypsin	(10	μg	ml-1),	phospholipases	(PLP)	A1,	A2	or	D	(each	at	
5	U	ml-1),	or	0.1%	Triton	X-100	(TX-100)	(n=4,	in	duplicate,	for	untreated	samples	vs	phospholipase	or	
TX-100-treated	samples	P	<	0.0001	(*).	Data	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	
test.	Where	shown,	error	bars	represent	the	standard	deviaKon	of	the	mean.			
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Figure	4.3	.	Agr-defecLve	S.	aureus	releases	membrane	phospholipids.		lipid	release	from	USA300	ΔagrA	
mutant	exposed,	or	not,	to	20	µg	ml-1	daptomycin	(n=3	in	duplicate,	for	daptomycin	treated	vs	untreated	P	
<	0.0001	at	indicated	Kme	points	(*).	Data	were	analysed	using	a	2-way	ANOVA	with	Dunnec’s	post-hoc	
test.	Where	shown,	error	bars	represent	the	standard	deviaKon	of	the	mean.			
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Figure	 4.5.	 Spent	 culture	 supernatant	 from	 ΔagrA	 USA300	 exposed	 to	 daptomycin	 contains	
membrane	phospholipids		
Thin-layer	 chromatography	 (TLC)	 plate	 spotted	with	 chloroform:methanol	 extracts	 from	 culture	
supernatant	of	TSB	only	(TSB),	TSB	containing	daptomycin,	filtered	culture	supernatant	from	the	
agrA	mutant	exposed	to	daptomycin	(agrA),	TSB	containing	daptomycin	and	various	phospholipids	
standards,	 including	 phosphatidylglycerol	 (PG)28,	 cardiolipin	 (CL)28,	 lysyl-phosphatidylglycerol	
(LPG)28,	 phosphatidylethanolamine	 (PE)469	 or	 phosphatidic	 acid	 (PA)469,	 and	 stained	 with	 iodine	
vapour	after	chromatography	in	chloroform:methanol:ammonium	hydroxide	(65:30:4	v/v/v).		
	
Table	4.1.	Identification	and	quantification	of	phospholipids	in	the	culture	supernatant	of	ΔagrA	
USA300	strain	exposed	to	daptomycin		
Lipids	were	 identified	 by	 reference	 to	 purified	 standards	 and	quantified	 as	 described	 in	 section	
2.17.	 Data	 are	 presented	 as	 the	 relative	 proportions	 of	 each	 phospholipid	 (relative	%)	 and	 the	
concentration	of	each	lipid	in	spent	culture	supernatant.	Data	shown	are	the	mean	averages	of	3	
independent	experiments	in	duplicate	±	the	standard	deviation	of	the	mean.		
	
	
	
	
	
	
	
	
	 USA300	ΔagrA	 USA300	WT	
Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
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	Figure	4.4	.	Spent	culture	supernatant	from	ΔagrA	USA300	exposed	to	daptomycin	contains	
membrane	phospholipids.	a,	Thin-layer	chromatography	(TLC)	plate	spoced	with	
chloroform:methanol	extracts	from	culture	supernatant	of	TSB	only	(TSB),	TSB	containing	
daptomycin,	ﬁltered	culture	supernatant	from	the	agrA	mutant	exposed	to	daptomycin	(agrA),	TSB	
containi g	daptomycin	and	various	phospholipids	previously	reported	to	occur	in	the	staphylococcal	
membrane	or	that	act	as	precursors:	phosphaKdylglycerol	(PG)24,	cardiolipin	(CL)24,	lysyl-
phosphaKdylglycerol	(LPG)24,	phosphaKdylethanolamine	(PE)57	or	phosphaKdic	acid	(PA)57,	and	
stained	with	iodine	vapour	a^er	chromatography	in	chloroform:methanol:ammonium	hydroxide	
(65:30:4	v/v/v).	All	images	are	representaKve	of	at	least	two	independent	experiments.	
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4.3 Purified	phosphatidylglycerol	inactivates	daptomycin	
To	determine	which	of	the	phospholipids	released	by	the	ΔagrA	mutant	inactivated	daptomycin,	
the	antibiotic	was	incubated	with	various	concentrations	of	purified	PG,	LPG,	CL,	phophatidic	acid	
(PA)	or	diacylglycerol	 (DAG).	The	activity	of	daptomycin	was	 then	determined	using	 the	 zone	of	
inhibition	assay	described	previously.	This	revealed	that,	at	concentrations	similar	to	those	found	
in	the	culture	supernatant,	purified	PG	inactivated	daptomycin	in	a	dose-dependent	manner	(Fig	
4.6a).	By	 contrast,	 LPG	only	 inhibited	daptomycin	activity	at	a	 supra-physiological	 concentration	
(100	μM),	whilst	CL,	PE,	PA	and	DAG	had	no	effect	on	the	antibiotic	at	any	of	the	concentrations	
used	(Fig	4.6a).	The	assay	was	then	repeated	using	a	mixture	of	PG,	LPG	and	CL	at	the	approximate	
ratio	found	in	the	culture	supernatant	and	the	staphylococcal	membrane	(8:1:1)28.	As	for	purified	
PG	 alone,	 this	 mixture	 of	 PG,	 LPG	 and	 CL	 also	 efficiently	 inactivated	 daptomycin	 in	 a	 dose	
dependent	manner	(Fig	4.6b).		
To	provide	additional	evidence	that	exogenous	PG	protected	S.	aureus	 from	daptomycin,	
an	MIC/MBC	 assay	 of	 the	wild-type	 and	 the	 ΔagrA	mutant	was	 undertaken	 in	 the	 presence	 of	
purified	 PG,	 LPG	 or	 CL.	 It	 was	 found	 that	 the	 daptomycin	MIC/MBC	 of	 both	 the	 strains	 in	 the	
absence	of	phospholipid	 (1	μg	ml-1)	was	 the	same	 in	 the	 in	 the	presence	of	CL.	By	contrast,	 the	
MIC/MBC	of	both	the	wild-type	ΔagrA	mutant	in	the	presence	of	PG	was	significantly	increased	(8	
μg	ml-1),	whilst	 the	 presence	 of	 LPG	 led	 to	 a	more	modest	 increase	 (4	 μg	ml-1).	 Therefore,	 the	
presence	 of	 exogenous	 PG,	 and	 to	 a	 lesser	 extent	 LPG,	 protected	 S.	 aureus	 from	 daptomycin,	
whilst	CL	did	not	(Fig	4.6c).	Together,	these	data	confirm	that	membrane	PG	released	from	the	S.	
aureus	ΔagrA	mutant	in	response	to	daptomycin	was	responsible	for	inactivating	the	antibiotic.	
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Figure	4.6.	Purified	membrane	phospholipids	inactivate	daptomycin		
Activity	 of	 daptomycin	 after	 incubation	 with	 purified	 phosphatidylglycerol	 (PG),	 lysyl-
phosphatidylglycerol	(LPG),	cardiolipin	(CL),	phosphatidic	acid	(PA),	or	diacylglycerol	(DAG)	at	the	
indicated	concentrations	(n=3	in	duplicate,	for	TSB	without	lipid	vs	indicated	lipids	(*)	P	<	0.0001)	
(a).	Activity	of	daptomycin	after	incubation	with	a	mixture	of	purified	PG,	LPG	and	CL	(8:1:1	ratio),	
which	approximates	that	found	in	the	staphylococcal	membrane	(n=3	in	duplicate,	for	TSB	without	
lipid	vs	indicated	lipid	concentrations	(*)	P	<	0.0001)	(b).	Daptomycin	MIC/MBC	of	wild-type	(WT)	
or	agrA	mutant	in	the	presence	of	10	µM	purified	PG,	CL	or	LPG	(n=3	in	duplicate,	data	represent	
the	median	values,	for	TSB	without	lipid	vs	indicated	lipids	(*)	P	<	0.0001	(c).	Data	in	panels	a,	b	
and	c	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	test.	Where	shown,	error	bars	
represent	the	standard	deviation	of	the	mean.			
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Figure	4.5	.	Agr-defecLve	S.	aureus	inacLvates	daptomycin	by	releasing	membrane	phospholipids.	a,	
acKvity	of	daptomycin	a^er	incubaKon	with	puriﬁed	phosphaKdylglycerol	(PG),	lysyl-phosphaKdylglycerol	
(LPG),	cardiolipin	(CL),	phosphaKdic	acid	(PA),	or	diacylglycerol	(DAG)	at	the	indicated	concentraKons	(n=3	
in	duplicate,	for	TSB	without	lipid	vs	 dicated	lipids	(*)	P	< 0.0001).	b,	acKvity	of	dapt mycin	a^er
incubaKon	with	a	mixture	of	puriﬁed	PG,	LPG	and	CL	(8:1:1	raKo),	which	approximates	that	found	in	the	
staphylococcal	membrane	(n=3	in	duplicate,	for	TSB	without	lipid	vs	indicated	lipid	concentraKons	(*)	P	<	
0.0001).	c,	daptomycin	MIC/MBC	of	wild-type	(WT)	or	agrA	mutant	in	the	presence	of	10	µM	puriﬁed	PG,	
CL	or	LPG	(n=3	in	duplicate,	data	represent	the	median	values,	for	TSB	without	lipid	vs	indicated	lipids	(*)	P	
<	0.0001.	Data	in	 anels	a,	b	and	c	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	pos -hoc	test.	
Where	shown,	error	bars	represent	the	standard	deviaKon	of	the	mean.			
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4.4 Daptomycin-triggered	phospholipid	release	occurs	via	an	active	process	
Having	 established	 that	 daptomycin	 was	 inactivated	 by	 released	 phospholipids,	 it	 was	 then	
investigated	 whether	 this	 occurred	 via	 an	 active	 process	 or	 was	 simply	 a	 consequence	 of	
membrane	damage	 caused	by	 the	 antibiotic.	 To	 do	 this,	 key	 cellular	 processes	were	 chemically	
inhibited	before	daptomycin	challenge	and	measurement	of	 released	phospholipids.	Respiration	
was	 Inhibited	 with	 2-n-Heptyl-4-hydroxyquinoline	 N-oxide	 (HQNO)	 or	 0.05%	 of	 Sodium	 azide	
(NaN3),	whilst	protein	biosynthesis	was	inhibited	using	tetracycline	(Tet)	or	chloramphenicol	(Chl).	
General	metabolism	was	inhibited	by	undertaking	experiments	at	4oC.		
	 As	expected,	at	37oC	in	the	absence	of	inhibitors,	daptomycin	exposure	of	S.	aureus	ΔagrA	
resulted	 in	 the	 release	 of	 high	 levels	 of	 phospholipid	 (Fig	 4.7).	 By	 contrast,	 the	 presence	 of	
inhibitors	of	 respiration,	protein	biosynthesis	or	 reduction	of	 the	 incubation	 temperature	 to	4oC	
reduced	phospholipid	release	to	almost	undetectable	levels	(Fig	4.7).		
In	an	additional	experiment,	the	role	of	phospholipid	biosynthesis	in	phospholipid	release	
was	determined	using	the	antibiotic	platensimycin,	which	blocks	fatty	acid	biosynthesis419.	The	
presence	of	platensimycin	completely	blocked	daptomycin-induced	phospholipid	release	(Fig	4.8).	
To	 ensure	 that	 the	 panel	 of	 inhibitors	 used	 did	 not	 interfere	 in	 any	 way	 with	 the	
phospholipid-release	 assay,	 experiments	 were	 repeated	 in	 the	 presence	 of	 lysostaphin,	 which	
degrades	the	cell	wall	and	results	in	bacterial	lysis,	or	high	temperature,	both	of	which	result	in	the	
release	of	bacterial	phospholipids	into	the	culture	supernatant.	These	assays	confirmed	that	none	
of	the	inhibitors	used	interfered	with	the	detection	of	phospholipids.	However,	it	should	be	noted	
that	 because	 lysostaphin	 is	 an	 enzyme,	 assays	 done	 at	 4oC	 resulted	 in	 reduced	 cell	 lysis	 and	
therefore	reduced	phospholipid	release	(Fig	4.9a,	b).		
	 In	 conclusion,	 these	 assays	 revealed	 that	 daptomycin-triggered	 phospholipid	
release	 from	 the	S.	 aureus	 ΔagrA	mutant	occurred	 via	 an	 active	mechanism	 that	 required	both	
protein	and	lipid	biosynthesis.			
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Figure	4.7.	Phospholipid	release	from	Agr-defective	S.	aureus	occurs	via	an	active	process	
	Lipid	release	from	the	USA300	ΔagrA	mutant	exposed	to	20	µg	ml-1	daptomycin	at	37oC	(CTL),	4oC,	
respiratory	 inhibitors	 2-n-Heptyl-4-hydroxyquinoline	 N-oxide	 (HQNO)	 or	 NaN3,	 or	 antibiotics	
tetracycline	 (Tet)	 or	 chloramphenicol	 (Chl).	 (n=3	 in	 duplicate,	 for	 TSB	 only	 (CTL)	 at	 8	 h	 vs	 TSB	
containing	 inhibitors	or	at	4	oC	 	P	<	0.0001	(*)	as	determined	by	a	one-way	ANOVA	and	Tukey’s	
post-hoc	test.	Error	bars	represent	the	standard	deviation	of	the	mean.	
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Figure	4.8.	Lipid	biosynthesis	is	required	for	phospholipid	release		
Lipid	release	from	USA300	ΔagrA	in	response	to	20	µg	ml-1	daptomycin	(dapt),	in	the	presence	or	
absence	of	a	sub-lethal	concentration	(7.5	µg	ml-1)	of	the	lipid	biosynthesis	inhibitor	platensimycin	
(Pla).	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed	by	a	two-way	ANOVA	and	
Dunnett’s	 post-hoc	 test.	 For	 bacteria	 treated	 with	 daptomycin	 only	 vs	 bacteria	 treated	 with	
daptomycin	 +	 platensimycin	P	<0.01	 at	 the	 time	 points	 indicated	 (*).	 	 Error	 bars	 represent	 the	
standard	deviation	of	the	mean.	
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Figure	 4.9.	 Lipid	 release	 due	 to	 heat	 or	 lysostaphin	 treatment	 is	 not	 affected	 by	 inhibition	 of	
protein	synthesis	or	the	respiratory	chain		
The	USA300	ΔagrA	mutant	was	exposed	 to	 to	 lysostaphin	 (a)	 (10	µg	ml-1,	8	h,	37oC)	or	heat	 (b)		
(100oC,	 20	 min)	 in	 the	 presence	 or	 absence	 (CTL)	 of	 the	 following:	 tetracycline	 (Tet),	
chloramphenicol	 (Chl),	 2-n-Heptyl-4-hydroxyquinoline	 N-oxide	 (HQNO)	 or	 NaN3	 and	 measured	
lipid	release.	In	each	case,	n=3	in	duplicate,	for	bacteria	at	37oC	without	inhibitor	vs	bacteria	at	4oC	
P	<	0.01	as	determined	by	a	one-way	ANOVA	and	Tukey’s	post-hoc	test	(panels	a	and	b).	Error	bars	
represent	the	standard	deviation	of	the	mean.		
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Figure	4.9		.	Lipid	release	due	to	heat	or	lysostaphin	treatment	is	not	aﬀected	by	inhibiLon	of	protein	
synthesis	or	the	respiratory	chain.	exposed	the	USA300	ΔagrA	mutant	to	lysostaphin	(b,	10	µg	ml-1,	8	h,	37	
oC)	or	heat	(c,	100	oC,	20	min)	in	the	presence	or	absence	(CTL)	of	the	following:	tetracycline	(Tet),	
chloramphenicol	(Chl),	2-n-Heptyl-4-hydroxyquinoline	N-oxide	(HQNO)	or	NaN3	and	measured	lipid	release.	
In	each	case,	n=3	in	duplicate,	for	bacteria	at	37	oC	without	inhibitor	vs	bacteria	at	4	oC	P	<	0.01	as	
determined	by	a	one-way	ANOVA	and	Tukey’s	post-hoc	test	(panels	a	and	b).	Error	bars	represent	the	
standard	deviaKon	of	the	mean.		
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4.5 VraUTSR	is	required	for	efficient	phospholipid	release	
Since	the	phospholipid	release	mechanism	was	found	to	be	an	active	process,	it	was	hypothesized	
that	it	is	subject	to	control	by	at	least	one	regulatory	element.	Previous	transcriptomic	profiling	of	
S.	aureus	revealed	that	daptomycin	induces	the	expression	of	genes	associated	with	the	cell	wall	
stress	 stimulon	 (CWSS),	 regulated	 by	 the	 products	 of	 the	 vraUTSR	 operon111,135,470.	 This	 operon	
encodes	an	inter-membrane	histidine	kinase	two-component	signaling	transduction	system	(TCS).	
Although	VraUTRS	 is	 characterized	 as	 vancomycin	 resistance	 associated,	 it	 detects	 cell	wall	 and	
membrane	damage	caused	by	 several	different	antibiotics,	 including	β-lactams,	vancomycin	and	
daptomycin111,135,470.	 VraS	 is	 the	 inner-membrane	 histidine	 kinase,	 but	 lacks	 a	 characteristic	
sensing	domain471,472.	 It	 responds	 to	 antimicrobial-induced	 cell	wall	 and/or	membrane	 stress	by	
autophosphorylation	 and	 then	 transphosphorylates	 VraR111,471.	 VraR	 is	 the	 cognate	 response	
regulator	of	 the	vraUTRS	 regulon.	Phosphorylated	VraR	binds	 to	 its	own	promoter	and	 those	of	
the	46	genes	that	are	part	of	the	VraUTRS	regulon,	inducing	or	enhancing	expression111,470.	Many	
of	these	genes	encode	proteins	associated	with	cell	wall	or	membrane	biosynthesis.	The	roles	of	
VraU	and	VraT	are	less	well	defined.	
To	 determine	 whether	 the	 VraUTSR/CWSS	 regulon	 contributes	 to	 the	 release	 of	
phospholipids	in	response	to	daptomycin,	wild-type	S.	aureus,	vraS::Tn	and	vraR::Tn	mutants	from	
the	 USA00	 JE2	 NARSA	 library398	 were	 grown	 under	 Agr-suppressed	 conditions	 (Agr-)	 using	
synthetic	AIP3,	which	blocks	the	type	I	Agr	system	in	USA300385.		
As	expected,	based	on	previous	results,	the	wild-type	bacteria	grown	under	Agr-	conditions	
survived	 exposure	 to	 daptomycin	 (Fig	 4.10a).	 By	 contrast,	 the	 survival	 of	 both	 vraS::Tn	 and	
vraR::Tn	mutants	 grown	 under	 Agr-	conditions	was	 significantly	 reduced	 compared	 to	 the	wild-
type.	 In	 addition,	 the	 release	 of	 phospholipids,	 and	 the	 inactivation	 of	 daptomycin,	 by	 both	
vraS::Tn	and	vraR::Tn	mutants	was	also	significantly	reduced	compared	to	the	wild-type	under	Agr-	
conditions	(Fig	4.10).		
To	confirm	a	role	for	VraUTSR	in	phospholipid	release,	assays	were	repeated	using	a	well-
characterised	 ΔvraUTSR	 deletion	 mutant	 in	 the	 USA300	 strain111.	 Similar	 to	 the	 vraS::Tn	 and	
vraR::Tn	mutants	it	was	observed	that	the	ΔvraUTSR	mutant	released	significantly	reduced	levels	
of	 phospholipid	 in	 response	 to	 daptomycin,	 which	 in	 turn	 reduced	 the	 rate	 of	 inactivation	 of	
daptomycin	and	enhanced	the	killing	of	the	mutants	(Fig	4.11).	
Overall,	 these	 experiments	 with	 S.	 aureus	 vra	 mutants	 strongly	 indicate	 that	 the	
VraUTSR/CWSS	 regulon	 is	 required	 for	 efficient	 release	 of	 phospholipids	 in	 response	 to	
daptomycin.	 	
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Figure	4.10.	vraS	and	vraR	are	required	for	daptomycin-induced	phospholipid	release		
Survival	(a),	daptomycin	activity	(b)	and	lipid	release	(c)	of	the	wild-type	and	vra	mutants	grown	
under	Agr	suppressed	conditions.	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed	
two-way	ANOVA	and	Dunnett’s	 post-hoc	 test.	 For	WT	Agr-	 bacteria	 treated	with	daptomycin	 vs	
VraS::Tn	 Agr-	 or	 VraR::Tn	 Agr-	 bacteria	 treated	 with	 daptomycin	 P	 <0.01	 at	 the	 time	 points	
indicated	(*).		For	all	panels	error	bars	represent	the	standard	deviation	of	the	mean.	
	
	
Figure	4.11.	vraUTSR	is	required	for	efficient	daptomycin-induced	phospholipid	release		
Survival	 (a),	 lipid	 release	 (b)	 and	 daptomycin	 activity	 (c)	 of	 the	 wild-type	 and	 vraUTSR	 mutant	
grown	under	Agr	suppressed	conditions.	Data	 represent	 the	mean	of	n=3	 in	duplicate	and	were	
analysed	 two-way	 ANOVA	 and	 Dunnett’s	 post-hoc	 test.	 For	 WT	 Agr-	 bacteria	 treated	 with	
daptomycin	 vs	 ΔVraUTSR	 Agr-	 bacteria	 treated	 with	 daptomycin	 P	 <0.01	 at	 the	 time	 points	
indicated	(*).		For	all	panels	error	bars	represent	the	standard	deviation	of	the	mean.	
Figure	4.10:	vraS	and	vraR	is	required	for	daptomycin-induced	phospholipid	release:	Survival	(a),	
daptomycin	acKvity	(b)	and	lipid	shedding	(c)	of	the	wild-type	and	derived	mutants	grown	under	Agr	
suppressed	condiKons.	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed	two-way	ANOVA	
and	Dunnec’s	post-hoc	test.	For	WT	Agr-	bacteria	treated	with	daptomycin	vs	VraS::Tn	Agr-	or	VraR::Tn	Agr-	
bacteria	treated	with	daptomycin	P	<0.01	at	the	Kme	points	indicated	(*).		For	all	panels	error	bars	
represent	the	standard	deviaKon	of	the	mean.	
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Figure	4.11:	vraUTSR	is	required	for	daptomycin-induced	phospholipid	release:	Survival	(a),	daptomycin	
acKvity	(b)	and	lipid	shedding	(c)	of	the	wild-type	and	derived	mutants	grown	under	Agr	suppressed	
condiKons.	Data	r pres nt	the	mean	of	n=3	in	duplicate	and	were	analysed	two-way	ANOVA	and	Dunnec’s	
post-hoc	test.	For	WT	Agr-	bacteria	treated	with	daptomycin	vs	ΔVraUTSR	Agr-	bacteria	treated	with	
daptomycin	P	<0.01	at	the	Kme	points	indicated	(*).		For	all	panels	error	bars	represent	the	standard	
deviaKon	of	the	mean.	
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4.6 A	 partial	 screen	 of	 the	 NARSA	 transposon	 mutant	 library	 reveals	 a	
requirement	 for	 PBP3	and	diacylglycerol	 glucosyltransferase	 in	daptomycin-
induced	phospholipid	release	
Having	 shown	 that	 daptomycin-induced	 phospholipid	 release	 is	 regulated	 by	 VraUTRS,	 it	 was	
decided	 to	 investigate	 the	 mechanism	 by	 which	 phospholipid	 release	 occurs.	 Our	 data	 from	
experiments	 with	 vra	 mutants	 indicated	 a	 role	 for	 cell	 wall	 remodeling,	 and	 previous	 studies	
indicated	 that	 daptomycin	 disrupts	 the	 cell	 membrane	 and	 division	 machinery126.	 Therefore,	 a	
limited	 transposon	 screen	 was	 undertaken	 on	 mutants	 with	 transposon	 insertions	 in	 genes	
involved	in	cell	wall	or	lipid	biosynthesis	or	that	were	involved	in	cell	division	(Table	4.2).	The	wild-
type	S.	aureus	and	 transposon	mutants	were	 incubated	with	daptomycin	at	37oC	 for	8	h	before	
phospholipid	levels	were	quantified.		This	revealed	defective	phospholipid	release	in	two	mutants:	
pbp3::Tn	(penicillin	binding	protein	3	 involved	in	peptidoglycan	synthesis)24	and	SAUSA_0918::Tn	
(diacylglycerol	 glucosyltransferase	 synthase	 involved	 in	 lipid	 metabolism	 and	 lipoteichoic	 acid	
anchoring)473,474	(Fig	4.12a).		
To	 ensure	 that	 the	 phenotypes	 observed	 were	 due	 to	 the	 inserted	 transposons,	 assays	
were	 repeated	 with	 SH1000	 strains	 into	 which	 selected	 transposons	 had	 been	 transduced:	
pbp3::Tn,	 SAUSA_0918::Tn,	 ftsK::Tn	 and	 ftsH::Tn	 (the	 latter	 two	were	 included	 as	 controls)	 (Fig	
4.12b).	 Similar	 to	 what	 was	 seen	 in	 the	 USA300	 background,	 mutants	 defective	 for	 PBP3	 or	
diacylglycerol	synthase	were	defective	 in	releasing	phospholipids	 in	response	to	daptomycin	(Fig	
4.12).	As	an	additional	control,	to	ensure	that	the	defect	in	phospholipid	release	was	not	due	to	a	
growth	defect,	the	growth	profiles	of	each	of	the	key	mutants	was	determined,	alongside	the	wild-
type.	 There	was	no	 significant	 growth	defect	 between	 the	wild-type	and	any	of	 the	 transposon	
mutants	(Fig	4.13).	
Overall,	 these	 findings	 indicate	 roles	 for	 cell	 wall	 remodeling	 and	 lipid	 biosynthesis	 in	
daptomycin-induced	 phospholipid	 release.	 These	 insights	 into	 the	 mechanism	 of	 phospholipid	
release	 may	 inform	 new	 therapeutic	 approaches	 that	 prevent	 daptomycin	 inactivation	 and	
improve	therapeutic	outcomes.		
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Table	4.2.	List	of	the	transposon	mutant	strains	used	in	Fig	4.12	and	4.13	
	
	
Gene	 FuncLon	
atl	 Autolysin	
lytN	 Cell	wall	hydrolase	
lytM	 PepKdoglycan	hydrolase	
SAUSA300_2100		 LyKc	regulatory	protein	
mecA	 Penicillin-binding	protein	2'	
pbp3	 Penicillin-binding	protein	3	
pbp4	 Penicillin-binding	protein	4	
fmtA	 Low-aﬃnity	penicillin-binding	protein		
cls	 Cardiolipin	synthase	
AsK	 DNA	translocase	FtsK	
AsH	 PutaKve	cell	division	protein	FtsH	
SAUSA300_1687	 FtsK/SpoIIIE	family	protein	
SAUSA300_1482	 FtsK/SpoIIIE	family	protein	
fadA	 PutaKve	acyl-CoA	acetyltransferase	
fadD	 Acyl-CoA	dehydrogenase	
fadE	 Acyl-CoA	synthetase	
fadX	 PutaKve	acyl-CoA	transferase	
SAUSA300_0394	 FAD/NAD(P)-binding	Rossmann	fold	superfamily	protein	
SAUSA300_0226	 3-hydroxyacyl-CoA	dehydrogenase	
SAUSA300_2615	 Acetyltransferase	
SAUSA300_1297	 Acylphosphatase	
SAUSA300_0918	 Diacylglycerol	glucosyltransferase	
SAUSA300_2504	 Acyltransferase	
SAUSA300_0535	 PutaKve	pyridoxal	phosphate-dependent	acyltransferase	
SAUSA300_0099	 1-phosphaKdylinositol	phosphodiesterase	
sgtA	 Probable	transglycosylase	
sgtB	 MonofuncKonal	glycosyltransferase	
a	Table	for	method	
Table	4.	List	of	the	strains	used		
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Figure	 4.12.	 A	 transposon	 screen	 reveals	 a	 requirement	 for	 PBP3	 and	 diacylglycerol	
glucosyltransferase	for	daptomycin-induced	phospholipid	release		
Lipid	release	from	wild-type	and	various	mutants	after	incubation	for	8	h	in	TSB	only	(open	bars)	
or	TSB	containing	daptomycin	(20	µg	ml-1,	closed	bars,	n=3	in	duplicate,	significant	differences	in	
lipid	release	between	TSB	only	and	TSB	containing	daptomycin	are	indicated:	*indicates	P	<	0.05)	
(a).	 Lipid	 release	of	SH1000	wild-type	and	mutants	exposed	 to	20	µg	ml-1	daptomycin	over	 time	
(b).	Data	 represent	 the	mean	average	of	n=3	 in	duplicate.	Values	 that	are	 significantly	different	
from	wild-type	are	indicated	(*indicates	P	<	0.05).		
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Figure	4.16	A	transposon	screen	reveals	a	requirement	for	PBP3	and	diacylglycerol	
glucosyltransferase	for	daptomycin-induced	phospholipid	release.	a,	lipid	release	from	wild-type	and	
various	mutants	a^er	incubaKon	for	8	h	in	TSB	only	(open	bars)	or	TSB	containing	daptomycin	(20	µg	
ml-1,	closed	bars).	n=3	in	duplicate,	signiﬁcant	diﬀerences	in	lipid	shedding	between	TSB	only	and	TSB	
containing	daptomycin	are	indicated	(*indicates	P=<	0.05).	b,	lipid	release	of	SH1000	wild-type	and	
mutants	exposed	to	20	µg	ml-1	daptomycin	over	Kme.	Data	represent	the	mean	average	of	n=3	in	
duplicate.	Values	that	are	signiﬁcantly	diﬀerent	from	wild-type	are	indicated	(*indicates	P=<	0.05).		
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Figure	4.13.	Growth	profiles	of	strains	used	in	experiments	detailed	in	Fig	4.12		
Growth	profile	of	selected	strains	from	the	NARSA	library	(USA300	JE2	(a))	or	transduced	strains	in	
the	SH1000	strain	(b)	(in	both	cases,	n=3	in	duplicate).	Data	represent	the	mean	average	of	n=3	in	
duplicate.		
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Figure	4.17.	Growth	proﬁles	of	strains	used	in	ﬁgure.	a,	growth	proﬁle	of	selected	strains	from	(Fig	a)	
(strains	wi h	defecKve lipid	relea e	were	included,	along	with	wild-type,	cls::Tn, tl::Tn	and lytM::Tn	as	
controls	since	these	were	not	defecKve	for	lipid	shedding,	n=3	in	duplicate).	Data	represent	the	mean	
average	of	n=3	in	duplicate.	b,	growth	proﬁle	of	strains	used	in	(Fig	b)	(n=3	in	duplicate).			
	
0	
0.5	
1	
1.5	
2	
0	 4	 8	 12	 16	
p  WT		X	pbp2a::Tn		¢	pbp3::Tn			l	pbp4::Tn			£	atl::Tn		
r	AsK::Tn		¸	AsH::Tn		¡	cls::Tn		I		SAUSA_0918::Tn	
u	lytM::Tn	 b	
O
D 6
00
	
Time	(h)	
USA300	JE2	a	
c	
		 137	
4.7 The	 cationic	 antimicrobial	 peptides	 (CAMPs)	 nisin	 and	 melittin	 trigger	 the	
release	of	phospholipids	from	the	ΔagrA	mutant	
Daptomycin	 is	 an	 anionic	 lipopeptide,	 which	 has	 a	 positive	 overall	 charge	 in	 the	 presence	 of	
calcium,	 and	 functions	 by	 targeting	 the	 membrane	 phospholipids	 of	 Gram-positive	 bacteria.	
CAMPs	 such	 as	 nisin	 and	melittin	 function	 in	 a	 similar	way	 to	 daptomycin.	 Nisin	 is	 a	 polycyclic	
cationic	 amphiphilic	 antibacterial	 peptide	 belonging	 to	 the	 lantibiotic	 family.	 It	 consists	 of	 34	
amino	acid	residues	and	functions	by	binding	to	the	membrane,	and	induces	pore	formation	in	S.	
aureus475–477.	Melittin	 is	 a	 lytic	 antimicrobial	 peptide	 of	 26	 amino	 acid	 residues.	 It	 binds	 to	 the	
membrane	and	once	it	reaches	a	threshold	it	forms	a	pore478–480.	Because	these	CAMPs	function	in	
a	 similar	 way	 to	 daptomycin	 it	 was	 hypothesised	 that	 phospholipid	 release	 may	 also	 confer	
protection	against	these	and	similar	membrane-acting	antimicrobials.		
To	test	this	hypothesis,	survival	and	phospholipid	release	was	measured	during	incubation	
of	 S.	 aureus	 wild-type	 or	 ΔagrA	 mutant	 with	 nisin	 or	melittin	 at	 37oC	 for	 8	 h.	 Similarly	 to	 the	
survival	 profile	 seen	with	 daptomycin,	 after	 an	 initial	 period	 of	 killing	 (10-fold	 decrease	 in	 CFU	
counts)	by	both	nisin	and	melittin,	the	ΔagrA	mutant	subsequently	recovered	more	rapidly	than	
the	wild-type	 (Fig	 4.14a,b).	 Again,	 as	 seen	 for	 daptomycin,	 both	 CAMPs	 triggered	 phospholipid	
release	 from	 the	 ΔagrA	 mutant,	 albeit	 to	 lower	 levels	 than	 that	 seen	 for	 the	 antibiotic.	
Surprisingly,	however,	both	nisin	and	melittin	exposure	resulted	in	significantly	reduced	quantity	
of	phospholipid	produced	by	the	wild-type	bacteria	(Fig	4.14c,d).		
Although	melittin	(2.8	kDa)	and	nisin	(3.5	kDa)475,477	are	relatively	small	peptides,	they	did	
not	 diffuse	 efficiently	 or	 uniformly	 in	 TSA	 plates	 and	 therefore,	 it	was	 not	 possible	 to	measure	
their	activity	using	the	zone	of	inhibition	assay	as	was	done	for	daptomycin.		
To	test	whether	PG	was	responsible	for	mediating	survival	of	the	ΔagrA	mutant	exposed	to	
either	 peptide,	 the	 MIC	 of	 both	 peptides	 was	 determined	 in	 the	 absence	 or	 presence	 of	 the	
phospholipid.	 It	was	found	that	the	presence	of	PG	increased	the	MIC	of	both	nisin	and	melittin	
44-fold	(Fig	4.15).		
Taken	 together,	 these	 data	 indicate	 that	 phospholipid	 release	may	 constitute	 a	 general	
defence	 mechanism	 against	 membrane-acting	 antibacterials	 and	 may	 provide	 clues	 as	 to	 the	
evolutionary	origins	of	the	system.	
	
	
.		 	
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Figure	4.14.	The	cationic	antimicrobial	peptides	nisin	and	melittin	 trigger	phospholipid	release	
from	ΔagrA	S.	aureus	USA300		
S.	aureus	ΔagrA	survived	exposure	to	nisin	(a)	or	melittin	(b)	better	than	the	wild-type.	Both	nisin	
and	melittin	exposure	reduced	the	quantity	of	lipid	produced	by	wild-type	bacteria	(CTL	vs	Nisin	or	
Melittin	 P	 <0.0001	 by	 one-way	 ANOVA	 with	 Tukey	 post-hoc	 test)	 (c)	 but	 triggered	 enhanced	
release	 of	 phospholipid	 from	 the	 ΔagrA	 mutant	 (CTL	 vs	 Nisin	 or	 Melittin	 P	 <0.01	 by	 one-way	
ANOVA	with	Tukey	post-hoc	test)	(d).	For	all	panels	n=3	in	duplicate	and	error	bars	represent	the	
standard	deviation	of	the	mean.		
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Figure	4.12	.	The	ca:onic	an:microbial	pep:des	nisin	and	meli?n	trigger	phospholipid	release	in	ΔagrA	
S.	aureus	USA300.	S.	aureus	ΔagrA	survived	exposure	to	nisin	(a)	or	meli0n	(b)	beJer	than	the	wild-type.	
Both	nisin	and	meli0n	exposure	reduces	the	quanQty	of	lipid	produced	by	wild-type	bacteria	(CTL	vs	Nisin	
or	Meli0n	P	<0.0001	by	one-way	ANOVA	with	Tukey	post-hoc	test)	(c)	but	trigger	enhanced	r lease	of	
lipid	from	the	ΔagrA	mutant	(CTL	vs	Nisin	or	Meli0n	P	<0.01	by	one-way	ANOVA	with	Tukey	post-hoc	test)	
(d).	For	all	panels	n=3	in	duplicate	and	error	bars	represent	the	standard	deviaQon	of	the	mean.		
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Figure	4.15.	PG	protected	the	USA300	ΔagrA	mutant	from	nisin	and	melittin		
The	presence	of	phosphatidylglycerol	(PG,	10	µM)	increased	the	nisin	and	melittin	MIC	values	for	
wild-type	S.	aureus	(TSB	only	vs	PG	P	<0.01,	for	both	Nisin	and	Melittin	by	one-way	ANOVA	with	
Tukey	post-hoc	test)	indicating	that	the	phospholipid	inactivates	both	antimicrobial	peptides.	n=3	
in	duplicate.		
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Figure	4.13	.	PG	protects	the	ΔagrA	S.	aureus	USA300	against	ca:onic	an:microbial	pep:des	nisin	and	
meli?n	.	The	presence	of	phosphaQdylglycerol	(PG,	10	µM)	increased	the	nisin	and	meli0n	MIC	values	for	
wild-type	S.	aureus	(TSB	only	vs	PG	P	<0.01,	for	both	Nisin	and	Meli0n	by	one-way	ANOVA	with	Tukey	
post-hoc	test)		indicaQng	that	the	phospholipid	inacQvates	both	anQmicrobial	pepQdes.	n=3	in	duplicate	
and	error	bars	represent	the	standard	deviaQon	of	the	mean.		
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4.8 Discussion	
4.8.1 A	 S.	 aureus	 ΔagrA	 mutant	 actively	 releases	 phospholipids	 in	 response	 to	
daptomycin	
The	 work	 described	 in	 this	 chapter	 revealed	 that	 the	 S.	 aureus	 ΔagrA	 mutant	 inactivates	
daptomycin	 via	 a	 novel,	 enzyme-independent,	mechanism.	Daptomycin	 triggered	 the	 release	 of	
phospholipids,	primarily	phosphatidylglycerol,	which	sequestered	daptomycin	and	inactivated	the	
antibiotic	 (Fig	 4.16).	 This	 finding	 is	 in	 keeping	 with	 previous	 reports	 that	 showed	 daptomycin	
challenge	leads	to	membrane	blebbing	in	S.	aureus126	and	that	daptomycin	can	extract	lipids	from	
artificial	 membrane	 vesicles462.	 However,	 the	 release	 of	 phospholipids	 is	 not	 passive	 or	 the	
consequence	 of	 membrane	 damage,	 rather	 it	 appears	 to	 be	 a	 complex	 and	 highly	 regulated	
process	that	requires	metabolic	activity,	as	well	as	protein	and	lipid	biosynthesis.	
	
4.8.2 PG	is	primarily	responsible	for	inactivating	daptomycin	
The	staphylococcal	membrane	is	primarily	composed	of	three	phospholipids:	Phosphatidylglycerol	
(~80%	total),	lysyl-phosphatidylglycerol	(~10%	total)	and	cardiolipin	(~10%	total).	The	composition	
of	phospholipid	released	in	response	to	daptomycin	is	very	similar	to	these	figures,	suggesting	that	
the	 formation	of	membrane	blebs	may	directly	 provide	 the	 released	 lipids,	 rather	 than	e.g.	 the	
secretion	of	specific	phospholipids.	Of	these	phospholipids,	only	phosphatidylglycerol	 inactivated	
daptomycin	at	the	concentrations	present.	This	is	perhaps	not	surprising	since	this	is	the	target	of	
daptomycin	 is	 the	membrane.	What	 is	more	surprising	 is	 that	daptomycin	appears	to	have	a	 far	
higher	affinity	for	phosphatidylglycerol	monomers	or	micelles	in	the	culture	supernatant	than	the	
bacterial	 membrane,	 since	 there	 is	 more	 phospholipid	 associated	 with	 the	 bacteria	 than	 in	
suspension.	This	may	reflect	the	fact	that	for	daptomycin	to	insert	its	lipid	tail	into	the	membrane,	
it	must	pass	the	anionic	phosphate	head	groups	on	the	phospholipid.	By	contrast,	monomeric	PG	
in	suspension	has	its	acyl	chains	exposed,	enabling	easy	access	to	the	daptomycin	lipid	tail.		
Based	on	the	experiments	with	phospholipases,	all	of	which	cleave	at	different	positions	on	
the	phospholipid	molecule,	it	is	apparent	that	cleavage	at	any	position	on	the	PG	molecule	results	
in	 loss	 of	 binding	 to	 daptomycin.	 This,	 indicates	 that	 the	 entire	 PG	 molecule	 is	 required	 to	
inactivate	daptomycin	and	suggests	that	the	anionic	phosphate	headgroup	binds	to	the	calcium-
loaded	peptide	ring	of	daptomycin.		
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Figure	4.16.	How	does	the	ΔagrA	mutant	inactivate	daptomycin?		
On	exposure	to	daptomycin	(red),	the	ΔagrA	mutant	actively	releases	phospholipids	(golden)	that	
sequester	 and	 inactivate	 daptomycin.	 This	 enables	 the	 ΔagrA	 mutant	 to	 survive	 daptomycin	
challenge	and	replicate.	
	 	
		 142	
	
	 The	 finding	 that	 free	 phospholipid	 sequesters	 daptomycin	 and	 enables	 staphylococcal	
survival	 is	 supported	by	a	previous	study	 from	Silverman	et.	al.,	 (2005),	who	demonstrated	that	
pulmonary	 surfactant	 reduces	 the	 activity	 of	 daptomycin,	making	 it	 an	 ineffective	 antibiotic	 to	
treat	pneumonia	caused	by	S.	aureus465.	Pulmonary	surfactant	is	rich	in	phosphatidylcholine	(PC),	
PG,	 cholesterol	 and	 neutral	 lipids	 and	 its	 role	 is	 to	 reduce	 the	 surface	 tension	 at	 the	 air-liquid	
interface	 in	 the	 lungs481.	However,	 the	phospholipids	 that	 form	 the	pulmonary	 surfactant	make	
daptomycin	largely	ineffective	at	combatting	infections	of	the	lower	respiratory	tract465.	Based	on	
our	data,	 it	 is	very	likely	that	the	high	concentration	of	PG	in	pulmonary	surfactant	explains	why	
daptomycin	does	not	function	in	the	lungs.		
The	specificity	of	daptomycin	for	PG	over	CL	 is	remarkable	given	the	similarities	between	
PG	and	CL,	which	is	essentially	dimeric	PG	(Fig	4.17).	In	addition,	the	ability	of	LPG,	which	consists	
of	a	PG	molecule	with	a	positively	charged	lysine	head	group,	to	inactivate	daptomycin,	albeit	4-
fold	 less	 efficiently	 than	 PG,	 was	 surprising.	 This	 is	 because	 the	 presence	 of	 elevated	
concentrations	of	 LPG	 in	 the	S.	 aureus	membrane	 is	 associated	with	decreased	 susceptibility	 to	
daptomycin130,482,483.	 One	 of	 the	 hypotheses	 to	 explain	 this	 is	 that	 the	 positively	 charged	 LPG	
headgroup	 repels	daptomycin.	However,	 recent	work	has	 shown	 that	 LPG	does	not	 significantly	
reduce	 the	 binding	 of	 daptomycin	 to	 lipid	 vesicles	 containing	 PG,	 suggesting	 that	 membrane	
stabilisation,	rather	than	repulsion,	by	LPG	is	responsible	for	daptomycin	resistance133.	In	addition,	
it	is	important	to	note	that	LPG	in	suspension	will	interact	with	daptomycin	differently	compared	
with	LPG	that	is	membrane	bound.	This	is	because	in	the	bacterial	membrane	only	the	positively	
charged	head	group	of	LPG	 is	accessible,	whereas	the	LPG	 in	suspension	will	expose	 its	 lipid	tail	
and	 negatively	 charged	 phosphate	 group	 which	 might	 explain	 its	 ability	 to	 interact	 with	
daptomycin484.	
	 	
		 143	
	
	
	
	
	
Figure	4.17.	The	structure	of	the	phospholipids	found	on	the	membrane	of	S.	aureus	
	Both	PG	and	CL	molecules	are	negatively	charged.	CL	 is	essentially	diphosphatidyl	glycerol	 (two	
PG	 molecules	 together)	 and	 includes	 4	 acyl	 groups	 (fatty	 acid	 chains)	 attached	 to	 negatively	
charged	phosphate	groups.	LPG	 includes	a	positively	charged	Lysine	head	group	attached	to	the	
phosphate	moiety.	
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4.8.3 	The	 cell	 wall	 stress	 stimulon	 vraUTRS	 is	 involved	 in	 regulating	 the	 release	 of	
phospholipids	in	response	to	daptomycin	
The	release	of	phospholipid	from	the	S.	aureus	ΔagrA	mutant	is	a	specific	response	to	daptomycin	
and	appears	 to	be	 regulated	by	 the	vraUTRS/CWSS	 regulon,	 at	 least	 in	part,	 since	phospholipid	
release	was	impaired	in	a	mutant	lacking	the	vraUTRS	operon.	Whilst	there	was	a	clear	phenotype	
for	the	mutant,	future	experiments	will	involve	complementation	of	the	mutant	with	the	wild-type	
vraUTRS	 operon	 followed	 by	 quantification	 of	 phospholipid	 release	 to	 confirm	 function.	 These	
data	build	on	evidence	that	the	vraUTRS/CWSS	regulon	is	upregulated	in	response	to	daptomycin,	
and	regulates	genes	that	are	required	to	repair	the	cell	wall	and	membrane	damage,	including	cell	
wall	and	phospholipid	biosynthesis111,135.		
Because	 the	phospholipids	must	 traverse	 the	 cell	wall	 to	be	 released,	 it	 is	not	 surprising	
that	a	regulator	of	cell	wall	biosynthesis	is	important	for	the	release	of	phospholipids	in	response	
to	 daptomycin.	 However,	 the	 mechanism	 by	 which	 these	 phospholipids	 cross	 the	 cell	 wall	 is	
currently	unknown.	To	 investigate	how	the	VraUTRS/CWSS	regulon	modifies	the	cell	wall,	 future	
work	 will	 look	 at	 the	 VraUTRS/CWSS	 regulon	 by	 using	 the	 mutants	 of	 the	 regulon.	 	 However,	
because	some	of	the	genes	are	essential	for	S.	aureus	survival,	chemical	inhibitors,	many	of	which	
are	 antibiotics,	 will	 be	 used	 to	 block	 the	 several	 essential	 steps	 in	 the	 biosynthesis	 of	 the	
peptidoglycan	layer.	If	the	use	of	these	cell	wall	acting	antibiotics	block	lipid	release	it	might	then	
constitute	 a	 useful	 therapeutic	 approach	 to	 improve	 the	 activity	 of	 daptomycin,	 as	 well	 as	
contribute	 towards	enhancing	our	understanding	about	 the	emerging	area	of	membrane	vesicle	
release	in	Gram	positive	bacteria	for	which	our	understanding	is	very	limited.	For	example,	it	has	
been	 hypothesised	 that	 the	 release	 of	 extracellular	membrane	 vesicles	might	 occur	 via	 protein	
channels	 that	may	guide	 the	membrane	vesicles	 towards	 the	extracellular	 space	and/or	pushed	
through	 the	 cell	 wall	 via	 turgor	 pressure	 after	 the	 release	 from	 the	 plasma	membrane	 and/or	
released	by	cell	wall	modifying	enzymes	that	loosen	the	cell	wall	and	increase	the	pore	size11.		
Additional	 further	work	will	also	 investigate	how	naturally	occurring	mutations	 in	the	vra	
operon	influence	phospholipid	release.	For	example,	daptomycin	is	often	used	to	treat	infections	
caused	by	VISA	isolates,	which	arise	via	gain	of	function	mutations	in	the	vra	operon,	resulting	in	a	
constitutively	active	CWSS112,472,485–489.	It	is	not	known	whether	daptomycin	triggers	phospholipid	
release	from	other	Gram-positive	bacteria.	However,	the	VraUTRS/CWSS	regulon	is	very	similar	to	
the	liaFS/CWSS	system	in	other	Gram-positive	bacteria	including	Bacilus	subtilis	and	Enterococcus	
faecalis.	 The	 liaFS/CWSS	 regulon	 in	 E.	 faecalis	 is	 activated	 by	 daptomycin	 and	 upregulates	
phospholipid	synthesis	to	alter	membrane	fluidity	by	increasing	the	amount	of	CL	incorporated	in	
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the	septum,	resulting	in	decreased	levels	of	daptomycin	inserting	at	the	septum490,491.	This	raises	
the	 possibility	 that	 phospholipid	 release	 in	 response	 to	 daptomycin	 is	 a	 conserved	mechanism	
across	several	different	Gram-positive	bacteria.	
	
4.8.4 Has	S.	aureus	evolved	to	release	phospholipids	in	response	to	CAMPs?	
Nisin	and	melittin	are	CAMPs,	which	share	functional	similarities	with	daptomycin.	Both	peptides	
target	 the	 staphylococcal	 membrane	 and	 cause	 pore	 formation.	 In	 addition,	 similarly	 to	
daptomycin,	Therrien	A.	et.	al.	(2016)	demonstrated	that	melittin	can	extract	lipids	from	artificial	
membrane	 vesicles479.	 Therefore,	 it	 was	 not	 surprising	 that	 the	 ΔagrA	 mutant	 released	
phospholipids	in	response	to	both	nisin	and	melittin	and	that	PG	provided	protection	against	the	
respective	CAMPs.		
However,	nisin	unlike	daptomycin	and	melittin	has	dual	activity,	which	includes	disrupting	
the	 membrane,	 and	 inhibiting	 cell	 wall	 synthesis.	 The	 reason	 why	 nisin	 reduces	 phospholipid	
release	in	the	wild-type	and	increases	phospholipid	release	in	the	ΔagrA	mutant	may	therefore	be	
because:	(i)	nisin	along	with	the	disruption	of	the	cell	membrane	also	blocks	the	cell	wall	synthesis	
in	wild-type	bacteria,	inhibiting	phospholipid	release	or	(ii)	rapid	killing	of	the	the	wild-type	makes	
it	unable	to	inactivate	nisin	at	the	same	rate	as	the	ΔagrA	mutant	(Fig	4.14c-d).	
The	 release	 of	 membrane	 phospholipids	 may	 confer	 protection	 against	 antimicrobial	
peptides	 in	addition	 to	daptomycin	and	these	may	have	provided	the	selection	pressure	 for	 the	
evolution	of	the	phospholipid	release	response	to	membrane	damage.	There	is	growing	evidence	
that	 antimicrobial	 peptides	 that	 are	 produced	 by	 almost	 all	 tissues	 play	 an	 important	 role	 in	
human	 immunity492.	 For	 example,	 antimicrobial	 peptides	 such	 as	 human	 β-defensins	 that	 are	
found	on	the	skin	epithelial	surfaces	show	antimicrobial	activity	against	both	Gram-negative	and	
Gram-positive	 bacteria492,493,	 and	 LL-37,	 which	 belongs	 to	 the	 cathelicidin-related	 antimicrobial	
family,	 is	 found	 in	 polymorphonuclear	 leukocytes	 and	 is	 an	 effector	 molecule	 of	 the	 innate	
immunity	 in	 the	 skin457,494,495.	 Since	 LL-37	 and	 β-defensins	 target	 the	 bacterial	 membrane	 and	
cause	 pore	 formation495,	 it	 would	 be	 interesting	 to	 investigate	 whether	 these	 host	 defence	
peptides	 trigger	 the	 release	 of	 phospholipids	 and	 whether	 released	 phospholipids	 conferred	
protection.		
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Chapter	5		
Agr-regulated	PSMα	peptides	prevent	
daptomycin	inactivation	by	S.	aureus	
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5.1 Introduction	
The	previous	chapter	described	how	the	ΔagrA	mutant	survived	daptomycin	challenge	by	actively	
releasing	 phospholipids,	 which	 sequestered	 the	 antibiotic,	 rendering	 it	 inactive.	 Therefore,	 the	
next	question	to	address	was	why	S.	aureus	lacking	a	functional	Agr	system,	but	not	the	wild-type,	
inactivated	 daptomycin.	 In	 particular,	why	 bacteria	 lacking	 genes	 encoding	 the	 quorum-sensing	
components	AgrA	or	AgrC,	but	not	the	RNAIII	component	of	the	Agr	quorum-sensing	system,	were	
able	to	survive	daptomycin	exposure.		
As	described	in	the	introduction,	the	Agr	quorum-sensing	system	in	S.	aureus	contains	two-
divergent	promoters,	P2	and	P3,	that	drive	the	expression	of	the	transcriptional	units	RNAII,	which	
consists	 of	 agrB,	 agrD,	 agrC	 and	 agrA	 that	 makes	 the	 quorum-sensing	 component	 and	 RNAIII	
which	 is	 the	 effector	 molecule	 of	 the	 Agr	 system140,496.	 Upon	 activation,	 AgrA	 (the	 response	
regulator)	binds	to	the	P2	promoter	region	and	drives	the	expression	of	RNAII	thus	completing	the	
autoactivation	circuit	and	also	binds	to	the	P3	promoter	region,	driving	the	expression	of	RNAIII	
that	regulates	most	of	the	genes	 in	the	Agr	regulon.	 In	addition,	activated	AgrA,	 independent	of	
the	 regulatory	 RNAIII	 factor,	 directly	 binds	 to	 the	 promoters	 and	 induces	 the	 expression	 of	 the	
PSMα	and	PSMβ	peptide	toxins.	AgrA	also	down-regulates	the	expression	of	~90	metabolic	genes	
involved	in	carbohydrate	and	amino	acid	metabolism140,158.	
There	 are	 7	 PSM	 peptide	 genes	 that	 are	 encoded	 at	 three	 different	 locations	 in	 the	
genome	 (Table	 5.1).	 The	 psmα	 operon	 encodes	 the	 4	 PSMα	 peptides	 (PSMα1-	 α4),	 the	 psmβ	
operon	encodes	2	PSMβ	peptides	(PSMβ1	–β2)	and	psmδ	encodes	the	δ-toxin	that	 is	embedded	
within	the	RNAIII	coding	sequence140,158,176,397.	PSMα1-	α4	and	PSMδ	are	~20-25	amino	acids	long,	
whereas	PSMβ1	–β2	peptides	are	~44	amino	acids	long.	A	domain	known	as	the	α-peptide	region	
covers	the	entire	length	of	the	PSMα1-α4	and	PSMδ	peptides,	and	is	also	present	at	the	carboxy-
terminus	of	 the	 longer	PSMβ1	–β2	peptides.	This	α-peptide	region	enables	the	formation	of	 the	
amphipathic	α-helix,	which	is	formed	by	all	the	7	peptides	and	confers	a	characteristic	surfactant-
like	 property.	 This	 amphipathic	 characteristic	 enables	 the	 PSMs	 to	 form	 aggregates,	 enable	
bacterial	spread	on	surfaces	and	the	formation	and	dispersal	of	biofilms140,332,497.		
	The	 PSMα	 peptides	 are	 positively	 charged	 and	 cytolytic,	 whilst	 the	 PSMβ	 peptides	 are	
negatively	 charged	 and	 are	 non-cytolytic.	 PSMδ	 is	 neutral	 in	 charge	 and	 moderately	 cytolytic	
158,176,397.	 The	 lytic	 activity	 of	 PSMα	 peptides	 extends	 to	 human	 neutrophils,	 erythrocytes,	
leukocytes,	osteoblasts	and	macrophages140,294,498	and	several	studies	in	animal	models	indicate	an	
important	 role	 in	 the	 pathogenesis	 of	 acute	 infections	 such	 as	 sepsis,	 skin	 and	 soft	 tissue	
infections	and	osteomyelitis140,294,499.		
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Table	5.1.	Phenol	Soluble	Modulin	(PSM)	amino	acid	sequence	and	charge		
All	PSMs	are	secreted	with	an	amino-terminal	N-formyl	methionine	(fM).	However,	the	impact	fM	
has	 on	 the	 biological	 function	 of	 PSMs	 is	 unknown.	 The	 underlined	 sequence	 indicates	 the	
aliphatic	α-helix.	This	table	is	adapted	from	Peschel	A.	and	Otto	M.,	2013176.		
	
	 	
Table	5.1	Phenol	Soluble	Modulin	(PSM)	amino	acid	sequence	and	charge.	This	table	is	adapted	from	
Peschel	A.	and	O7o	M.,	2013.		
PSM	 Amino	acid	sequence	 PepAde	length	 charge	
δ-toxin	 fMAQDIISTIGDLVKWIIDTVNKFTKK	 26	 0	
α1	 fMGIIAGIIKVIKSLIEQFTGK	 21	 +1	
α2	 fMGIIAGIIKFIKGLIEKFTGK	 21	 +2	
α3	 fMEFVAKLFKFFKDLLGKFLGNN	 22	 +1	
α4	 fMAIVGTIIKIIKAIIDIFAK	 22	 +1	
β1	 fMEGLFNAIKDTVTAAINNDGAKLGTSIVSIVENGVGLLGKLFGF	 44	 -2	
β2	 fMTGLAEAIANTVQAAQQHDSVKLGTSIVDIVANGVGLLGKLFGF	 44	 -1	
(fM)	–	All	PSMs	are	secreted	with	an	amino-terminal	N-formyl	methionine.	However,	the	impact	fM	
has	on	the	biological	funcAon	of	PSMs	is	unknown.	Underlined	sequence	–	indicates	the	
amphipathic	α-helix	
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By	 contrast	 to	 the	 psm	 genes,	 AgrA	 down-regulates	 the	 expression	 of	 ~90	 genes	 that	
encode	enzymes	 involved	 in	 carbohydrate	 and	amino	acid	metabolism.	However,	 the	 impact	of	
this	regulation	on	bacterial	physiology	is	largely	unexplored.	
The	 data	 presented	 in	 the	 previous	 chapter	 clearly	 demonstrated	 that	 Agr	 activity	
significantly	reduces	the	efficiency	of	daptomycin	inactivation.	However,	based	on	the	functions	of	
the	genes	regulated	by	AgrA,	it	was	not	clear	how	these	would	influence	the	ability	of	S.	aureus	to	
inactivate	daptomycin.	Therefore,	two	competing	hypotheses	were	generated:	
	
Hypothesis	 1.	 Agr	 activity	 prevented	 wild-type	 bacteria	 from	 releasing	 phospholipids	 in	
response	to	daptomycin.		
Hypothesis	 2.	 Agr	 activity	 triggered	 the	 production	 of	 an	 inhibitor	 of	 the	 daptomycin-
inactivation	mechanism.		
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5.2 Wild-type	 S.	 aureus	 releases	 membrane	 phospholipids	 in	 response	 to	
daptomycin		
To	determine	whether	Agr	activity	influenced	daptomycin-induced	phospholipid	release,	wild-type	
S.	 aureus	 was	 incubated	 with	 daptomycin	 and	 the	 phospholipid	 released	 in	 the	 culture	
supernatant	was	measured	 every	 2	 h	 (Fig	 5.1).	 By	 contrast	 to	 the	 ΔagrA	mutant,	 the	wild-type	
released	some	phospholipid	in	the	absence	of	daptomycin.	However,	the	quantity	of	phospholipid	
released	by	wild-type	 bacteria	 in	 response	 to	 daptomycin	was	 significantly	 greater	 than	 that	 of	
wild-type	bacteria	in	the	absence	of	daptomycin,	and	similar	to	that	seen	for	the	ΔagrA	mutant	in	
response	to	daptomycin	(Fig	4.4	and	5.1).	This	demonstrated	that	both	wild-type	S.	aureus	and	the	
ΔagrA	 mutant	 released	 phospholipids	 in	 response	 to	 daptomycin,	 demonstrating	 that	 the	 Agr-
quorum	sensing	system	does	not	influence	daptomycin-induced	phospholipid	release.		
	
5.3 The	membrane	phospholipids	released	by	wild-type	S.	aureus	are	the	same	as	
those	released	by	the	ΔagrA	mutant	
Since	wild-type	bacteria	released	phospholipids	 in	response	to	daptomycin,	the	next	question	to	
address	 was	 why	 does	 the	 phospholipid	 released	 from	 the	 wild-type	 bacteria	 not	 inactivate	
daptomycin?	 Since	 PG	 was	 shown	 to	 be	 essential	 for	 the	 inactivation	 of	 daptomycin,	 it	 was	
hypothesized	that	wild-type	bacteria	did	not	release	this	type	of	phospholipid.	To	test	this,	culture	
supernatant	 from	 wild-type	 bacteria	 exposed	 to	 daptomycin	 was	 analysed	 using	 thin-layer	
chromatography	(TLC)	as	described	before	in	chapter	4	(Fig	4.5	and	Fig	5.2a).	As	demonstrated	for	
the	ΔagrA	mutant	previously	(Table	4.1),	this	analysis	identified	PG	as	the	most	abundant	(>65%)	
phospholipid	species	present,	along	with	small	quantities	of	CL	and	LPG	in	the	culture	supernatant	
(Fig	 5.2b,	 Table	 5.2).	 Therefore,	 the	 wild-type	 bacteria	 exposed	 to	 daptomycin	 released	
phospholipids	that	were	very	similar	in	composition	to	the	ΔagrA	mutant.		
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Figure	5.1.	Phospholipid	released	from	the	USA300	wild-type	S.	aureus		
Phospholipid	 release	 from	USA300	wild-type	exposed,	or	not,	 to	20	µg	ml-1	 daptomycin	 (n=3	 in	
duplicate,	for	wild-type	without	daptomycin	vs	wild-type	with	daptomycin	P	<	0.0001).	Data	were	
analysed	using	a	two-way	ANOVA	with	Dunnett’s	post-hoc	test.	Error	bars	represent	the	standard	
deviation	of	the	mean.	
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Figure	5.1.	Phospholipid	released	from	the	USA300	wild-type	S.	aureus.	lipid	shedding	from	USA300	
wild-type	exposed,	or	not,	to	20	µg	ml-1	daptomycin	(n=3	in	duplicate,	for	wild-type	without	
daptomycin	vs	wild-type	with	daptomycin	P	<	0.0001).	Data	was	analysed	using	a	two-way	ANOVA	with	
Dunne7’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
addiAonal	
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Figure	5.2.	Spent	culture	supernatant	from	wild-type	and	ΔagrA	USA300	exposed	to	daptomycin	
contains	membrane	phospholipids		
Silica-based	 thin-layer	 chromatography	 (TLC)	 plates	 were	 spotted	 with	 chloroform:methanol	
extracts	 from	TSB	 containing	 daptomycin,	 purified	 PG,	 both	 or	 neither,	 and	 stained	with	 iodine	
vapour	 after	 chromatography	 in	 chloroform:methanol:ammonium	hydroxide	 (65:30:4	 v/v/v)	 (a).	
TLC	of	chloroform:methanol	extracts	from	culture	supernatant	of	wild-type	(WT)	or	ΔagrA	(agrA)	
mutant	 exposed	 or	 not	 to	 daptomycin	 were	 adjusted	 to	 the	 same	 lipid	 concentrations	 and	
processed	 as	 described	 in	 a	 (b).	 The	 migration	 of	 lipids	 in	 the	 extract	 from	 spent	 culture	
supernatant	 match	 those	 generated	 by	 PG.	 All	 images	 are	 representative	 of	 at	 least	 two	
independent	experiments.	
	
	
Table	 5.2.	 Identification	 and	 quantification	 of	 phospholipids	 in	 the	 culture	 supernatant	 of	
USA300	strains	exposed	to	daptomycin		
There	were	no	significant	differences	in	the	composition	of	the	lipids	between	the	wild-type	and	
ΔagrA	mutant.		
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Figure	5.2.	Spent	culture	supernatant	from	ΔagrA	USA300	exposed	to	daptomycin	contains	
membrane	phospholipids.	a,	Silica-based	thin-layer	chromatography	(TLC)	plate	spo7ed	with	
chloroform:methanol	extracts	from	TSB	containing	daptomycin,	puriﬁed	PG,	both	or	neither,	and	
stained	with	iodine	vapour	ajer	chro atography	in	chloroform:methanol:ammonium	hydroxide	
(65:30:4	v/v/v).	b,	TLC	of	chloroform:methanol	extracts	from	culture	supernatant	of	wild-type	(WT)	or	
ΔagrA	(agrA)	mutant	exposed	or	not	to	daptomycin,	adjusted	to	the	same	lipid	concentraAons	and	
processed	as	described	in	a.	The	migraAon	of	lipids	in	the	extract	from	spent	culture	supernatant	
match	those	generated	by	PG.	All	images	are	representaAve	of	at	least	two	independent	experiments.	
	
	
	
	
	
	 USA300	ΔagrA	 USA300	WT	
Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
	
	
Supplementary	Table	2.	 Identification	and	quantification	of	phospholipids	 in	the	culture	supernatant	of	
USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	
quantified	 as	 described	 in	 the	methods	 section.	 Data	 are	 presented	 as	 the	 relative	 proportions	 of	 each	
phospholipid	(relative	%)	and	the	concentration	of	each	lipid	in	spent	culture	supernatant.	Data	shown	are	
the	mean	averages	of	3	independent	experiments	in	duplicate	±	the	standard	deviation	of	the	mean.	There	
were	no	significant	differences	in	the	composition	of	the	lipids	from	the	wild-type	or	agrA	mutant.		
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	 USA300	ΔagrA	 USA300	WT	
Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
	
	
Supplementary	Table	2.	 Identification	and	q antific tion	of	phospholipids	 in	the	culture	supernatant	of	
USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	
quantified	 as	 described	 in	 the	methods	 section.	 Data	 are	 presented	 as	 the	 relative	 proportions	 of	 each	
phospholipid	(relative	%)	and	the	concentration	of	each	lipid	in	spent	culture	supernatant.	Data	shown	are	
the	mean	averages	of	3	independent	experiments	in	duplicate	±	the	standard	deviation	of	the	mean.	There	
were	no	significant	differences	in	the	composition	of	the	lipids	from	the	wild-type	or	agrA	mutant.		
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	 USA300	ΔagrA	 USA300	WT	
Lipid	species	 Relative	%	 [supernatant]	(µM)	 Relative	%	 [supernatant]	(µM)	
PG	 70.2±9.6	 59±8.1	 67.6±13.9	 65.5±13.5	
LPG	 16.8±1.6	 14.2±1.4	 9.6±5.5	 9.3±5.4	
CL	 12.5±2.0	 10.5±3.4	 16.0±3.2	 15.5±3.1	
Other	 0.4±1.6	 0.3±1.4	 6.9±5.1	 6.7±5.0	
	
	
Supplementary	Table	2.	 Identification	and	quantification	of	phospholipids	 in	the	culture	supernatant	of	
USA300	 strains	 exposed	 to	 daptomycin.	 Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	
quantified	 as	 described	 in	 the	methods	 section.	 Data	 are	 presented	 as	 the	 relative	 proportions	 of	 each	
phospholipid	(relative	%)	and	the	concentration	of	each	lipid	in	spent	culture	supernatant.	Data	shown	are	
the	mean	averages	of	3	independent	experiments	in	duplicate	±	the	standard	deviation	of	the	mean.	There	
were	no	significant	differences	in	the	composition	of	the	lipids	from	the	wild-type	or	agrA	mutant.		
	
	
		
	
	
	
	
	
	
	
		 153	
	
5.4 Most	 of	 the	 phospholipids	 released	 in	 response	 to	 daptomycin	 are	 in	 the	
form	of	monomers	or	small	micelles	and	not	membrane	vesicles		
Since	wild-type	 bacteria	 released	 the	 same	 phospholipid	 species	 and	 in	 similar	 amounts	 to	 the	
ΔagrA	mutant,	the	phospholipid	released	from	the	wild-type	was	unable	to	inactivate	daptomycin.		
Phospholipids	 can	 exist	 in	 different	 physical	 states,	 including	 monomers,	 micelles	 and	
vesicles.	 Previous	 work	 with	 Escherichia	 coli	 suggested	 that	 membrane	 vesicles	 provided	
protection	against	membrane-targeting	antimicrobials	such	as	polymyxin	antibiotics500.	Therefore,	
it	was	 hypothesized	 that	wild-type	 and	 ΔagrA	mutant	 S.	 aureus	might	 release	 phospholipids	 in	
different	physical	states,	which	in	turn	affected	the	efficiency	of	daptomycin	inactivation.	
To	determine	the	physical	form	of	the	lipid	released	by	S.	aureus	exposed	to	daptomycin,	a	
well-characterised	 method	 was	 used	 to	 fractionate	 released	 phospholipids	 in	 vesicles	 and	
monomers/micelles11.	Culture	supernatant	from	the	USA300	wild-type	or	ΔagrA	mutant	exposed	
to	20	µg	ml-1	daptomycin	was	subjected	to	ultracentrifugation	at	150,000	×	g	and	the	amount	of	
lipid	 that	was	 recovered	 as	 a	 pellet	 (vesicles)	was	 compared	with	 that	 remaining	 in	 suspension	
(monomers/micelles)	using	FM-4-64	dye.	This	 indicated	that	25±1%	of	the	 lipid	released	from	S.	
aureus	ΔagrA	 cultures	 exposed	 to	 daptomycin	was	 in	 the	 form	 of	 vesicles,	 compared	with	 just	
12±1%	of	the	phospholipid	released	by	the	wild-type,	(Fig	5.3a).		
To	 determine	 whether	 the	 phospholipid	 vesicles	 were	 responsible	 for	 inactivating	
daptomycin,	 Bodipy-tagged	 daptomycin	 was	 used	 to	 challenge	 S.	 aureus,	 and	 the	 culture	
supernatant	 was	 subsequently	 subjected	 to	 ultracentrifugation	 at	 150,000	 ×	 g	 to	 recover	
phospholipid	 vesicles.	 This	 revealed	 that	 membrane	 vesicles	 were	 associated	 with	 very	 little	
BoDipy-tagged	 daptomycin,	 which	 was	 mostly	 associated	 with	 monomeric/micellular	
phospholipids	in	suspension	(Fig	5.3b).	To	confirm	that	phospholipid	vesicles	were	not	responsible	
for	 inactivating	 daptomycin,	 culture	 supernatant	 from	 the	 ΔagrA	mutant	 was	 fractionated	 into	
vesicles	 and	 monomers/micelles,	 mixed	 with	 daptomycin,	 and	 the	 activity	 of	 the	 antibiotic	
measured.	This	revealed	that	daptomycin	activity	 in	the	presence	of	purified	membrane	vesicles	
was	unaffected.	By	comparison,	daptomycin	that	had	been	incubated	with	the	monomer/micelle	
fraction	was	 significantly	 reduced	 (Fig	5.3c).	 This	 confirmed	 that	phospholipid	 vesicles	were	not	
responsible	for	inactivating	daptomycin,	and	that	phospholipids	in	the	form	of	monomers	and/or	
micelles	 mediated	 inactivation	 of	 the	 antibiotic.	 Furthermore,	 this	 ruled	 out	 differences	 in	 the	
physical	 form	 of	 phospholipids	 as	 an	 explanantion	 for	 why	wild-type	 bacteria	 are	 less	 efficient	
than	ΔagrA	mutant	S.	aureus	at	inactivating	daptomycin.	
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To	 fully	 determine	 the	 physical	 form	 of	 the	 phospholipid	 that	 inactivated	 daptomycin	 it	
was	 necessary	 to	 differentiate	 between	 phospholipids	 in	 the	 form	 of	 small	 micelles	 and	
monomers.	To	do	this	culture	supernatant	from	S.	aureus	ΔagrA	mutant	exposed	to	daptomycin	
was	fractionated	using	a	3	kDa	filter,	into	filtrate	(<	3	kDa,	monomers),	retentate	(>	3kDa,	micelles)	
or	a	mixture	of	both.	Once	fractionated,	fresh	daptomycin	was	added	to	the	respective	fractions	
and,	 after	 incubation,	 the	 activity	 of	 the	 antibiotic	 measured	 (Fig	 5.4).	 It	 was	 found	 that	
daptomycin	activity	in	the	retentate	(>	3kDa,	micelles)	was	significantly	greater	than	the	<	3	kDa	
fraction	contining	monomeric	phospholipids,	or	the	mixture	of	both	fractions	(Fig	5.4).	
Taken	together,	these	experiments	demonstrated	that	most	of	the	phospholipid	released	
by	 both	 wild-type	 and	 ΔagrA	 mutant	 S.	 aureus	 existed	 as	 monomers	 or	 small	 micelles	 and	
although	 some	 of	 the	 released	 phospholipid	 was	 in	 the	 form	 of	 membrane	 vesicles,	 these	
contained	very	little	daptomycin	and	were	inefficient	at	inactivating	the	antibiotic	(Fig	5.3a-c	and	
5.4).	 Rather,	 the	data	 show	 that	monomeric	phospholipid	molecules	were	primarily	 responsible	
for	inactivating	daptomycin.	
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Figure	5.3.	Daptomycin	triggers	the	release	of	phospholipid	membrane	vesicles	(MV)	but	they	do	
not	inactivate	daptomycin		
Supernatant	 from	 the	 USA300	 wild-type	 or	 ΔagrA	 mutant	 exposed,	 or	 not,	 to	 20	 µg	 ml-1	
daptomycin	was	subjected	to	ultracentrifugation	at	150,000	×	g	and	the	quantity	of	phospholipid	
that	was	recovered	was	compared	with	that	remaining	 in	suspension	using	FM-4-64	dye	(n=3	 in	
duplicate)	 (a).	 Using	 BoDipy-tagged	 daptomycin	 it	 was	 found	 that	 membrane	 vesicles	 were	
associated	with	very	little	daptomycin	(n=3)	(b).	Purified	membrane	vesicles	were	compared	with	
the	remaining	lipid	in	suspension	for	their	ability	to	inactivate	daptomycin	(c).	(n=3,	for	wild-type	
supernatant	 vs	ΔagrA	 supernatant	P	 <0.01	 for	 indicated	 lipid	 types	 (*).	 In	 each	 case,	 error	bars	
represent	the	standard	deviation	of	the	mean.	Data	were	analysed	using	a	two-way	ANOVA	with	
Sidak’s	post-hoc	test.		
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	Figure	4.8.	Daptomycin	triggers	the	release	of	membrane	vesicles	(MV)	but	they	do	not	inacLvate	
daptomycin.	a,	Supernatant	from	the	USA300	wild-type	or	ΔagrA	mutant	exposed	to	20	µg	ml-1	
daptomycin	was	subjected	to	ultracentrifugaKon	at	150,000	×	g	and	the	amount	of	lipid	that	was	
recovered	was	compared	with	that	remaining	in	suspension	using	FM-4-64	dye	(n=3	in	duplicate).	
However,	the	diﬀerences	were	not	signiﬁcant	between	WT	and	ΔagrA	mutant	exposed	to	daptomycin	
P	>0.05.	b,	using	BoDipy-tagged	daptomycin	it	was	found	that	membrane	vesicles	were	associated	
with	very	licle	daptomycin	(n=3).	c,	Puriﬁed	membrane	vesicles	were	compared	with	the	remaining	
lipid	in	suspension	for	their	ability	to	inacKvate	daptomycin.	(n=3,	for	wild-type	supernatant	vs	ΔagrA	
supernatant	P	<0.01	for	indicated	lipid	types	(*).	In	each	case,	error	bars	represent	the	standard	
deviaKon	of	the	mean.	Data	were	analysed	using	a	Two-way	ANOVA	with	Sidak’s	post-hoc	test.	In	all	
cases,	error	bars	represent	the	standard	deviaKon	of	the	mean.	
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Figure	5.4.	Phospholipids	released	in	the	form	of	monomers	inactivate	daptomycin		
The	activity	of	daptomycin	 incubated	with	culture	supernatant	from	S.	aureus	ΔagrA	exposed	to	
daptomycin	 was	 fractionated	 using	 a	 3	 kDa	 filter	 into	 filtrate	 (<	 3	 kDa,	 containing	 monomeric	
phospholipid),	retentate	(>	3kDa,	containing	micelles)	or	a	mixture	of	both	(n=3,	for	the	fraction	>3	
kDa	vs	<3	kDa	or	a	mixture	of	both	P	<	0.0001	(*).	Error	bars	represent	the	standard	deviation	of	
the	mean.	Data	were	analysed	using	a	Two-way	ANOVA	with	Sidak’s	post-hoc	test.		
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Figure	4.7.	Phospholipids	released	in	the	form	of	monomers	or	micelles	inacLvate	daptomycin.	
AcKvity	of	daptomycin	incubated	with	culture	supernatant	from	S.	aureus	ΔagrA	exposed	to	
daptomycin	fracKonated	using	a	3	kDa	ﬁlter	into	ﬁltrate	(<	3	kDa),	retentate	(>	3kDa)	or	a	mixture	of	
both	(n=3,	for	retentate	>3	kDa	vs	<3	kDa	or	a	mixture	of	both	P	<	0.0001	(*).	Error	bars	represent	the	
standard	deviaKon	of	the	mean.	Data	were	analysed	using	a	Two-way	ANOVA	with	Sidak’s	post-hoc	
test.	In	all	cases,	error	bars	represent	the	standard	deviaKon	of	the	mean.	
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5.5 Phospholipids	released	from	wild-type	S.	aureus	do	not	bind	daptomycin	
Although	the	wild-type	bacteria	released	the	same	phospholipid	species,	in	similar	quantities	and	
similar	 physical	 forms	 to	 the	 ΔagrA	 mutant,	 the	 phospholipid	 released	 from	 the	wild-type	was	
unable	to	inactivate	daptomycin.	To	investigate	why	the	phospholipid	released	from	the	wild-type	
did	not	inactivate	daptomycin,	a	daptomycin	pull-down	assay	was	established	to	measure	binding	
of	phospholipid	to	daptomycin	(Fig	5.5).		
Daptomycin	was	labeled	with	biotin	via	its	single	primary	amine	group	in	the	peptide	ring,	
which	 was	 confirmed	 by	 mass-spectroscopy	 (Fig	 2.1)	 (Fig	 5.6).	 Thereafter,	 streptavidin-coated	
agarose	 beads501	 were	 used	 to	 pull-down	 the	 biotin-labeled	 daptomycin	 and	 any	 bound	
phospholipid	 released	 from	 the	 wild-type	 or	 the	 ΔagrA	 mutant	 that	 had	 been	 exposed	 to	
daptomycin.		
Daptomycin	 pull	 down	 significantly	 reduced	 the	 concentration	 of	 phospholipid	 in	 the	
culture	supernatant	of	the	ΔagrA	mutant	(Fig	5.7a).		By	contrast,	there	was	no	significant	change	
in	 the	 quantity	 of	 phospholipid	 in	 the	 culture	 supernatant	 of	 wild-type	 bacteria	 after	 the	 pull-
down	assay	(Fig	5.7a).	In	keeping	with	this,	it	was	found	that	the	quantity	of	phospholipid	bound	
to	the	biotin-labeled	daptomycin	was	far	greater	for	the	ΔagrA	mutant	culture	supernatant	than	
the	wild-type	supernatant	(Fig	5.7b).	Therefore,	despite	releasing	a	very	similar	composition	and	
concentration	of	phospholipids,	daptomycin	was	found	to	bind	only	phospholipids	that	had	been	
released	into	the	culture	supernatant	from	the	ΔagrA	mutant	but	not	wild-type	S.	aureus	(Fig	5.7a	
and	b).		
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Figure	5.5.	Schematic	of	the	daptomycin	pull	down	assay		
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Figure	5.6.	Analysis	of	modified	daptomycin		
Time	of	Flight	(ToF)	mass	spectroscopy	was	used	to	confirm	successful	modification	of	daptomycin	
(a)	 to	 desthiobiotinylated-daptomycin	 (b).	 Experimentally-derived	masses	 were	 similar	 to	 those	
predicted	for	each	molecule	(c).	Data	shown	in	panel	b	were	generated	from	analysis	of	a	single	
batch	of	desthiobiotinylated-	daptomycin	that	were	subsequently	used	 in	all	assays.	Unmodified	
and	 modified	 daptomycin	 MICs	 were	 established	 in	 TSB	 to	 determine	 whether	 modification	
altered	activity.	Despite	modifications,	the	MIC	of	modified	daptomycin	was	the	same	as	that	of	
unmodified	daptomycin	(median	values	shown	from	3	independent	experiments).		
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Figure	5.3.	Analysis	of	modiﬁed	daptomycin.	Time	of	Flight	mass	spectroscopy	was	used	to	conﬁrm	
successful	modiﬁcaAon	of	daptomycin	(a)	to	desthiobioAnylated-daptomycin	(b).	Experimentally-
derived	masses	were	similar	to	 hose	predicted	for	each	molecule	(c).	Data	shown in	panel	b	w s
generated	from	analysis	of	single	batches	of	desthiobioAnylated-	daptomycin	that	were	subsequently	
used	in	all	assays.	Data	in	panel	a,	for	unmodiﬁed	daptomycin	is	shown	for	comparison	and	is	
representaAve	of	at	least	3	independent	analyses.	Unmodiﬁed	and	modiﬁed	daptomycin	MICs	were	
established	in	TSB	 	determine	whether	modiﬁcaAon	altered	acAvity.	Despite	modiﬁcaAons,	the	MIC	
of	modiﬁed	daptomycin	was	the	same	as	that	of	unmodiﬁed	daptomycin	(median	values	shown	from	3	
independent	experiments)		
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Figure	5.7.	Phospholipid	released	from	the	USA300	ΔagrA	mutant,	but	not	wild-type	S.	aureus,	
binds	daptomycin		
The	 concentration	 of	 lipid	 remaining	 in	 culture	 supernatant	 from	 USA300	 wild-type	 or	 ΔagrA	
mutant	 previously	 exposed	 to	 20	 µg	 ml-1	 daptomycin	 and	 incubated	 with	 or	 without	 biotin-
labelled	 daptomycin	 (Bio-dapt)	 and	 streptavidin-coated	 agarose	 beads	 (n=3,	 for	 supernatant	
without	daptomycin	vs	supernatant	with	daptomycin	P	<	0.01)	(a).	The	quantity	of	lipid	bound	to	
streptavidin-coated	beads	with	or	without	biotin-labelled	daptomycin	after	 incubation	 in	culture	
supernatants	(n=3,	for	wild-type	supernatant	vs	ΔagrA	supernatant	P	<	0.001)	(b).	Data	in	panels	a	
and	b	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	 test.	 In	all	 cases	error	bars	
represent	the	standard	deviation	of	the	mean.	
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Figure.	Phospholipid	released	from	the	USA300	ΔagrA	mutant,	but	not	wild-type	S.	aureus,	binds	
daptomycin.	a,	lipid	shedding	from	USA300	wild-type	exposed,	or	not,	to	20	µg	ml-1	daptomycin	(n=3	
in	duplicate,	for	wild-type	without	daptomycin	vs	wild-type	with	daptomycin	P	<	0.0001).	b,	
concentraAon	of	lipid	remaining	in	culture	supernatant	from	USA300	wild-type	or	ΔagrA	mutant	
exposed	to	20	µg	ml-1	daptomycin	and	incubated	with	or	without	bioAn-labelled	daptomycin	(Bio-dapt)	
and	streptavidin-coated	agarose	beads	(n=3,	for	supernatant	without	daptomycin	vs	supernatant	with	
daptomycin	P	<	0.01).	c,	quanAty	of	lipid	bound	to	streptavidin-coated	beads	with	or	without	bioAn-
labelled	daptomycin	ajer	incubaAon	in	culture	supernatants	described	in	(a)	(n=3,	for	wild-type	
supernatant	vs	ΔagrA	supernatant	P	<	0.001.	Data	in	panel	a	were	analysed	using	a	two-way	ANOVA	
with	Dunne7’s	post-hoc	test.	Data	in	panels	b	and	c	were	analysed	using	a	one-way	ANOVA	with	
Tukey’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
Figure	5.3.	Phospholipid	released	from	the	USA300	ΔagrA	mutant,	but	not	wild-type	S.	aureus,	binds	
daptomycin.	a,	concentraAon	of	lipid	remaining	in	culture	supernatant	from USA300	wild-type	or	
ΔagrA	mutant	exposed	to	20	µg	ml-1	daptomycin	and	incubated	with	or	without	bioAn-labelled	
daptomycin	(Bio-dapt)	and	streptavidin-coated	agarose	beads	(n=3,	for	supernatant	without	
daptomycin	vs	supernatant	with	daptomycin	P	<	0.01).	b,	quanAty	of	lipid	bound	to	streptavidin-coated	
beads	with	or	without	bioAn-labelled	daptomycin	ajer	incubaAon	in	culture	supernatants	described	in	
(a)	(n=3,	for	wild-type	supernatant	vs	ΔagrA	supernatant	P	<	0.001.	Data	in	panels	a	and	b	were	
analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	test.	In	all	cases	error	bar 	rep esent	the	
standard	deviaAon	of	the	mean.	
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5.6 A	 small	molecule	 in	 the	 culture	 supernatant	 of	wild-type	 bacteria	 prevents	
phospholipid	from	inactivating	daptomycin	
S.	aureus	 releases	phospholipids	 in	 response	 to	daptomycin,	 independently	of	 the	expression	of	
AgrA.	However,	by	contrast	to	those	of	the	ΔagrA	mutant,	phospholipids	released	by	the	wild-type	
S.	 aureus,	which	 has	 a	 functional	 Agr	 system,	 were	 unable	 to	 bind	 and	 inactivate	 daptomycin.	
Because	 AgrA	 triggers	 the	 secretion	 of	 numerous	 products	 including	 metabolic	 products	 and	
toxins	 such	 as	 PSM	 peptides158,176,397,	 it	 was	 hypothesised	 that	 these	 prevented	 the	 binding	 of	
daptomycin	by	phospholipid	released	from	wild-type	bacteria.			
To	test	this	hypothesis,	wild-type	bacteria	and	the	ΔagrA	mutant	were	grown	to	stationary	
phase	and	 the	culture	 supernatants	extracted.	Thereafter,	 the	ΔagrA	mutant	 cells	were	washed	
and	incubated	with	TSB	containing	0,	5%	or	10%	of	the	spent-culture	supernatant	from	the	wild-
type	 bacteria	 and	 daptomycin	 at	 37oC	 for	 8	 h.	 The	 presence	 of	 5%	 or	 10%	 spent	 culture	
supernatant	 from	wild-type	bacteria	 significantly	 reduced	 the	 survival	 of	 the	ΔagrA	mutant	 and	
inactivation	 of	 daptomycin	 compared	 to	 the	 TSB	 only	 condition	 (Fig	 5.8a	 and	 b).	 Therefore,	 in	
support	of	the	hypothesis,	it	was	found	that	spent	culture	supernatant	from	the	wild-type	bacteria	
prevented	the	ΔagrA	mutant	from	inactivating	daptomycin	(Fig	5.8a	and	b).	
To	 characterize	 the	agent(s)	 responsible	 for	disrupting	 the	phospholipid	 sequestration	of	
daptomycin,	 culture	 supernatant	 from	 the	 wild-type	 bacteria	 and	 the	 ΔagrA	 mutant	 were	
fractionated	 using	 a	 centricon	 filter	 into	 >	 or	 <	 3	 kDa.	 The	ΔagrA	mutant	was	 then	 exposed	 to	
daptomycin	 in	 the	 presence	 of	 each	 fraction	 and	 daptomycin	 activity	 determined	 after	 8	 h.	
Daptomycin	was	 inactivated	efficiently	 in	 the	presence	of	 culture	 supernatant	 from	the	>	3	kDa	
fraction.	However,	 the	<	3	kDa	fraction	significantly	 inhibited	the	ability	of	 the	ΔagrA	mutant	 to	
inactivate	 daptomycin	 (Fig	 5.8c).	 Neither	 fraction	 from	 the	 ΔagrA	 mutant	 supernatant	 affected	
daptomycin	inactivation	(Fig	5.8c).	
Next,	 to	determine	 the	 thermal	 stability	of	 the	<	3	kDa	element	 responsible	 for	 interfering	with	
the	 inactivation	of	daptomycin,	 culture	 supernatants	were	heat	 treated	at	80oC	 for	20	minutes.	
The	ΔagrA	mutant	was	then	incubated	with	TSB	supplemented	with	daptomycin	and	10%	of	the	
heat-treated	 or	 untreated	 culture	 supernatant	 of	 the	 wild-type.	 Heat	 treatment	 significantly	
reduced	the	ability	of	the	wild-type	supernatant	to	block	daptomycin	inactivation	(Fig	5.8d).		
Together,	these	findings	indicated	that	phospholipid-mediated	inactivation	of	daptomycin	
could	be	inhibited	by		small	peptides	secreted	by	Agr-functional	wild-type	S.	aureus.	 	
		 162	
	
Figure	 5.8.	 Spent-culture	 supernatant	 containing	 small	 peptides	 from	 wild-type	 S.	 aureus	
prevents	the	agrA	mutant	from	inactivating	daptomycin		
The	 USA300	 ΔagrA	 mutant	 was	 inoculated	 into	 TSB	 containing	 0,	 5	 or	 10%	 spent	 culture	
supernatant	 from	 stationary-phase	 wild-type	 USA300,	 daptomycin	 (20	 µg	 ml-1)	 and	 CaCl2	 (0.5	
mM).	 Bacterial	 survival	 (a)	 and	 daptomycin	 activity	 (b)	 were	 then	 measured	 over	 time.	 Data	
represent	 the	 mean	 of	 3	 independent	 experiments	 done	 in	 duplicate.	 Spent	 wild-type	 culture	
supernatant	significantly	reduced	bacterial	survival	and	daptomycin	inactivation	(for	TSB	without	
WT	supernatant	vs	TSB	with	5%	or	10%	WT	supernatant	P	<	0.01	at	the	indicated	time	points	(*)	
by	 two-way	 ANOVA	 and	 Dunnett’s	 post-hoc	 test).	 To	 characterise	 the	 factor	 responsible	 for	
blocking	 daptomycin	 inactivation,	 culture	 supernatants	 from	 the	 USA300	 wild-type	 or	 ΔagrA	
mutant	 were	 fractionated	 into	 >	 or	 <	 3	 kDa	 (c),	 or	 (d),	 heat	 treated	 (80oC,	 20	 min).	 Treated	
supernatants	were	then	used	at	10%	as	described	above	for	panels	(a)	and	(b).	This	revealed	that	
the	inhibition	of	daptomycin	inactivation	by	the	wild-type	was	due	to	a	heat-sensitive	factor	of	less	
than	3	kDa	 (n=3	 in	duplicate,	 for	wild-type	supernatant	>3	kDa	vs	wild-type	supernatant	<3	kDa	
and	 unheated	 wild-type	 supernatant	 vs	 heated	 wild-type	 supernatant	 P	 <	 0.001	 by	 one-way	
ANOVA	with	Tukey’s	post-hoc	test.).	 In	all	panels	error	bars	 represent	 the	standard	deviation	of	
the	mean.	
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Figure	5.5.	Culture	supernatant	from	wild-type	S.	aureus	prevents	an	agrA	mutant	from	inacNvaNng	
daptomycin.	The	USA300	ΔagrA	mutant	was	inoculated	into	TSB	containing	0,	5	or	10%	spent	culture	
supernatant	from	staAo ary-phase	wild-type	USA300,	daptomycin	(20	µg	ml-1)	and	CaCl2	(0.5	mM).	
Bacterial	survival	(a)	and	daptomycin	acAvity	(b)	were	then	followed	over	Ame.	Data	represent	the	mean	
of	3	independent	experiments	done	in	duplicate.	Error	bars	represent	the	standard	deviaAon	of	the	mean.		
	The	presence	of	spent	wild-type	culture	supernatant	signiﬁcantly	reduced	bacterial	survival	and	reduced	
daptomycin	inacAvaAon	at	the	indicated	Ame	points	(for	TSB	without	WT	supernatant	vs	TSB	with	5%	or	
10%	WT	supernatant	P	<	0.01	at	the	indicated	Ame	points	(*)	as	determined	using	a	two-way	ANOVA	and	
Dunne7’s	post-hoc	test).	As	a	ﬁrst	step	to	idenAfy	the	factor	responsible	for	blocking	daptomycin	
inacAvaAon,	culture	supernatants	from	the	USA300	wild-type	or	ΔagrA	mutant	were	either	fracAonated	
using	a	centricon	ﬁlter	into	fracAons	that	contained	proteins	>	or	<	3	kDa	(c),	or	d,	heat	treated	(80	oC,	20	
min).	Treated	supernatants	were	then	used	at	10%	as	described	above	for	panels	a	and	b.	This	revealed	
that	the	ability	of	wild-type	supernatant	to	block	daptomycin	inacAvaAon	by	the	ΔagrA	mutant	was	
dependent	upon	a	factor	of	less	than	3 kDa	and	was	parAally	sensiAve	to	h at	(n=3	in	duplicate,	for	wild-
type	supernatant	>3	kDa	vs	wild-type	supernatant	<3	kDa	and	unheated	wild-type	supernatant	vs	heated	
wild-type	supernatant	P	<	0.001	as	determined	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	test.).	In	all	
panels	error	bars	represent	the	standard	deviaAon	of	the	mean.	
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5.7 AgrA-triggered	 PSMα	 production	 compromises	 daptomycin	 inactivation	 by	
released	phospholipids	
AgrA	not	only	regulates	the	quorum-sensing	system	but	also	directly	regulates	the	expression	of	7	
small	 peptide	 cytolysins	 known	 as	 phenol	 soluble	 modulins	 (PSMs),	 categorized	 into	 alpha	
(PSMα1-4)	or	beta	(PSMβ1,2)	families,	as	well	as	the	PSMδ	peptide	encoded	by	the	hld	gene	found	
within	 RNAIII140,158.	 Given	 the	 surfactant	 properties	 of	 PSMs	 it	 was	 hypothesised	 that	 these	
cytolysins	prevented	the	sequestration	of	daptomycin	by	phospholipids.	
To	test	 this	hypothesis,	mutants	 lacking	PSMα,	PSMβ	or	both	 families	of	peptides	 in	 two	
different	S.	aureus	strain	backgrounds,	USA300	and	SH1000	were	employed322,391.	Firstly,	strains	
were	characterised	by	measuring	growth	profiles	to	ensure	that	bacteria	were	in	the	same	growth	
phase	when	used	in	assays	(Fig	5.9).	This	confirmed	that	the	lack	of	the	PSM	toxins	did	not	have	an	
impact	on	the	growth	rate	of	S.	aureus.	 In	addition,	the	MIC	of	daptomycin	for	the	mutants	was	
the	same	(1	μg	ml-1)	as	that	of	the	wild-type	(Table	5.3).	
To	 determine	 whether	 the	 Agr-dependent	 production	 of	 PSM	 peptides	 explained	 the	
differences	in	daptomycin	killing	between	wild-type	and	ΔagrA	strains,	each	of	the	wild-type	and	
Δpsm	mutants	were	incubated	with	daptomycin	at	37oC	for	8	h	and	survival,	phospholipid	release	
and	daptomycin	activity	measured	every	2	h	for	up	to	8	h.	Survival	of	the	Δpsmαβ	and	the	Δpsmα	
mutants	 was	 significantly	 greater	 than	 that	 of	 the	 wild-type	 both	 USA300	 and	 SH1000,	 with	 a	
similar	initial	drop	in	CFU	counts,	followed	by	recovery,	as	seen	previously	for	the	ΔagrA	mutants.	
(Fig	5.10a	and	5.11a,	3.3a	and	c).	By	contrast,	survival	of	the	Δpsmβ	mutant	was	similar	to	wild-
type	S.	aureus,	with	>4	 log	reduction	 in	CFU	counts	by	8	h	 (Fig	5.10a	and	5.11a).	Therefore,	 the	
presence	of	PSMα	peptides	dramatically	enhanced	daptomycin-mediated	killing	of	S.	aureus.	
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Figure	5.9.	Growth	profiles	of	wild-type	and	Δpsm	mutants		
Growth	 of	wild-type	 and	Δpsm	mutants	 from	 the	USA300	 (a)	 and	 SH1000	 (b)	 backgrounds	was	
determined	by	taking	OD600	measurements	over	time	(n=3	in	duplicate,	error	bars	represent	the	
standard	deviation	of	the	mean).	There	was	no	significant	difference	in	growth	between	the	wild-
type	and	psm	mutants	at	any	 time	point	as	determined	using	a	 two-way	ANOVA	and	Dunnett’s	
post-hoc	test).	
	
	
Table	5.3.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentrations	for	wild-type	
and	Δpsm	mutant	strains			
Data	 show	 the	MIC/MBC	 (μg	 ml-1)	 for	 daptomycin	 in	 TSB	 (Tryptic	 Soy	 Broth)	 or	MHB	 (Muller-
Hinton	 Broth)	 determined	 by	 broth	 microdilution	 as	 described	 previously.	 All	 media	 were	
supplemented	 with	 CaCl2	 (0.5	 mM)	 and	 MIC/MBC	 determined	 after	 24	 h	 incubation.	 Data	
represent	 the	 median	 value	 of	 3	 independent	 experiments	 done	 in	 duplicate.	 In	 keeping	 with	
previous	findings,	the	values	for	MIC	and	MBC	were	identical.		
	
	 	
	 	
USA300	–	derived	
Medium	+	
Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraNons	for	strains	used	in	this	
study.	Data	show	the	MIC	 (μg	ml-1)	 for	daptomycin	 in	TSB	 (TrypAc	Soy	Broth)	or	MHB	(Muller-Hinton	
Broth)	determined	by	broth	microdiluAon	as	described	previously.	All	media	were	supplemented	with	
CaCl2	to	50	μg	ml-1	and	MIC/MBC	determined	ajer	24	h	incubaAon.	Data	represent	the	median	value	of	
3	independent	experiments	done	in	duplicate.	In	keeping	with	previous	ﬁndings,	the	values	for	MIC		and	
MBC	were	idenAcal.		
SH1000	–	derived	
Medium	+	
	Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	
Dapt.	 thrC	 ebpS	 murA	
Membran
e	protein	 tcaA	
Universal	
stress	
protein	
hlgA	 htrA	 clpC	
MerR	family	
transcripAona
l	regulator	
MerR	family	
transcripAonal	
regulator	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	
Table:		
Table:		
Table:		
Table:		
USA300	–	derived	
Medium	+	
Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
Table.	Daptomycin	minimal	inhibitory	and	minimal	bactericidal	concentraNons	for	strains	used	in	this	
study.	Data	show	the	MIC	 (μg	ml-1)	 for	daptomycin	 in	TSB	 (TrypAc	Soy	Broth)	or	MHB	(Muller-Hinton	
Broth)	determined	by	broth	microdiluAon	as	described	previously.	All	media	were	supplemented	with	
CaCl2	to	50	μg	ml-1	and	MIC/MBC	determined	ajer	24	h	incubaAon.	Data	represent	the	median	value	of	
3	independent	expe iments	done	in	duplicate.	In	keeping	with	previous	ﬁndings,	the	values	for	MIC		and	
MBC	were	idenAcal.		
SH1000	–	derived	
Medium	+	
	Dapt.	 WT	 Δpsmα	 Δpsmβ	 Δpsmαβ	
TSB	 1	 1	 1	 1	
MHB	 0.5	 0.5	 0.5	 0.5	
USA300	JE2	–	derived	
Medium	+	
Dapt.	 WT	 ΔagrA	 ΔvraT	 ΔvraTpEmpty	 ΔvraTpagrC	 ΔvraU	 ΔvraR	 ΔvraS	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	
USA300	JE2	–	derived	(vra	regulon)	
Medium	+	
Dapt.	 thrC	 ebpS	 murA	
Membran
e	protein	 tcaA	
Universal	
stress	
protein	
hlgA	 htrA	 clpC	
MerR	family	
transcripAona
l	regulator	
MerR	family	
transcripAonal	
regulator	
TSB	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	
Table:		
Table:		
Table:		
Table:		
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Figure	5.6.	 	 roﬁles	of	wild-type	and	psm	mutants.	Growth	of	wild-type	and	psm	mutants	
from	the	USA300	(a)	and	SH1000	(b)	backgrounds	was	determined	by	taking	OD600	measurements	
over	Ame	(n=3	in	duplicate,	error bars	represent	the	standard	deviaAon	of	the	mean. .	There	was	no	
signiﬁcant	diﬀerence	in	growth	between	the	wild-type	and	psm	mutants	at	any	Ame	point	as	
determined	using	a	two-way	ANOVA	and	Dunne7’s	post-hoc	test).	
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To	test	whether	PSMα	peptides	promoted	daptomycin-mediated	killing	by	preventing	the	
inactivation	of	daptomycin,	the	activity	of	the	antibiotic	in	the	culture	supernatants	of	each	of	the	
strains	was	determined.	In	keeping	with	the	survival	data,	there	was	a	modest	2-fold	reduction	in	
in	 the	 bactericidal	 activity	 of	 daptomycin	 in	 cultures	 of	 the	 wild-type	 bacteria,	 and	 the	 Δpsmβ	
mutant	 (Fig	 5.10b	 and	 5.11b)	 By	 contrast,	 both	 the	 Δpsmα	 and	 Δpsmαβ	 mutants	 rapidly	
inactivated	 daptomycin,	with	 similar	 kinetics	 to	 that	 seen	 previously	 for	 the	 ΔagrA	mutant	 (Fig	
5.10b	 and	 5.11b),	 confirming	 that	 PSMα	 peptides	 compromised	 the	 ability	 of	 the	 wild-type	 S.	
aureus	 to	 inactivate	 daptomycin.	 The	 differences	 in	 daptomycin	 inactivation	 were	 not	 due	 to	
defective	phospholipid	release	since,	as	expected	from	previous	experiments	with	ΔagrA	mutants,	
it	was	found	that	the	wild-type,	Δpsmα,	Δpsmβ	and	Δpsmαβ	mutants	released	similar	quantities	of	
phospholipids	in	response	to	daptomycin	(Fig	5.10c	and	5.12).		
Together,	these	experiments	using	mutants	in	both	the	USA300	and	SH1000	backgrounds,	
provided	very	strong	evidence	that	the	secretion	of	PSMα	peptides	by	Agr-functional	wild-type	S.	
aureus	prevents	the	inactivation	of	daptomycin	by	released	phospholipids.	
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Figure	5.10.	PSMα	peptides	prevent	daptomycin	inactivation	by	S.	aureus	USA300		
To	 determine	 whether	 PSM	 peptides	 influenced	 susceptibility	 of	 S.	 aureus	 to	 daptomycin,	 the	
survival	 (a)	of	USA300	wild-type	or	psm	mutants	during	exposure	 to	20	µg	ml-1	daptomycin	and	
the	activity	(b)	of	the	antibiotic	 in	associated	culture	supernatants	was	determined	over	time	(in	
both	cases	n=3	in	duplicate,	for	WT	vs	Δpsmα	or	Δpsmαβ	P	<	0.0001	at	indicated	time	points	(*).	
In	 (b)	 open	 circles	 are	 obscured	 by	 filled	 circles	 at	 4,	 6	 and	 8	 h.	 The	 quantity	 of	 phospholipid	
released	from	USA300	wild-type	or	psm	mutants	 incubated	with	daptomycin	was	also	measured	
(c).	Data	in	panels	a,	b,	and	c	were	analysed	using	a	two-way	ANOVA	with	Dunnett’s	post-hoc	test.	
Where	shown,	error	bars	represent	the	standard	deviation	of	the	mean.			
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Figure	5.7	.	Alpha	phenol	soluble	modulins	prevent	daptomycin	inacNvaNon	by	USA300	S.	aureus.	
To	determine	whether	PSM	pepAdes	inﬂuenced	suscepAbility	of	S.	aureus	to	daptomycin,	we	
measured	a,	survival	of	USA300	wild-type	or	psm	mutants	during	exposure	to	20	µg	ml-1	daptomycin	
and	b,	the	acAvity	of	the	anAbioAc	in	associated	culture	supernatants	(in	both	cases	n=3	in	duplicate,		
for	WT	vs	Δpsmα	or	Δpsmαβ	P	<	0.0001	at	indicated	Ame	points	(*).	In	b,	open	circles	are	obscured	
by	ﬁlled	circles	at	4,	6	and	8	h	c,	the	quanAty	of	lipid	shed	from	USA300	wild-type	or	psm	mutants	
incubated	with	daptomycin	in	a.	Data	in	panels	a,	b,	and	c	were	analysed	using	a	2-way	ANOVA	with	
Dunne7’s	post-hoc	test.	Where	shown,	error	bars	represent	the	standard	deviaAon	of	the	mean.			
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Figure	5.11.	PSMα	peptides	prevent	daptomycin	inactivation	by	S.	aureus	SH1000		
To	determine	whether	PSM	peptides	influenced	susceptibility	of	S.	aureus	SH1000	to	daptomycin,	
the	survival	(a)	of	SH1000	wild-type	or	psm	mutants	during	exposure	to	20	µg	ml-1	daptomycin	and	
the	 activity	 of	 the	 antibiotic	 (b)	 in	 culture	 supernatants	 was	 determined	 (in	 both	 cases	 n=3	 in	
duplicate,	 (*	 P	 <	 0.01	 compared	 to	 Δpsmαβ	mutant).	 For	 wild-type	 vs	 Δpsmαβ	 P	 <0.01	 at	 the	
indicated	time	points.	Data	in	panels	a-b	were	analysed	by	two-way	ANOVA	with	Dunnett’s	post-
hoc	test.	In	all	cases	error	bars	represent	the	standard	deviation	of	the	mean.	
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	Figure	5.8.	Alpha	phenol	soluble	modulins	prevent	daptomycin	inacNvaNon	by	SH1000	S.	aureus.	To	
determine	whether	PSM	pepAdes	inﬂuenced	suscepAbility	of	S.	aureus	to	daptomycin,	we	measured	a,	
survival	of	SH1000	wild-type	or	psm	mutants	during	exposure	to	20	µg	ml-1	daptomycin	and	b,	the	acAvity	
of	the	anAbioAc	in	culture	supernatants	(in	both	cases	n=3	in	duplicate,		*	P	<	0.01	compared	to	Δpsmαβ	
mutant).	The	absence	of	PSMα,	but	not	PSMβ,	pepAde	producAon	resulted	in	signiﬁcantly	higher	bacterial	
survival	(wild-type	vs	Δpsmαβ	P	<0.01)	at	the	indicated	Ame	points.	Data	in	panels	a-c	were	analysed	by	
two-way	ANOVA	with	Dunne7’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	deviaAon	of	
the	mean.	
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Figure	5.12.	Daptomycin	induces	similar	levels	of	lipid	release	from	S.	aureus	SH1000	strains	
SH1000	 wild-type	 (WT),	 agrA	 mutant	 (agr)	 or	 mutants	 lacking	 psmα,	 psmβ	 or	 psmαβ	 were	
incubated	 with	 or	 without	 daptomycin	 for	 8	 h.	 The	 presence	 of	 lipid	 was	 then	 detected	 and	
quantified	in	the	culture	supernatant	from	each	strain	using	FM-4-64	dye	as	described	in	section	
2.16.	Data	represent	the	mean	average	of	3	independent	experiments	done	in	duplicate	(wild-type	
vs	agr	mutant	 in	 the	 absence	 of	 daptomycin	P	 <	 0.01	 as	 determined	 by	 one-way	 ANOVA	with	
Tukey	post-hoc	test).	Error	bars	represent	the	standard	deviation	of	the	mean.		
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	Figure	5.9.	Daptomycin	induces	lipid	release	from	S.	aureus	SH1000	strains.	SH1000	wild-type	(WT),	
agrA	mutant	(agr)	or	mutants	lacking	psmα,	psmβ	or	psmαβ	were	incubated	with	or	without	
daptomycin	for	8	h.	The	presence	of	lipid	was	then	detected	in	the	culture	supernatant	from	each	strain	
using	FM-4-64	dye	and	quanAﬁed	using	a	microAtre	platereader	as	described	in	the	methods	secAon.	
Data	represent	the	mean	average	of	3	independent	experiments	done	in	duplicate	(wild-type	vs	agr	
mutant	in	the	absence	of	daptomycin	P	<	0.01	as	determined	by	one-way	ANOVA	with	Tukey	post-hoc	
test).	Error	bars	represent	the	standard	deviaAon	of	the	mean.		
	
		 169	
5.8 Synthetic	PSMα	peptides	prevent	the	inactivation	of	daptomycin	and	restore	
the	wild-type	S.	aureus	killing	phenotype	
To	provide	additional	evidence	that	PSMα	peptides	enhanced	daptomycin-mediated	killing,	and	to	
determine	 which	 of	 the	 4	 PSMα	 peptides	 inhibited	 the	 inactivation	 of	 daptomycin,	 synthetic	
PSMα1,	α2,	α3,	α4,	β1	and	β2	peptides	were	utilized	(generated	by	Peptide	Protein	Research	Ltd).	
Wild-type	 bacteria,	 the	 Δpsmαβ	 mutant	 or	 the	 Δpsmαβ	 mutant	 supplemented	 with	 either	 a	
mixture	of	PSM	alpha	peptides	(α1-4),	PSM	beta	peptides	(β1-2)	or	PSM	alpha	+	beta	peptides	(α1-
4	+	β1-2)	were	incubated	with	daptomycin	at	37oC	for	8	h.	Each	peptide	was	used	at	10	µM,	since	
this	 approximated	 to	 the	 concentration	 produced	 by	 wild-type	 USA300	 in	 stationary	 phase	
158,176,397.	
As	 expected	 from	 the	 previous	 findings	with	Δpsm	mutants,	 the	 survival	 of	 the	Δpsmαβ	
mutant	 was	 significantly	 greater	 than	 wild-type	 exposed	 to	 daptomycin	 (Fig	 5.13a	 and	 5.14a).	
Similarly,	survival	of	the	Δpsmαβ	mutant	supplemented	with	a	mixture	of	PSMβ1-2	peptides	was	
also	significantly	greater	than	wild-type	(Fig	5.13a	and	5.14a).	By	contrast,	survival	of	the	Δpsmαβ	
mutant	 supplemented	with	 a	mixture	 of	 PSMα1-4	 peptides	 or	 a	mixture	 of	 PSMα1-4	 and	 β1-2	
peptides,	was	similar	to	the	wild-type	(Fig	5.13a	and	5.14a),	confirming	that	the	presence	of	PSMα	
peptides	significantly	enhances	daptomycin-mediated	killing	of	S.	aureus.			
To	test	whether	the	presence	of	synthetic	PSMα	peptides	promoted	staphylococcal	killing	
by	preventing	the	inactivation	of	daptomycin,	the	activity	of	the	antibiotic	in	culture	supernatants	
was	measured.	As	expected	from	previous	experiments	with	Δpsm	mutants,	there	was	a	50%	loss	
in	the	bactericidal	activity	of	daptomycin	in	the	culture	supernatants	from	wild-type	bacteria	and	
the	 Δpsmαβ	 mutant	 supplemented	 with	 a	 mixture	 of	 PSMα1-4	 peptides	 or	 PSMα1-4	 +	 β1-2	
peptides	 (Fig	 5.13b	 and	 5.14b).	 By	 contrast,	 the	 Δpsmαβ	 mutant	 without	 peptides,	 and	 the	
Δpsmαβ	 mutant	 supplemented	 with	 a	 mixture	 of	 PSMβ1-2	 rapidly	 inactivated	 daptomycin	
similarly	 to	 that	 seen	 previously	 for	 the	 ΔagrA	 mutant	 (Fig	 5.13b	 and	 5.14b).	 Therefore,	 as	
observed	 for	 the	 Δpsm	 mutants,	 the	 presence	 of	 PSMα	 peptides,	 but	 not	 the	 PSMβ	 peptides,	
prevented	 the	 inactivation	 of	 daptomycin	 by	 S.	 aureus	 and	 thereby	 enhanced	 the	 bactericidal	
activity	of	the	antibiotic.	
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Figure	5.13.	The	effect	of	 synthetic	PSM	peptides	on	 survival	of	USA300	S.	aureus	 exposed	 to	
daptomycin		
To	 determine	whether	 synthetic	 PSMα	 or	 PSMβ	 peptides	 restored	 daptomycin	 susceptibility	 to	
the	 Δpsmαβ	mutant,	 survival	 (a)	 of	 the	 USA300	 psmαβ	mutant	 in	 the	 absence	 or	 presence	 of	
mixtures	of	PSMα	peptides	(α1-4),	PSMβ	peptides	(β1,2)	or	PSMα	and	PSMβ	(α1-4,	β1,2)	during	
exposure	 to	 20	 µg	 ml-1	 daptomycin	 was	 measured.	 The	 survival	 of	 wild-type	 S.	 aureus	 in	 the	
absence	of	peptides	is	included	for	comparison	(n=3	in	duplicate,	for	Δpsmαβ	without	peptides	vs	
Δpsmαβ	 with	 PSMα	 peptides	 P	 <	 0.0001	 at	 the	 indicated	 time	 points	 (*).	 Filled	 triangles	 are	
obscured	 by	 filled	 squares	 and	 filled	 circles.	 The	 activity	 of	 daptomycin	 in	 culture	 supernatants	
from	the	experiment	described	in	(a)	are	shown	in	panel	(b)	(n=3	in	duplicate,	for	Δpsmαβ	without	
peptides	 vs	 Δpsmαβ	 with	 PSMα	 peptides	 P	 <	 0.0001	 at	 the	 indicated	 time	 points	 (*).	 Data	 in	
panels	 a	 and	 b	 were	 analysed	 using	 a	 two-way	 ANOVA	 with	 Dunnett’s	 post-hoc	 test.	 Where	
shown,	error	bars	represent	the	standard	deviation	of	the	mean.			
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Figure	5.10.	The	eﬀect	of	syntheNc	PSM	pepNdes	on	survival	of	USA300	S.	aureus	exposed	to	
daptomycin.	To	determine	whether	syntheAc	PSMα	or	PSMβ	pepAdes	restored	daptomycin	
suscepAbility	to	the	Δpsmαβ	mutant	by	measuring		a,	survival	of	the	USA300	psmαβ	mutant	in	the	
absence	or	presence	of	mixtures	of	PSMα	pepAdes	(α1-4),	PSMβ	pepAdes	(β1,2)	or	PSMα	and	PSMβ	
(α1-4,	β1,2)	during	exposure	to	20	µg	ml-1	daptomycin	.	The	survival	of	wild-type	S.	aureus	in	the	
absenc 	of	pepAdes	is	included	for	comparison	(n=3 in	duplicate,	for Δpsmαβ	without	pepAdes	vs	
Δpsmαβ	with	PSMα	pepAdes	P	<	0.0001	at	the	indicated	Ame	points	(*).	Filled	triangles	are	obscured	
by	ﬁlled	squares	and	ﬁlled	circles.	b,	the	acAvity	of	daptomycin	in	culture	supernatants	from	the	
experiment	described	in	a	(n=3	in	duplicate,	for	Δpsmαβ	without	pepAdes	vs	Δpsmαβ	with	PSMα	
pepAdes	P	<	0.0001	at	the	indicated	Ame	points	(*).	Data	in	panels	a	and	b	were	analysed	using	a	2-
way	ANOVA	with	Dunne7’s	post-hoc	test.	Where	shown,	error	bars	represent	the	standard	deviaAon	
of	the	m an.			
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Figure	5.14.	 The	effect	of	 synthetic	PSM	peptides	on	 survival	of	 SH1000	S.	aureus	 exposed	 to	
daptomycin		
To	 determine	whether	 synthetic	 PSMα	 or	 PSMβ	 peptides	 restored	 daptomycin	 susceptibility	 to	
the	SH1000	Δpsmαβ	mutant,	survival	(a)	was	measured	during	exposure	to	20	µg	ml-1	daptomycin	
and	 the	 activity	 of	 the	 antibiotic	 (b)	 measured	 in	 the	 presence	 or	 absence	 of	 PSMα,	 PSMβ	 or	
PSMαβ	peptides	(in	both	cases	n=3	in	duplicate.	The	presence	of	PSMα,	but	not	PSMβ,	peptides	
restored	daptomycin	susceptibility	to	the	Δpsmαβ	mutant	(Δpsmαβ	vs	Δpsmαβ	+	PSMα	peptides	P	
<0.01).	Data	in	panels	a-b	were	analysed	by	two-way	ANOVA	with	Dunnett’s	post-hoc	test.	 In	all	
cases	error	bars	represent	the	standard	deviation	of	the	mean.	
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	Figure	5.11.	The	eﬀect	of	syntheNc	PSM	pepNdes	on	survival	of	SH1000	S.	aureus	exposed	to	
daptomycin.	To	determine	whether	syntheAc	PSMα	or	PSMβ	pepAdes	restored	daptomycin	suscepAbility	
to	the	Δps αβ	mutant	by	measuring	a,	survival	during	exposure	to	20	µg	ml-1	daptomycin	and	b,	the	
acAvity	of	the	anAbioAc	in	culture	supernatants	in	the	presence	or	absence	of	PSMα,	PSMβ	or	PSMαβ	
pepAdes	(in	both	cases	n=3	in	duplicate.	The	presence	of	PSMα,	but	not	PSMβ,	pepAdes	restored	
daptomycin	suscepAbility	to	the	Δpsmαβ	mutant	(Δpsmαβ	vs	Δpsmαβ	+	PSMα	pepAdes	P	<0.01).	Data	in	
panels	a-b	were	analysed	by	two-way	ANOVA	with	Du ne7’s	po t-hoc	test.	In	all	cases	error	bars	represent	
the	standard	deviaAon	of	the	mean.	
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To	 determine	 the	 effect	 of	 individual	 PSM	 peptides	 on	 daptomycin	 inactivation,	 the	
USA300	 Δpsmαβ	 mutant	 was	 incubated	 with	 daptomycin	 in	 the	 presence	 or	 absence	 of	 each	
synthetic	 PSM	 peptide.	 In	 keeping	 with	 the	 previous	 data	 (Fig	 5.13a	 and	 5.14a),	 the	 Δpsmαβ	
mutant	 without	 the	 peptides	 and	 the	 Δpsmαβ	 mutant	 supplemented	 with	 PSMβ1	 or	 PSMβ2	
survived	daptomycin	challenge	(Fig	5.15a).	However,	the	survival	of	the	Δpsmαβ	mutant	exposed	
to	daptomycin	in	the	absence	of	PSM	peptides	was	significantly	greater	than	the	Δpsmαβ	mutant	
supplemented	with	the	PSMα1	peptide,	and	to	a	 lesser	extent,	PSMα2	peptides	 (Fig	5.15a).	The	
presence	of	PSMα3	or	PSMα4	had	no	detectable	effect	on	daptomycin	susceptibility	(Fig	5.15a).	
As	 expected	 from	 the	 survival	 data,	 the	 presence	 of	 PSMβ1,	 PSMβ2,	 PSMα3	 or	 PSMα4	
peptides	had	no	effect	on	the	ability	of	S.	aureus	to	inactivate	daptomycin	(Fig	5.15b).	By	contrast,	
the	Δpsmαβ	mutant	 supplemented	with	 the	 PSMα1	peptide	 had	 a	 significantly	 reduced	 rate	 of	
inactivation	of	daptomycin	compared	to	the	Δpsmαβ	mutant	without	the	peptides	(Fig	5.15b).	The	
presence	 of	 the	 PSMα2	 peptide	 had	 a	 negligible	 effect.	 Together,	 these	 data	 demonstrate	 that	
PSMα1	is	primarily	responsible	for	preventing	daptomycin	inactivation	by	phospholipids	released	
from	wild-type	S.	aureus	(Fig	5.15a	and	b).	
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Figure	5.15.	The	effect	of	individual	peptides	on	daptomycin	susceptibility		
USA300	Δpsmαβ	was	 incubated	with	20	µg	ml-1	daptomycin	 in	 the	presence	or	absence	of	each	
peptide	 (10	 µM)	 and	 survival	 (a)	 and	 antibiotic	 activity	 (b)	 determined	 (in	 both	 cases	 n=3	 in	
duplicate,	for	Δpsmαβ	mutant	without	peptide	vs	Δpsmαβ	mutant	with	PSMα1	or	PSMα2	peptide	
P	<	0.01	at	the	indicated	time	points	(*).	PSMα1	was	the	most	potent	in	lowering	bacterial	survival	
and	reduced	daptomycin	inactivation.	Data	in	panels	a-b	were	analysed	by	two-way	ANOVA	with	
Dunnett’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	deviation	of	the	mean.	
	 	
USA300	
0.01	
0.1	
1	
10	
100	
1000	
0	 2	 4	 6	 8	
%
	su
rv
iv
al
	
¢	WT	
	Δpsmα/β																										
	Δpsmα/β	+	α1																
p	Δpsmα/β	+	α2																
u	Δpsmα/β	+	α3																		
!	Δpsmα/β	+	α4																
r	Δpsmα/β	+	β1																
£	Δpsmα/β	+	β2	
Time	(h)	
*	
*	
*	
0	
20	
40	
60	
80	
100	
120	
0	 2	 4	 6	 8	
USA300	
%
	d
ap
t.	
in
hi
bi
to
ry
	a
cA
vi
ty
	
¢	WT	
	Δpsmα/β																										
	Δpsmα/β	+	α1																
p	Δpsmα/β	+	α2																
u	Δpsmα/β	+	α3																		
!	Δpsmα/β	+	α4																
r	Δpsmα/β	+	β1																
£	Δpsmα/β	+	β2	
Time	(h)	
*	*	
*	*	
Figure	5.12.	The	eﬀect	of	individual	pepNdes	on	dapto ycin	suscepNbility.	USA300	Δpsmαβ	was	
incubated	with	20	µg	ml-1	daptomycin	in	the	presence	or	absence	of	each	pepAde	(10	µM)	and	
survival	(a)	and	anAbioAc	acAvity	(b)	determined	(in	both	cases	n=3	in	duplicate,	for	Δpsmαβ	mutant	
without	pepAde	vs	Δpsmαβ	mutant	with	PSMα1	or	PSMα2	pepAde	P	<	0.01	at	the	indicated	Ame	
points	(*).	PSMα1	was	the	most	potent	in	low ring	bacterial	s rvival	and	reduced	daptomycin	
inacAvaAon.	Data	in	panels	a-b	were	analysed	by	two-way	ANOVA	with	Dunne7’s	post-hoc	test.	In	all	
cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
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Figure	5.14	.	Alpha	phenol	soluble	modulins	prevent	daptomycin	inacNvaNon	by	puriﬁed	PG.	
acAvity	of	daptomycin	in	the	presence	of	25	µM	phosphaAdylglycerol	(PG)	±	20	µM	PSMα1	(n=4,	for	
PG	without	PSMα1	vs	PG	with	PSMα1	P	<	0.01)	at	the	indicated	Ame	points	(*).	Data	in	panel	a	was	
analysed	using	a	student’s	t-test.	Where	shown,	error	bars	represent	the	standard	deviaAon	of	the	
mean.		
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Although	 the	 data	 described	 above	 demonstrated	 that	 PSMα	 peptides	 delayed	 the	
inactivation	of	daptomycin	without	affecting	the	rate	and	amount	of	phospholipid	release,	it	was	
important	to	rule	out	a	contributory	effect	from	other	AgrA-regulated	genes.	To	do	this,	the	ΔagrA	
mutant	was	 challenged	with	daptomycin	 in	 the	 absence	or	 presence	of	 the	PSMα1	peptide	 (10	
μM)	(Fig	5.16a).	In	these	experiments,	a	second	peptide	was	also	examined,	which	consisted	of	the	
PSMα1	 peptide	 sequence	 in	 reverse	 (PM-Rev).	 This	 peptide	 has	 significantly	 reduced	 cytolytic	
activity	due	to	a	loss	of	protein	structure,	but	its	surfactant	properties	remained	largely	intact	(Fig	
5.17).	
As	before,	 in	the	absence	of	PSMα,	the	ΔagrA	mutant	survived	daptomycin	exposure	(Fig	
5.16a).	By	contrast,	 survival	of	 the	ΔagrA	mutant	was	diminished	 in	 the	presence	of	 the	PSMα1	
peptide	(Fig	5.16a).	Interestingly,	the	PSM-rev	peptide	had	a	similar	effect	to	the	PSMα1	peptide,	
significantly	reducing	survival	of	the	ΔagrA	mutant	(Fig	5.16a).	Both	peptides	reduced	the	rate	of	
daptomycin	 inactivation	 by	 the	 ΔagrA	 mutant,	 although	 the	 PSM-rev	 peptide	 did	 not	 block	
daptomycin	inactivation	as	efficiently	as	the	PSMα1	peptide	(Fig	5.16b).		
Therefore,	production	of	the	PSMα1	peptide	in	response	to	Agr	activity	by	S.	aureus	is	the	
critical	 determinant	 in	 the	 efficiency	 of	 phospholipid-mediated	 daptomycin	 inactivation.	
Furthermore,	 it	 appears	 that	 PSMα1	 prevents	 the	 inactivation	 of	 daptomycin	 by	
phosphatidylglycerol	 via	 its	 surfactant	 property,	 rather	 than	 a	 mechanism	 that	 relies	 on	 its	
structure.		
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Figure	5.16.	The	lack	of	PSMα	peptide	production	by	the	ΔagrA	mutant	was	responsible	for	its	
lack	of	susceptibility	to	daptomycin		
Survival	(a)	and	daptomycin	activity	(b)	was	measured	in	the	presence	(10	µM)	or	absence	of	the	
PSMα1	peptide	during	exposure	to	20	µg	ml-1	daptomycin.	ΔagrA	without	peptides	vs	ΔagrA	with	
peptides	P	<0.01.	Data	for	(a)	and	(b)	represent	the	mean	of	3	independent	experiments	done	in	
duplicate.	Error	bars	represent	the	standard	deviation	of	the	mean.		*	indicates	P	<	0.05	compared	
with	the	ΔagrA	mutant	without	peptide	by	two-way	ANOVA	with	Dunnett’s	post-hoc	test.		
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	Figure	5.13.	To	conﬁrm	that	the	lack	of	PSMα	pepNde	producNon	by	the	ΔagrA	mutant	was	responsible	
for	its	lack	of	suscepNbility	to	daptomycin	we	measured	survival	(a)	and	daptomycin	acAvity	(b)	in	the	
presence	(10	µM)	or	absence	of	the	PSMα1	pepAde	during	exposure	to	20	µg	ml-1	daptomycin.	The	
pepAde	promoted	killing	of	the	ΔagrA	mutant	by	preserving	daptomycin	acAvity.	The	presence	of	the	
PSMα1	pepAde	restored	daptomycin	suscepAbility	to	the	ΔagrA	mutant	(ΔagrA	without	pepAdes	vs	
ΔagrA	with	pepAdes	P	<0.01).	We	also	assessed	the	ability	of	the	syntheAc	PSMα1	to	prevent	inacAvaAon	
of	daptomycin	by	spent	culture	supernatant	from	the	USA300	ΔagrA	 utant	exposed	to	daptomycin	(c).	
This	demonstrated	th t	PSMα1	preve ted	the	inacAvaAon	of	daptomycin	by	released	membrane	
phospholipid,	rather	than	an	indirect	eﬀect	on	the	bacterial	cells	(ΔagrA	without	pepAdes	vs	ΔagrA	with	
pepAdes	P	<0.01).	Data	for	a,	b,	c	represent	the	mean	of	3	independent	experiments	done	in	duplicate.	
Error	bars	represent	the	standard	deviaAon	of	the	mean.		*	indicates	P	<	0.05	compared	with	the	ΔagrA	
mutant	without	pepAde.	Experiments	in	a,	b,	c	show	that	the	PSM-rev	pepAde	reduced	inacAvaAon	of	
daptomycin,	albeit	less	eﬃciently	than	PSMα1,	suggesAng	a	key	role	for	the	surfactant	property	of	the	
pepAde	(ref	ﬁgure	next	slide).	Data	in	panels	a-c	were	analysed	by	two-way	ANOVA	with	Dunne7’s	post-
hoc	test.	In	all	cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
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Figure	5.17.	Characterisation	of	the	haemolytic	and	surfactant	activity	of	the	PSMα1	and	PSM-
rev	peptides		
Haemolysis	 (a)	 and	 surfactant	 (b)	 activity	 were	 determined	 using	 previously	 described	
protocols397,392.	 In	 both	 cases	 n=3	 in	 duplicate,	 PSMα1	 vs	 PSM-rev	 P	 <0.05	 by	 student’s	 t-test.	
Error	bars	represent	the	standard	deviation	of	the	mean.	
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To		test	whether	the	surfactant	property	of	PSMα1	was	responsible	for	prevenAng	daptomycin	
inacAvaAon	and	so	repeated	the	experiment	with	a	pepAde	comprised	of	the	reverse	sequence	of	
PSMα1	(PSM-rev).		
Figure	5.15.	CharacterisaNon	of		the	haemolyNc	and	surfactant	acNvity	of	the	PSMα1	and	
PSM-rev	pepNde.		This	pepAde	is	defecAve	for	haemolysis	(a)	but	retains	a	high	degree	of	
surfactant	acAvity	(b),	as	determined	using	previously	described	protocols31,53	(in	both	cases	
n=3	in	duplicate,	PSMα1	vs	PSM-rev	P	<0.05).	Data	in	panels	a	and	b	were	analysed	by	two-
way	ANOVA	with	Dunne7’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	
deviaAon	of	the	mean.	
	
Figure	5.16.	Released	membrane	phospholipids	block	PSM	haemolyNc	acNvity.	To	test	whether	PSMα	
pepAdes	bind	phospholipid,	we	measured	the	haemolyAc	acAvity	of	the	cytolysin	in	the	presence	or	
absence	of	phospholipid	shed	from	the	ΔagrA	mutant	in	response	to	daptomycin	(a)	(n=3	in	triplicate,	
PSMα1	in	supernatant	from	ΔagrA	mutant	not	exposed	to	daptomycin	vs	ΔagrA	mutant	exposed	to	
daptomycin	P	<	0.01).	b,	the	haemolyAc	acAvity	of	PSMα1	was	also	assessed	in	the	absence	or	presence	of	
puriﬁed	phosphaAdylglycerol	(PG)	(n=3,	PSMα1	in	TSB	only	vs	TSB	containing	PG	P	<	0.01).	In	both	panels,	
data	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	test.	Error	bars	represent	the	standard	
deviaAon	of	the	mean.		
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5.9 PSMα1	 blocks	 the	 interaction	 of	 phodphatidylglycerol	 with	 daptomycin	 by	
directly	binding	the	phospholipid	
The	 most	 likely	 mechanism	 by	 which	 PSMα1	 inhibited	 the	 inactivation	 of	 daptomycin	 by	
phospholipids	was	by	direct	competition	with	the	antibiotic	for	the	lipid.	However,	an	alternative	
hypothesis	 was	 that	 PSMα1	 interacted	 with	 the	 bacterium	 and	 promoted	 attachment	 of	
daptomycin.	 To	 test	 this,	 a	 cell-free	 system	 using	 spent	 culture	 supernatant	 from	 the	 USA300	
ΔagrA	mutant	exposed	to	daptomycin	was	employed.	The	supernatant	was	mixed	with	additional	
daptomycin	 in	the	presence	or	absence	of	synthetic	PSMα1	or	PSM-rev	peptide.	As	expected,	 in	
the	absence	of	synthetic	peptides,	 the	supernatant	 inactivated	daptomycin	rapidly	 (Fig	5.18).	By	
contrast,	the	presence	of	the	PSMα1	peptide,	and	to	a	lesser	extent	PSM-rev,	significantly	reduced	
the	 inactivation	of	daptomycin	 in	 the	 spent	 culture	 supernatant	 (Fig	5.18).	 This	provided	 strong	
evidence	that	 the	PSMα1	peptide	directly	prevented	the	 inactivation	of	daptomycin	by	 released	
membrane	phospholipids,	rather	than	an	indirect	effect	on	the	bacterial	cells.	
As	a	follow	up	to	this	experiment,	the	ability	of	purified	PG	to	inactivate	daptomycin	was	
measured	 in	 the	 absence	 or	 presence	 of	 the	 PSMα1	 peptide.	 As	 observed	 for	 spent	 culture	
supernatant,	the	presence	of	synthetic	PSMα1	peptide	blocked	the	inhibition	of	the	antibiotic	by	
the	 phospholipid	 (Fig	 5.19).	 This	 again	 indicated	 that	 PSMα1	 competes	 with	 daptomycin	 for	
phosphatidylglycerol.	
As	 a	 final	 confirmation,	 the	 hemolytic	 activity	 of	 PSMα1	 in	 the	 presence	 or	 absence	 of	
spent	 culture	 supernatant	 was	 tested.	 It	 was	 hypothesized	 that	 if	 PSMα1	 bound	 directly	 to	
phosphatidylglycerol	 then	 there	 would	 be	 a	 loss	 of	 hemolytic	 activity.	 In	 support	 of	 this	
hypothesis,	 it	 was	 found	 that	 the	 PSMα1	 toxin	 in	 the	 presence	 of	 the	 released	 membrane	
phospholipids	 from	the	ΔagrA	mutant	was	significantly	 less	haemolytic	 than	PSMα1	toxin	 in	the	
absence	 of	 released	 membrane	 phospholipids	 (Fig	 5.20a).	 This	 assay	 was	 then	 repeated	 with	
purified	 PG	 instead	 of	 the	 culture	 supernatant	 of	 the	 ΔagrA	mutant	 and	 it	was	 found	 that	 the	
PSMα1	toxin	 incubated	with	the	phospholipid	was	significantly	 less	haemolytic	compared	to	the	
PSMα1	 toxin	 incubated	with	 TSB	 only	 (Fig	 5.20b).	 Therefore,	 the	 presence	 of	 PG,	 either	 in	 the	
form	of	 released	membrane	phospholipids	or	purified	 lipid,	 completely	 inhibited	 the	haemolytic	
activity	of	PSMα1,	indicating	direct	binding	of	the	PSMα1	peptide	to	the	phospholipid	(Fig	5.20).			
	 Together,	 these	 data	 strongly	 indicated	 that	 PSMα1	 peptides	 do	 indeed	 compete	 with	
daptomycin	for	binding	to	PG.	
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Figure	5.18.	PSMα1	prevents	daptomycin	inactivation	by	released	membrane	phospholipids	
Culture	supernatant	from	the	USA300	ΔagrA	mutant	exposed	to	daptomycin	was	mixed	with	PSM	
α1,	PSM-rev	or	neither,	and	a	 fresh	dose	of	daptomycin.	The	activity	of	 the	antibiotic	was	 then	
measured	over	 time.	The	presence	of	 the	peptides	 significantly	 reduced	 the	 rate	of	daptomycin	
inactivation	(*	 indicates	P	<	0.05	compared	with	the	ΔagrA	mutant	without	peptide	by	two-way	
ANOVA	with	 Dunnett’s	 post-hoc	 test).	 Data	 represent	 the	mean	 of	 3	 independent	 experiments	
done	in	duplicate.	Error	bars	represent	the	standard	deviation	of	the	mean.			
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	Figure	5.13.	To	conﬁrm	that	the	lack	of	PSMα	pepNde	producNon	by	the	ΔagrA	mutant	was	responsible	
for	its	lack	of	suscepNbility	to	daptomycin	we	measured	survival	(a)	and	daptomycin	acAvity	(b)	in	the	
presence	(10	µM)	or	absence	of	the	PSMα1	pepAde	during	exposure	to	20	µg	ml-1	daptomycin.	The	
pepAde	promoted	killing	of	the	ΔagrA	mutant	by	preserving	daptomycin	acAvity.	The	presence	of	the	
PSMα1	pepAde	restored	daptomycin	suscepAbility	to	the	ΔagrA	mutant	(ΔagrA	without	pepAdes	vs	
ΔagrA	with	pepAdes	P	<0.01).	We	also	assessed	the	ability	of	the	syntheAc	PSMα1	to	prevent	inacAvaAon	
of	daptomycin	by	spent	culture	supernatant	from	the	USA300	ΔagrA	mutant	exposed	to	daptomycin	(c).	
This	demonstrated	that	PSMα1	prevented	the	inacAvaAon	of	daptomycin	by	released	membrane	
phospholipid,	rather	than	an	indirect	eﬀect	on	the	bacterial	cells	(ΔagrA	without	pepAdes	vs	ΔagrA	with	
pepAdes	P	<0.01).	Data	for	a,	b,	c	represent	the	mean	of	3	independent	experiments	done	in	duplicate.	
Error	bars	represent	the	standard	deviaAon	of	the	mean.		*	indicates	P	<	0.05	compared	with	the	ΔagrA	
mutant	without	pepAde.	Experiments	in	a,	b,	c	show	that	the	PSM-rev	pepAde	reduced	inacAvaAon	of	
daptomycin,	albeit	less	eﬃciently	than	PSMα1,	suggesAng	a	key	role	for	the	surfactant	property	of	the	
pepAde	(ref	ﬁgure	next	slide).	Data	in	panels	a-c	were	analysed	by	two-way	ANOVA	with	Dunne7’s	post-
hoc	test.	In	all	cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
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Figure	5.19.	PSMα1	prevents	daptomycin	inactivation	by	purified	PG		
Activity	of	daptomycin	in	the	presence	of	25	µM	phosphatidylglycerol	(PG)	±	20	µM	PSMα1	(n=4,	
for	PG	without	PSMα1	vs	PG	with	PSMα1	P	 <	0.01)	at	 the	 indicated	 time	points	 (*).	Data	were	
analysed	using	a	student’s	t-test.	Error	bars	represent	the	standard	deviation	of	the	mean.		
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Figure	5.12.	The	eﬀect	of	individual	pepNdes	on	daptomycin	suscepNbility.	USA300	Δpsmαβ	was	
incubated	with	20	µg	ml-1	daptomycin	in	the	presence	or	absence	of	each	pepAde	(10	µM)	and	
survival	(a)	and	anAbioAc	acAvity	(b)	determined	(in	both	cases	n=3	in	duplicate,	for	Δpsmαβ	mutant	
without	pepAde	vs	Δpsmαβ	mutant	with	PSMα1	or	PSMα2	pepAde	P	<	0.01	at	the	indicated	Ame	
points	(*).	PSMα1	was	the	most	potent	in	lowering	bacterial	survival	and	reduced	daptomycin	
inacAvaAon.	Data	in	panels	a-b	were	analysed	by	two-way	ANOVA	with	Dunne7’s	post-hoc	test.	In	all	
cases	error	bars	represent	the	standard	deviaAon	of	the	mean.	
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Figure	5.14	.	Alpha	phenol	soluble	modulins	prevent	daptomycin	inacNvaNon	by	puriﬁed	PG.	
acAvity	of	daptomycin	in	the	presence	of	25	µM	phosphaAdylglycerol	(PG)	±	20	µM	PSMα1	(n=4,	for	
PG	without	PSMα1	vs	PG	with	PSMα1	P	<	0.01)	at	the	indicated	Ame	points	(*).	Data	in	panel	a	was	
analysed	using	a	student’s	t-test.	Where	shown,	error	bars	represent	the	standard	deviaAon	of	the	
mean.		
a b
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Figure	5.20.	Released	membrane	phospholipids	block	PSMα1	haemolytic	activity		
To	test	whether	PSMα	peptides	bind	phospholipids,	the	haemolytic	activity	of	the	cytolysin	in	the	
presence	 or	 absence	 of	 phospholipid	 shed	 from	 the	 ΔagrA	 mutant	 (a)	 or	 purified	 PG	 (b)	 was	
measured.	 In	 both	 panels,	 n=3	 in	 triplicate.	 Data	 were	 analysed	 using	 a	 one-way	 ANOVA	 with	
Tukey’s	post-hoc	test.	Error	bars	represent	the	standard	deviation	of	the	mean.	For	(a)	PSMα1	in	
supernatant	 from	 the	 ΔagrA	 mutant	 not	 exposed	 to	 daptomycin	 vs	 ΔagrA	 mutant	 exposed	 to	
daptomycin	P	<	0.01.	For	(b)	the	haemolytic	activity	of	PSMα1in	TSB	only	vs	TSB	containing	PG	P	<	
0.01.		
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To		test	whether	the	surfactant	property	of	PSMα1	was	responsible	for	prevenAng	daptomycin	
inacAvaAon	and	so	repeated	the	experiment	with	a	pepAde	comprised	of	the	reverse	sequence	of	
PSMα1	(PSM-rev).		
Figure	5.15.	CharacterisaNon	of		the	haemolyNc	and	surfactant	acNvity	of	the	PSMα1	and	
PSM-rev	pepNde.		This	pepAde	is	defecAve	for	haemolysis	(a)	but	retains	a	high	degree	of	
surfactant	acAvity	(b),	as	determined	using	previously	described	protocols31,53	(in	both	cases	
n=3	in	duplicate,	PSMα1	vs	PSM-rev	P	<0.05).	Data	in	panels	a	and	b	were	analysed	by	two-
way	ANOVA	with	Dunne7’s	post-hoc	test.	In	all	cases	error	bars	represent	the	standard	
deviaAon	of	the	mean.	
	
Figure	5.16.	Released	membrane	phospholipids	block	PSM	haemolyNc	acNvity.	To	test	whether	PSMα	
pepAdes	bind	phospholipid,	we	measured	the	haemolyAc	acAvity	of	the	cytolysin	in	the	presence	or	
absence	of	phospholipid	shed	from	the	ΔagrA	mutant	in	response	to	daptomycin	(a)	(n=3	in	triplicate,	
PSMα1	in	supernatant	from	ΔagrA	mutant	not	 xposed	to	daptomycin	vs	ΔagrA	mutant	exposed	to	
dapto ycin	P	<	0.01).	b,	the	haemolyAc	acAvity	of	PSMα1	was	also	a sessed	in	the	absence	or	presence	of	
puriﬁed	phosphaAdylglycerol	(PG)	(n=3,	PSMα1	in	TSB	only	vs	TSB	containing	PG	P	<	0.01).	In	both	panels,	
data	were	analysed	using	a	one-way	ANOVA	with	Tukey’s	post-hoc	test.	Error	bars	represent	the	standard	
deviaAon	of	the	mean.		
	
		 181	
	
5.10 The	 inhibition	of	phospholipid-mediated	daptomycin	 inactivation	by	PSMα1	
enhances	daptomycin-binding	to	S.	aureus	
The	data	presented	so	far	demonstrate	that	PG	binds	and	inactivates	daptomycin,	and	that	PSMα1	
prevents	 this	 by	 binding	 to	 the	 phospholipid.	 Therefore,	 it	 was	 hypothesised	 that	 PSMα1	
enhanced	daptomycin-mediated	killing	of	S.	aureus	by	preventing	the	phospholipid	sequestration	
of	daptomycin	and	enabling	binding	of	the	antibiotic	to	the	bacterium.	To	test	this,	we	first	tagged	
daptomycin	with	 BoDipy	 to	measure	 its	 binding	 to	S.	 aureus	 (Fig	 5.21).	 Thereafter,	wild-type	S.	
aureus,	the	ΔagrA	mutant	and	the	ΔagrA	mutant	supplemented	with	PSMα1	were	incubated	with	
BoDipy-tagged	 daptomycin	 at	 37oC	 for	 up	 to	 8	 h.	 Every	 two	 hours	 bacteria	 were	 harvested,	
washed,	and	resuspended	in	fresh	TSB	to	measure	the	relative	fluorescence	generated	by	the	cell	
bound	 BoDipy-tagged	 daptomycin.	 This	 revealed	 that	 wild-type	 S.	 aureus	 steadily	 accumulated	
daptomycin	over	 time	 (Fig	5.22).	By	contrast,	binding	of	daptomycin	 to	S.	aureus	ΔagrA	mutant	
significantly	decreased	over	 time	compared	 to	 the	wild-type,	presumably	because	 the	antibiotic	
was	 sequestered	 by	 the	 released	 PG	 (Fig	 5.22).	 In	 the	 presence	 of	 PSMα1	 peptide,	 however,	
daptomycin	 bound	 strongly	 to	 the	 ΔagrA	 mutant,	 demonstrating	 that	 this	 cytolysin	 promoted	
binding	of	the	antibiotic	to	bacteria	by	preventing	its	sequestration	by	released	phospholipids,	as	
observed	for	the	wild-type	(Fig	5.22).	Therefore,	Agr-triggered	PSMα1	secretion	compromises	the	
inactivation	of	daptomycin	by	the	phospholipid	PG,	resulting	in	increased	binding	of	the	antibiotic	
to	the	staphylococcal	membrane,	resulting	in	bacterial	death.	
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Figure	5.21.	Analysis	of	Bodipy-labelled	daptomycin		
Time	of	Flight	mass	spectroscopy	was	used	 to	confirm	successful	modification	of	daptomycin	 to	
bodipy-daptomycin	 (a).	 Experimentally-derived	masses	were	almost	 identical	 to	 those	predicted	
for	 each	molecule	 (b).	Data	 shown	 in	 panel	 b	was	 generated	 from	analysis	 of	 single	 batches	 of	
bodipy-	daptomycin	that	were	subsequently	used	in	all	assays.	Data	in	panel	a,	is	representative	of	
at	least	3	independent	analyses.	MICs	of	unmodified	and	modified	daptomycin	were	established	in	
TSB	 to	 determine	 whether	 modification	 altered	 activity.	 Despite	 modifications,	 the	 MIC	 of	
modified	daptomycin	was	the	same	as	that	of	unmodified	daptomycin	(median	values	shown	from	
3	independent	experiments).		
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Figure.	Analysis	of	modiﬁed	daptomycin.	Time	of	Flight	mass	spectroscopy	was	used	to	conﬁrm	
successful	modiﬁcaAon	of	daptomycin	(a)	to	bodipy-daptomycin.	Experimentally-derived	masses	were	
similar	to	those	predicted	for	each	molecule	(b).	Data	shown	in	panel	b	was	generated	from	analysis	of	
single	batches	of	bodipy-	daptomycin	that	were	subsequently	used	in	all	assays.	Data	in	panel	a,	is	
representaAve	of	at	least	3	independent	analyses.	Unmodiﬁed	and	modiﬁed	daptomycin	MICs	were	
established	in	TSB	to	determine	whether	modiﬁcaAon	altered	acAvity.	Despite	modiﬁcaAons,	the	MIC	
of	modiﬁed	daptomycin	was	the	same	as	that	of	unmodiﬁed	daptomycin	(median	values	shown	from	3	
independent	experiments)		
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Figure	5.22.	PSMα1	promotes	binding	of	daptomycin	to	bacteria		
Binding	 of	 BoDipy-labelled	 daptomycin	 to	 wild-type,	 ΔagrA	 mutant	 or	 ΔagrA	 mutant	 in	 the	
presence	of	PSMα1	(n=3	in	triplicate,	for	WT	vs	agrA	P	<	0.001	at	the	indicated	time	points	(*)).	
Data	were	 analysed	 by	 two-way	ANOVA	with	Dunnett’s	 post-hoc	 test.	 Error	 bars	 represent	 the	
standard	deviation	of	the	mean.		
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	Figure.	Daptomycin	induces	lipid	release	from	S.	aureus	SH1000	strains.	SH1000	wild-type	(WT),	agrA	
mutant	(agr)	or	mutants	lacking	psmα,	psmβ	or	psmαβ	were	incubated	with	or	without	daptomycin	for	
8	h.	The	presence	of	lipid	was	then	detected	in	the	culture	supernatant	from	each	strain	using	FM-4-64	
dye	and	quanAﬁed	using	a	microAtre	platereader	as	described	in	the	methods	secAon.	Data	represent	
the	mean	average	of	3	independent	experiments	done	in	duplicate	(wild-type	vs	agr	mutant	in	the	
absence	of	daptomycin	P	<	0.01	as	determined	by	one-way	ANOVA	with	Tukey	post-hoc	test).	Error	bars	
represent	the	standard	deviaAon	of	the	mean.		
	
Figure	5.17.	Alpha	phenol	soluble	modulins	promoted	binding	of	daptomycin	to	bacteria	a,	binding	
of	BoDipy-labelled	daptomycin	to	wild-type,	ΔagrA	mutant	or	ΔagrA	mutant	in	the	presence	of	
PSMα1	(n=3	in	triplicate,	for	WT	vs	agrA	P	<	0.001	at	the	indicated	Ame	points	(*).	Data	in	panel	a	
were	analysed	were	analysed	using	a	2-way	ANOVA	with	Dunne7’s	post-hoc	test.	Where	shown,	
error	bars	represent	the	standard	deviaAon	of	the	mean.		
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5.11 Oxacillin	 promotes	 daptomycin	 activity	 by	 reducing	 daptomycin-induced	
phospholipid	release		
Having	discovered	that	the	ΔagrA	mutant	employs	a	phospholipid	release	mechanism	to	survive	
daptomycin	 exposure,	 attention	 turned	 to	 finding	 a	 therapeutic	 approach	 to	 overcome	 this	
defence	strategy	and	thereby	improve	daptomycin	treatment	outcomes.	
Previous	studies	have	shown	that	β-lactam	antibiotics	with	affinity	for	S.	aureus	penicillin-
binding	proteins	significantly	enhance	daptomycin	activity,	even	against	MRSA,	which	are	resistant	
to	 β-lactam	 antibiotics418,502.	 Although	 the	 underlying	 mechanism	 is	 unclear,	 one	 of	 the	
explanations	 for	 this	 is	 that	 there	 is	 an	 increase	 in	 the	 binding	 of	 daptomycin	 to	 the	 bacterial	
membrane	 in	 the	 presence	 of	 β-lactams	 that	 inhibit	 PBP1413,418,502.	 In	 addition,	 because	
peptidoglycan	biosynthesis	occurs	at	the	site	of	daptomycin	insertion	and	membrane	blebbing	in	
Bacillus	subtilis126,	it	was	hypothesised	that	a	β-lactam	antibiotic	that	targeted	PBP1	may	promote	
daptomycin	activity	by	inhibiting	phospholipid	release.		
To	test	 this	hypothesis,	 survival	of	 the	ΔagrA	mutant	during	exposure	to	a	sub-inhibitory	
concentration	 of	 the	 β-lactam	 antibiotic	 oxacillin	 (0.25	 µg	 ml-1),	 20	 µg	 ml-1	 daptomycin,	 both	
antibiotics	together	or	neither	was	measured	over	time.	As	expected,	the	ΔagrA	mutant	grew	well	
in	media	without	 antibiotics	 or	 in	media	 supplemented	with	oxacillin	 alone	 (Fig	 5.23a).	Also,	 as	
expected	 from	 previous	 results,	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin	 alone,	 suffered	 an	
initial	10-fold	decrease	in	CFU	during	the	first	2	hr,	before	recovering.	However,	CFU	counts	of	the	
ΔagrA	mutant	exposed	to	the	combination	of	oxacillin	and	daptomycin	dropped	1000-fold,	before	
slowly	 beginning	 to	 recover	 after	 6	 hr	 (Fig	 5.23a).	 To	 determine	 whether	 oxacillin	 enhanced	
daptomycin-mediated	 killing	 of	 the	 ΔagrA	 mutant	 by	 inhibiting	 the	 release	 of	 phospholipids,	
culture	 supernatants	 from	 the	assays	described	above	were	 recovered	and	mixed	with	FM-4-64	
dye.	 This	 revealed	 that	 the	 phospholipid	 released	 from	 the	 ΔagrA	 mutant	 exposed	 to	 the	
combination	of	oxacillin	and	daptomycin	was	significantly	reduced	compared	to	the	ΔagrA	mutant	
exposed	to	daptomycin	alone	(Fig	5.23b,c).	 In	keeping	with	this	finding,	the	presence	of	oxacillin	
significantly	 delayed	 the	 inactivation	 of	 daptomycin	 by	 ΔagrA	 mutant,	 relative	 to	 the	 rate	 of	
inactivation	of	daptomycin	in	the	absence	of	the	β-lactam	(Fig	5.23b,c).	In	control	experiments	to	
ensure	that	the	presence	of	oxacillin	did	not	affect	the	size	of	the	zone	of	inhibition	produced	by	
daptomycin	 and	 thereby	 confound	 our	 activity	 assays,	 we	 mixed	 0.25	 µg	 ml-1	of	 oxacillin	 with	
increasing	concentrations	of	daptomycin	and	generated	a	standard	plot	of	the	size	of	the	zone	of	
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inhibition.	The	presence	of	oxacillin	did	not	affect	the	size	of	the	zone	of	 inhibition	produced	by	
daptomycin	(Fig	3.10a).	
Together,	 these	 findings	 indicated	 that	 the	presence	of	a	 sub-inhibitory	concentration	of	
the	β-lactam	antibiotic	oxacillin	enhanced	killing	of	the	S.	aureus	ΔagrA	mutant	by	daptomycin,	by	
reducing	the	rate	of	phospholipid	release	and	therefore	prolonging	the	activity	of	daptomycin	(Fig	
5.23a,b,c).		
To	investigate	whether	oxacillin	also	enhanced	the	activity	of	daptomycin	against	wild-type	
S.	aureus,	the	assay	described	above	was	repeated.	As	expected	from	our	previous	assays,	it	was	
found	 that	 wild-type	 S.	 aureus	 was	 killed	 rapidly	 by	 daptomycin	 alone	 (Fig	 5.23d).	 However,	
although	 the	 wild-type	 S.	 aureus	 was	 rapidly	 killed	 by	 the	 combination	 of	 oxacillin	 and	
daptomycin,	 there	was	no	 significant	difference	between	 the	 survival	of	 the	wild-type	S.	aureus	
exposed	 to	 the	 combination	 of	 oxacillin	 and	 daptomycin	 and	 daptomycin	 alone	 (Fig	 5.23d).	
Although	 the	 phospholipid	 released	 by	 the	 wild-type	 S.	 aureus	 exposed	 to	 the	 combination	 of	
oxacillin	and	daptomycin	was	significantly	reduced	compared	to	the	wild-type	S.	aureus	exposed	
to	 daptomycin	 alone	 (Fig	 5.23e),	 this	 did	 not	 affect	 the	 degree	 to	 which	 daptomycin	 was	
inactivated	by	wild-type	bacteria	 (Fig	5.23f).	Therefore,	unlike	 for	 the	ΔagrA	mutant	phenotype,	
oxacillin	 did	 not	 show	 synergy	 with	 daptomycin	 against	 wild-type	 S.	 aureus,	 despite	 reducing	
phospholipid	 release,	 most	 likely	 because	 the	 phospholipid	 release	 mechanism	 is	 already	
compromised	by	the	presence	of	PSMα	peptides		(Fig	5.23d,e,f).		
Since	 oxacillin	 and	 daptomycin	were	 synergistic	 against	 the	 ΔagrA	mutant	 but	 not	wild-
type	bacteria,	it	was	decided	to	investigate	whether	oxacillin	promoted	the	activity	of	daptomycin	
against	mixed	populations	of	both	wild-type	and	ΔagrA	mutant.	Therefore,	assays	were	repeated	
using	a	1:1	ratio	of	the	wild-type	S.	aureus	and	ΔagrA	mutant.	Similar	to	what	was	observed	for	
the	ΔagrA	mutant	phenotype,	it	was	found	that	the	survival,	phospholipid	release	and	the	rate	of	
inactivation	of	daptomycin	of	the	mixed	population	exposed	to	both	oxacillin	and	daptomycin	was	
significantly	 reduced	 compared	 to	 the	 mixed	 population	 exposed	 to	 daptomycin	 alone	 (Fig	
5.23g,h,i).	
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Figure	5.23.	Oxacillin	prevents	phospholipid	release	and	daptomycin	inactivation		
USA300	 ΔagrA	 was	 exposed	 to	 a	 sub-inhibitory	 concentration	 (0.25	 µg	 ml-1)	 of	 oxacillin	 (oxa),	
daptomycin	(20	µg	ml-1)	(dapt),	both	antibiotics	(or	neither)	in	combination,	and	survival	(a),	lipid	
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release	 (b)	 and	daptomycin	 activity	 (c)	measured	over	 8	h	 (n=3	 in	duplicate,	 for	 TSB	 containing	
daptomycin	only	vs	daptomycin	+	oxacillin	P	<	0.001	at	the	indicated	time	points	(*).	USA300	wild-
type	 exposed	 to	 0.25	 µg	 ml-1	 of	 oxacillin,	 daptomycin	 (20	 µg	 ml-1)	 or	 both	 antibiotics	 in	
combination	and	survival	(d),	lipid	release	(e)	and	daptomycin	activity	(f)	measured	after	8	h	(n=3	
in	 duplicate,	 for	 TSB	 containing	 daptomycin	 only	 vs	 daptomycin	 +	 oxacillin	 P	 <	 0.001	 at	 the	
indicated	 time	 points	 (*).USA300	wild-type	 and	 ΔagrA	 at	 a	 1:1	 ratio	were	 exposed	 to	 oxacillin,	
daptomycin	or	both	antibiotics	 in	 combination	and	 survival	 (g)	 lipid	 release	 (h)	 and	daptomycin	
activity	(i)	measured	over	8	h	(n=3	in	duplicate,	for	TSB	containing	daptomycin	only	vs	daptomycin	
+	oxacillin	P	<	0.0001	at	the	indicated	time	points	(*).	Data	in	all	panels	were	analysed	by	two-way	
ANOVA	with	Dunnett’s	post-hoc	test.	Error	bars	represent	the	standard	deviation	of	the	mean.			 	
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Since	the	presence	of	oxacillin	enhanced	daptomycin	activity	against	the	ΔagrA	mutant	in	
vitro,	 it	 was	 next	 investigated	 whether	 this	 combination	 therapy	 could	 improve	 treatment	
outcomes	of	 infection	caused	by	mixed	population	of	S.	aureus	as	seen	 in	vitro	 (Fig	5.23g-i).	For	
this,	 the	 same	 in	 vivo	 murine	 model	 of	 S.	 aureus	 invasive	 infection	 as	 described	 previously	 in	
chapter	 3	was	 used.	Mice	were	 infected	with	 a	 1:1	 ratio	 of	 the	wild-type	 S.	 aureus	 and	 ΔagrA	
mutant	and	treated	 it	with	sub	 inhibitory	concentration	of	the	β-lactam	antibiotic	oxacillin	 (0.25	
µg	ml-1),	20	µg	ml-1	daptomycin,	both	antibiotics	together	or	neither	for	8	h.	As	expected	based	on	
previous	 animal	 studies	 (Fig	 3.7)	 and	 the	 in	 vitro	 experiments	 described	 above,	 there	 was	 no	
significant	difference	in	the	CFU	counts	recovered	from	mice	infected	with	the	mixed	population	
and	 treated	with	daptomycin	only,	 oxacillin	only	or	 not	 treated	 (Fig	 5.24).	 By	 contrast,	 the	CFU	
counts	recovered	from	mice	that	were	 infected	with	the	mixed	population	and	treated	with	the	
combination	 of	 oxacillin	 and	 daptomycin	 were	 significantly	 reduced	 compared	 to	 untreated	
animals	(Fig	5.24).		
Overall,	these	studies	demonstrated	that	daptomycin	and	β-lactam	combination	therapy	is	
more	effective	than	daptomycin	alone,	which	could	reduce	treatment	failure	due	to	agr-mutant	S.	
aureus	in	clinical	settings.		
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Figure	5.24.	Oxacillin	enhances	the	bactericidal	activity	of	daptomycin	in	vivo		
CFU	counts	from	the	peritoneal	cavities	of	mice	infected	with	USA300	wild-type	and	ΔagrA	at	a	1:1	
ratio	after	8	h	treatment	with	oxacillin,	daptomycin,	neither	or	both	antibiotics	in	combination	(*	P	
<	0.05,	NS	P	>	0.05,	each	circle	represents	a	single	mouse,	for	each	group	n=5).	Data	were	analysed	
by	two-way	ANOVA	with	Dunnett’s	post-hoc	test.		
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5.12 Discussion	
	
5.12.1 	Agr-triggered	PSMα1	production	explains	why	daptomycin	 is	more	active	against	
wild-type	than	Agr-defective	S.	aureus	
In	 chapter	 3	 it	 was	 observed	 that	 daptomycin	 is	 more	 bactericidal	 against	 wild-type	 than	 Agr-
defective	mutants.	The	aim	of	 the	work	 in	 this	 chapter	was	 to	explain	 this	phenomenon.	 It	was	
discovered	that	the	release	of	membrane	phospholipids,	including	PG,	in	response	to	daptomycin	
is	 independent	of	 the	Agr	quorum-sensing	 system	and	occurs	 in	both	wild-type	and	agr-mutant	
strains.	 In	 the	 absence	 of	 Agr,	 the	 released	 PG	 binds	 and	 inactivates	 daptomycin.	 However,	 S.	
aureus	with	an	activated	Agr	quorum-sensing	system	compromises	 this	mechanism	by	secreting	
PSMα1	 peptides,	 which	 compete	 with	 daptomycin	 for	 binding	 to	 PG.	 The	 inability	 of	 PG	 to	
inactivate	 daptomycin	 in	 the	 presence	 of	 PSMα	 cytolysins	 results	 in	 enhanced	 binding	 of	
daptomycin	to	the	S.	aureus	membrane	and	increased	bacterial	killing	(Fig	5.25).		
As	described	in	the	introduction	to	this	chapter,	all	7	PSM	peptides	exhibit	surfactant-like	
activity	owing	to	their	amphipathic	nature,	which	is	conferred	by	the	hydrophobic	and	hydrophilic	
amino	acids	that	are	found	on	opposite	sides	of	the	α-helix176,397	(Table	5.1).	Since	both	classes	of	
the	PSMα	and	PSMβ	peptides	have	surfactant	activity,	 it	 is	not	clear	yet	why	PSMα	but	not	 the	
PSMβ	peptides	inhibited	the	sequestration	of	daptomycin	by	released	phospholipid	PG.	However,	
in	addition	to	their	surfactant	properties,	PSMs	also	carry	a	net	charge.	The	PSMα	peptides	have	a	
net	charge	of	+2	whereas	PSMβ	peptides	have	a	net	charge	of	-1.	Since	PG	is	negatively	charged,	
the	reason	as	to	why	the	PSMα	but	not	PSMβ	peptides	inhibit	the	phospholipid	sequestration	of	
daptomycin	may	be	explained	by	these	differences	 in	charge176,397.	 It	 is	also	unclear	why	PSMα1	
was	significantly	more	inhibitory	than	PSMα2,	which	was	more	inhibitory	than	PSMα3	or	PSMα4.	
However,	 it	 is	 well	 established	 that	 the	 cytolytic	 properties	 of	 the	 PSMα	 peptides	 varies176,	
suggesting	 subtle	 differences	 in	 the	 properties	 of	 the	 toxins,	 which	 presumably	 affects	 their	
interaction	with	membrane	phospholipids.	
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Figure	5.25.	Why	wild-type	S.	aureus	does	not	inactivate	daptomycin?		
On	exposure	to	daptomycin	(red),	wild-type	S.	aureus	 releases	phospholipids	(golden).	However,	
the	presence	of	the	PSMα	toxins	(purple	ring)	disrupts	the	phospholipid-mediated	sequestration	
of	daptomycin.	This	results	in	daptomycin	binding	to	the	cell	membrane,	resulting	in	cell-death.		
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5.12.2 	Why	does	S.	aureus	compromise	its	own	resistance	mechanism?		
It	 appears	 paradoxical	 for	 S.	 aureus	 to	 produce	 cytolysins	 (PSMs)	 that	 compromise	 the	
phospholipid	 release	 defence	 mechanism	 that	 protects	 the	 cell	 from	 daptomycin	 and	 CAMPs.		
However,	it	is	essential	to	consider	that	PSMs	are	not	produced	constitutively	by	S.	aureus	and	are	
only	 secreted	when	 the	Agr	quorum	sensing	 system	 is	 activated140,158,176.	 	 This	occurs	when	 the	
bacterial	cells	reach	a	certain	density	threshold	and	is	subject	to	additional	control	by	numerous	
transcription	 factors	 that	 respond	 to	 environmental	 stimuli140,142,158,183,503.	 For	 example,	 during	
times	of	stress	the	alternative	sigma	factor	B	ensures	that	S.	aureus	does	not	activate	the	quorum	
sensing	 system,	 which	 is	 energetically	 costly	 to	 the	 bacteria202,504.	 In	 nutrient	 limiting	
environmental	 conditions,	 in	 particular,	 the	 limitation	 of	 isoleucine	 (an	 amino	 acid	 required	 to	
build	 branched	 chain	 fatty	 acids),	 the	 transcription	 factor	 CodY	 delays	 the	 quorum-sensing	
activation	 until	 the	 bacteria	 are	 in	 a	 nutrient	 rich	 environment202,505,506.	 This	 may	 explain	 why,	
during	 infection,	 it	 is	often	the	case	that	only	a	sub-population	of	bacteria	expresses	Agr,	whilst	
many	staphylococci	do	not507.		
Evidence	from	animal	studies	using	agr	and	psm	mutant	strains	indicates	that	both	Agr	and	
PSMs	are	required	to	establish	infections176,294,508.	Furthermore,	strains	with	defective	Agr	systems	
are	 rarely	 isolated	 from	 acute	 skin	 infections509,22,23,	 suggesting	 that	 these	 toxins	 are	 essential	
during	the	early	stages	of	infection.	Neutrophils	are	the	key	host	defence	against	S.	aureus	and	are	
rapidly	recruited	to	sites	of	infection.	These	immune	cells	function	by	engulfing	the	bacterium	via	
phagocytosis	and	then	activating	the	oxidative	burst511.	However,	once	S.	aureus	 is	engulfed,	the	
Agr	system,	 in	conjunction	with	the	stringent	response,	 is	activated,	resulting	 in	the	secretion	of	
PSMs	 that	 lyse	 the	 neutrophils	 from	within176,512.	 PSMs	 also	 appear	 to	 play	 an	 essential	 role	 in	
establishing	 biofilms	 and	 biofilm-associated	 infections.	 The	 PSM	 surfactant-like	 property	 and	
colony	spreading	activity	enables	S.	aureus	to	 form	and	disperse	biofilms	on	biological	materials	
such	 as	 implants	 and	 intravenous-catheters140,425,513,514.	 These	 findings	 demonstrate	 a	 clear	 role	
for	 Agr	 and	 PSMs	 in	 establishing	 acute	 infections,	 particularly	 those	 affecting	 the	 skin	 and	 soft	
tissues.	
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However,	Agr,	and	thus	PSMs,	appear	to	be	dispensable	for	invasive	or	chronic	infections	in	
humans,	from	which	agr-mutants	are	frequently	isolated368,388.	In	addition	to	mutations	within	the	
agr	 locus,	 Agr-defective	 strains	 also	 arise	 via	 the	 acquisition	 of	mutations	 at	 other	 loci,	 such	 as	
rsp205,380,	whilst	Agr	activity	may	also	be	reduced	via	the	acquisition	of	resistance	to	methicillin	or	
vancomycin,	which	appears	to	be	due	to	changes	in	cell	wall	architecture	375,437,438,515,516,438.	This	is	
particularly	relevant	to	daptomycin	since	it	is	reserved	for	treatment	of	infections	caused	by	MRSA	
or	VISA	strains132,517.		
Whilst	 mutations	 can	 affect	 PSM	 production	 indirectly	 by	 reducing	 or	 abrogating	 Agr	
activity,	 mutations	 within	 the	 psm	 locus	 itself	 can	 result	 in	 reduced	 expression	 levels	 or	 the	
expression	 of	 PSM	 variants,	 which	 may	 not	 prevent	 the	 inactivation	 of	 daptomycin	 by	
phospholipids194,375,437,498.	 For	example,	 in	 this	 study	we	 found	 that	wild-type	SH1000	was	more	
efficient	than	USA300	at	inactivating	daptomycin,	which	may	be	due	to	the	presence	of	mutations	
within	the	psmα	locus	that	reduce	PSMα	production390.	
In	addition	to	regulatory	and	mutational	causes	of	Agr	inactivity,	the	host	also	appears	to	
suppress	Agr	activity140,142,503	.	For	example,	serum	lipoproteins	sequester	and	inactivate	both	the	
AIP	 signaling	molecule	 and	 PSM	 toxins.	 Therefore,	 Agr	 is	 active	 in	 only	 a	 subset	 of	 bacteria	 in	
certain	host	niches,	 tissues	and	biofilms509,518,519.	 This	 implies	 that,	during	 infection,	wild-type	S.	
aureus	may	 respond	 very	 differently	 to	 daptomycin,	 depending	 on	 its	 anatomical	 location.	 For	
example,	in	skin	and	soft	tissue	infections	where	Agr	is	active	and	PSMs	are	expressed,	it	would	be	
expected	that	daptomycin	would	be	highly	effective.	By	contrast,	during	invasive	infections,	when	
Agr	activity	 is	absent	or	reduced,	 it	would	be	expected	that	daptomycin	would	be	 less	effective.	
Indeed,	 analyses	 of	 daptomycin	 treatment	 outcomes	 suggest	 that	 the	 antibiotic	 is	 far	 more	
effective	in	combatting	skin	infection	relative	to	bacteraemia520–523,70.	Whilst	treatment	outcomes	
are	 influenced	 by	 several	 different	 factors,	 the	 role	 of	 the	 host	 environment	 likely	 makes	 a	
significant	contribution	to	the	ability	of	S.	aureus	to	survive	daptomycin	treatment.	
Therefore,	the	ability	of	a	particular	staphylococcal	strain	to	 inactivate	daptomycin	 is	not	
simply	defined	by	the	integrity	of	its	Agr	system.	It	is	entirely	possible	that	wild-type	bacteria	may	
successfully	employ	the	phospholipid-release	defensive	system	against	daptomycin	during	certain	
types	of	S.	aureus	infection439,524.		
	
5.12.3 	Membrane	vesicles	do	not	efficiently	inactivate	daptomycin	
In	addition	to	differences	in	the	ability	of	different	types	of	phospholipid	to	inactivate	daptomycin,	
the	physical	form	of	the	lipid	also	appears	to	be	critical.	The	phospholipids	that	were	released	in	
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response	 to	 daptomycin	 were	 mainly	 in	 the	 form	 of	 monomers	 or	 small	 micelles,	 rather	 than	
membrane	 vesicles	 secreted	 by	 Gram-negative	 bacteria	 such	 as	 E.	 coli.	 Although	 some	 of	 the	
released	phospholipids	existed	as	membrane	vesicles,	these	contained	very	little	daptomycin	and	
were	inefficient	at	inactivating	the	antibiotic.		
This	was	 surprising	 since	previous	work	 has	 shown	 that	E.	 coli	outer	membrane	 vesicles	
provided	 protection	 against	 membrane-targeting	 antimicrobial	 peptides	 such	 as	 colistin	 and	
polymyxin	 B	 500,	 which	 are	 cyclic	 CAMPs	 that	 target	 the	 Lipopolysaccharide	 (LPS)	 of	 the	 outer	
membrane	and	phospholipids,	 leading	to	pore	formation	and	membrane	permeability.	However,	
whilst	LPS	is	readily	accessible	on	the	surface	of	membrane	vesicles,	the	interaction	of	daptomycin	
with	monomeric	phospholipids	appears	to	be	higher	affinity	and/or	energetically	favourable	over	
the	interaction	of	daptomycin	with	membrane-bound	phospholipids,	which	requires	insertion	of	a	
lipid	tail	past	anionic	phosphate	headgroups.	
	
5.12.4 	β-lactam	oxacillin	 enhances	 the	 activity	 of	 daptomycin	by	 reducing	phospholipid	
release	
S.	aureus	 encodes	4	PBPs,	of	which	PBP1	and	PBP2	are	essential	 for	building	 the	peptidoglycan	
layer	 required	 for	 cell	 wall	 synthesis	 and	 S.	 aureus	 growth24.	 β-lactam	 antibiotics	 have	 variable	
affinities	 for	each	of	 the	PBPs	but	 the	anti-staphylococcal	penicillin	oxacillin	 targets	all	 4.	MRSA	
strains	encode	an	addition	PBP,	PBP2a,	which	is	has	a	very	low	affinity	for	β-lactam	antibiotics	and	
therefore	confers	resistance24.	
In	 this	 chapter,	 it	 was	 described	 how	 the	 β-lactam	 oxacillin	 enhanced	 the	 activity	 of	
daptomycin	by	reducing	the	release	of	phospholipids	 in	 response	to	daptomycin,	despite	having	
no	 effect	 on	 bacterial	 growth.	 In	 support	 of	 these	 findings,	 we	 also	 found	 in	 chapter	 4	 that	
mutants	with	transposon	insertions	in	the	pbp3	gene	were	impaired	in	releasing	phospholipids	in	
response	to	daptomycin.	These	findings	indicate	that	cell	wall	biosynthesis	and/or	remodelling	is	
required	to	enable	the	release	of	phospholipids,	which	is	also	in	agreement	with	the	finding	that	
the	VraUTSR/CWSS	system	is	required	for	phospholipid	release	(as	described	in	chapter	4).		
Furthermore,	 these	 data	 are	 in	 agreement	 with	 previous	 work	 showing	 that	 β-lactam	
antibiotics	that	target	PBP1	promote	the	activity	of	daptomycin413,525,	presumably	because	PBP1,	
which	 is	 required	 for	 peptidoglycan	 synthesis,	 occurs	 at	 the	 site	 of	 daptomycin	 insertion	 and	
reduces	 the	 release	 of	 phospholipids.	 There	 is	 also	 evidence	 that	 β-lactam	 antibiotics	 promote	
daptomycin	 activity	 against	wild-type	 S.	 aureus	 by	 increasing	 the	 binding	 of	 daptomycin	 to	 the	
bacterial	 membrane413,418,502,526.	 Although	 the	 underlying	 mechanism	 is	 unclear,	 It	 has	 been	
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hypothesised	that	β-lactams	alter	the	staphylococcal	surface	charge,	enabling	more	daptomycin	to	
bind	 to	 the	membrane502.	Our	 data	 provide	 an	 alternative	 hypothesis,	 that	 β-lactam	 antibiotics	
promote	daptomycin	activity	by	preventing	its	inactivation	by	released	phospholipid.	
	 Regardless	of	the	molecular	mechanism	however,	the	data	from	murine	S.	aureus	infection	
studies,	along	with	 the	 in	vitro	data,	are	 in	agreement	with	several	other	studies	 indicating	 that	
the	dual-therapeutic	approach	of	combining	oxacillin	and	daptomycin	could	improve	daptomycin	
treatment	outcomes	against	MRSA	infections.		
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Chapter	6		
Phospholipid	release	in	the	host	context		 	
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6.1 Introduction	
In	 previous	 chapters	 I	 described	 the	 identification	 and	 characterization	 of	 a	 novel	 daptomycin	
defence	 mechanism	 whereby	 S.	 aureus	 releases	 membrane	 phospholipids	 that	 sequester	 and	
inactivate	the	antibiotic.	This	mechanism	is	active	and	requires	de	novo	phospholipid	biosynthesis,	
as	demonstrated	by	the	ability	of	platensimycin	to	completely	block	phospholipid	release	(Fig	4.8).		
	Phospholipids	are	comprised	of	a	glycerol	phosphate	head	group	and	two	fatty	acid	chains	
that	occupy	positions	1	and	2	of	the	glycerol	moiety	(Fig	6.1).	Phosphatidic	acid	(PA)	is	the	central	
phospholipid	precursor,	synthesized	from	fatty	acids	and	glycerol-3	phosphate	(Fig	6.1).	PA	then	
provides	 the	 precursor	 to	 all	membrane	 phospholipids	 such	 as	 phosphatidylglycerol,	 cardiolipin	
and	 lysyl-phosphatidylglycerol.	 Phosphatidylglycerol	 is	 synthesized	 from	 PA	 and	 cytosine	
diphosphate	diacyglycerol	(CDP-DAG),	cardiolipin	is	synthesized	through	the	condensation	of	two	
phosphatidylglycerol	molecules	and	lysyl-phosphatidyl	glycerol	is	synthesized	by	attaching	a	lysine	
head	group	to	phosphatidylglycerol	via	the	phosphate	group	in	a	reaction	catalyzed	by	MprF527–529.	
Fatty	acids	(FAs)	can	be	synthesised	endogenously	or	acquired	from	the	host.	In	the	case	of	
endogenous	 fatty	 acid	 synthesis,	S.	 aureus	 uses	 the	 Fatty	Acid	 Synthase	 II	 (FAS	 II)	 pathway	 (Fig	
6.1),	which	is	comprised	of	mono-functional	enzymes	and	is	broken	down	into	3	phases.	
Phase	1:	Initiation.	This	phase	is	catalyzed	by	2	enzymes	(Fig	6.2a).	
(i) The	 acetyl-CoA	 carboxylase	 (ACC)	 catalyzes	 the	 first	 step	 in	 the	 fatty	 acid	 biosynthesis	
pathway,	which	is	the	conversion	of	acetyl-CoA	to	Malonyl-CoA	by	the	addition	of	bicarbonate	
to	 acetyl-CoA.	 Thereafter,	 FabD	 catalyses	 the	 transfer	 of	 the	 malonyl	 group	 to	 acyl	 carrier	
protein	 (ACP)	 to	 yield	 Malonyl-ACP.	 Subsequently,	 Malonyl-ACP	 and	 the	 FabH	 enzyme	 are	
required	 to	 initiate	 the	 fatty	 acid	 biosynthesis	 by	 the	 formation	 of	 new	 acyl-chains	 (i.e.	
formation	of	new	fatty	acid	chains)	(Fig	6.2a)529,530.	
(ii) FabH	 is	 a	 condensing	 enzyme	 that	 catalyzes	 the	 first	 condensation	 step	 that	 results	 in	 the	
formation	of	new	acyl-chain,	β-ketoacyl-ACP	(Fig	6.2a).	This	is	the	first	intermediate	in	the	FAS	
II	pathway	and	 is	 formed	by	condensing	the	acyl-CoA	primer	with	Malonyl-ACP.	 	 In	addition,	
FabH	can	accommodate,	and	preferentially	utilizes,	 larger	branched-chain	substrates,	such	as	
branched	chain	acyl-CoA,	which	are	introduced	into	the	pathway	in	the	initiation	phase	and	is	
specific	to	Gram	positive	bacteria529,531.	Of	note,	branched	chain	acyl-CoA	is	produced	by	the	
keto-acid	dehydrogenase	 from	precursors	 such	as	 leucine,	valine	and	 isoleucine529,532–535	 (Fig	
6.3).	
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Figure	6.1.	The	structure	of	Phosphatidic	acid		
Phosphatidic	acid	is	synthesized	from	2	fatty	acids	and	glycerol-3	phosphate.	In	S.	aureus,	anteiso	
C17:0	 and	 anteiso	 C15:0	 branched	 chain	 fatty	 acids	 occupy	 the	 1	 and	 2	 positions	 of	 glycerol-3	
phosphate	respectively.	
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Figure	6.2.	The	S.	aureus	fatty	acid	biosynthesis	type	II	endogenous	pathway	and	the	exogenous	
pathway	for	the	formation	of	phosphatidic	acid	in	bacteria		
The	 endogenous	 pathway	 arrows	 are	 shown	 in	 black	 and	 the	 exogenous	 pathway	 arrows	 are	
shown	 in	 red.	 (a),	 Phase	 1:	 The	 initiation	 of	 the	 type	 II	 fatty	 acid	 synthesis.	 Acetyl-CoA	
carboxylase	(ACC)	is	composed	of	four	subunits	(ABCD)	and	provides	malonyl-CoA	elongation	units	
to	 the	elongation	 cycle.	 The	malonyl	 groups	are	 transferred	 to	 the	acyl	 carrier	protein	 (ACP)	by	
malonyl-CoA–ACP	transacylase	 (FadD).	β-ketoacyl-ACP	synthase	 III	 (FabH)	starts	a	new	fatty	acid	
by	 initiating	the	condensation	of	malonyl-ACP	and	an	acyl-CoA	primer	to	form	a	β-ketoacyl-ACP.	
(b),	Phase	2:	the	elongation	of	the	fatty	acid	chain:	The	β-ketoacyl-ACP	intermediate	is	reduced	
by	 the	 FabG	 β-ketoreductase,	 and	 the	 β-hydroxyacyl-ACP	 is	 dehydrated	 to	 enoyl-ACP	 by	 the	
dehydrase	 FabZ.	 FabI	 is	 an	 enoyl-ACP	 reductase	 that	 pulls	 the	 elongation	 cycle	 together.	 The	
saturated	acyl-ACP	is	a	substrate	for	FabF.	FabF	is	an	elongation	condensing	enzyme	and	initiates	
the	 additional	 rounds	 of	 elongation.	 (c),	 Transfer	 of	 fatty	 acids	 to	 glycerol-3-phosphate	 into	
membrane	phospholipids:	The	long-chain	acyl-ACP	end	products	are	recognized	as	substrates	by	
the	 acyltransferases.	 The	 peripheral	 membrane	 protein	 PlsX	 catalyses	 the	 formation	 of	 an	
acylphosphate(Acyl-P)	from	acyl-ACP,	and	PlsY	uses	this	unique	intermediate	to	acylate	glycerol-3-
phosphate	 to	 1-acyl-glycerol-3-phosphate	 (also	 known	 as	 lysophosphatidic	 acid	 (LPA)).	 PlsB	
acylates	glycerol-3-phosphate	using	either	acyl-ACP	or	acyl-CoA	as	the	acyl	donor.	PlsC	transfers	a	
fatty	 acid	 to	 the	 2-position	 of	 LPA	 to	 form	 phosphatidic	 acid	 (PA),	 the	 key	 intermediate	 in	 the	
synthesis	 of	 all	 membrane	 glycerolipids	 including	 phosphatidylglycerol,	 cardiolipin	 and	 lysyl-	
phosphatidylglycerol.	 (d),	 The	 incorporation	 of	 exogenous	 fatty	 acids	 into	 phospholipids	 in	 S.	
aureus:	Exogenous	fatty	acids	are	flipped	to	the	interior	of	the	cell	and	phosphorylated	by	Fak.	The	
acyl-PO4	 is	 either	 ligated	 to	 the	 1-position	 of	 sn-	 glycerol-3-phosphate	 by	 PlsY	 or	 converted	 to	
acyl-ACP	by	PlsX.	The	acyl-ACP	can	either	be	elongated	by	the	FASII	enzymes	or	ligated	into	the	2-
position	 of	 lysophosphatidic	 acid	 by	 PlsC,	 only	 if	 it	 is	 C15:0	 branched	 chain	 fatty	 acid.	 The	
phosphatidic	 acid	 product	 is	 the	 precursor	 to	 all	 membrane	 phospholipids.	 For	 S.	 aureus,	
exogenous	oleic	acid	was	only	incorporated	in	the	1-position	of	phosphatidylglycerol.	Inhibitors	of	
the	FabI	enzyme	from	S.	aureus	used	in	this	study:	indicated	in	purple	text,	Platensimycin,	which	
blocks	FabF	and	AFN-1252	which	blocks	FabI.	Adapted	from	Sheibel	et	al.,	2012,	Zhang	and	Rock.,	
2008529,535	
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Figure	6.3.	The	biosynthesis	of	a	branched	chain	fatty	acid	from	a	branched	chain	amino	acid		
S.	 aureus	 FabH	 prefers	 branched-chain	 acyl-CoAs,	 which	 yield	 branched-chain	 fatty	 acids.	 The	
branched-chain	primers	isobutyryl-CoA,	isovaleryl-CoA	and	2-methylbutyryl-CoA	are	derived	from	
valine,	 leucine	 and	 isoleucine,	 respectively,	 through	 the	 actions	 of	 the	 branched-chain	
aminotransferase	BAT	(ilvE),	and	the	branched-chain	α-ketoacid	dehydrogenase	BKD	(lpd,	bkdA1,	
bkdA2	and	bkdB).	The	branched-chain	acyl-CoAs	yield	iso-C14	and	iso-C16	(isobutyryl),	iso-C15	and	
iso-C17	(isovaleryl),	and	anteiso-C15	and	anteiso-C17	(2-	methylbutyryl)	fatty	acids.	Adapted	from	
Shiebel	et	al.,	2012535.		
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Phase	 2.	 Elongation.	 This	 phase	 is	 catalyzed	 by	 4	 enzymatic	 reactions	 (Fig	 6.2b).	 Each	 of	 the	
reactions	are	 initiated	by	an	elongation-condensing	enzyme.	Enzymes	such	as	 (i)	FabG,	 (ii)	FabZ,	
(iii)	FabI	and	(iv)	FabF	enable	the	advancement	of	the	growing	acyl-chain	by	2	carbons.	In	brief,	the	
β-ketoacyl-ACP	 is	 converted	 to	enoyl-ACP	 (i.e.	 saturated	acyl-ACP)	by	 first	being	 reduced	by	 the	
NADPH	dependent	FabG	enzyme	and	 then	dehydrated	by	FabZ	and	FabI	ezymes	 to	yield	enoyl-
ACP.	Subsequently,	FabF	catalyses	the	condensation	reaction	by	using	enoyl-ACP	as	 its	substrate	
for	 the	 additional	 rounds	 of	 elongation.	 Finally,	 the	 cycle	 of	 the	 fatty	 acid	 chain	 elongation	 is	
brought	to	completion	by	the	FabI	(enoyl-ACP	reductase)	enzyme	(Fig	6.2b)529,531,536.	
Phase	3.	Transfer	to	the	membrane:	In	this	phase,	the	PlsX-PlsY	pathway	catalyzes	the	formation	
of	membrane	 phospholipids	 by	 the	 transfer	 of	 fatty	 acids	 to	 glycerol-3	 phosphate	 (Fig	 6.1	 and	
6.2c)529,531,537,538.	PlsX	 is	a	peripheral	membrane	protein	that	transfers	the	fatty	acid,	which	 is	an	
acyl-group	 that	 originated	 from	 the	 end-product	 of	 the	 elongation	 cycle	 to	 the	 inorganic	
phosphate	molecule	 to	 form	 a	 reactive	 acylphosphate	 intermediate.	 Thereafter,	 the	 transfer	 of	
this	activated	fatty	acid	to	the	1-position	of	glycerol-3	phosphate	can	be	performed	via	2	routes.	
(i) Via	PlsY,	which	is	an	integral	membrane	protein	that	uses	the	reactivate	fatty	acid	phosphate	
to	 acylate	 the	 1-position	 of	 glycerol-3	 phosphate,	 which	 results	 in	 the	 formation	 of	
lysophospatidic	acid	(LPA)	(Fig	6.1	and	6.2c)537,538.	
(ii) Via	PlsB,	an	inner	membrane	protein	that	can	either	use	the	PlsX	processed	fatty	acid	or	acyl-
CoA	as	the	fatty	acid	to	be	transferred	to	the	position	1	of	the	glycerol-3	phosphate.	This	leads	
to	the	formation	of	LPA	(Fig	6.1	and	6.2c)539.		
Only	when	the	position	1	of	the	glycerol-3	phosphate	is	filled	with	the	fatty	acid,	will	the	position	2	
of	the	glycerol-3	phosphate	be	occupied	by	the	appropriate	fatty	acid.	The	PlsC	enzyme,	which	is	
an	 integral	membrane	protein	 transfers	 the	next	 fatty	acid	 to	 the	2-position	of	 the	LPA	 to	 form	
phosphatidic	acid	(PA)	(Fig	6.1	and	6.2c)539.	Significantly,	in	S.	aureus,	PlsC	can	only	utilize	the	FAS	
II	synthesized	acyl-ACP	as	its	substrate	(anteiso	C15:0	branched	chain	fatty	acid)	for	position	2	of	
the	glycerol	phosphate.	Since	this	substrate	is	not	widely	available	in	the	host,	this	endogenously	
synthesized	fatty	acid	appears	to	be	indispensable	for	S.	aureus	growth	(Fig	6.1)529,531,539,540.	
However,	despite	the	strict	requirement	for	the	anteiso	C15:0	branched	chain	fatty	acid	at	
position	2,	S.	aureus	can	utilize	exogenously	available	fatty	acids	for	the	formation	of	membrane	
phospholipids	 at	 position	 1	 on	 the	 glycerol	 phosphate	 moiety	 (Fig	 6.1).	 Protonated	 fatty	 acids	
diffuse	 through	 the	cell	membrane	where	 they	are	processed	by	 the	 fatty	acid	kinase	 (FaK)	and	
PlsX	enzymes	 (Fig	 6.2d).	 These	enzymes	 activate	 the	 fatty	 acid	by	 catalyzing	 the	 formation	of	 a	
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reactive	fatty	acid	phosphate540,541.	If	this	substrate	is	not	of	an	appropriate	fatty	acid	chain	length	
it	will	get	converted	to	an	acyl	carrier	protein	(ACP)	by	the	PlsX	enzyme	where	it	then	enters	the	
FAS	II	pathway	to	be	elongated	(Fig	6.2b,	c	and	d).	If,	however,	the	reactive	fatty	acid	phosphate	is	
of	an	appropriate	chain	length,	it	will	be	processed	by	PlsY	to	acylate	the	position	1	of	the	glycerol-
3	phosphate	 (Fig	6.2d).	Only	 the	1-position	of	 the	glycerol-3	phosphate	 can	be	occupied	by	 the	
exogenous	fatty	acid	and	not	the	2-position	as	mentioned	above	(Fig	6.1)529,531,537,538,540.	
Overall,	 the	 FAS	 II	 pathway	 and	 the	 PlsX-PlsY	 pathway	 enable	 S.	 aureus	 to	 utilize	 both	
endogenously	 and	 exogenously	 synthesized	 fatty	 acids	 to	 form	 membrane	 phospholipids	
529,531,540,542–544.	However,	the	contribution	of	host-derived	nutrients	and	phospholipid	precursors	
towards	the	daptomycin-induced	phospholipid	release	mechanism	is	unknown.	
Because	fatty	acid	biosynthesis	is	essential	for	S.	aureus	phospholipid	synthesis	and	growth	
there	have	been	efforts	to	develop	small	molecule	inhibitors	of	the	FAS	II	pathway	to	provide	new	
therapeutics.	 These	 next-generation	 antibiotics	 that	 inhibit	 the	 FAS	 II	 pathway	 predominantly	
target	the	fatty	acid	chain	elongation	and	completion	steps	in	the	pathway	such	as	the	FabF,	FabG,	
FabZ	 and	 FabI	 enzymes529,535,545–548.	 For	 example,	 platensimycin	 functions	 by	 blocking	 the	 FabF	
enzyme	which	is	a	fatty	acid	elongation	condensation	enzyme	(Fig	6.2b)549.	By	contrast,	AFN-1252	
functions	by	blocking	the	FabI	enzyme,	which	functions	by	bringing	the	fatty	acid	elongation	cycle	
to	 completion	 (Fig	 6.2b).	 This	 is	 the	 step	 that	 occurs	 immediately	 before	 the	 fatty	 acid	 is	
transferred	 to	 the	 glycerol-3	 phosphate	 to	 form	 a	 membrane	 phospholipid541,543,550.	 Whilst,	
platensimycin	 is	 a	 good	 experimental	 drug	 it	 does	 not	 have	 a	 good	 pharmokinetic	 profile	 and	
therefore	cannot	be	used	therapeutically420.	By	contrast,	AFN-1252,	which	has	a	different	target	to	
that	of	platensimycin	in	the	same	FAS	II	pathway	is	currently	in	advanced	clinical	development	and	
shows	potent	activity	against	S.	aureus550–552.	Although	S.	aureus	can	utilize	 fatty	acids	 from	the	
host	for	growth,	AFN-1252	is	toxic	to	S.	aureus	because	the	bacterium	still	requires	fatty	acids	that	
are	synthesized	using	its	endogenous	FAS	II	pathway529,531,540,542,544.		
Several	studies	have	shed	light	on	phospholipid	biosynthesis	in	S.	aureus,	including	the	role	
of	 host-derived	 fatty	 acids,	 however,	 it	 was	 not	 clear	 whether	 these	 findings	 applied	 to	 the	
daptomycin-induced	phospholipid	release	mechanism	described	in	previous	chapters.	Therefore,	
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Aim	 1	 of	 this	 chapter	 was	 to	 determine	 whether	 host-derived	 fatty	 acids	 contribute	 to	
daptomycin	induced	phospholipid	release.	
	
Furthermore,	 the	 ability	 of	 platensimycin	 to	 block	 daptomycin-induced	 phospholipid	
release	indicates	an	opportunity	to	use	inhibitors	of	fatty	acid	biosynthesis	to	enhance	daptomycin	
activity.	However,	 the	efficacy	of	such	 inhibitors	against	phospholipid	release	 in	 the	presence	of	
host-derived	fatty	acids	is	unclear529,535.	Therefore,		
	
Aim	 2	 of	 this	 chapter	 was	 to	 investigate	 whether	 the	 use	 of	 a	 next-generation	 fatty	 acid	
biosynthesis	inhibitor	blocked	the	daptomycin	induced	phospholipid	release	in	the	presence	of	
exogenous	fatty	acids.	
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6.2 Physiological	concentrations	of	free	fatty	acids	do	not	inactivate	daptomycin	
or	interfere	with	measurements	of	phospholipid	release	
The	host	environment	 is	 abundant	with	 free	and	protein-bound	 fatty	acids.	 The	most	abundant	
are	 listed	 in	 Table	 6.1,	 together	 with	 their	 concentrations	 in	 the	 serum	 or	 plasma	 of	 healthy	
humans553.	These	data	were	used	to	guide	the	concentrations	used	in	subsequent	experiments.		
Fatty	 acids	 are	 aliphatic	 monocarboxylic	 acids	 and	 commonly	 have	 a	 chain	 of	 4	 to	 28	
carbons,	which	may	be	saturated	or	unsaturated554.	Saturated	fatty	acids	do	not	contain	double	
bonds	 as	 all	 its	 carbon	 atoms	 (apart	 from	 the	 carboxylic	 acid	 group	 –	 COOH-)	 contain	 as	many	
hydrogen	atoms	it	can	bind	to554.	For	example,	the	carbon	atom	at	the	end	of	the	saturated	fatty	
acid	 chain	 holds	 3	 hydrogen	 atoms	 (CH3-)	 and	 each	 carbon	within	 the	 chain	 holds	 2	 hydrogen	
atoms.	 Conversely,	 unsaturated	 fatty	 acids	 contain	 double	 bonds	 i.e.	 single	 bonded	 (-CH2-CH2-)	
part	of	the	chain	is	substituted	with	a	carbon-double	bonded	to	another	carbon	(-CH=CH-).	
The	simplest	and	shortest	description	of	fatty	acids	provides	the	number	of	carbon	atoms	
and	double	bonds	attached	to	the	carbon	atoms554	(Fig	6.4).	For	example,	the	abbreviated	IUPAC	
nomenclature	for	Lauric	acid	is	C12:0,	where	C	indicates	the	number	of	carbon	atoms	on	the	fatty	
acid	 chain	 and	 because	n=0	 it	 indicates	 that	 it	 is	 a	 saturated	 fatty	 acid	 as	 there	 are	 no	 double	
bonds	within	the	fatty	acid	chain.	Oleic	acid	 is	C18:1	where	C	 indicates	that	there	are	18	carbon	
atoms	on	the	fatty	acid	chain,	which	contains	a	single	double	bond554.	The	location	of	the	double	
bond	is	indicated	by	a	Δx,	where	x	denotes	the	location	number,	counting	from	the	carboxylic	acid	
end	of	the	fatty	acid	chain554.	
Saturated	fatty	acids	are	compactly	packed	together,	which	is	useful	to	conceal	biological	
substances.	By	contrast,	unsaturated	fatty	acids	are	useful	and	important	in	constructing	biological	
cell	membranes554.	
In	 addition	 to	 providing	 phospholipid	 precursors	 to	 bacteria,	 long	 chain	 fatty	 acids	 are	
potent	 antibacterials	 and	 are	 abundant	 on	 the	 skin,	 with	 sebum	 consisting	 of	 ~28%	 free	 fatty	
acids555,556,	 in	 nasal	 secretions	 at	 µM	 concentrations556,557	 and	 in	 abscesses	 at	 mM	
concentrations556,558.	
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Table	6.1.	Concentrations	(μM)	of	Free	Fatty	Acids	(FFAs)	in	the	bloodstream		
Detected	by	TLC/GC-MS	of	healthy	patients	in	serum	and	plasma	respectively	(n=70)559.	
	
	
	
	
	
	
	
	
	 	
Lipid	class	 Free	Fa-y	Acids	(FFAs)	Serum	 Free	Fa-y	Acids	(FFAs)	
Plasma	
Mean	 SD	 Mean	 SD	
C12:0	(lauric	acid)	 9.1-12	 2-37	 1.47	 +	0.68	
	
C14:0	(myrisGc	acid)	 15.46	 4.02	 7.16	 +	3	
	
C16:0	(palmiGc	acid)	 66.01	 9.88	 122	 +	48	
	
C18:1n9	(oleic	acid)	 49.24	 19.31	 122	 +	56	
	
C18:2n6	(linoleic	acid)	 14.73	 14.73	 83.8	 +	38	
	
Table	6.1.	ConcentraGons	(μM)	of	Free	Fa-y	Acids	(FFAs)	and	non-esteriﬁed	FFAs	detected	by	
TLC/GC-MS	of	healthy	paGents	in	serum	and	plasma	respecGvely	(n=70)	
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Figure	6.4.	The	structures	of	the	fatty	acids	used	in	this	chapter	 	
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Prior	to	investigating	the	effect	of	fatty	acids	on	phospholipid	release,	a	control	experiment	
was	undertaken	to	test	whether	fatty	acids	could	directly	inactivate	daptomycin.	Several	different	
fatty	 acids	 (20	 μM)	 were	 examined	 under	 conditions	 used	 in	 our	 daptomycin-challenge	
experiments.	However,	none	of	the	fatty	acids	reduced	the	activity	of	daptomycin,	even	when	the	
concentration	of	a	representative	 lipid,	oleic	acid,	was	 increased	to	100	μM	(Fig	6.5a,	b).	Having	
established	that	fatty	acids	do	not	directly	affect	the	activity	of	daptomycin,	we	determined	that	
these	fatty	acids	could	be	used	in	subsequent	experiments	without	modification	of	our	standard	
protocols.	Therefore,	a	second	control	experiment	was	undertaken	to	determine	the	specificity	of	
the	 lipid-reactive	 dye	 FM-4-64,	 using	 the	 same	 range	 of	 fatty	 acids	 at	 the	 same	 concentrations	
described	above.	These	data	indicated	that	the	presence	of	fatty	acids	had	no	significant	effect	on	
RFU	 readings.	However,	 as	 an	 additional	 control,	 it	was	decided	 to	use	 TSB	 containing	 relevant	
fatty	acids	to	blank	experimental	data	sets	(Fig	6.6a,	b).	
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Figure	6.5.	Fatty	acids	in	the	absence	of	bacterial	cells	do	not	decrease	daptomycin	activity		
Daptomycin	activity	in	TSB	supplemented	with	or	without	fatty	acids,	C18:1,	C18:2,	C16:0,	C14:0	or	
C12:0	at	20	μM	 (a)	 and	 increasing	 concentrations	of	C18:1	 (oleic	 acid)	 from	0-100	μM	 (b)	were	
incubated	with	daptomycin	over	8	h	before	antibiotic	activity	was	determined.	
	
	
Figure	6.6.	The	lipid-dye	FM-4-64	does	not	react	strongly	with	fatty	acids		
TSB	 supplemented	 with	 or	 without	 C18:1,	 C16:0,	 C14:0,	 C12:0	 fatty	 acids	 at	 20	 µM	 (a)	 or	
increasing	concentrations	of	C18:1	(b)	were	incubated	with	daptomycin	over	8	h	before	reactivity	
with	the	lipid-dye	was	determined.	
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Figure 6.2.	Fa7y	acids	i 	the	absence	of	bacteri l	cell do	not	decrease	daptomycin	ac?vity	
over	the	period	of	8	h.	Daptomycin	acGvity	in	TSB	supplemented	with	or	without	fa-y	acids	– a,	
C18:1	=	oleic	acid,	C18:2	=	linoleic	acid,	C16:0	=	palmiGc	acid,	C14:0	=	myrmisGc	acid	and	C12:0	=	
lauric	acid	at	20	μM	and		b,	increasing	concentraGons	of	oleic	acid	0,	10,	20,	50	and	100	μM	
were	incubated	with	daptomycin	over	8	h.	
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Figure	6.3.	The	lipid-dye	d es	not	react	 ith	various	fa7y	acids	and	increasing	concentra?ons	
of	oleic	aci 	in	the	pres nce	of	daptomycin.	TSB	supplemented	with	or	without	a,	C18:1,	C16:0,	
C14:0,	C12:0	fa-y	acids	and	b,	increasing	concentraGons	of	C18:1	and		were	incubated	with	
daptomycin	over	8	h.	
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6.3 Free	fatty	acids	do	not	affect	the	daptomycin	MIC	of	S.	aureus	
Previous	 studies	 have	 shown	 that	 the	 presence	 of	 free	 fatty	 acids	 results	 in	 altered	membrane	
fatty	 acid	 and	 staphyloxanthin	 content,	 which	 could,	 in	 turn	 affect	 bacterial	 susceptibility	 to	
daptomycin426.	Therefore,	the	daptomycin	MIC	of	the	ΔagrA	mutant	was	determined	in	TSB	alone	
or	 supplemented	with	various	 fatty	acids	at	20	µM.	For	most	of	 the	 fatty	acids	 tested	 including	
oleic	acid,	linoleic	acid,	palmitic	acid,	myristic	acid	or	lauric	acid	the	daptomycin	MIC	of	the	ΔagrA	
mutant	was	 the	 same	 (1	 μg	ml-1)	 as	 for	 TSB	without	 fatty	 acid.	 	 However,	 the	 turbidity	 of	 the	
ΔagrA	mutant	exposed	to	daptomycin	supplemented	with	linoleic	acid	was	reduced	compared	to	
the	other	fatty	acids	or	TSB	alone,	indicating	that	this	fatty	acid	is	inhibitory	to	S.	aureus	growth.	
This	is	in	keeping	with	previous	studies,	which	have	shown	that	sub-inhibitory	(25	µM)	and	growth	
inhibitory	concentrations	(50	µM)	of	linoleic	acid	led	to	a	12	h	lag	phase	followed	by	unhampered	
exponential	 phase	 growth556,560.	 In	 addition,	 previous	 studies	 have	 shown	 that	 antibacterial	
activity	 is	 restricted	 to	unsaturated	 fatty	acids	 including	 linoleic	acid.	 The	only	exception	 to	 this	
was	 the	 unsaturated	 fatty	 acid	 oleic	 acid,	 which	 was	 not	 growth	 inhibitory	 even	 at	 a	 supra-
physiological	concentration	of	500	µM556,561.		
	
6.4 Free	 fatty	 acids	 promote	 bacterial	 survival,	 phospholipid	 release	 and	
daptomycin	inactivation		
Having	established	that	fatty	acids	did	not	interfere	with	our	standard	daptomycin	challenge	assay	
protocols,	 it	 was	 then	 investigated	 whether	 free	 fatty	 acids	 modulated	 phospholipid	 release,	
daptomycin	inactivation	and	bacterial	survival.	S.	aureus	ΔagrA	was	added	to	TSB	containing	each	
fatty	 acid	 at	 a	 single,	 physiologically-relevant	 concentration	 (20	 µM)	 as	 described	 for	 control	
experiments	and	then	challenged	with	daptomycin.	Bacterial	survival,	daptomycin	inactivation	and	
phospholipid	release	were	then	measured	over	8	h	(Fig	6.7).		
As	expected	from	previous	results	(Fig	3.3),	daptomycin	triggered	an	initial	period	of	killing	
and	 subsequent	 recovery	 of	 the	 ΔagrA	 mutant.	 There	 was	 no	 significant	 effect	 when	 the	
experiment	was	repeated	in	the	presence	of	palmitic	acid,	linoleic	acid	or	myristic	acid.	However,	
in	the	presence	of	oleic	acid	or	lauric	acid,	survival	of	the	ΔagrA	mutant	was	significantly	greater	
than	that	of	the	ΔagrA	mutant	exposed	to	daptomycin	alone	(Fig	6.7a).	To	test	whether	the	effect	
of	 exogenous	 fatty	 acids	 on	 the	 survival	 of	 the	 ΔagrA	 mutant	 correlated	 with	 daptomycin	
inactivation,	the	activity	of	the	antibiotic	in	culture	supernatants	was	determined	(Fig	6.7b).	There	
were	 no	 significant	 differences	 observed	 between	 the	 inactivation	 of	 daptomycin	 by	 the	ΔagrA	
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mutant	 in	 TSB	 only	 or	 TSB	 supplemented	 with	 palmitic	 acid	 or	 myristic	 acid.	 The	 presence	 of	
linoleic	acid	caused	a	delay	in	the	inactivation	of	daptomycin	by	the	ΔagrA	mutant,	relative	to	TSB	
without	 fatty	 acids.	However,	 in	 keeping	with	our	 survival	 data,	we	 found	 that	 the	presence	of	
oleic	 acid	 or	 lauric	 acid	 increased	 the	 rate	 at	which	 the	 ΔagrA	mutant	 inactivated	 daptomycin,	
compared	to	fatty	acid-free	conditions	(Fig	6.7b).	Finally,	to	determine	whether	the	enhanced	rate	
of	 daptomycin	 inactivation	 was	 due	 to	 an	 increase	 in	 the	 rate	 or	 quantity	 of	 release	 of	
phospholipids,	 culture	 supernatants	 were	 examined	 for	 phospholipid	 content	 (Fig	 6.7c).	 As	
expected	 from	the	 survival	and	antibiotic	 inactivation	data,	 the	presence	of	 linoleic	acid	had	no	
effect	 on	 phospholipid	 release,	 relative	 to	 TSB	without	 fatty	 acids.	 The	 presence	 of	 palmitic	 or	
myristic	 acids	 resulted	 in	 a	 small	 but	 significant	 increase	 in	 phospholipid	 release	 at	 later	 time	
points	(6	and	8	h).	However,	both	oleic	and	lauric	acid	promoted	a	substantial	increase	in	both	the	
rate	and	quantity	of	phospholipid	released	at	the	2,	4,	6	and	8	h	time	points.	
Taken	together,	these	findings	demonstrate	that	the	presence	of	specific	free	fatty	acids,	
oleic	 and	 lauric	 acids,	 increased	 the	 rate	 and	 quantity	 of	 phospholipid	 release	 in	 response	 to	
daptomycin,	 which	 led	 to	 the	 accelerated	 inactivation	 of	 daptomycin	 and	 enhanced	 bacterial	
survival.	This	likely	reflects	preferential	use	of	these	fatty	acids	at	physiological	concentrations	(20	
µM)	by	S.	aureus	 in	phospholipid	biosynthesis.	By	contrast,	 lauric	acid	appeared	to	be	inhibitory.	
This	 is	 in	 keeping	with	 previous	 studies	 showing	 that	 oleic	 acid	 is	 an	 appropriate	 substrate	 for	
phospholipid	 synthesis	 in	 S.	 aureus,	 whereas,	 lauric	 acid	 is	 growth	 inhibitory,	 albeit	 at	 supra-
physiological	concentration	(250		µM)556,561.		
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Figure	 6.7.	 Exogenous	 fatty	 acids	 influence	 bacterial	 survival,	 phospholipid	 release	 and	
daptomycin	inactivation		
USA300	ΔagrA	survival	(a)	daptomycin	activity	(b)	and	phospholipid	release	(c)	in	the	presence	or	
absence	of	fatty	acids	C18:1,	C18:2,	C16:0,	C14:0	or	C12:0	at	20	µM	during	exposure	to	20	µg	ml-1	
daptomycin	(dapt).	Data	represent	the	mean	of	3	independent	experiments	done	in	duplicate	and	
were	analysed	by	two-way	ANOVA	and	Dunnett’s	post-hoc	test.	For	bacteria	treated	with	C18:1	+	
daptomycin	vs	bacteria	 treated	with	daptomycin	only	P	<0.01,	P	<0.001,	P	<0.00001	at	 the	time	
points	 indicated	 (*),(**),(****)	 respectively.	 	 For	 all	 panels	 error	 bars	 represent	 the	 standard	
deviation	of	the	mean.	
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Figure	6.5.	Exogenous	fa7y	acids	promote	bacterial	survival,	phospholipid	release	and	daptomycin	
inac?va?on	in	response	to	daptomycin	in	TSB.	USA300	ΔagrA	survival	a,	daptomycin	acGvity	b,	
phospholipid	release	c,	in	the	presence	or	absence	of	diﬀerent	fa-y	acids	C18:1,	C18:2,	C16:0,	C14:0,	
C12:0	at	20	µMon	exposure	to	20	µby	tg	ml-1	daptomycin	(dapt).	Data	represent	the	mean	of	n=3	in	
duplicate	and	were	analysed		he	two-way	ANOVA	and	Du ne-’s	post-hoc	test.	For	bacteria	treated	
with	C18:0 +	daptomycin	vs	bacteria	treated	with	daptomycin	only	P	<0.01	at	the	Gme	points	
indicated	(*).		For	all	panels	error	bars	represent	the	standard	deviaGon	of	the	mean.	
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		Having	established	 the	effect	of	 various	 free	 fatty	 acids	on	phospholipid	 release,	 it	was	
next	investigated	how	the	concentration	of	the	free	fatty	acid	modulated	this	process.	Since	oleic	
acid	 is	 abundant	 in	 the	host	 and	 significantly	 enhanced	 the	 rate	of	 phospholipid	 release	by	 the	
ΔagrA	mutant,	it	was	selected	for	further	investigation.	
Initially,	the	effect	of	a	range	of	oleic	acid	concentrations	(0-100	μM,	which	is	well	within	
the	physiological	range)	on	the	daptomycin	MIC	was	tested.	However,	as	for	the	previous	assay,	
the	MIC	of	the	ΔagrA	mutant	exposed	to	daptomycin	alone	was	the	same	(1	μg	ml-1)	as	the	MIC	of	
the	ΔagrA	mutant	exposed	to	daptomycin	in	the	presence	of	up	to	100	μM	oleic	acid.		
Next,	 the	effect	of	oleic	 acid	 concentration	on	 the	 survival	 kinetics	of	 the	ΔagrA	mutant	
exposed	 to	 daptomycin	 were	 determined	 over	 8	 h.	 The	 presence	 of	 oleic	 acid	 at	 any	 of	 the	
concentrations	 examined	 increased	 bacterial	 survival	 above	 that	 of	 bacteria	 exposed	 to	
daptomycin	in	the	absence	of	fatty	acid.	However,	at	the	highest	concentrations	of	oleic	acid	(50,	
100	 μM)	 there	 was	 slightly	 elevated	 CFU	 counts	 at	 the	 latest	 time	 point,	 relative	 to	 bacteria	
incubated	 with	 lower	 concentrations	 of	 the	 fatty	 acid	 (Fig	 6.8a).	 In	 keeping	 with	 the	 bacterial	
survival	data,	the	presence	of	oleic	acid	at	all	of	the	concentrations	examined	increased	the	rate	of	
daptomycin	 inactivation	 and	 the	 rate	 of	 phospholipid	 released	 above	 that	 of	 bacteria	 in	 TSB	
without	 fatty	 acid	 supplementation	 (Fig.	 6.8b,c).	 However,	 there	 was	 no	 significant	 effect	 of	
increasing	oleic	acid	concentration	above	10	µM.	
These	 data	 demonstrate	 that	 the	 presence	 of	 physiological	 concentrations	 of	 oleic	 acid	
enhance	the	rate	of	phospholipid	release	and	therefore	the	rate	of	daptomycin	 inactivation	and	
bacterial	survival.	However,	this	process	is	rate	limited	and	increasing	concentrations	of	oleic	acid	
alone	are	not	sufficient	to	enhance	phospholipid	release	above	a	maximum	threshold.	Since	fatty	
acids	diffuse	freely	across	the	bacterial	membrane,	it	is	likely	that	the	rate	limiting	step	relates	to	
endogenous	 fatty	 acid	 biosynthesis	 required	 for	 the	 2-position	 of	 the	 glycerol	 phosphate	 head	
group.	Therefore,	 in	addition	 to	 fatty	acids,	 the	availability	of	other	nutrients,	 such	as	branched	
chain	amino	acids,	very	likely	regulate	the	rate	at	which	S.	aureus	releases	phospholipids.	
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Figure	6.8.	Oleic	acid	promotes	bacterial	survival	during	daptomycin	exposure	
USA300	ΔagrA	survival	(a)	daptomycin	activity	(b)	and	phospholipid	release	(c)	in	the	presence	or	
absence	of	a	 range	of	C18:1	 (µM)	concentrations	on	exposure	 to	20	µg	ml-1	daptomycin	 (Dapt).	
Data	 represent	 the	 mean	 of	 n=3	 in	 duplicate	 and	 were	 analysed	 by	 the	 two-way	 ANOVA	 and	
Dunnett’s	 post-hoc	 test.	 For	 bacteria	 treated	with	 C18:1	 +	 daptomycin	 vs	 bacteria	 treated	with	
daptomycin	 only	 P	 <0.01,	 P	 <0.0001,	 P	 <0.00001	 at	 the	 time	 points	 indicated	 (*),(***),(****)	
respectively.		For	all	panels	error	bars	represent	the	standard	deviation	of	the	mean.	
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6.5 S.	aureus	releases	both		pre-existing	and	the	newly	synthesized	phospholipids	
in	response	to	daptomycin	
Having	 established	 that	 de	 novo	 phospholipid	 biosynthesis	 is	 required	 for	 daptomycin-induced	
phospholipid	release	using	platensimycin	(Fig	4.8),	and	shown	that	the	presence	of	free	fatty	acids	
accelerates	 the	 rate	 of	 phospholipid	 release	 (Fig	 6.7	 and	 6.8),	 the	 next	 objective	 was	 to	
understand	 whether:	 (i)	 the	 ΔagrA	 mutant	 releases	 the	 newly	 synthesized	 phospholipids	 in	
response	 to	daptomycin,	or	 (ii)	 the	newly	synthesized	phospholipids	 facilitate	 the	 release	of	 the	
pre-existing	 phospholipids,	 or	 (iii)	 a	 combination	 of	 both	 newly-synthesised	 and	 pre-existing	
phospholipids	are	released	(Fig	6.9).	To	investigate	this,	phospholipids	of	the	ΔagrA	mutant	were	
labelled	by	incubating	the	bacterium	with	BoDipy-labelled	palmitic	acid	until	stationary	phase.	To	
confirm	 that	 S.	 aureus	 incorporated	 the	 BoDipy-labelled	 palmitic	 acid	 into	 membrane	
phospholipids,	TLC	was	performed	on	these	cells	(Fig	6.10a,b).	Total	lipids	were	extracted	from	the	
cells	of	the	ΔagrA	mutant	that	had	been	incubated	with	BoDipy-labelled	palmitic	acid	by	the	Bligh-
Dyer	 method	 (as	 described	 in	 chapter	 2).	 Thereafter,	 2D-TLC	 and	 iodine	 vapor	 was	 used	 to	
separate	and	identify	the	phospholipids	respectively	and	UV	light	to	 identify	the	BoDipy-labelled	
phospholipid.	 This	 confirmed	 that	 S.	 aureus	 incorporated	 the	 BoDipy-labelled	 palmitic	 acid	 into	
membrane	phospholipids.	This	is	in	agreement	with	previous	studies	which	have	shown	that	in	S.	
aureus	 almost	 all	 fatty	 acids	 either	 endogenously	 synthesized	 or	 acquired	 exogenously	 and	
activated	 by	 the	 FAS	 II	 pathway	 are	 converted	 to	 a	 phospholipid	 and	 incorporated	 into	 the	
membrane542,562.	 In	 addition,	 because	 S.	 aureus	 lacks	 the	 enzymes	 necessary	 for	 β-oxidation,	 it	
does	not	have	the	capacity	to	metabolize	fatty	acids	to	use	it	as	a	means	for	energy	by	breaking	it	
down	in	to	two-carbon	acetyl-CoA	molecules	by	β-oxidation	for	entrance	into	the	tricarboxylic	acid	
cycle556,563.	 After	 incubating	 the	 ΔagrA	 mutant	 with	 the	 BoDipy-labelled	 palmitic	 acid,	 the	 cells	
were	washed	to	remove	unincorporated	BoDipy-labelled	palmitic	acid	and	thereafter,	used	in	the	
subsequent	experiments	to	track	the	release	of	phospholipids.		
However,	 before	 starting	 assays,	 a	 standard	 plot	 of	 the	 relative	 fluorescence	 of	 BoDipy-
labelled	 palmitic	 acid	 was	 generated	 to	 enable	 correlation	 between	 the	 RFU	 values	 and	 the	
concentration	of	 the	BoDipy-labelled	palmitic	 acid	 (Fig	 6.10c).	 This	 revealed	 that	 the	 signal	was	
saturated	at	concentrations	>	3	µM.		
To	ensure	 that	 the	Bodipy-labelled	phospholipid	could	be	detected,	whilst	also	using	 the	
FM-4-64	dye	to	detect	total	phospholipids	in	the	supernatant,	the	laser	settings	in	the	platereader	
were	appropriately	adjusted	(Fig	6.11).	The	compatibility	of	the	dyes	is	in	keeping	with	a	previous	
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study	that	used	BoDipy-labelled	daptomycin	to	study	how	daptomycin	affected	the	cell	membrane	
structure	which	was	detected	with	lipid-dye	FM	4-64563,564.			
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Figure	6.9.	Hypothesis	for	the	phospholipid	release	mechanism:	
	(i)	 Exclusively	 newly-synthesised	 phospholipids	 or	 (ii)	 exclusively	 pre-existing	 phospholipids	 are	
released	in	response	to	daptomycin,	or	(iii)	a	combination	of	both	(not	shown).	
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Figure	6.10.	The	TLC	 image	of	BoDipy-labelled	phospholipid	extracted	from	ΔagrA	mutant	and	
standard	plot	of	the	concentrations	of	BoDipy-labelled	C16:0	
Silica-based	 thin-layer	 chromatography	 (TLC)	 plate	 spotted	 with	 chloroform:methanol(2:1	 v/v)	
extracted	lipids	from	ΔagrA	cells	that	had	been	incubated	with	BoDipy-labelled	C16:0.	For	2D	TLC,	
the	TLC	was	 first	 run	 in	 chloroform:methanol:ammonium	hydroxide	 (65:30:4	v/v/v).	 Then	dried,	
turned	at	an	angle	of	90°	and	run	in	chloroform:methanol:acetic	acid:water		(170:25:25:4	v/v/v/v).	
The	black	arrows	 indicate	the	direction	of	the	migration	of	the	solvents.	The	black/white	dotted	
lines	depict	the	solvent	front	(i.e.	the	line	where	the	first	solvent	rose	up	to	on	the	TLC	plate).	(a),	
The	migration	of	the	lipids	extracted	from	the	cells	were	detected	by	staining	with	iodine	vapour	
and	 (b),	 imaged	 using	 the	 Biorad	 EZ	 imager	 (wavelength	 530	 nm)	 to	 detect	 the	 fluorescent	
molecule	 (BoDipy).	 The	 numbers	 denote	 the	 identified	 spots	 of	 phospholipid.	 All	 images	 are	
representative	of	 at	 least	 three	 independent	experiments.	 (c),	 To	measure	 the	 concentration	of	
Bodipy-labelled	C16:0	a	standard	plot	of	the	relative	fluorescence	was	generated	using	increasing	
concentrations	of	BoDipy-labelled	C16:0.	
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Figure	6.10.	The	specificity	of	the	 lipid	dye	and	standard	plot	of	the	concentrations	of	BoDipy-
labelled	C16:0.	
a,	 To	 measure	 the	 concentration	 of	 Bodipy-labelled	 C16:0.	 a	 standard	 plot	 of	 the	 relative	
fluorescence	 was	 generated	 using	 increasing	 concentrations	 of	 BoDipy-labelled	 C16:0.	 b,	 The	
specificity	 of	 the	 lipid	 dye	 was	 measured	 by	 using	 increasing	 concentrations	 of	 purified	
phospholipid	standards	including	phosphatidyl	glycerol	(PG),	cardiolipin	(CL),	 lysyl-PG	(LPG),	fatty	
acids	including	BoDipy-labelled	C16:0,	C18:0,	C16:0,	C14:0,	C12:0.	
	
	
	
	 	
Figure.	The	speciﬁcity	of	the	lipid	dye	was	measured	by	using	increasing	concentra8ons	of	puriﬁed	
phospholipid	standards	including	phospha8dyl	glycerol	(PG),	cardiolipin	(CL),		lysyl-PG	(LPG),	fa,y	
acids	including	BoDipy-labelled	C16:0,	C18:0,	C16:0,	C14:0,	C12:0.	
To	measure	the	concentraEon	of	Bodipy-labelled	C16:0.	Standard	plot	of	the	rela8ve	ﬂuorescence	
unit	was	generated	using	increasing	concentra8ons	of	BoDipy-labelled	C16:0	
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Figure	6.11.	The	fluorescence	spectra	of	FM-4-64	and	BoDipy	demonstrate	compatibility	of	the	
two	fluorophores564		
Image	generated	from	the	Thermo-Fisher	Scientific	Molecular	ProbesTM	website.	
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To	investigate	whether	the	ΔagrA	mutant	releases	pre-existing	phospholipids	 in	response	
to	 daptomycin,	 the	 BoDipy-labelled	 ΔagrA	 mutant	 was	 incubated	 with	 or	 without	 daptomycin,	
samples	taken	and	split	 into	culture	supernatant	and	bacterial	cells	by	centrifugation.	Cells	were	
washed	and	the	fluorescence	measured	and	corrected	for	cell	biomass	by	adjusting	RFU	values	by	
dividing	by	OD600	values.	The	fluorescence	of	the	culture	supernatant	was	determined	to	measure	
BoDipy	fluorescence	and	total	phospholipid	content	determined	using	FM-4-64.		
Upon	 challenge	 with	 daptomycin,	 the	 RFU	 in	 the	 culture	 supernatant	 from	 the	 BoDipy-
labelled	 phospholipid	 rapidly	 increased	 to	 levels	 significantly	 higher	 than	 that	 of	 bacteria	 not	
exposed	to	daptomycin,	which	remained	at	basal	 levels	during	the	entire	8	h	growth	period	(Fig	
6.12a)	This	provided	evidence	that	daptomycin	triggered	the	release	of	pre-existing	phospholipids	
from	 the	 bacterial	 membrane.	 However,	 analysis	 of	 the	 BoDipy-mediated	 fluorescence	 of	 S.	
aureus	 cells	 found	 no	 difference	 between	 the	 RFU	 of	 the	 BoDipy-labelled	 ΔagrA	 mutant	 cell	
exposed	 to	 daptomycin	 compared	 to	 the	 BoDipy-labelled	 ΔagrA	 mutant	 cell	 not	 exposed	 to	
daptomycin	 (Fig	 6.12b).	 This	 indicated	 that	 although	 there	 is	 a	 release	 of	 BoDipy-labelled	
phospholipid	 into	 the	 culture	 supernatant,	 a	 large	 fraction	 of	 the	 pre-existing	 (BoDipy-labelled)	
phospholipid	 is	 retained	 in	 the	 membrane.	 i.e.	 only	 a	 relatively	 small	 fraction	 of	 pre-existing	
phospholipid	 is	 released	 in	 response	 to	 daptomycin	 and	 de	 novo	 phospholipid	 biosynthesis	 in	
response	to	daptomycin	does	not	significantly	reduce	the	quantity	of	pre-existing	phospholipid	in	
the	membrane.	
Since	the	excitation	and	emission	wavelength	was	different	between	the	BoDipy-labelled	
palmitic	 acid	 and	 the	 FM-4-64	 lipid-dye,	 it	 was	 possible	 to	 measure	 the	 phospholipid	 being	
released	into	the	supernatant	by	the	ΔagrA	mutant	in	response	to	daptomycin.	As	expected,	the	
ΔagrA	mutant	released	a	significant	amount	of	phospholipid	in	response	to	daptomycin	compared	
to	the	ΔagrA	mutant	not	exposed	to	daptomycin	(Fig	6.12c).	
The	 data	 presented	 in	 Fig	 6.12	 indicated	 that	 upon	 daptomycin	 challenge	 pre-existing	
phospholipids	are	 released	 into	 the	culture	 supernatant.	To	confirm	 the	 findings	obtained	using	
fluorescent	dyes,	2D-TLC	was	used	to	separate	and	identify	 lipids.	After	separation,	 iodine	vapor	
was	 used	 to	 stain	 the	 phospholipids	 and	 UV	 light	 was	 used	 to	 detect	 lipids	 containing	 the	
fluorophore	BoDipy.	 The	 identity	 of	 each	 spot	was	 determined	by	 comparison	 to	 the	migration	
pattern	of	the	purified	phospholipid	standards	i.e.	PG,	LPG,	CL	and	BoDipy-labelled	palmitic	acid.	
As	 before,	 to	 ensure	 the	 correct	 identification	 of	 the	 phospholipids	 in	 the	 culture	 supernatant,	
purified	phospholipid	standards	were	mixed	with	TSB	at	100	μM	before	being	subjected	to	 lipid	
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extraction	 and	 TLC	 analysis	 to	 mimic	 the	 processing	 of	 staphylococcal	 lipids	 in	 culture	
supernatants	(Fig	6.13a,b,c,e).	As	expected,	staining	of	the	TLC	plate	by	iodine	vapour	revealed	the	
presence	of	 LPG,	PG	and	BoDipy-labelled	phospholipids	 in	 the	culture	supernatant	of	 the	ΔagrA	
mutant	exposed	to	daptomycin	(Fig	6.13d).	Visualization	of	the	TLC	plates	under	UV	light	revealed	
the	 presence	 of	 BoDipy-labelled	 phospholipids,	 confirming	 the	 incorporation	 of	 the	 BoDipy-
labelled	 palmitic	 acid	 into	 phospholipids	 that	 were	 released	 upon	 daptomycin	 challenge	 (Fig	
6.13f).	This	analysis	also	revealed	that	not	all	phospholipids	in	the	membrane	contained	BoDipy.	
	
	 	
		 222	
	
	
Figure	6.12.	S.	aureus	releases	the	pre-existing	BoDipy-labelled	phospholipids		
S.	aureus	was	 incubated	with	BoDipy-labelled	C16:0	 (20	µM)	until	 stationary	phase	and	washed	
before	being	exposed	or	not	exposed	to	daptomycin	for	8	h.	Presence	of	BoDipy-labelled	C16:0	in	
the	culture	supernatant	(a)	and	cells	(b)	of	the	USA300	ΔagrA	mutant	exposed	or	not	exposed	to	
20	 µg	ml-1	 daptomycin	 for	 8	 h.	 Total	 phospholipid	 release	 (c)	 from	 the	 USA300	 ΔagrA	 mutant	
exposed	or	not	exposed	to	daptomycin	was	also	measured.	Data	in	panels	a-c	represent	the	mean	
of	n=3	 in	duplicate	and	were	analysed	by	 the	 two-way	ANOVA	and	Dunnett’s	post-hoc	 test.	For	
bacteria	treated	with	daptomycin	vs	bacteria	not	treated	with	daptomycin	P	<0.001,	P	<0.00001	at	
the	 time	 points	 indicated	 (**),	 (****)	 respectively	 and	 ns	 =	 non-significant.	 For	 all	 panels	 error	
bars	represent	the	standard	deviation	of	the	mean.	
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Figure	6.9.	S.	aureus	releases	the	pre-exis?ng	BoDipy-labelled	C16:0	phospholipids.	
BoDipy-labelled	C16:0	(20	µM)	was	incubated	unGl	staGonary	phase	and	washed	before	being	
exposed	or	not	exposed	to	daptomycin	for	8	h.	Presence	of	BoDipy-labelled	C16:0	in	the	a,	culture	
supernatant	and	b,	cells	of	the	USA300	ΔagrA	mutant	exposed	or	not	exposed	to	daptomycin	for	8	h.	
c,	lipid	release	from	the	USA300	ΔagrA	mutant	exposed	or	not	exposed	to	daptomycin	for	8	h.	Data	in	
panels	a-e	represent	the	mean	of	n=3	in	duplicate	and	were	analysed		by	the	two-way	ANOVA	and	
Dunne-’s	p st-hoc	test.	For	bacteria	treated	with	daptomycin		vs	bacteria	not	treated	with	
daptomycin	P	<0.01	at	the	Gme	points	indicated	(*).	For	all	panels	error	bars	represent	the	standard	
deviaGon	of	the	mean	
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Figure	6.13.	S.	aureus	releases	the	pre-existing	and	newly	synthesised	membrane	phospholipids		
Silica-based	 thin-layer	 chromatography	 (TLC)	 plates	were	 spotted	with	 chloroform:methanol(2:1	
v/v)	 extracts	 from	 (a)	 purified	 phospholipid	 (PL)	 standards	 including	 phosphatidylglycerol	 (PG),	
cardiolipin	 (CL),	 lysyl-phosphatidylglycerol	 (LPG);	 (b),	 PL	 standards	 made	 in	 TSB;	 (c,e),	 BoDipy-
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labelled	 C16:0	 is	 denoted	 as	 BoDipy-labelled	 fatty	 acid	 (BoDipy-FA);	 (d,f)	 TSB,	 filtered	 culture	
supernatant	from	the	BoDipy-labelled	agrA	mutant	 	exposed	to	daptomycin	(ΔagrA	+	dapt.).	For	
2D	TLC,	the	TLC	plate	was	first	run	in	chloroform:methanol:ammonium	hydroxide	(65:30:4	v/v/v).	
Then	 dried,	 turned	 at	 an	 angle	 of	 90	 °C	 and	 run	 in	 chloroform:methanol:acetic	 acid:water		
(170:25:25:4	v/v/v/v).	The	black	arrows	indicate	the	direction	of	the	migration	of	the	solvents.	The	
black/white	dotted	lines	depict	the	solvent	front	(i.e.	the	line	where	the	first	solvent	rose	up	to	on	
the	TLC	plate).	The	numbers	denote	the	identified	spots	of	phospholipids	that	were	scraped	from	
the	 TLC	 plate	 to	 quantify	 the	 phosphate	 content	 in	 the	 phospholipid.	 The	migration	 of	 purified	
phospholipid	 (PL)	standards	CL,	LPG	or	PG	extracted	 in	the	absence	(a)	and	presence	of	TSB	(b);	
BoDipy-FA	(c)	match	those	generated	by	the	lipids	extracted	from	spent	culture	supernatant	which	
was	detected	by	 staining	with	 iodine	 vapour	 (d).	 In	 addition,	 TLC	plates	were	 imaged	using	 the	
Biorad	 EZ	 imager	 (wavelength	 530	 nm)	 to	 detect	 the	 fluorescent	 molecule	 (BoDipy)	 (f,g).	 All	
images	are	representative	of	at	least	three	independent	experiments.	
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The	migration	pattern	of	the	BoDipy-labelled	phospholipid	was	very	different	to	that	of	the	
phospholipid	 standards	 including	 PG,	 CL,	 LPG	 and	 BoDipy-labeled	 fatty	 acid.	 Therefore,	 as	 an	
additional	 confirmation	 that	 the	 spot	 identified	 as	 Bodipy-labelled	 phospholipid	 was	 a	
phospholipid,	iodine	stained	spots	were	scraped	and	subjected	to	a	colorimetric	assay	that	detects	
phosphate	 (Fig	 6.13).	 This	 assay	 confirmed	 the	 presence	 of	 a	 phosphate	 group	 attached	 to	 the	
identified	BoDipy-labelled	lipid	molecules	(Fig	6.14).	Thus,	this	finding	indicated	that	the	cells	pre-
labelled	 with	 BoDipy-labelled	 fatty	 acid	 is	 incorporated	 into	 a	 phospholipid	 and	 subsequently	
released	on	exposure	to	daptomycin,	but	the	precise	identity	of	the	phospholipid	species	remains	
to	be	confirmed	since	appropriate	standards	are	unavailable.		
Therefore,	 daptomycin	exposure	 triggers	 the	 release	of	phospholipids	 already	present	 in	
the	 bacterial	 membrane.	 This	 does	 not	 rule	 out	 the	 possibility	 that	 de	 novo	 synthesized	
phospholipids	are	also	released	but	additional	work	is	required	to	resolve	this	issue.		
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Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	the	culture	supernatant	of	USA300	ΔagrA	strain	exposed	to	daptomycin	
	Lipids	were	 identified	by	 reference	 to	purified	 standards	and	quantified	as	described	 in	 section	
2.17.	 The	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	 ΔagrA+Dapt	 =	
BoDipy-phospholipid	 labelled	ΔagrA	mutant	exposed	to	daptomycin,	PG	=	phosphatidyl	glycerol,	
LPG	 =	 Lysyl	 PG,	 BoDipy-PL	 =	 BoDipy	 phospholipid	 and	 BoDipy-FA	 =	 BoDipy	 fatty	 acid.	 Data	 are	
presented	 as	 the	 relative	 proportions	 of	 each	 phospholipid,	 fatty	 acid	 standards	 and	 each	
phospholipid	 in	 the	 spent	 culture	 supernatant	 (relative	 absorbance	 values	 of	 the	 phosphate	
content).	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	one-way	ANOVA	
and	 Tukey’s	 post-hoc	 test.	 For	 BoDipy-PL	 vs	 BoDipy-FA	 standard	P	<0.00001	 at	 the	 time	 points	
indicated	 (****)	 respectively.	 For	 all	 panels	 error	 bars	 represent	 the	 standard	 deviation	 of	 the	
mean.	
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Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	the	culture	supernatant	of	USA300	ΔagrA	strain	exposed	to	daptomycin	
	Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	 quantified	 as	 described	 in	 the	
methods	 section.	 The	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	
ΔagrA+Dapt	 =	 BoDipy-phospholipid	 labelled	 ΔagrA	 mutant	 exposed	 to	 daptomycin,	 PG	 =	
phosphatidyl	glycerol,	LPG	=	Lysyl	PG,	BoDipy-PL	=	BoDipy	phospholipid	and	BoDipy-FA	=	BoDipy	
fatty	 acid.	 Data	 are	 presented	 as	 the	 relative	 proportions	 of	 each	 phospholipid,	 fatty	 acid	
standards	and	each	phospholipid	in	the	spent	culture	supernatant	(relative	absorbance	values	of	
the	phosphate	content).	Data	 represent	the	mean	of	n=3	 in	duplicate	and	were	analysed	by	the	
one-way	ANOVA	and	Tukey’s	post-hoc	 test.	For	BoDipy-PL	vs	BoDipy-FA	standard	P	<0.00001	at	
the	 time	 points	 indicated	 (****)	 respectively.	 For	 all	 panels	 error	 bars	 represent	 the	 standard	
deviation	of	the	mean.	
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Figure	 6.14.	 Identification	 and	 quantification	 of	 pre-existing	 and	 newly-synthesised	
phospholipids	in	 he	culture	supernatan 	 f	USA300	ΔagrA	strain	exposed	to	dap omycin.	
	Lipids	 were	 identified	 by	 reference	 to	 purified	 standards	 and	 quantified	 as	 described	 in	 the	
methods	 section.	 Th 	 numbers	 indicate	 the	 identity	 of	 the	 spots	 as	 denoted	 in	 Fig	 6.13	 and	
ΔagrA+Dapt	 =	 BoDipy	 C16:0	 labeled	 ΔagrA	mutant	 exposed	 to	 daptomycin,	 PG	 =	 phosphatidyl	
glycerol,	LPG	=	Lysyl	PG,	BoDipy-PL	=	BoDipy	ph spholipid	and	BoDipy-FA	=	BoDipy	fatty	acid.	Data	
are	 presented	 as	 the	 relative	 pro ortions	 of	 each	 phospholipid,	 fatty	 acid	 standards	 and	 each	
phospholipid	 in	 the	 spent	 culture	 supernatant	 (relative	 absorbance	 values	 of	 the	 p osphate	
content).	Data	r present	the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	one-way	ANOVA	
and	 Tukey’s	 post- oc	 test.	 For	 BoDipy-PL	 vs	 BoDipy-FA	 standard	 P	 <0.01	 at	 the	 time	 points	
indicated	(*).	For	all	panels	error	bar 	represent	the	standard	deviation	of	the	mean.	
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6.6 Serum	promotes	the	survival	of	S.	aureus	exposed	to	daptomycin	
To	explore	the	utilization	of	host-derived	fatty	acids	 further,	a	more	relevant	model	system	was	
used	 to	 better	 replicate	 in	 vivo	 conditions.	 Human	 serum	 is	 a	 clinically	 relevant	 ex	 vivo	model,	
which	contains	fatty	acids	and	provided	an	efficient	and	reproducible	way	to	assess	the	survival	of	
the	wild-type	S.	aureus	and	the	ΔagrA	mutant	in	the	presence	of	daptomycin.	We	used	a	mixture	
of	TSB	and	human	serum	(50:50)	to	avoid	the	clumping	of	S.	aureus,	which	is	observed	in	serum	
alone.		
The	 first	 assay	 was	 to	 determine	 the	 daptomycin	 MIC	 in	 serum.	 Using	 a	 checkerboard	
method,	it	was	found	that	the	susceptibility	of	S.	aureus	to	daptomycin	was	reduced	slightly	with	
increasing	concentrations	of	human	serum	for	both	wild-type	and	ΔagrA	strains	(Table	6.2).	This	
indicated	that	daptomycin	was	 likely	binding	to	serum	proteins,	which	resulted	 in	an	 increase	 in	
the	MIC	of	daptomycin	compared	to	TSB	only.	This	 is	 in	keeping	with	previous	studies	that	have	
shown	 that	 ~90%	 of	 daptomycin	 binds	 to	 proteins	 in	 serum,	 independent	 of	 the	 drug	
concentration131,184,581–584.	 However,	 in	 agreement	 with	 our	 data,	 several	 studies	 have	
demonstrated	that	human	serum	only	moderately	reduces	the	bactericidal	activity	of	daptomycin	
(i.e.	 2-4	 fold	 increase),	 presumably	 because	 daptomycin	 binding	 to	 serum	proteins	 is	weak	 and	
reversible185,569,570.	
To	 investigate	 the	 role	 of	 fatty	 acids	 in	 serum	 towards	 the	 survival	 of	 S.	 aureus	when	
challenged	 with	 daptomycin,	 bacteria	 were	 incubated	 in	 serum:TSB	 supplemented	 with	
daptomycin	or	TSB	only	 supplemented	with	daptomycin.	As	expected	based	on	previous	 results	
(Fig	3.3),	in	TSB	only,	the	wild-type	strain	was	rapidly	killed	by	daptomycin	(Fig	6.15a)	whereas	the	
ΔagrA	mutant	survived	(Fig	6.15b).	In	keeping	with	this,	in	TSB	only,	the	ΔagrA	mutant	inactivated	
daptomycin	but	the	wild-type	did	not	(Fig	6.15c).	By	contrast,	in	the	presence	of	serum,	the	wild-
type	 strain	 survived	 daptomycin	 challenge	 and	 completely	 inactivated	 daptomycin	 by	 4	 h	 (Fig	
6.15a,c).	This	phenotype	was	similar	 to	 the	survival	phenotype	of	 the	ΔagrA	mutant	exposed	to	
daptomycin	in	TSB	only	(Fig	6.15b,c).		
Because	 serum	 suppresses	 Agr	 activity	 and	 sequesters	 PSMs185,524,	 the	 greatly	 increased	
survival	of	wild-type	bacteria	in	serum	was	likely	due	to	the	absence	of	PSMα1,	which	inhibits	the	
inactivation	 of	 daptomycin	 by	 released	 phospholipids.	 However,	 of	 note,	 there	 was	 a	 4-fold	
increase	 in	 the	survival	of	 the	ΔagrA	mutant	exposed	 to	daptomycin	 in	 serum:TSB	compared	 to	
the	ΔagrA	mutant	exposed	to	daptomycin	in	TSB	alone	(Fig	6.15b).	The	ΔagrA	mutant	completely	
inactivated	daptomycin	by	4	h	in	both	the	presence	and	absence	of	serum.	However,	there	was	no	
difference	between	the	inactivation	of	daptomycin	by	the	ΔagrA	mutant	exposed	to	daptomycin	
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in	serum:TSB	and	TSB	(Fig	6.15c),	suggesting	a	negligible	effect	on	phospholipid	release.	However,	
because	serum	contains	high	concentrations	of	lipoproteins	the	FM-4-64	dye	could	not	be	used	to	
accurately	quantify	the	phospholipid	released	by	S.	aureus	exposed	to	daptomycin.	
Taken	 together,	 these	data	 indicated	 that	 serum	promotes	 the	survival	of	both	 the	wild-
type	and	the	ΔagrA	mutant	when	exposed	to	daptomycin.	The	fact	that	there	is	a	difference	in	the	
survival	 of	 the	 ΔagrA	 mutant	 with	 serum	 compared	 with	 the	 ΔagrA	 mutant	 without	 serum	
suggests	the	availability	of	nutrients	such	as	fatty	acids	may	play	a	role	in	promoting	the	survival	of	
the	ΔagrA	mutant	on	exposure	 to	daptomycin.	However,	an	alternative	 reason	 for	 the	elevated	
bacterial	survival	could	be	due	to	the	fact	that	the	activity	of	daptomycin	is	diminished	in	serum.	
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Table	6.2.	 The	 susceptibility	of	S.	aureus	 to	daptomycin	 is	 reduced	 in	 the	presence	of	Human	
serum		
The	checkerboard	plate	 contains	a	 range	of	 concentrations	of	daptomycin	and	human	 serum	 in	
TSB	(50:50)	determined	by	broth	microdilution	as	described	previously,	with	microtitre	wells	that	
contain	the	highest	concentration	of	daptomycin	(μg	ml-1)	and	human	serum	in	the	same	well.	All	
media	were	 supplemented	with	 CaCl2	 to	 50	μg	ml-1	and	MIC	 determined	 after	 24	 h	 incubation.	
Data	represent	the	median	value	of	3	independent	experiments	done	in	duplicate.	In	keeping	with	
previous	findings,	the	values	for	the	daptomycin	MIC	were	identical	between	strains.		
	
	
	 	 USA300		
	 	 Percentage	of	Human	Serum		
	 	 0	 1.6	 3.1	 6.25	 12.5	 25	 50	
Daptomycin	 Wild-type	 1	 1	 2	 2	 2	 2	 2	
(μg	ml-1)	 ΔagrA	 1	 1	 2	 2	 2	 2	 2	
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Figure	 6.15.	 The	 presence	 of	 human	 serum	 enables	 the	 wild-type	 to	 survive	 daptomycin	
exposure	but	does	not	drastically	enhance	the	survival	of	the	ΔagrA	mutant		
Survival	of	USA300	wild-type	(a)	and	ΔagrA	mutant	(b),	and	daptomycin	activity	of	both	strains	(c)	
in	response	to	20	µg	ml-1	daptomycin	(dapt),	in	50%	serum	or	TSB	only.	Data	represent	the	mean	
of	n=3	 in	duplicate	and	were	analysed	by	 the	 two-way	ANOVA	and	Dunnett’s	post-hoc	 test.	For	
bacteria	treated	with	daptomycin	inTSB	+	serum	vs	bacteria	treated	with	daptomycin	in	TSB	only	P	
<0.01,	P	<0.00001	at	 the	time	points	 indicated	(*),	 (****)	respectively.	 	For	all	panels	error	bars	
represent	the	standard	deviation	of	the	mean.	
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Figure	6.13.	The	presence	of	human	serum	enables	the	WT	to	survive	the	exposure	to	daptomycin	
but	does	not	dras?cally	enhance	the	survival	and	inac?va?on	of	daptomycin	of	the	AgrA	mutant.	
Survival	a,	USA300	WT	and	b,	ΔagrA	mutant	c,	daptomycin	acGvity	of	both	the	strains	in	response	to	
20	µg	ml-1	daptomycin	(dapt),	in	serum	(i.e.	TSB	+	serum,	50:50)	or	in	TSB.	Data	represent	the	mean	
of	n=3	in	duplicate	and	were	analysed		by	the	t o-way	ANOVA	and	Dunne-’s	post-hoc	test.	For	
bacte ia	treated	with	daptomyc 	inTSB +	serum	vs	bacteria	t ith	daptomycin	in	TSB	only	P	
<0.01	at	the	Gme	points	indicated	(*).		For	all	panels	error	bars	represent	the	standard	deviaGon	of	
the	mean.	
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6.7 Serum	 albumin	 prevents	 the	 utilization	 of	 exogenous	 fatty	 acids	 in	
phospholipid	release	
Free	 fatty	 acids	 in	 TSB	 promoted	 phospholipid	 release	 and	 daptomycin	 inactivation.	 However,	
despite	the	presence	of	high	concentrations	of	fatty	acids	in	serum,	there	was	very	little	effect	on	
daptomycin	inactivation.	Serum	contains	several	proteins,	of	which	albumin	is	the	most	abundant,	
representing	about	half	of	the	total	serum	proteins	(35-50	g	l-1)571.	Its	main	function	is	to	bind	and	
transport	 the	 high	 concentrations	 of	 free	 fatty	 acids	 to	 vital	 organs	 and	 to	 increase	 the	
concentration	 of	 fatty	 acids	 in	 vascular	 and	 interstitial	 compartments	 572.	 Given	 this	 role	 for	
albumin,	the	next	set	of	experiments	was	designed	to	investigate	how	binding	of	free	fatty	acids	to	
serum	albumin	affected	the	utilization	of	fatty	acids	by	S.	aureus	for	phospholipid	release	during	
exposure	to	daptomycin.	
However,	prior	 to	 investigating	 the	effect	of	albumin-bound	 fatty	acids	 in	promoting	 the	
survival	of	S.	aureus,	a	control	experiment	was	undertaken	to	ensure	that	delipidated	serum	(DLS)	
with	and	without	fatty	acids	and	purified	human	serum	albumin	(HSA)	with	and	without	fatty	acids	
did	not	directly	inactivate	daptomycin.	Daptomycin	was	incubated	with	HSA	with	or	without	fatty	
acids	or	50%	DLS	in	TSB	with	or	without	fatty	acids.	There	was	a	small	(1.25-fold),	but	insignificant,	
decrease	 in	 the	 activity	 of	 daptomycin	 in	 both	 HSA	 and	 DLS	most	 likely	 due	 to	 binding	 of	 the	
antibiotic	to	the	protein	(Fig	6.16).	
To	test	whether	the	ΔagrA	mutant	was	able	to	utilize	fatty	acids	for	phospholipid	release	in	
the	presence	of	serum	proteins,	delipidated	serum	was	supplemented	with	or	without	oleic	acid	
(20	 µM)	 before	 inoculation	with	 the	 ΔagrA	mutant	 and	 addition	 of	 daptomycin.	 By	 contrast	 to	
experiments	done	in	TSB,	no	significant	differences	in	bacterial	survival	or	daptomycin	inactivation	
were	observed	between	the	ΔagrA	mutant	exposed	to	daptomycin	in	the	presence	of	delipidated	
serum	only	or	delipidated	serum	supplemented	with	the	fatty	acid	(Fig	6.17a,	b).	
To	 understand	whether	 the	differences	 seen	between	 TSB	 and	 serum	were	due	 to	 fatty	
acid	 binding	 by	HSA,	 assays	were	 repeated	 in	 TSB	 supplemented	with	 the	 serum	protein.	 Fatty	
acid-free	HSA	was	supplemented	with	or	without	oleic	acid	(20	µM)	before	being	added	to	ΔagrA	
mutant	 cultures,	which	were	 then	 exposed	 to	 daptomycin.	 Similar	 to	 the	 results	 obtained	with	
DLS,	 no	 significant	 differences	 in	 bacterial	 survival	 or	 daptomycin	 inactivation	 was	 observed	
between	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin	 in	 the	 presence	 of	 HSA	 only	 or	 fatty	 acid-
supplemented	HSA	(Fig	6.18a,	b).		
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Taken	together,	these	experiments	indicate	that	the	presence	of	serum	albumin	prevents	
the	utilization	of	exogenous	fatty	acids	by	S.	aureus	to	enhance	phospholipid	release.	Although	it	
was	not	tested,	it	is	likely	that	the	sequestration	of	the	fatty	acid	by	HSA	prevents	its	acquisition	by	
S.	aureus.	 Instead,	it	appears	that	S.	aureus	uses	endogenously	synthesized	fatty	acids	to	release	
the	phospholipids	 in	 response	 to	daptomycin	 (Fig	6.7	and	6.8).	This	 result	was	a	 little	 surprising	
since	 previous	 work	 has	 shown	 that	 S.	 aureus	 can	 utilize	 fatty	 acids	 in	 the	 presence	 of	 HSA.	
However,	whilst	this	study	used	a	similar	HSA	concentration	to	that	used	here,	the	concentration	
of	fatty	acids	used	 in	previous	work	were	far	 in	excess	of	the	physiological	range,	which	may	be	
greater	 than	 can	 be	 sequestered	 by	 albumin561,573	 i.e.	 providing	 a	 source	 of	 free	 fatty	 acids	
unbound	by	HSA.	 	
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Figure	6.16.	Serum	albumin	does	not	decrease	daptomycin	bactericidal	activity		
Daptomycin	activity	before	(0	h)	or	after	8h	incubation	in	the	presence	of	Human	Serum	Albumin	
(HSA)	with	or	without	C18:1	(oleic	acid)	at	20	μM,	or	 in	delipidated	serum	(DLS)	with	or	without	
oleic	acid.	Data	represent	the	mean,	with	error	bars	representing	the	standard	deviation.	
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Figure	6.16.	Seru 	albu in	does	not	decrease	daptomycin	bactericidal	activity	over	the	period	
of	8	h.		
Daptomycin	activity	of	Human	Serum	Albumin	(H.S.A)	with	or	without	C18:1	(oleic	acid	-	fatty	acid)	
at	 20	 μM	 and	 Delipidated	 serum	 (D.L.S)	 with	 or	 without	 fatty	 acids	 were	 incubated	 with	
daptomycin	over	8	h.	
	 	
Figure	6.14.	Serum	in	the	absence	of	bacterial	cells	does	not	decrease	daptomycin	ac?vity	over	
the	period	of	8	h.	Daptomycin	acGvity	of	Human	Serum	Albumin	(H.S.A)	with	or	without	C18:1	
(oleic	acid	-	fa-y	acid)	at	20	μM	and	Delipidated	serum	(D.L.S)	with	or	without	fa-y	acids	were	
incubated	with	daptomycin	over	8	h.	
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Figure	6.17.	Survival	of	the	ΔagrA	mutant	exposed	to	daptomycin	in	serum	is	unaffected	by	the	
presence	of	oleic	acid		
The	USA300	ΔagrA	mutant	was	 inoculated	 in	50%	delipidated	 serum	supplemented	or	not	with	
oleic	acid	(20	µM)	and	survival	(a)	and	daptomycin	activity	(b)	measured	over	time.	Data	represent	
the	mean	of	n=3	in	duplicate	and	were	analysed	by	two-way	ANOVA	and	Dunnett’s	post-hoc	test.	
For	bacteria	treated	with	C18:1	+	daptomycin	vs	bacteria	treated	with	daptomycin	only	ns	=	non-
significant.	Error	bars	represent	the	standard	deviation	of	the	mean.	
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Figure	6.16.	Fa7y	acids	in	delipidated	serum	do	no 	enhance	the	Δ	agrA	m tant’s	survival	and	
inac?va?on	of	daptomycin	in	the		presence	of	daptomycin.	USA300	ΔagrA	a,	survival	and	b,	
daptomycin	acGvity	in	response	to	20	µg	ml-1	daptomycin	(dapt),	in	the	presence	or	absence	of	C18:1	
(concentraGon	20	µM	).	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed		by	the	two-
way	ANOVA	and	Dunne-’s	post-hoc	test.	For	bacteria	treated	with	C18:1	+	daptomycin	vs	bacteria	
treated	with	daptomycin	only	P	<0.01	at	the	Gme	points	indicated	(*).		For	all	panels	error	bars	
represent	the	standard	deviaGon	of	the	mean.	
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Figure	 6.18.	 HSA	 prevents	 the	 utilisation	 of	 fatty	 acids	 by	 S.	 aureus	 to	 promote	 phospholipid	
release		
The	USA300	ΔagrA	mutant	was	inoculated	into	TSB	containing	HSA	and	supplemented	or	not	with	
oleic	acid	(20	µM)	and	survival	(a)	and	daptomycin	activity	(b)	measured	over	time.	Data	represent	
the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	two-way	ANOVA	and	Dunnett’s	post-hoc	
test.	For	bacteria	treated	with	C18:1	+	daptomycin	vs	bacteria	treated	with	daptomycin	only	ns	=	
non-significant.	Error	bars	represent	the	standard	deviation	of	the	mean.	
	 	
0 2 4 6 8
0
20
40
60
80
100
Time	(h)
%
	d
ap
t.	
in
hi
bi
to
ry
	a
c;
vi
ty
	No	AB
	C18:1
	Dapt.
	C18:1	+	Dapt.
USA300	ΔagrA
0 2 4 6 8
1
10
100
1000
Time	(h)
%
	su
rv
iv
al
	No	AB
C18:1
	Dapt.
C18:1	+	Dapt.
USA300	ΔagrA
ns
Figure	6.15.	Fa7y	acids	in	human	serum	albumin	do	not	enhance	the	survival	and	inac?va?on	of	
daptomycin	of	the	AgrA	mutant	in	the		presence	of	daptomycin.	USA300	ΔagrA	a,	survival	and	b,	
daptomycin	acGvity	in	response	to	20	µg	ml-1	daptomycin	(dapt),	in	the	presence	or	absence	of	C18:1	
(concentraGon	20	µM	).	Data	represent	the	mean	of	n=3	in	duplicate	and	were	analysed		by	the	two-
way ANOV and	Dunne-’s	post-hoc	test.	F r	bacteria	treated	with	C18:1 +	da to ycin	vs	bacteria	
treated	with	daptomycin	only	P	<0.01	at	the	Gme	points	indicated	(*).		For	all	panels	error	bars	
represent	the	standard	deviaGon	of	the	mean.	
ba	
		 236	
	
6.8 AFN-1252	promotes	daptomycin	activity	by	inhibiting	phospholipid	release		
AFN-1252	 is	 an	 inhibitor	 of	 the	 FabI	 enzyme	 involved	 in	 staphylococcal	 fatty	 acid	 biosynthesis,	
which	 appears	 to	 be	 essential	 for	 daptomycin-induced	 phospholipid	 release.	 This	 suggests	 that	
combination	 therapy	 using	 AFN-1252	 and	 daptomycin	 could	 significantly	 improve	 treatment	
outcomes.	However,	there	is	some	evidence	that	the	presence	of	exogenous	fatty	acids,	as	occurs	
during	 infection,	 can	 enable	 by-pass	 of	 FabI,	 rendering	 AFN-1252	 ineffective573.	 Therefore,	 the	
potential	for	AFN-1252	to	enhance	daptomycin	treatment	outcomes	is	unclear.	
As	a	first	step	to	investigate	this,	the	MIC	of	AFN-1252	was	determined	to	be	0.004	μg	ml-1	,	
which	is	similar	to	that	reported	previously550	(Table	6.3).	To	test	whether	free	fatty	acids	enabled	
by-pass	of	AFN-1252-mediated	FabI	inhibition,	TSB	was	supplemented	with	or	without	exogenous	
oleic	acid	(20	µM)	and	MIC	assays	repeated.	This	revealed	that	the	presence	of	oleic	acid	had	no	
effect	on	the	MIC	of	AFN-1252	of	the	wild-type	or	ΔagrA	mutant	(Table	6.3).	Together,	these	data	
indicated	that	the	supplementation	of	fatty	acids	into	TSB	did	not	affect	the	ability	of	AFN-1252	or	
daptomycin	to	inhibit	the	growth	of	S.	aureus.	
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Table	6.3.	Oleic	acid	does	not	reduce	the	MIC	of	AFN-1252		
Data	 show	 the	 MIC	 (μg	 ml-1)	 for	 AFN-1252	 in	 TSB	 determined	 by	 broth	 microdilution.	 Data	
represent	the	median	value	of	3	independent	experiments	done	in	duplicate.		
	
	
	
	
	 	
USA300		
Medium	+	AFN-1252	 WT	 ΔagrA	
TSB	 0.004	 0.004	
TSB	+	Oleic	acid	 0.004	 0.004	
USA300	–	derived	
M ium	+	Platensimycin	 WT	 ΔagrA	
TSB	 15	 15	
Table:	a		
Table:	b		
Table.	Fa7y	acid	synthase	II	(FASII)	inhibitors	minimal	inhibitory	concentra?ons	for	strains	used	in	this	
study.	 Data	 show	 the	MIC	 (μg	ml-1)	 for	 Platensimycin	 (a)	 and	AFN-125	 (b)	 in	 TSB	 (TrypGc	 Soy	 Broth)	
determined	 by	 broth	 microdiluGon	 as	 described	 previously.	 The	 MIC	 was	 determined	 a_er	 24	 h	
incubaGon.	 Data	 represent	 the	 median	 value	 of	 3	 independent	 experiments	 done	 in	 duplicate.	 In	
keeping	with	previous	ﬁndings,	the	values	for	MIC	were	idenGcal.		
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To	 test	whether	 AFN-1252	 could	 block	 phospholipid	 release	 in	 response	 to	 daptomycin,	
assays	were	first	done	without	fatty	acids	to	establish	appropriate	AFN-1252	concentrations.	TSB	
was	supplemented	with	AFN-1252	at	1x,	5x,	10x,	30x	or	60x	the	MIC	in	the	presence	or	absence	of	
a	 single	 concentration	 of	 daptomycin	 (20	 µg	 ml-1)	 before	 the	 addition	 of	 the	 ΔagrA	 mutant.	
Bacterial	 survival	 and	 phospholipid	 release	 were	 then	 measured	 over	 time	 (Fig	 6.19a,b).	 As	
expected,	 in	 the	 absence	 of	 daptomycin,	 increasing	 concentrations	 of	 AFN-1252	 resulted	 in	
bacteriostatic	 activity.	 Also,	 as	 expected,	 daptomycin	 alone	 failed	 to	 kill	 the	 ΔagrA	mutant	 and	
there	was	a	 significant	quantity	of	phospholipid	 released	 into	 the	culture	 supernatant.	 This	was	
unaffected	 by	 the	 presence	 of	 AFN-1252	 at	 1X	 or	 5X	 the	 MIC	 (Fig	 6.19a,b).	 However,	 the	
combination	of	AFN-1252	at	10X	MIC	or	greater,	with	daptomycin,	resulted	in	significant	bacterial	
death	(>500-fold),	and	an	almost	total	lack	of	phospholipid	release	(Fig	6.19a,b).	Unfortunately,	it	
was	not	possible	to	measure	daptomycin	activity	using	the	zone	of	 inhibition	assay	as	AFN-1252	
also	produced	a	zone	of	inhibition	at	the	concentrations	used.		
Therefore,	as	for	platensimicin,	the	inhibition	of	fatty	acid	biosynthesis	by	AFN-1252	blocks	
daptomycin-induced	 phospholipid	 release	 and	 thereby	 significantly	 enhances	 the	 bactericidal	
activity	of	daptomycin	against	the	ΔagrA	mutant.		
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Figure	 6.19.	 AFN-1252	 prevents	 phospholipid	 release	 and	 promotes	 bacterial	 killing	 by	
daptomycin			
The	 USA300	 ΔagrA	 mutant	 was	 exposed	 to	 combinations	 of	 AFN-1252	 and	 daptomycin,	 and	
survival	(a),	and	lipid	release	(b)	measured	over	time.	Data	represent	the	mean	of	n=3	in	duplicate	
and	were	analysed	by	the	two-way	ANOVA	and	Dunnett’s	post-hoc	test.	For	bacteria	treated	with	
daptomycin	only	vs	bacteria	treated	with	daptomycin	+	AFN-1252	P	<0.00001	at	the	time	points	
indicated	(****).		Error	bars	represent	the	standard	deviation	of	the	mean.	
	 	
Figure	6.27.	Lipid	biosynthesis	inhibitor	AFN-1252	prevents	phospholipid	shedding	and	inac?va?on	
of	daptomycin	and	promotes	bacterial	killing	by	the	lipopep?de	an?bio?c	USA300	ΔagrA	a,	survival,	
b,	lipid	release	in	response	to	20	µg	ml-1	daptomycin	(dapt.),	in	the	presence	or	absence	sub-lethal	
concentraGons	(1x	–	60x	MIC,	MIC	=	0.004	µg	ml-1	)	of	the	lipid	biosynthesis	inhibitor	AFN-125.	Data	
represent the	mean	of	n=3	in	duplicate	and	were	a alysed		by	the	two-way	ANOVA	and	Dunne-’s	
post-hoc	test.	For	bacteria	treated	with	daptomycin	only	vs	bact ria	treated	with	daptomycin	+	
AFN-125	and	no	anGbioGc	(No	AB)	P	<0.01	at	the	Gme	points	indicated	(*).		For	all	panels	error	bars	
represent	the	standard	deviaGon	of	the	mean.	
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Next,	it	was	tested	whether	the	presence	of	exogenous	fatty	acid	enabled	S.	aureus	to	by	
pass	AFN-1252	mediated	 inhibition	of	 FabI	 and	 release	phospholipids.	 To	 test	 this,	 the	previous	
experiment	described	in	Fig	6.19	was	repeated	in	the	presence	of	20	μM	oleic	acid	(Fig	6.20a,b).		
As	 expected,	 the	 ΔagrA	 mutant	 was	 able	 to	 survive	 daptomycin	 exposure	 by	 releasing	
phospholipids	 (Fig	 6.20a,b).	 By	 contrast,	 the	 ΔagrA	mutant	was	 killed	 and	 phospholipid	 release	
completely	inhibited	when	AFN-1252	was	present	at	10x,	MIC	or	greater.	
Therefore,	 regardless	 of	 the	 availability	 of	 exogenous	 fatty	 acids,	 AFN-1252/daptomycin	
combination	 therapy	was	 significantly	more	effective	 than	daptomycin	 alone.	 These	 findings	do	
not	rule	out	the	possibility	that	exogenous	fatty	acids	enable	by-pass	of	FabI.	However,	if	this	does	
happen	 it	 is	 not	 efficient	 enough	 to	 supply	 the	 large	 quantity	 of	 phospholipids	 required	 to	
inactivate	daptomycin	before	bacterial	cell	death	occurs.		
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Figure	6.20.	Regardless	of	the	presence	of	 free	C18:1	the	 lipid	biosynthesis	 inhibitor	AFN-1252	
prevents	phospholipid	release	and	promotes	bacterial	killing	by	daptomycin		
The	 USA300	 ΔagrA	 mutant	 was	 exposed	 to	 combinations	 of	 AFN-1252	 and	 daptomycin	 in	 the	
presence	of	oleic	acid,	and	survival	(a),	and	lipid	release	(b)	measured	over	time.	Data	represent	
the	mean	of	n=3	in	duplicate	and	were	analysed	by	the	two-way	ANOVA	and	Dunnett’s	post-hoc	
test.	For	bacteria	treated	with	daptomycin	only	vs	bacteria	treated	with	daptomycin	+	AFN-1252	P	
<0.00001	at	the	time	points	indicated	(****).		Error	bars	represent	the	standard	deviation	of	the	
mean.	
	 	
Figure	6.28.	Regardless	of	the	presence	of	C18:1	the	lipid	biosynthesis	inhibitor	AFN-1252	prevents	
phospholipid	shedding,	inac?va?on	of	 aptomycin	 nd	promotes	bacterial	killing	by	the	
lipopep?de	an?bio?c	USA300	Δ grA	a,	survival,	b,	lipid	releas 	in	 sp nse	 o	20	µg	ml-1	daptomycin	
(dapt.),	in	the	presence	or	absence	sub-lethal	concentraGon	(1x	–	60x	MIC,	MIC	=	0.004	µg	ml-1	)	of	
the	lipid	biosynthesis	inhibitor	AFN-125.	Data	represent	the	mean	of	n=3	in	duplicate	and	were	
analysed		by	the	two-way	ANOVA	and	Dunne-’s	post-hoc	test.	For	bacteria	treated	with	daptomycin	
only	vs	bacteria	treated	with	daptomycin	+	AFN-125	and	no	anGbioGc	(No	AB)	P	<0.01	at	the	Gme	
points	indicated	(*).		For	all	panels	error	bars	represent	the	standard	deviaGon	of	the	mean.	
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6.9 Discussion	
The	aims	of	the	work	in	this	chapter	were	to	determine	how	the	presence	of	fatty	acids	in	the	host	
environment	 are	 likely	 to	 affect	 phospholipid	 release	 and	 whether	 a	 FabI	 inhibitor	 in	 clinical	
development	 could	 provide	 a	 useful	 adjunctive	 to	 daptomycin	 therapy.	 These	 experiments	
revealed	that	fatty	acid	utilization	during	daptomycin	exposure	is	complex,	but	provided	evidence	
that	 AFN-1252	 has	 the	 potential	 to	 improve	 daptomycin	 treatment	 outcomes	 by	 suppressing	
phospholipid	release.				
6.9.1 Certain	exogenous	fatty	acids	promote	daptomycin-induced	phospholipid	release		
In	 chapter	 4,	 it	 was	 shown	 that	 daptomycin-induced	 phospholipid	 release	 was	 blocked	 by	
platensimicin,	 demonstrating	 that	 this	 process	 is	 dependent	 upon	 de	 novo	 phospholipid	
production.	 Since	 S.	 aureus	 phospholipid	 biosynthesis	 can	 utilise	 exogenous	 fatty	 acids,	 it	 was	
explored	whether	these	enhanced	phospholipid	release529,531,540.	The	experiments	done	with	free	
fatty	acids	 in	TSB	demonstrated	 that,	 in	principle,	 the	presence	of	 specific	exogenous	 free	 fatty	
acids	 significantly	 enhance	 phospholipid	 release	 in	 response	 to	 daptomycin.	 However,	 the	
presence	 of	 some	 fatty	 acids	 inhibited	 phospholipid	 release,	 which	 reflects	 the	 high	 degree	 of	
specificity	in	the	staphylococcal	FASII	system.		
	 During	 growth,	 95%	 of	 the	 cell’s	 energy	 is	 spent	 on	 re-generating	 the	 phospholipid	
membrane529,	 which	 suggests	 that	 phospholipid	 release	 is	 a	 very	 costly	 process.	 However,	 S.	
aureus	 cannot	 divert	 the	 fatty	 acids	 to	 energy	 production	 since	 S.	 aureus	 lacks	 the	 β-oxidation	
pathway	 and	 cannot	 therefore	break	 fatty	 acids	 down	 to	 acetyl-CoA	 to	 release	 energy542,544.	 As	
such,	it	was	unsurprising	that	the	presence	of	suitable	phospholipid	biosynthesis	precursors	such	
as	oleic	acid	increases	the	efficiency	of	the	process.	However,	it	 is	important	to	consider	that,	to	
utilize	these	free	fatty	acids,	S.	aureus	requires	additional	carbon	and	nitrogen	sources,	as	well	as	
branched	 chain	 amino	 acids,	 to	 build	 phospholipids426.	 For	 example,	 isoleucine	 is	 needed	 to	
synthesize	 anteiso	 odd-numbered	 fatty	 acids	 and	 leucine	 is	 needed	 for	 iso	 odd-numbered	 fatty	
acids535,562	(Fig	6.3).	Thus,	although	the	availability	of	particular	fatty	acids	appars	to	enhance	the	
efficiency	 of	 phospholipid	 release,	 S.	 aureus	must	 also	 acquire	 other	 nutrients	 from	within	 the	
host	 environment.	 Therefore,	 whilst	 it	 appears	 energetically	 favourable	 for	 S.	 aureus	 to	 utilize	
host-derived	fatty	acids,	it	might	not	necessarily	be	the	most	efficient	way	to	enable	the	release	of	
phospholipids	in	response	to	daptomycin	within	the	host	milieu.		
It	is	also	important	to	consider	that	S.	aureus	takes	up	fatty	acids	via	diffusion	through	the	
membrane,	 but	 has	 limited	 means	 to	 eject	 those	 fatty	 acids	 that	 cannot	 be	 incorporated	 into	
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phospholipids.	Thus,	host	derived	fatty	acids	which	are	toxic	to	S.	aureus	such	as	16:1Δ9	and	found	
on	 the	 skin	 cause	 membrane	 disruption	 and	 growth	 inhibition562.	 We	 do	 not	 yet	 know	 the	
consequences	of	 host	 environments	 that	 contain	 complex	mixtures	 of	 both	beneficial	 and	 toxic	
fatty	acids.	This	is	particularly	challenging	to	model	since	a	single	fatty	acid	can	be	either	beneficial	
or	toxic	depending	on	its	concentration.		
	
6.9.2 Serum	albumin	blocks	the	utilization	of	fatty	acids	by	S.	aureus	
A	total	of	3381	types	of	 lipids	are	 found	 in	 the	human	serum	metabolome	of	which	27	types	of	
lipids	are	found	as	free	fatty	acids	(the	upper	limit	of	the	concentration	range	can	be	as	high	as	66	
μM)	574.	Fatty	acids	are	important	substrates	for	the	synthesis	of	membrane	phospholipids	in	host	
cells	 and	 an	 important	 source	 of	 energy572.	 Fatty	 acids	 exist	 in	 the	 plasma	 as	 anions	 and	 the	
aqueous	solubility	of	the	monomeric	forms	of	fatty	acids	including	oleic	acid	and	palmitic	acid	are	
~10-20	 μM	 575,576.	 To	 enable	 the	 transport	 of	 fatty	 acids	 via	 the	 bloodstream,	 these	 lipids	 are	
carried	and	delivered	to	the	cells	by	the	serum	albumin	protein,	which	is	the	key	carrier	of	fatty	
acids577,578,575.			
	 Clearly,	 the	binding	of	 fatty	acids	to	albumin	 is	reversible	and	the	 lipids	can	be	extracted	
from	the	protein	by	host	cells.	However,	the	kinetics	of	the	desorption	of	the	fatty	acid	from	the	
albumin	protein	to	the	membrane	is	dependent	on	the	fatty	acid	chain	length579–581.	Previous	work	
suggests	that	S.	aureus	can	utilize	albumin-bound	fatty	acids	for	growth,	albeit	less	efficiently	than	
endogenous	phospholipid	production542,544,573.	
	 An	additional	consideration	when	assessing	the	utilization	of	exogenous	fatty	acids	 is	the	
rate	at	which	phospholipids	are	released.	Because	daptomycin	is	rapidly	bactericidal,	it	is	essential	
for	S.	 aureus	 to	 rapidly	 release	 phospholipids	 to	 inactivate	 the	 antibiotic	 as	 quickly	 as	 possible.	
Therefore,	 the	 fact	 that	 HSA	 simply	 reduces	 the	 efficiency	 of	 staphylococcal	 utilization	 of	 fatty	
acids	 to	 generate	 phospholipids	 for	 release,	 is	 sufficient	 to	 prevent	 their	 contribution	 to	
daptomycin	inactivation.	What	is	unknown,	and	warrants	investigation,	is	whether	cells	lysed	by	S.	
aureus	 release	 unbound	 fatty	 acids	 and	 whether	 these	 are	 present	 in	 sufficient	 quantities	 to	
enhance	phospholipid	release.	
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6.9.3 Serum-protein	 sequestration	 of	 AIP	 and	 PSM	 enable	 daptomycin	 survival	 by	 the	
wild-type	
An	interesting	observation	was	made	when	serum	dramatically	improved	the	survival	of	the	wild-
type	 in	 the	 presence	 of	 daptomycin.	 However,	 the	 findings	 suggest	 that	 this	 is	 due	 to	 the	
suppression	of	the	Agr	quorum-sensing	system	and/or	sequestration	of	PSMs	since	serum	had	a	
very	 modest	 effect	 on	 the	 survival	 of	 the	 ΔagrA	 mutant	 exposed	 to	 daptomycin.	 It	 is	 well	
established	 that	 serum	 contains	 lipoproteins	 which	 sequesters	 the	 AIP	 molecule	 required	 to	
activate	 the	 Agr-quorum	 sensing	 system.	 Serum	 proteins	 also	 directly	 bind	 and	 inactivate	 the	
PSMs	that	interfere	with	the	lipid	sequestration	of	daptomycin	which	then	results	in	the	wild-type	
S.	aureus	being	killed	by	daptomycin185,524.	Presumably	at	certain	sites	within	the	host,	 the	wild-
type	bacteria	will	have	an	Agr	‘off’	phenotype,	which	would	enable	them	to	efficiently	inactivate	
daptomycin	as	discussed	in	chapter	3.	
	
6.9.4 The	potential	of	AFN-1252/daptomycin	combination	therapy	against	S.	aureus		
AFN-1252	 inhibits	 the	 FabI	 enzyme	 in	 the	 FAS	 II	 pathway,	 which	 blocks	 the	 endogenously	
synthesized	fatty	acids	required	to	form	phospholipids	542,550,541,543.	The	FabI	enzyme	is	an	essential	
enzyme	 in	S.	 aureus	 as	 it	 is	 the	 sole	 form	of	 the	enoyl-ACP	 reductase	enzyme	 in	S.	 aureus	 that	
catalyses	 the	completion	of	 the	elongation	cycle	of	 the	 fatty	acids,	which	 is	 the	step	before	 the	
fatty	 acid	 becomes	 a	 phospholipid550,541.	 	 AFN-1252,	which	 is	 the	 first	 antibiotic	 in	 its	 class	 has	
been	 assessed	 for	 efficacy	 in	 treating	 acute	 bacterial	 skin	 and	 skin	 structure	 infection	 (ABSSSI)	
caused	by	S.	aureus.	A	recent	phase	II	clinical	trial	demonstrated	this	drug	to	be	generally	effective	
in	treating	ABSSSI	caused	by	S.	aureus551,	although	the	clinical	development	pathway	is	 long	and	
additional	hurdles	need	to	be	passed	before	it	is	licenced	for	clinical	use.	
Previous	studies	have	shown	that,	although	S.	aureus	can	utilize	host-derived	fatty	acids	its	
FAS	II	synthesized	pathway	seems	indispensible	as	half	of	the	phospholipid	fatty	acid	moiety	must	
be	provided	by	de	novo	FAS	II	synthesis542,544,541,540.	Furthermore,	in	vitro	studies	have	shown	that	
blocking	the	FAS	II	pathway	by	AFN-1252	inhibits	S.	aureus	growth	in	the	presence	of	fatty	acids	
531,542,543.	However,	despite	 the	 fact	 that	S.	aureus	FAS	 II	 is	essential	 for	 the	 fatty	acid	synthesis,	
even	 in	 the	presence	of	host-derived	 fatty	acids,	 it	 is	unclear	whether	AFN-1252	 is	viable	 in	 the	
host	 in	 the	 presence	 of	 complex	 mixtures	 of	 host-derived	 fatty	 acids	 generated	 during	
infection552,582,583,540.	Furthermore,	recent	work	has	suggested	that	the	presence	of	free	fatty	acids	
may	enable	FabI	bypass573.		
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The	findings	described	here	indicate	that	AFN-1252	blocks	the	de	novo	FAS	II	pathway	even	
in	 the	 presence	 of	 host-derived	 fatty	 acids	 by	 completely	 shutting	 down	 daptomycin-induced	
phospholipid	 release	 and	 thereby	 enhancing	 daptomycin	 activity.	 Thus,	 the	 use	 of	 AFN-1252	
alongside	daptomycin	provides	a	viable	dual	therapeutic	approach	with	the	potential	to	improve	
daptomycin	 treatment	 outcomes.	 However,	 further	 studies	 on	 how	 this	 combination	 therapy	
would	 work	 in	 the	 host	 remains	 to	 be	 addressed,	 in	 particular	 using	 appropriate	 mammalian	
infection	models	 to	 test	 the	efficiency	of	 the	dual	 therapy.	 In	addition,	 since	 resistance	 to	both	
daptomycin	and	AFN-1252	can	arise	 spontaneously,	 it	would	be	valuable	 to	determine	whether	
dual	therapy	provides	a	mechanism	to	reduce	the	frequency	at	which	resistance	emerges.		
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Discussion	
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7.1 The	selective	advantage	of	Agr-dysfunction	
There	 is	 a	 growing	 body	 of	 evidence	 that	 persistent	 and	 invasive	 staphylococcal	 infections	 are	
caused	by	 strains	 defective	 for	Agr	 function.	However,	 it	 is	 not	 clear	what,	 if	 any,	 advantage	S.	
aureus	 gains	 from	 losing	 Agr	 activity.	 S.	 aureus	 faces	 two	 major	 threats	 during	 infection:	 host	
immunity	 and	 antibiotics.	 Since	 we	 have	 shown	 previously	 that	 loss	 of	 Agr	 function	 does	 not	
promote	staphylococcal	survival	in	blood183,385,	the	hypothesis	for	this	project	was	that	loss	of	Agr	
function	 reduced	 antibiotic	 susceptibility.	 This	 was	 supported	 by	 several	 reports	 linking	 Agr-
dysfunction	 to	 chronic	 infection	 and	 the	 emergence	 of	 antibiotic	 resistance183,368,377,389,425.	
However,	 a	 direct,	 mechanistic,	 link	 between	 Agr	 and	 antibiotic	 susceptibility	 had	 not	 been	
investigated.	Using	a	panel	of	well-defined	mutants	and	standard	antibiotic	susceptibility	testing	
protocols,	 it	 was	 found	 that	 there	was	 no	 link	 between	 Agr	 activity	 and	 drug	 susceptibility	 for	
several	 clinically-relevant	 antibiotics.	 There	 was,	 however,	 one	 notable	 exception	 to	 this.	
Daptomycin,	a	lipopeptide	antibiotic	of	last	resort	for	MRSA	and	VISA	infections,	was	significantly	
more	active	against	wild-type	than	Agr-defective	S.	aureus.	This	finding	 led	to	the	discovery	of	a	
novel	mechanism	of	 antibiotic	 resistance,	 and	 the	 identification	of	 new	 therapeutic	 approaches	
that	may	improve	daptomycin	treatment	outcomes.			
	
7.1.1 Agr-dysfunction	promotes	staphylococcal	survival	during	daptomycin	exposure	
Defects	in	Agr	function	can	arise	via	mutations	in	the	agr	locus	or	elsewhere	on	the	chromosome,	
due	to	the	acquisition	of	methicillin	or	vancomycin	resistance,	or	due	to	sequestration	of	AIP	by	
host	 apolipoproteins14,183,375,377,378,389,399.	 For	 example,	 a	 large	proportion	of	MRSA	 strains	 in	 the	
UK	 have	 reduced	 or	 absent	 Agr	 activity	 due	 to	 the	 action	 of	 the	 alternative	 penicillin-binding	
protein	2a375,438.	
Using	 a	 combination	 of	 agr	 mutant	 strains	 and	 clinical	 isolates	 with	 Agr-functional	 or	
dysfunctional	 phenotypes,	 it	was	 observed	 that	 the	 absence	 of	 Agr	 activity	 enabled	 bacteria	 to	
survive	daptomycin	more	efficiently	than	bacteria	with	functional	Agr	systems.	Subsequent	work	
showed	 that	 the	 presence	 of	 serum,	 which	 inhibits	 Agr	 enables	 wild-type	 bacteria	 to	 survive	
daptomycin	exposure.		
Agr	regulates	the	expression	of	numerous	virulence	factors	and	metabolic	genes158.	Since	
antibiotics	target	essential	processes,	it	was	surprising	that	Agr-regulated	PSMα	toxin	production	
promoted	the	killing	of	S.	aureus.	Whilst	several	studies	have	shown	a	trade-off	between	virulence	
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and	 antibiotic	 resistance,	 this	 may	 be	 the	 only	 case	 of	 a	 virulence	 factor	 directly	 sensitizing	 a	
pathogen	 to	 an	 antibiotic375,377,378,380.	 Therefore,	whilst	 the	 initial	 hypothesis	 of	 this	 project	was	
that	 loss	 of	 Agr	 function	 reduces	 susceptibility,	 it	may	 be	more	 correct	 to	 say	 that	 Agr	 activity	
increases	susceptibility	by	compromising	the	phospholipid-release	defence	mechanism.	
The	finding	that	phospholipid-mediated	inactivation	of	daptomycin	is	compromised	by	the	
Agr-dependent	 secretion	 of	 PSMs	 may	 appear	 paradoxical.	 However,	 whilst	 Agr	 is	 certainly	
required	during	the	early	stages	of	acute	infection,	it	appears	dispensable	for	invasive	or	chronic	
infection	 in	 humans,	 from	 which	 agr-mutants	 are	 frequently	 isolated115,368,380,387,388,425.	
Furthermore,	 even	when	 the	Agr	 system	 is	 functional,	Agr	 is	 active	 in	only	 a	 subset	of	 bacteria	
during	acute	infection,	whether	in	tissue	or	biofilm507,509,518.	Therefore,	as	infection	progresses,	the	
staphylococcal	population	consists	of	a	mixture	of	Agr	active	and	Agr	inactive	cells,	meaning	that	
PSMs	are	not	 expressed	by	 all	 or	 even	most	bacteria.	 Since	daptomycin	 is	 often	not	 a	 first	 line	
therapeutic,	it	is	typically	used	to	treat	established	infection,	when	Agr	activity	is	most	likely	to	be	
variable	or	absent,	 rather	than	during	the	early	stages	of	 infection	when	Agr	activity	 is	greatest.	
Heterogeneity	 in	 Agr	 activity	 within	 S.	 aureus	 populations	 may	 therefore	 enable	 S.	 aureus	 to	
effectively	balance	virulence	and	daptomycin	susceptibility	by	producing	enough	toxins	to	sustain	
infection	but	without	significantly	 impairing	 the	 lipid-release	defence	mechanism.	This	 is	akin	 to	
the	 mixtures	 of	 wild-type	 and	 agr-mutant	 S.	 aureus	 strains	 that	 survived	 in	 vivo	 despite	 host	
defences	and	daptomycin	treatment,	and	fits	with	the	growing	appreciation	of	the	role	population	
heterogeneity	plays	in	bacterial	survival	during	antibiotic	exposure405,584,585.		
	
7.1.2 Antibiotic	inactivation	without	an	enzyme	
The	inactivation	of	antibiotics	by	bacteria	is	a	major	mechanism	of	antibiotic	resistance	and	almost	
exclusively	occurs	via	enzymes	that	hydrolyse	or	otherwise	modify	the	antibacterial	so	that	 it	no	
longer	functions.	This	 includes	daptomycin,	with	previous	work	showing	that	daptomycin	can	be	
inactivated	 by	 enzymes	 produced	 by	 various	 environmental	 organisms,	 as	 well	 as	 mammalian	
proteases434.	 However,	 whilst	 S.	 aureus	 produces	 several	 proteases,	 it	 does	 not	 hydrolyse	
daptomycin.	Instead,	the	data	presented	here	reveal	that	S.	aureus	can	inactivate	daptomycin	via	
an	 enzyme-independent	 mechanism,	 by	 showing	 that	 membrane	 phospholipid	 released	 by	 S.	
aureus	 sequesters	 and	 inactivates	 the	 antibiotic.	 In	 addition,	 recent	 work	 from	 our	 group	 has	
revealed	 that	 daptomycin-induced	 phospholipid	 release	 occurs	 in	 several	 Gram-positive	
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pathogens	including	Enterococcus	faecalis,	Streptococcus	pyogenes,	Streptococcus	agalactiae	and	
Streptococcus	gordonii586.			
The	 release	 of	 phospholipid,	 it	 appears	 is	 a	 specific	 response	 to	 the	 presence	 of	
daptomycin,	and	results	in	the	release	of	all	membrane	phospholipids	at	approximately	the	same	
relative	abundances	found	in	the	membrane.	However,	despite	similarities	in	the	structure	of	the	
major	 staphylococcal	 phospholipids,	 the	 data	 show	 that	 PG	 was	 significantly	 more	 efficient	 at	
inactivating	 daptomycin	 than	 LPG.	 This	 suggests	 that	 S.	 aureus	 releases	 phospholipids	 directly	
from	 the	membrane,	 rather	 than	 employ	 a	 dedicated	 release	mechanism	 such	 as	 a	 pump	 that	
would	 be	 expected	 to	 release	 PG	 exclusively.	 However,	 the	 mechanism	 responsible	 for	
phospholipid	release	remains	to	be	elucidated.		
	
7.1.3 The	contribution	of	phospholipid	release	to	daptomycin	treatment	failure	
The	phospholipid	release	mechanism	described	here	is	not	the	only	route	by	which	S.	aureus	can	
survive	daptomycin	exposure.	Several	reports	have	described	strains	that	have	acquired	mutations	
that	result	in	altered	membrane	phospholipid	content	or	surface	charge.	These	mutations	result	in	
moderate	 increases	 in	 the	 MIC	 (2-4-fold),	 but	 these	 are	 often	 sufficient	 to	 enable	 growth	 at	
clinically-achievable	 daptomycin	 concentrations132,440.	 However,	 the	 emergence	 of	 these	
‘daptomycin	non-susceptible’	 strains	 is	a	 relatively	 rare	event	and	do	not	 therefore	explain	why	
daptomycin	treatment	failure	occurs	in	up	to	30	%	of	cases136.	
The	data	presented	in	this	thesis	provides	evidence	that	Agr	status	influences	daptomycin	
treatment	 outcomes	 but	 does	 not	 directly	 demonstrate	 that	 phospholipid	 release	 influences	
therapeutic	 outcomes.	 Evidence	 is	 also	 provided	 that	 combining	 the	 β-lactam	 antibiotic	 with	
daptomycin	 improved	 daptomycin	 efficacy	 in	 a	 murine	 model.	 This	 is	 agreement	 with	 other	
studies	 showing	 synergistic	 activity	 of	 daptomycin	 and	 β-lactam	 antibiotics	 and	 the	 CAMERA2	
clinical	trial	is	currently	underway	to	determine	if	this	constitutes	a	clinically	efficacious	approach	
in	 humans587.	 However,	 whilst	 the	 data	 presented	 here	 indicate	 that	 the	 β-lactam	 oxacillin	
promotes	daptomycin	efficacy	by	 inhibiting	phospholipid	release,	additional	mechanisms	for	this	
synergy	 have	 been	 proposed.	 The	 best	 supported	 is	 the	 ‘see-saw	 effect’	 in	 which	 daptomycin	
reduces	PBP2a	expression,	sensitizing	bacteria	to	β-lactams502,588,589.	 In	turn,	β-lactam	antibiotics	
increase	binding	of	daptomycin	to	S.	aureus,	promoting	bacterial	susceptibility	to	the	lipopeptide	
antibiotic502,588.	These	reports	underline	the	complex	nature	of	the	interaction	of	daptomycin	with	
S.	aureus,	which	results	in	the	interruption	of	both	membrane	function	and	cell	wall	biosynthesis,	
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and	demonstrates	that	significantly	more	work	is	required	to	fully	understand	its	mode	of	action,	
both	as	a	single	therapeutic	agent	and	in	combination	with	other	antibiotics.	
	
7.1.4 Resistance,	persistence,	tolerance	and	evasion	
The	discovery	of	this	novel	phospholipid-mediated	mechanism	expands	the	current	understanding	
of	 the	 range	 of	 different	 mechanisms	 by	 which	 bacteria	 can	 withstand	 antibiotic	 exposure.	 In	
general,	there	are	4	well-described	mechanisms	by	which	bacteria	can	resistant	antibiotics,	which	
require	 the	 acquisition	 of	 genes	 or	 mutations.	 Resistance	 enables	 bacteria	 to	 replicate	 in	
concentrations	of	antibiotic	that	would	otherwise	be	inhibitory	and	typically	occurs	via	four	main	
mechanisms446,590,591:	 (i)	 enzyme-mediated	 antibiotic	 hydrolysis	 or	 modification;	 (ii)	 antibiotic	
efflux	 pumps,	 which	 results	 in	 the	 reduction	 of	 the	 intracellular	 antibiotic	 concentration;	 (iii)	
altered	target	site	i.e.	genetic	mutation	or	post-translational	modification	of	the	antibiotic	target	
site,	 and	 (iv)	 target	 over-expression446.	 In	 addition	 to	 these	 dedicated	 resistance	 mechanisms,	
some	 bacteria	 are	 intrinsically	 resistant	 to	 certain	 antibiotics.	 For	 example,	 E.	 faecalis	 encodes	
PBPs	with	low	affinity	for	β-lactam	antibiotics,	whilst	the	dual	phospholipid	membranes	of	Gram-
negative	bacteria	preclude	entry	of	several	antibiotics.		
In	addition	to	resistance,	other	mechanisms	of	bacterial	 survival	of	antibiotics	have	been	
described.	 For	 example,	 persister	 cells	 are	 a	 subpopulation	 of	 non-replicating,	 phenotypically-
tolerant	bacteria	that	can	survive	exposure	to	antibiotics	that	kill	 the	majority	of	 the	population	
585,590,592.	Bacteria	can	also	acquire	tolerance,	which	enables	the	organism	to	survive	exposure	to	
bactericidal	antibiotics	for	a	greater	duration	than	susceptible	bacteria590,593.		
In	 addition	 to	 these	well-described	phenomena	of	 resistance,	 persistence	 and	 tolerance,	
there	 is	an	 increasing	recognition	of	extracellular	mechanisms	by	which	bacteria	can	survive	the	
exposure	to	antibiotics,	which	our	group	have	termed	‘antibiotic	interceptors'.	The	inactivation	of	
antibiotics	 before	 they	 engage	with	 the	 organism	 enables	 bacteria	 to	 evade	 killing,	 akin	 to	 the	
ability	 of	 S.	 aureus	 to	 evade	 complement	 deposition	 by	 releasing	 inhibitors	 of	 complement	
activation271–273.		
These	 antibiotic	 interception	mechanisms	 involve	 diverse	mechanisms	 but	 share	 several	
similarities	 with	 the	 phospholipid	 release	 mechanism	 described	 in	 this	 thesis	 (Fig	 7.1).	 For	
example,	antibiotic	interceptors	include	the	release	of	molecules	that	mimic	the	intended	target,	
such	as	outer	membrane	vesicles	(OMVs),	which	act	as	decoys	for	membrane-targeting	antibiotics	
such	 as	 colistin594,595.	 Other	 interceptors	 do	 not	 appear	 to	 act	 as	 decoys.	 For	 example,	 the	
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lipochalins	 are	 secreted	 proteins,	 which	 bind	 multiple	 classes	 of	 antibiotics	 and	 CAMPs	 via	 a	
hydrophobic	pocket.	As	for	phospholipid	release	in	S.	aureus,	lipocalins	are	produced	in	response	
to	antibiotic	exposure,	indicating	they	form	part	of	a	dedicated	defence	mechanism.	Furthermore,	
just	 as	 phospholipid	 release	 is	 compromised	 by	 PSMα	 peptides,	 so	 the	 ability	 of	 lipochalins	 to	
sequester	antibiotics	is	blocked	by	the	presence	of	fat-soluble	vitamins596.			
Another	example	of	an	antibiotic	interceptor	is	capsular	polysaccharide,	which	is	released	
by	bacteria	such	as	Pseudomonas	aeruginosa	 in	 response	to	colistin597,598.	The	released	capsular	
polysaccharide	then	sequesters	the	colistin,	enabling	bacterial	survival	of	an	otherwise	lethal	dose	
of	 the	 antibiotic.	 Similarly,	 the	 exposure	 of	 Accinetobacter	 baumannii	 to	 sub-inhibitory	
concentrations	 of	 chloramphenicol	 or	 erythromycin	 resulted	 in	 the	 hyperproduction	 of	 the	
exopolysaccharide	 capsule,	which	 then	 contributed	 to	 the	 increased	 resistance	 to	 antibiotics	 by	
forming	a	protective	shield599,600.	Therefore,	as	for	daptomycin-induced	phospholipid	release,	the	
production	of	antibiotic	interceptors	constitutes	a	specific	defence	mechanism	against	antibiotics	
and	is	not	simply	the	consequence	of	antibiotic-mediated	damage.	
In	addition	to	antibiotic	interception,	a	hybrid	resistance	mechanism	has	evolved,	whereby	
the	 well-characterised	 resistance	 determinant	 β-lactamase	 is	 released	 in	 OMVs.	 This	 enables	
bacteria	to	 inactivate	β-lactam	antibiotics	before	they	contact	the	cell	and	may	also	shield	other	
bacteria	from	the	antibiotic594,601.	
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Figure	7.1.	Antibiotic	interceptors	prevent	antibacterials	from	engaging	with	the	bacterial	cell		
A.	 baumanii	 increases	 the	 production	 of	 the	 extracellular	 polysaccharide	 capsule	 that	 can	 be	
released	 in	to	the	extracellular	space	and	 is	 involved	 in	resisting	and	preventing	antibiotics	from	
entering	the	cell	(a).	Lipocalins	are	secreted	by	bacteria	into	the	extracellular	space	to	sequester	
antibiotics	(b).	OMVs	release	by	Gram-negative	bacteria	has	been	suggested	to	provide	protection	
against	CAMPs	and	antibiotics	by	acting	as	decoys	(c).	S.	aureus	releases	OMVs	that	contain	the	β-
lactamase	enzyme	which	hydrolyzes	and	 inactivates	β-lactam	antibiotics	 (d).	 (c)	and	 (d)	adapted	
from	Brown.	L	et.	al.,	201511.	
c	
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7.1.5 Evolutionary	origins	of	the	phospholipid	release	mechanism	
Many	 of	 the	 antibiotic	 interception	 mechanisms	 described	 above	 provide	 protection	 from	
membrane-acting	 antimicrobial	 peptides,	 which	 are	 functionally	 similar	 to	 daptomycin	 and	
colistin595.	Antimicrobial	peptides	are	produced	by	bacteria	 to	provide	a	competitive	advantage,	
and	mammals	as	a	defence	mechanism	to	protect	against	fungal,	bacterial	or	viral	infections602,603.	
S.	aureus	encounters	AMPs	such	as	dermicidin	produced	by	the	skin	and	nasal	passages,	which	are	
important	 colonization	 sites602,604–606.	During	 infection,	 S.	 aureus	 will	 also	 be	 exposed	 to	 AMPs	
produced	by	neutrophils	and	other	immune	cells	including	the	cationic	peptides	cathelicidin	LL-37,	
human	 β-defensin,	 protegrin	 and	 human	 neutrophil	 peptide	 α-defensin275,607.	 All	 of	 these	
contribute	 to	 innate	 immunity	 and	 derivatives	 of	 these	 have	 been	 developed	 as	 topical	
bactericidal	agents	to	treat	infections608.	For	example,	OP-145	(P60.4AC)	is	derived	from	LL-37	and	
is	under	phase	2	clinical	trial	for	treating	chronic	ear	infections602,609,610.		
In	 this	 thesis,	 it	 was	 shown	 that	 the	 S.	 aureus	ΔagrA	 mutant	 released	 phospholipids	 in	
response	to	the	CAMPs	melittin	and	nisin	(Fig	7.2).	It	is	not	yet	known	whether	mammalian	host	
defence	peptides	such	as	β-defensins,	cathelicidin	LL-37,	gramicidin	or	PR-39	induce	phospholipid	
release	 in	 S.	 aureus.	However,	 since	 colistin	 and	 daptomycin	 are	 used	 rarely	 in	 humans,	whilst	
bacteria	 frequently	 encounter	 antimicrobial	 peptides	 from	 host	 defences	 and/or	 competitor	
species,	 it	 appears	 much	 more	 likely	 that	 peptides	 provided	 the	 selection	 pressure	 for	 these	
antibiotic	 interceptor	mechanisms.	Furthermore,	 if	AMPs	 from	competitors	or	 the	host	 selected	
for	the	phospholipid	release	mechanism	then	it	 is	also	possible	that	these	same	pressures	select	
for	the	loss	of	Agr	function,	since	this	dramatically	increases	the	efficacy	of	the	system.		
	
7.2 Summary	
In	 summary,	 this	 thesis	 describes	 the	 discovery	 and	 characterization	 of	 a	 novel	 mechanism	 of	
antibiotic	inactivation,	whereby	S.	aureus	releases	phospholipids,	which	sequester	daptomycin	(Fig	
7.3).	 This	 system	 is	 compromised	 by	 the	 Agr-triggered	 secretion	 of	 PSMα	 toxins,	 but	 the	 host	
environment	may	enhance	the	efficiency	of	this	system	by	suppressing	Agr	activity	and	providing	
phospholipid	precursors	 in	the	form	of	fatty	acids.	However,	additional	work	 identified	potential	
therapeutic	 approaches	 to	 inhibit	 phospholipid	 release	 and	 thereby	 enhance	 daptomycin	
treatment	efficacy.	
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Figure	7.2.	Phospholipid-release	is	also	triggered	by	CAMPs		
On	exposure	 to	nisin	or	melittin,	S.	aureus	 releases	phospholipids,	which	protect	 the	bacterium	
from	 the	 respective	 CAMPs.	 However,	 a	 major	 question	 is	 whether	 S.	 aureus	 releases	
phospholipids	in	response	to	host	defences	AMPs	such	as	LL-37	and	defensins,	and	does	released	
phospholipid	 inactivate	 these	 AMPs?	 It	 also	 remains	 to	 be	 determined	 whether	 host	 defence	
AMPS	 provide	 a	 selective	 pressure	 for	 the	 evolution	 of	 the	 phospholipid-release	 defence	
mechanism.	
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Figure	7.3.	Thesis	summary	model	
On	exposure	to	daptomycin,	the	agrA	mutant	actively	releases	phospholipids	that	sequester	and	
inactivate	 daptomycin.	 This	 enables	 the	 agrA	 mutant	 to	 survive	 daptomycin	 exposure	 and	
replicate.	 By	 contrast,	 although	 the	 wild-type	 also	 releases	 phospholipids,	 the	 presence	 of	 the	
PSMα	toxins	interferes	with	the	phospholipid-sequestration	of	daptomycin.	This	renders	the	wild-
type	susceptible	to	daptomycin,	which	results	in	cell-death.	
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7.3 Outstanding	questions	and	future	work			
As	 discussed	 above,	 the	 discovery	 of	 daptomycin-induced	 phospholipid	 release	 has	 raised	 a	
number	of	questions,	particularly	with	respect	to	the	underlying	mechanism,	evolutionary	origins	
and	therapeutic	approaches	that	can	enhance	daptomycin	treatment	outcomes.	In	this	part	of	the	
thesis,	key	questions	are	posed	and	experimental	approaches	described	to	resolve	these	gaps	 in	
our	knowledge.	In	particular:	
1. What	signals	phospholipid-release	in	response	to	daptomycin?	
2. How	is	phospholipid	released	from	the	membrane	in	response	to	daptomycin?	
3. What	is	the	role	of	the	cell	wall	during	the	release	of	phospholipids?	
4. Is	 phospholipid	 release	 heterogeneous	 at	 the	 population	 level	 and	 how	 does	 this	 affect	
bacterial	survival?		
5. Can	 the	 information	 generated	 in	 this	 and	 future	 studies	 improve	 daptomycin	 treatment	
outcomes?	
	
7.3.1 What	signals	phospholipid-release	in	response	to	daptomycin?	
The	results	described	in	chapter	4	indicated	that	the	vraUTRS	regulon	is	required	for	daptomycin-
induced	 phospholipid-release	 (Fig	 4.11)	 and	 (Fig	 7.4).	 This	 is	 in	 agreement	 with	 previous	
transcriptomic	profiling	of	S.	 aureus,	which	 revealed	 that	daptomycin	 induces	 the	expression	of	
genes	associated	with	the	cell	wall	stress	stimulon,	regulated	by	VraUTRS111.		VraUTRS	is	activated	
in	response	to	damage	caused	by	cell	wall	and	cell	membrane	acting	antibiotics	and	antimicrobial	
peptides,	 including	 daptomycin,	 vancomycin,	 oxacillin	 and	 nisin611.	 Therefore,	 it	 is	 hypothesized	
that	 the	 VraUTRS	 system	 detects	 the	 presence	 of	 daptomycin	 and	 signals	 the	 release	 of	
membrane	 phospholipids.	 To	 test	 this	 hypothesis,	 and	 determine	 how	 VraUTRS	 modulates	
phospholipid	release,	the	following	experiments	are	proposed:	
a. The	 first	 objective	 would	 be	 to	 determine	 which	 components	 of	 the	 VraUTRS	 system	
contribute	 to	 daptomycin-induced	 phospholipid-release	 and	 the	 effects	 of	 clinically-relevant	
mutations	in	the	vra	operon.	For	example,	VISA	isolates	often	have	gain	of	function	mutations	
in	vraS	 or	vraR,	 leading	 to	 a	 constitutively	 active	 phenotype	 and	decreased	 susceptibility	 to	
vancomycin	 and	 daptomycin	 612.	 However,	 the	 effect	 of	 these	 mutations	 on	 phospholipid	
release	is	unclear.	The	USA300	ΔvraUTRS	mutant	would	be	complemented	with	plasmid	pCL55	
containing	either	 the	entire	vraUTRS	 operon,	or	mutated	versions	 lacking	each	of	 the	genes	
(ΔvraU,	ΔvraT,	ΔvraR,	ΔvraS),	under	the	control	of	the	native	promoter.	This	vector	inserts	as	a	
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single	 stable	 copy	 on	 the	 chromosome	 at	 the	 geh	 locus,	 removing	 the	 requirement	 for	
antibiotic	 selection	 that	 might	 confound	 subsequent	 experiments613,614.	 To	 determine	 the	
contribution	of	each	gene	within	the	vra	operon,	each	of	the	complemented	strains	would	be	
subjected	 to	 daptomycin-challenge	 and	 bacterial	 survival,	 phospholipid	 release	 and	
daptomycin	 inactivation	measured.	 Experiments	would	 be	 repeated	 in	 the	 SH1000	 strain	 to	
account	for	any	regulatory	variations	between	strains.		
b. If	 the	 Vra	 system	 is	 responsible	 for	 triggering	 phospholipid	 release,	 then	 activation	 of	 the	
CWSS	 should	 lead	 to	 phospholipid	 release.	 Therefore,	 the	 temporal	 relationship	 between	
induction	of	the	CWSS	by	daptomycin	and	phospholipid	release	would	be	determined.	CWSS	
induction	could	be	quantified	by	measuring	transcription	of	vraR	and/or	vraS	using	RT-PCR	at	
various	 times	 after	 exposure	 to	 daptomycin,	 and	 compared	 with	 measurements	 of	
phospholipid	in	the	culture	supernatant	at	identical	time	points111,612.			
c. Next,	 it	 would	 be	 determined	 whether	 activation	 of	 VraUTRS	 alone	 is	 sufficient	 for	
phospholipid	 release.	 As	 described	 above,	 several	 mutations	 in	 vraR	 or	 vraS	 have	 been	
identified	in	clinical	isolates	that	confer	a	constitutively	active	CWSS	phenotype	and	decreased	
susceptibility	to	daptomycin612.	Strains	containing	these	mutations	will	be	generated	and	used	
to	 determine	 whether	 constitutive	 CWSS	 activity	 alone	 results	 in	 phospholipid	 release,	 or	
whether	the	presence	of	daptomycin	is	still	required.	
d. The	VraUTRS	regulon	modulates	expression	of	~40	genes	involved	in	cell	wall	and	membrane	
biogenesis.	To	determine	which	genes	 in	the	regulon	contribute	to	phospholipid-release,	 the	
NARSA	Tn	library,	which	contains	mutants	lacking	copies	of	most	of	the	relevant	genes	could	
be	used.	However,	some	of	the	genes	regulated	by	VraUTRS	are	 likely	to	be	essential	and	so	
these	 could	 be	 placed	 under	 the	 control	 of	 an	 inducible	 promoter	 to	 enable	 them	 to	 be	
switched	off	during	assays.	For	example,	a	copy	of	the	respective	essential	gene	will	be	placed	
under	 the	 control	 of	 the	 IPTG-inducible	 Pspac	 promoter,	 which	 has	 been	 used	 in	 previous	
studies	to	investigate	the	interaction	between	LTA	synthesis	and	cell	division	proteins	that	are	
essential	for	S.	aureus	growth615,616.	
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Figure	7.4.	How	does	S.	aureus	regulate	phospholipid-release?		
The	CWSS/VraUTRS	is	involved	in	regulating	the	phospholipid	release	in	response	to	daptomycin.	
However,	which	genes	 from	the	Vra	regulon	(including	cell	wall	 synthesis	and	 lipid	biosynthesis)	
contribute	to	phospholipid	release	remain	to	be	determined.	
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7.3.2 How	is	phospholipid	released	from	the	membrane	in	response	to	daptomycin?	
The	 results	 in	 chapters	4	and	6	 show	 that	blocking	 lipid	metabolism	also	blocks	 lipid	 release.	 In	
addition,	 experiments	 indicated	 that	 S.	 aureus	 utilizes	 host-associated	 fatty	 acids	 to	 promote	
phospholipid	release	in	response	to	daptomycin	(chapter	6).	However,	it	is	not	clear	whether	the	
newly	synthesized	phospholipids	are	released.	The	data	do	show	that	at	least	some	of	the	released	
phospholipids	 existed	 prior	 to	 daptomycin	 challenge.	 However,	 this	 does	 not	 rule	 out	 the	
possibility	that	newly	synthesized	phospholipids	are	also	released	and	additional	experiments	are	
therefore	 needed	 to	 understand	 how	 phospholipids	 are	 released	 from	 the	 membrane.	 In	
particular,	
a. To	 determine	 whether	 any	 of	 the	 released	 phospholipid	 is	 newly	 synthesized,	 radiolabeled	
(C14)	oleic	acid	could	be	used	to	track	phospholipid	biogenesis	and	release.	Bacteria	could	be	
pre-labelled,	 prior	 to	 daptomycin	 challenge	 to	monitor	 release	 of	 ‘old	 phospholipid’,	 or	 fed	
oleic	acid	during	daptomycin	challenge	as	described	in	chapter	6	to	detect	‘new’	phospholipid	
production.		
b. The	results	in	chapter	5	indicated	that	most	of	the	phospholipid	released	into	the	extracellular	
space	consists	of	small	micelles	or	monomers	and	some	as	membrane	vesicles,	which	contain	
very	 little	 daptomycin.	 Future	 experiments	 will	 identify	 whether	 individual	 monomeric	
phospholipids	 are	 directly	 released	 or	 whether	 phospholipids	 are	 released	 as	 membrane	
vesicles	 that	 subsequently	 lyse	 (Fig	 7.5).	 This	 could	 be	 determined	 by	 performing	 the	 same	
daptomycin-induced	phospholipid	release	assay	(as	described	in	chapter	2)	but	in	in	hypertonic	
spheroplasting	buffer,	which	is	expected	to	prevent	lysis	of	vesicles.		
c. The	determination	of	whether	 phospholipids	 are	 released	 from	 the	membrane	 as	 individual	
phospholipids	or	as	vesicles	will	be	an	important	step	in	our	understanding	of	the	requirement	
of	 cell	wall	 rearrangement.	 If	 the	phospholipids	are	 released	 in	 the	 form	of	vesicles	 it	must,	
presumably,	 require	 either	 a	 pore	 (opening)	 in	 the	peptidoglycan	big	 enough	 for	 the	MV	 to	
pass	 through	 or	 change	 in	 cell	 wall	 thickness,	 both	 of	 which	 then	 requires	 cell	 wall	
rearrangement11	.	To	explore	this	further,	the	architecture	of	the	cell	wall,	and	the	emergence	
of	 membrane	 blebs	 in	 response	 to	 daptomycin	 would	 be	 assessed.	 Specifically,	 the	
deformability	(change	in	the	shape)	of	the	cell	caused	by	turgor	pressure	build	up	within	the	
cell	on	exposure	to	daptomycin	would	be	assessed	by	atomic	force	microscopy617.	This	would	
reveal	whether	blebs	emerge	at	particular	points	in	the	cell	and	whether	there	are	pores	in	the	
peptidoglycan	through	which	blebs	could	emerge.		
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Figure	7.5.	How	are	the	monomeric	phospholipids	released	from	the	cell?			
	
	 	
Daptomycin	inserts	
into	the	membrane	
A	membrane	
vesicle	forms	
The	membrane	
vesicle	is	released	
The	presence	of	
daptomycin	
destabilises	the	
vesicle	
The	vesicle	lyses	
genera$ng	monomeric	
phospholipids	that	bind	
free	daptomycin	
The	presence	of	
daptomycin	destabilises	
the	membrane	
Membrane	phospholipids	are	
released	in	the	form	of	
monomers	or	small	micelles	
		 262	
	
7.3.3 What	is	the	role	of	the	cell	wall	in	the	release	of	phospholipids?	
Two	 key	 findings	 presented	 in	 this	 thesis	 indicate	 that	 cell	 wall	 biosynthesis	 modulates	
phospholipid	release:	 inhibition	of	phospholipid	release	by	oxacillin	and	the	requirement	for	the	
VraUTRS	system	for	maximal	phospholipid	release.	
a. Therefore,	 future	 work	 will	 determine	 whether	 VraUTSR/CWSS	 contributes	 to	 phospholipid	
release	 via	 its	 role	 in	 regulating	 cell	 wall	 biosynthesis.	 However,	 many	 VraUTSR-regulated	
genes	 are	 essential	 and	 cell	wall	 biosynthesis	 is	 complex.	 To	 untangle	 this,	 a	 large	 panel	 of	
specific	inhibitors	of	individual	PBPs	and	other	enzymes	involved	in	peptidoglycan	biosynthesis	
would	be	employed	525,618.	For	example,	we	will	use	a	panel	of	commercially	available	β-lactam	
antibiotics	 with	 specificity	 for	 each	 of	 the	 4	 PBPs	 to	 determine	 which	 are	 required	 for	
phospholipid-release619.	 Next,	 various	 inhibitors	 of	 other	 steps	 in	 cell	 wall	 biosynthesis,	
including	 fosfomycin,	 D-cycloserine,	 tunicamycin,	 bacitracin,	 flavomycin,	 vancomycin	 and	
teicoplanin	 could	 be	 used	 to	 identify	 the	 various	 stages	 of	 the	 cell	 wall	 synthesis	 that	 are	
required	 to	 enable	phospholipid	 release	 (Fig	 7.6)611,620.	 For	 this	 the	ΔagrA	mutant	would	be	
exposed	 to	 sub-inhibitory	 concentrations	 of	 the	 respective	 cell-wall	 inhibitors	 along	 with	
daptomycin	 for	 8	 h,	 as	 described	 for	 oxacillin,	 and	 the	 same	 phospholipid	 release	 assay	 (as	
described	in	chapter	2)	used	to	measure	phospholipid	release	in	response	to	daptomycin.	
b. In	addition	to	cell	wall	biosynthesis,	it	is	also	possible	that	cell	wall	is	degraded.	For	example,	
as	 discussed	 above,	 in	 the	 event	 that	 phospholipids	 are	 released	 in	 the	 form	 of	 vesicles	 by	
forming	pores	in	the	cell	wall	it	is	likely	that	pores	are	created	in	the	wall	to	enable	passage	of	
the	vesicle.	In	keeping	with	this,	previous	reports	describing	the	release	of	S.	aureus	MVs	have	
indicated	that	cell-wall	degrading	enzymes	are	released	along	with	MVs	to	loosen	the	cell-wall	
and	increase	the	pore	size11,621.	Therefore,	it	is	expected	that	peptidoglycan	fragments	would	
be	 released	 if	 cell	wall	 degradation	occurs.	 The	 release	of	 peptidoglycan	 fragments	 into	 the	
culture	supernatant	could	be	detected	by	using	a	Nod2/NF-κB-dependent	 luciferase	reporter	
assay.	In	addition,	high	performance	liquid	chromatography	(HPLC)	or	ultra	performance	liquid	
chromatography	(UPLC)	could	be	used	to	detect	purified	PG	 in	the	culture	supernatant	 from	
the	bacteria	exposed	to	daptomycin622.		
	 	
		 263	
Together,	 these	 experiments	 will	 provide	 an	 understanding	 of	 how	 S.	 aureus	 detects	
daptomycin	through	the	CWSS	and	how	cell	wall	remodelling	contributes	to	phospholipid	release	
from	 the	membrane	 and	 through	 the	 cell	 wall	 in	 S.	 aureus.	 Studies	 with	 inhibitors	 of	 cell	 wall	
biosynthesis	 will	 provide	 mechanistic	 insight	 and	 may	 identify	 therapeutic	 approaches	 that	
promote	 daptomycin	 efficacy	 by	 blocking	 phospholipid	 release,	 as	 was	 shown	 previously	 for	
oxacillin	(chapter	5).		
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Figure	 7.6.	 Schematic	 representation	 of	 the	 enzymatic	 steps	 involved	 in	 S.	 aureus	 cell	 wall	
synthesis	and	the	targets	of	cell	wall	active	antibiotics	
	(Adapted	 from	N	McCallum	2011	and	Pinho	2013)	 611,623.	Fosfomycin	 inhibits	 the	enzyme	MurA	
(UDP-N-acetylglucosamine-3-enolpyruvyl	 transferase)	 that	 catalyses	 the	 addition	 of	
phosphoenolpyruvate	(PEP)	to	UDP-N-acetyl-glucosamine	(GlcNAc)	to	form	UDP-N-acetyl-muramic	
acid	 (UDP-MurNAc).	 D-cycloserine	 prevents	 the	 addition	 of	 D-alanine	 to	 the	 peptidoglycan	
precursor	 by	 inhibiting	 D-alanine:D-alanine	 ligase	 A	 and	 alanine	 racemase.	 Tunicamycin	 is	 a	
glycoprotein	 antibiotic	 that	 inhibits	 the	 transfer	 of	 peptidoglycan	 precursor	 (phospho-MurNAc-
pentapeptide)	to	the	lipid	carrier	undecaprenyl	pyrophosphate	(or	C55-isoprenyl	pyrophosphate),	
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catalysed	by	the	translocase	MraY.	Sub-lethal	concentrations	of	tunicamycin	also	inhibit	TarO,	the	
first	enzyme	in	the	wall	teichoic	acid	pathway.	Bacitracin	forms	a	metal-dependent	complex	with	
the	 lipid	 carrier	 undecaprenyl	 pyrophosphate,	 thereby	 preventing	 dephosphorylation	 and	 the	
recycling	of	the	lipid	carrier	required	for	cell	wall	synthesis.	Flavomycin	(a	moenomycin	complex)	is	
a	 phosphoglycolipid	 antibiotic	 that	 inhibits	 transglycosylation	 through	 binding	 of	 the	
transglycosylase	 domain	of	 penicillin-binding	 protein	 2	 (PBP2).	Glycopeptide	 antibiotics,	 such	 as	
vancomycin	and	teicoplanin,	inhibit	cell	wall	synthesis	by	binding	the	D-ala-D-ala	of	the	lipid	II	and	
sterically	 hindering	 transglycosylation	 and	 transpeptidation.	 Teicoplanin	 activity	 is	 enhanced	
through	 its	 interaction	 with	 the	 cytoplasmic	 membrane.	 β-lactam	 antibiotics,	 such	 as	 oxacillin,	
bind	 the	 transpeptidase	 active	domain	of	 penicillin-binding	proteins	 (PBPs)	 by	mimicking	 the	D-
ala-D-ala	 end	 of	 the	 pentapeptide.	 Lysostaphin	 is	 a	 zinc	 metalloenzyme	 that	 cleaves	 the	
pentaglycine	crosslinking	bridge	specific	for	the	cell	wall	of	S.	aureus.	
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7.3.4 Is	phospholipid	release	heterogeneous	at	the	population	level	and	how	does	this	
affect	bacterial	survival?		
Upon	daptomycin	exposure,	>90%	of	 the	ΔagrA	bacterial	population	 is	killed,	but	 the	 remaining	
staphylococci	 survive	 and	 then	 start	 to	 replicate.	 This	 heterogeneity	 ensures	 and	 prevents	
eradication	of	the	population	by	the	antibiotic,	but	the	underlying	reason	why	some	bacteria	die	
whilst	others	live	is	unknown	(Fig	7.7).		Therefore,	the	following	questions	should	be	addressed:	
a. Do	all	bacteria	release	lipid	in	response	to	daptomycin?	
b. Is	this	linked	to	levels	of	daptomycin	insertion	into	the	membrane?		
c. Is	there	a	correlation	between	the	cells	that	have	released	membrane	lipid	and	survival?	
Similar	 to	 Silverman	 et	 al.,	 2011	 and	 Chen	 et	 al.,	 2014	 single	 cell	 time-lapse	
microscopy125,121,462	could	be	used	in	conjunction	with	a	microfluidic	system	(Zeiss	Axio	Observer,	
cell	asic	ONIX	available	at	the	FILM	facility,	Imperial	College).	Specifically,	the	S.	aureus	membrane	
will	 be	 stained	 with	 FM4-64	 (lipophilic	 dye),	 whilst	 fluorescently	 tagged	 fatty	 acids	 (Life	
Technologies)	could	be	used	to	track	lipid	metabolism.	Fluorescently	(BoDipy)	labeled	daptomycin	
could	be	used	to	detect	insertion	of	the	antibiotic	into	the	membrane	and	a	live/dead	stain	(Sytox	
green)	 could	be	used	 to	detect	which	bacteria	are	dead	or	alive.	 These	 techniques	and	kits	will	
enable	 to	 determine	 –	 (i)	 which	 cells	 release	 lipid	 in	 response	 to	 daptomycin	 and	 (ii)	 correlate	
daptomycin	binding	with	phospholipid	release.		
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Figure	7.7.	What	determines	whether	a	specific	bacterium	lives	or	dies	during	the	exposure	to	
daptomycin?		
It	is	unknown	whether	daptomycin	binds	to	all	the	cells	in	a	population	in	equal	amounts.	If	there	
is	population	heterogeneity	in	the	amount	of	daptomycin	bound	to	the	cell,	this	likely	influences	
phospholipid	release	and	survival	of	individual	bacteria.	
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7.3.5 Can	 the	 information	 generated	 in	 this	 and	 future	 studies	 improve	 daptomycin	
treatment	outcomes?	
The	 mechanism	 by	 which	 phospholipid-release	 occurs	 provides	 opportunities	 for	 interventions	
that	 enhance	 the	 efficacy	 of	 daptomycin	 therapy.	 The	 data	 presented	 in	 this	 thesis	 support	
previous	 reports	 demonstrating	 synergy	 between	 daptomycin	 and	 β-lactam	 antibiotics,	 which	
target	 penicillin-binding	 proteins	 (PBPs)413,418.	 S.	 aureus	 encodes	 4	 PBPs,	 with	 MRSA	 strains	
additionally	 encoding	 PBP2a	 which	 has	 low	 affinity	 for	 β-lactam	 antibiotics24.	 Our	 experiments	
revealed	 an	 important	 role	 for	 PBP3,	 but	 not	 PBP4,	 in	 daptomycin-triggered	 lipid	 release.	 This	
explains	 why	 oxacillin,	 which	 inhibits	 the	 function	 of	 PBPs	 1-4	 (but	 not	 PBP2a),	 inhibits	
daptomycin-triggered	 phospholipid-release	 in	 MRSA,	 even	 though	 it	 cannot	 inhibit	 MRSA	
replication.	 The	 role	 of	 PBP3	 in	 phospholipid-release	 could	 be	 confirmed	 using	 clean	 deletion	
mutants	in	the	USA300	and	SH1000	strains,	and	complemented	strains	expressing	PBP3.		
Previous	work	 has	 implicated	 a	 role	 for	 PBP1	 in	 the	 synergistic	 action	 of	 β-lactams	 and	
daptomycin,	 which,	 together	 with	 our	 data	 showing	 a	 role	 for	 PBP3,	 indicate	 that	 cell	 wall	
remodeling	 is	 part	 of	 the	 staphylococcal	 response	 to	 daptomycin	 exposure35.	 This	 is	 in	 keeping	
with	a	study	of	the	transcriptional	response	of	S.	aureus	to	daptomycin,	which	showed	increased	
expression	of	several	genes	involved	in	peptidoglycan	biosynthesis135.		
β-lactam	 antibiotics	 appear	 to	 promote	 daptomycin	 activity	 by	 increasing	 the	 binding	 of	
the	 lipopetide	antibiotic	 to	the	staphylococcal	membrane413,418,502,526.	This	has	been	proposed	to	
occur	 via	 the	 modulation	 of	 surface	 charge	 by	 the	 β-lactam,	 enabling	 greater	 binding	 of	
daptomycin502,526,	 although	 this	 was	 not	 observed	 in	 another	 study413,418.	 Our	 data	 provide	 an	
additional	explanation	for	the	observed	synergy	between	daptomycin	β-lactams	by	showing	that	
membrane	phospholipid	release,	which	reduces	daptomycin	binding	to	the	bacterial	membrane,	is	
inhibited	by	the	β-lactam	oxacillin.		
An	 additional	 potential	 therapeutic	 approach	 arises	 from	 the	 growing	 interest	 in	
developing	 inhibitors	 of	 S.	 aureus	 lipid	 biosynthesis624.	 Two	 such	 inhibitors,	 platensimycin	 and	
AFN-1252,	 completely	blocked	daptomycin-triggered	phospholipid-release	and	enabled	killing	of	
agr-mutant	S.	aureus,	suggesting	that	combination	therapy	in	patients	may	be	highly	efficacious.	
In	keeping	with	these	data,	it	was	found	that	phospholipid-release	required	a	gene	that	encodes	a	
diacylglycerol	 glucosyltransferase	 involved	 in	 glycolipid	 biosynthesis.	 This	 finding	 should	 be	
confirmed	using	clean	deletion	mutant	and	complemented	strains473.	
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However,	this,	together	with	the	requirement	for	cell	wall	remodeling,	supports	other	data	
showing	that	phospholipid	release	 is	an	active	process	that	 is	 triggered	by	daptomycin	exposure	
and	 explains	 why	 it	 was	 completely	 inhibited	 by	 blocking	 protein	 synthesis	 or	 respiration.	
Therefore,	 the	 release	 of	 membrane	 lipid	 is	 not	 simply	 due	 to	 membrane	 disruption	 by	
daptomycin	 but	 the	 result	 of	 a	 complex	 and	 coordinated	 response	 by	 the	 bacterium	 to	 survive	
exposure	to	an	otherwise	lethal	antibiotic	challenge.		
In	summary	(Fig	7.8),	by	identifying	and	elucidating	this	phospholipid-release	response	to	
daptomycin,	 this	 study	discovered	 two	dual-therapeutic	approaches.	Our	animal	data	show	that	
the	use	of	β-lactam	antibiotics	in	combination	with	daptomycin	could	be	therapeutically	beneficial	
at	overcoming	daptomycin	treatment	failure	even	against	MRSA	strains	and	easily	applied	to	the	
clinic.	In	addition,	longer-term,	the	in	vitro	data	show	that	an	even	more	effective	dual-therapeutic	
approach	 would	 be	 the	 combination	 of	 next-generation	 lipid-biosynthesis	 inhibitors	 and	
daptomycin.	There	is	some	controversy	over	the	value	of	phospholipid	biosynthesis	inhibitors	such	
as	AFN-1252	due	to	the	potential	for	target	by-pass	by	utilistion	of	fatty	acids	from	the	host531,625.	
Although	we	saw	no	evidence	for	this	in	media	supplemented	with	free	fatty	acids,	the	efficacy	of	
dual	 daptomycin/lipid-biosynthesis	 inhibitor	 therapeutic	 approach	 should	 be	 tested	 within	 a	
relevant	host	model	system.		
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Figure	 7.8.	 S.	 aureus	 PBPs	 and	 the	 FAS	 II	 pathway	 are	 potential	 targets	 for	 adjunctive	
therapeutic	approaches	that	improve	daptomycin	efficacy		
Sub-inhibitory	 concentrations	 of	 a	 β-lactam	 antibiotic	 that	 blocks	 PBPs	 1-4	 and	 platensimycin/	
AFN-1252	that	blocks	the	FAS	II	pathway	result	in	the	inhibition	of	phospholipid-release.	
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